<SEC-DOCUMENT>0001178913-23-003334.txt : 20231016
<SEC-HEADER>0001178913-23-003334.hdr.sgml : 20231016
<ACCEPTANCE-DATETIME>20231016162503
ACCESSION NUMBER:		0001178913-23-003334
CONFORMED SUBMISSION TYPE:	F-3
PUBLIC DOCUMENT COUNT:		10
FILED AS OF DATE:		20231016
DATE AS OF CHANGE:		20231016

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813676773
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275002
		FILM NUMBER:		231327582

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-3
<SEQUENCE>1
<FILENAME>zk2330374.htm
<DESCRIPTION>F-3
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
      <div style="line-height: 1.25; font-weight: bold;">As filed with the Securities and Exchange Commission on October 16, 2023</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;">Registration No. 333- &#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">UNITED STATES<br>
      SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">WASHINGTON, D.C. 20549</div>
    <div style="text-align: center; line-height: 1.25;">&#160; <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM F-3</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REGISTRATION STATEMENT</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">UNDER<br>
      THE SECURITIES ACT OF 1933</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><font style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">CHEMOMAB THERAPEUTICS LTD.</font><br>
      (Exact Name of Registrant as Specified in its Charter)</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7c31964d19db41ce99cbd6fa886e4bbd">

        <tr>
          <td style="width: 49%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">State of Israel</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 49%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Not Applicable</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-style: italic;">(State or Other Jurisdiction of</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-style: italic;">(I.R.S. Employer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-style: italic;">Incorporation or Organization)</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-style: italic;">Identification No.)</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Kiryat Atidim, Building 7</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Tel Aviv, Israel 6158002</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">+972-77-331-0156</div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices)</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160; <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Chemomab Therapeutics, Inc.<br>
      One Kendall Square<br>
      Building 1400E<br>
      Suite 14-105<br>
      Cambridge, MA 02139<br>
      (857) 259-4622</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">&#160; <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">Copies to:</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z0b7d3dc8c1f348aea4c5f795bd3e756b">

        <tr>
          <td style="width: 33.05%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">David S. Glatt</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Ronen Bezalel<br>
              Matthew Rudolph<br>
              Meitar | Law Offices<br>
              16 Abba Hillel Rd.<br>
              Ramat Gan 5250608, Israel<br>
              +972 (3)&#160;610-3100</div>
          </td>
          <td style="width: 33.98%; vertical-align: top;">&#160;</td>
          <td style="width: 32.98%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Michal Berkner</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Joshua A. Kaufman</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Daniel I. Goldberg</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Cooley LLP</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">55 Hudson Yards</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">New York, New York 10001</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">+1 212 479 6000</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">Approximate date of commencement of proposed sale to the public:</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">From time to time after the effectiveness of this registration statement.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement
      number of the earlier effective registration statement for the same offering.&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier
      effective registration statement for the same offering. <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier
      effective registration statement for the same offering. <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Emerging growth company&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for
      complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically
      states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this Registration Statement shall become effective on such date as the Securities and Exchange Commission
      (the &#8220;SEC&#8221;), acting pursuant to said Section 8(a), may determine.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXPLANATORY NOTE</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">This registration statement is a replacement registration statement being filed pursuant to Rule 415(a)(6) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), with respect to
      securities which remain unsold under the Registration Statement on Form S-3 (File No. 333-255658) filed on April 30, 2021, and declared effective on May 17, 2021 which is due to expire on May 16, 2024 (&#8220;Prior Registration Statement&#8221;). Pursuant to
      Rule 415(a)(5)(ii) under the Securities Act, by filing this registration statement on Form F-3 (the &#8220;Registration Statement&#8221;), the Company may issue and sell securities under the Prior Registration Statement until the earlier of the effective date of
      this Registration Statement or 180 days after May 16, 2024. Furthermore, as of June 30, 2023, our board of directors determined that we meet the definition of a foreign private issuer within the meaning of the Securities and Exchange Act of 1933, as
      amended, and therefore unlike the Prior Registration Statement which was filed under Form S-3, we are filing this Registration Statement under Form F-3.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">This registration statement contains two prospectuses:</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="ze6a4f9c77ebd4d8e8495012bf9b211c3">

        <tr>
          <td style="width: 1.34%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.78%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 94.88%; vertical-align: top;">
            <div style="line-height: 1.25;">a base prospectus which covers the offering, issuance and sale by us of up to $200 million of ordinary shares, ADSs, debt securities, warrants and units comprising any combination of these securities;&#160;and</div>
          </td>
        </tr>

    </table>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zbfea6d526bb04a689a80705450d6506d">

        <tr>
          <td style="width: 1.34%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.78%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 94.88%; vertical-align: top;">
            <div style="line-height: 1.25;">a sales agreement prospectus supplement covering the offering, issuance and sale by us of up to $2,863,664 of ADSs that may be issued and sold under the Sales Agreement&#160;with Roth Capital Partners, LLC, as sales
              agent.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the
      base prospectus.</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The sales agreement prospectus supplement immediately follows the base prospectus. The ADSs that may be offered, issued and sold by us under the sales agreement prospectus supplement are included in
      the $200 million of securities that may be offered, issued and sold by us under the base prospectus. In the event of the termination of the offering of ADSs under the sales agreement prospectus supplement, any portion of the $2,863,664 aggregate
      offering price for the ADSs covered by the sales agreement prospectus supplement that has not been sold pursuant to the sales agreement prospectus supplement will be available for sale in other offerings pursuant to the base prospectus.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(255, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Information
      in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it
      is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(255, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
    <div style="text-align: center; margin-left: 3.6pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(255, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">SUBJECT TO COMPLETION, DATED OCTOBER 16, 2023</div>
      </div>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">PROSPECTUS</div>
    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">$200,000,000</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Ordinary Shares, ADSs, Debt, Warrants</div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">and Units offered by the Company&#160;</font>&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><img width="253" height="132" src="image0.jpg">&#160; <br>
    </div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: normal; font-variant: normal; text-transform: none;">Chemomab Therapeutics Ltd.&#160;</font><font style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</font></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We may offer, issue and sell from time to time, in one or more offerings, ordinary shares, including ordinary shares represented by American Depositary Shares, or the ADSs, debt, warrants or units,
      which we collectively refer to as the &#8220;securities.&#8221; Each ADS represents twenty (20) of our ordinary shares. The aggregate initial offering price of the securities that we may offer and sell under this prospectus will not exceed $200 million.</div>
    <div style="line-height: 1.25;">&#160;&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We may offer and sell any combination of the securities described in this prospectus in different series, at times, in amounts, at prices and on terms to be determined at or prior to the time of each
      offering. This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. Each time we sell securities pursuant to this prospectus, we will provide a supplement to this prospectus that
      contains specific information about the offering and the specific terms of the securities offered. The prospectus supplement will also describe the specific manner in which these securities will be offered and may also supplement, update or amend
      information contained in this prospectus. You should read this prospectus and any applicable prospectus supplement before you invest.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The securities covered by this prospectus may be offered through one or more underwriters, dealers and agents, or directly to purchasers. The names of any underwriters, dealers or agents, if any, will
      be included in a supplement to this prospectus. For general information about the distribution of securities offered, please see &#8220;Plan of Distribution&#8221; beginning on page 36.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">ADSs are traded on the Nasdaq Capital Market under the symbol &#8220;CMMB.&#8221; The last reported sale price of ADSs on the Nasdaq Capital Market on October 13, 2023 was $0.89 per ADS.</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">On October 11, 2023, the aggregate market value worldwide of our outstanding voting and non-voting common equity held by non-affiliates was approximately $12.8 million, based on 225,089,800 ordinary
      shares outstanding (which would be represented by 11,254,490 ADSs) and a per ADS price of $1.14 based on the highest closing sale price of ADS on the Nasdaq Capital Market during the 60 day period prior to October 11, 2023. As of the date hereof, we
      have sold or offered 772,900 ADSs for a total of approximately $1.4 million pursuant to General Instruction I.B.5 of Form F-3 during the prior 12 calendar month period that ends on and includes the date hereof. Pursuant to General Instruction I.B.5
      of Form F-3, in no event will we sell securities registered on this registration statement of which any prospectus supplement forms a part in a public primary offering with a value exceeding one-third of our outstanding voting and nonvoting common
      equity held by non-affiliates (the &#8220;public float&#8221;) in any 12-month period so long as our public float remains below $75 million.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in the
      applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus as described on page 41 of this prospectus.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
      or complete. Any representation to the contrary is a criminal offense.</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">
      <div style="line-height: 1.25;">The date of this prospectus is&#160;&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160;, 2023</div>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; margin-right: 5.75pt; margin-left: 5.75pt; line-height: 1.25; font-weight: bold;">Table of Contents</div>
    <div style="text-align: center; margin-right: 5.75pt; margin-left: 5.75pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf249a673a2cf4472af5d2c8bc2e39247">

        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Page</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#ABOUTTHISPROSPECTUS"><u>ABOUT THIS PROSPECTUS</u></a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">3</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#SPECIALNOTEREGARDINGFORWA"><u>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</u></a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">4</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#ABOUTCHEMOMABTHERAPEUTICS"><u>ABOUT CHEMOMAB THERAPEUTICS LTD.</u></a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">6<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#FACTORS"><u>RISK FACTORS</u></a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">8<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#OF"><u>USE OF PROCEEDS</u></a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">9<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#CAPITALIZATION"><u>CAPITALIZATION</u></a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">10<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFSECURITIES"><u>DESCRIPTION OF SECURITIES</u></a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">11</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFSHARECAPITAL"><u>DESCRIPTION OF SHARE CAPITAL</u></a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">12</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#NDEPOSITARYSHARES"><u>DESCRIPTION OF AMERICAN DEPOSITARY SHARES</u></a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">19</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFDEBTSECURITI"><u>DESCRIPTION OF DEBT SECURITIES</u></a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">27</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFWARRANTS"><u>DESCRIPTION OF WARRANTS</u></a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">34<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFUNITS"><u>DESCRIPTION OF UNITS</u></a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">35<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#PLANOFDISTRIBUTION"><u>PLAN OF DISTRIBUTION</u></a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">36<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#ENFORCEMENTOFCIVILLIABILI"><u>ENFORCEMENT OF CIVIL LIABILITIES</u></a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">37<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#EXPENSES"><u>EXPENSES</u></a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">38<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#LEGALMATTERS"><u>LEGAL MATTERS</u></a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">39<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#EXPERTS"><u>EXPERTS</u></a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">40<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12.12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 87.88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;"><a href="#WHEREYOUCANFINDMOREINFORM">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</a></div>
          </td>
          <td style="width: 12.12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">41<br>
            </div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; margin-left: 3.6pt; line-height: 1.25;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; margin-left: 3.6pt; line-height: 1.25; font-weight: bold;"><a name="ABOUTTHISPROSPECTUS"><!--Anchor--></a>ABOUT THIS PROSPECTUS</div>
    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, as part of a &#8220;shelf&#8221; registration process.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Under this shelf registration, we may offer any combination of the securities described in this prospectus from time to time in one or more offerings. This prospectus only provides you with a general
      description of the securities we may offer. Each time we sell securities described herein, we will provide prospective investors with a supplement to this prospectus that will contain specific information about the terms of that offering, including
      the specific amounts, prices and terms of the securities offered. The prospectus supplement may also add to, update or change information contained in this prospectus. We may also authorize one or more free writing prospectuses to be provided to you
      that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus
      or in any documents that we have incorporated by reference into this prospectus. Accordingly, to the extent inconsistent, information in this prospectus is superseded by the information in any prospectus supplement or any related free writing
      prospectus that we may authorize. You should carefully read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the heading
      &#8220;Incorporation of Certain Information by Reference,&#8221; before investing in any of the securities offered.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Unless otherwise indicated, &#8220;Chemomab Therapeutics,&#8221; &#8220;Chemomab,&#8221; &#8220;the Company,&#8221; &#8220;our company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Chemomab Therapeutics Ltd. and its wholly owned subsidiary, Chemomab Ltd.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Chemomab is a trademark of ours that we use in this prospectus. This prospectus also includes trademarks, tradenames and service marks that are the property of other organizations. Solely for
      convenience, our trademarks and tradenames referred to in this prospectus appear without the&#160;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>&#160;or &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable
      law, our rights, or the right of the applicable licensor to our trademark and tradenames.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The terms &#8220;shekel,&#8221; &#8220;Israeli shekel&#8221; and &#8220;NIS&#8221; refer to New Israeli Shekels, the lawful currency of the State of Israel, and the terms &#8220;dollar,&#8221; &#8220;U.S. dollar&#8221; or &#8220;$&#8221; refer to United States dollars, the
      lawful currency of the United States. All references to &#8220;shares&#8221; in this prospectus refer to ADSs, or the ordinary shares, no par value, represented by the ADSs, of Chemomab Therapeutics Ltd.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the
      summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this
      prospectus is a part, and you may obtain copies of those documents as described below under the heading &#8220;Where You Can Find More Information.&#8221;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Neither we, nor any agent, underwriter or dealer has authorized any person to give any information or to make any representation other than those contained or incorporated by reference in this
      prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on behalf of us or to which we have referred you. This prospectus, any applicable supplement to this prospectus or any related free writing
      prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor does this prospectus, any applicable supplement to this prospectus or any related free
      writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set
      forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or
      any related free writing prospectus is delivered, or securities are sold, on a later date.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">For investors outside the United States: We have not done anything that would permit the offering or possession or distribution of this prospectus in any jurisdiction where action
      for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities
      described herein and the distribution of this prospectus outside the United States.</div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
      <br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="SPECIALNOTEREGARDINGFORWA"><!--Anchor--></a>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">This prospectus, any prospectus supplement and the information incorporated by reference in this prospectus and any prospectus supplement contain forward-looking statements within the meaning of
      Section 27A of the Securities Act, and Section 21E of the Exchange Act of 1934, as amended, or the Exchange Act, that involve substantial risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our
      management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from
      results and outcomes discussed in the forward-looking statements.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">All statements other than present and historical facts and conditions contained in this prospectus, any prospectus supplement and the information incorporated by reference in this prospectus and any
      prospectus supplement including statements regarding our future results of operations and financial positions, business strategy, plans and our objectives for future operations, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221;
      &#8220;continue&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;ongoing,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will&#8221; and &#8220;would,&#8221; or the negative of these and similar expressions identify forward-looking statements.
      Forward-looking statements include, but are not limited to, statements about:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb87978af87534a75b5fce6e7b0af489e">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we have incurred significant losses since inception and anticipate that we will continue to incur increasing levels of operating losses over the next several&#160;years and for the foreseeable future;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z16fd9ad4540b4f4d985dbb050b954fb5">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we are unable to predict the extent of any future losses or when we will become profitable, if at all;&#160;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0f154652f6f140f395a72c068ba1b6f3">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>even if we become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc930a8935d5940bf842886405d8df2ad">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we have a limited operating history and funding, which may make it difficult to evaluate our prospects and likelihood of success;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za7ef94fe944d431fb6726bc8248b3094">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>our business is highly dependent on the success of our lead product candidate, CM-101, and any other product candidates that we advance into clinical studies;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdb9f944b0c7247069a39f01083b895ac">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>all of our programs will require significant additional clinical development;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z029b7b1e50d845dfbbe270f1e67fcc2f">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>our&#160;central objective is to design and develop targeted treatments for inflammation and fibrosis with an initial focus on the antagonism of CCL24 signaling, which is known to regulate fibrotic and inflammatory processes;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z150233706e5845c0a83b9e732455f037">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>while several studies are currently underway, our approach in the area of fibrotic diseases is novel and unproven and may not result in marketable products;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z66bbeca92fe94802b6ad1137d69f8c6d">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>the successful completion of clinical studies is a prerequisite to submitting a marketing application to the FDA and similar marketing applications to comparable foreign regulatory authorities, for each product candidate and, consequently,
              the ultimate approval and commercial marketing of any product candidates;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9131b333693a49889bd91c7139428328">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we may experience negative or inconclusive results, which may result in us deciding, or regulators requiring us, to conduct additional clinical studies or trials or abandon some or all of its product development programs, which could have
              a material adverse effect on our business;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z32211c5352104a4682f2e0fe15580c66">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we may encounter difficulties enrolling patients in our clinical studies, including due to the continuing effects of the COVID-19 pandemic, or other public health emergencies and related clinical development activities could be delayed or
              otherwise adversely affected;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9c0c567e721d4a39be6a13b93c20070e">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>our ongoing and future clinical studies may reveal significant adverse events or immunogenicity-related responses and may result in a safety profile that could delay or prevent regulatory approval or market acceptance of our product
              candidate;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6e72379b63c843ff80b680bc06556daa">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for CM-101 or any other product
              candidates, our business will be substantially harmed;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z91a2df20fb2d4962981334d7ef52f20c">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>if we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and our business will be harmed;</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">4</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za5ea223ea19f4b068d3f35f3c4385566">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than us;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfff24e5a2dcc4992a7ab1570d12e12fc">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we have been granted Orphan Drug Designation for CM-101 in connection with three indications and may seek Orphan Drug Designation for other indications or product candidates, and we may be unable to maintain the benefits associated with
              Orphan Drug Designation, including the potential for market exclusivity, and may not receive Orphan Drug Designation for other indications or for its other product candidates;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z027aa986476c4443b7d1395fe0c119dd">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we expect to experience significant growth in the number of our employees over time and the scope of our operations, particularly in the areas of product candidate development, regulatory affairs and sales and marketing;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3bd0c807297f45cc85ea02e0a0fa9931">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we will therefore need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3604ea26e7aa49e4afa45a53006427cf">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>if we are unable to protect our patents or other proprietary rights, or if we infringe the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z974bec2a32b040f98a59b9e9f3aeef07">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6f14c4b6756e4bbb99f7e1aaee17a2b2">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>risks related to our operations in Israel could materially adversely impact our business, financial condition and results of operations;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z05f997721da9482fbe0c1a6511b2c5c9">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>our principal executive offices are located in Israel and certain of our product candidates may be manufactured at third-party facilities located in Europe. In addition, our business strategy includes potentially expanding internationally
              if any of its product candidates receives regulatory approval;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3acfd879fec443c29ed213762fe098fa">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>holders of ADSs may not have the same voting rights as the holders of our ordinary shares and may not receive voting materials in time to be able to exercise their right to vote;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc02c9c8204b4441a9509ef3e56d0ce54">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z01e121d110e94168a10a3b6258b70a22">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we are entitled to amend the deposit agreement and to change the rights of ADS holders under the terms of such agreement, or to terminate the deposit agreement, without the prior consent of the ADS holders;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8889e01469e74d68a16da5f0f1cda94b">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action; and</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z79cd765e79e044c581d85e63d3c110b8">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we presently anticipate that we will be classified as a passive foreign investment company, which could result in adverse U.S. federal income tax consequences to U.S. Holders of our ordinary shares.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus, any prospectus supplement and the information incorporated by reference in this prospectus and
      any prospectus supplement will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not
      regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements,
      whether as a result of new information, future events or otherwise, except as required by law.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">You should read this prospectus, any prospectus supplement and the information incorporated by reference in this prospectus and any prospectus supplement completely and with the understanding that our
      actual future results may be materially different from what we expect. We qualify all of our forward- looking statements by these cautionary statements.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">This prospectus, any prospectus supplement and the information incorporated by reference in this prospectus and any prospectus supplement may contain market data and industry forecasts that were
      obtained from industry publications. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we believe the market position, market opportunity and market size information
      included in this prospectus, any prospectus supplement and the information incorporated by reference in this prospectus and any prospectus supplement is generally reliable, such information is inherently imprecise.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date the
      statements were made, and while we believed such information formed a reasonable basis for such statements at the time they were made, such information may be limited or incomplete, and our statements should not be read to indicate that we have
      conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">5</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; margin-left: 3.6pt; line-height: 1.25; font-weight: bold;"><a name="ABOUTCHEMOMABTHERAPEUTICS"><!--Anchor--></a>ABOUT CHEMOMAB THERAPEUTICS LTD.</div>
    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic;">This summary provides an overview of selected information contained elsewhere or incorporated by reference in this prospectus and does not contain all of the information you should
      consider before investing in our securities. You should carefully read the prospectus, the applicable prospectus supplement and any related free writing prospectus, the information incorporated by reference herein and the registration statement of
      which this prospectus is a part in their entirety before investing in our securities, including the information discussed under &#8220;Risk Factors&#8221; in this prospectus and the documents incorporated by reference and our financial statements and related
      notes that are incorporated by reference in this prospectus.</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Company Overview</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">We are a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet needs. Based on the unique and
        pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, we have developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and
        life-threatening fibrotic and inflammatory diseases.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">We have pioneered the therapeutic targeting of CCL24, a chemokine that promotes various types of cellular processes that regulate inflammatory and fibrotic activities through the CCR3 receptor. The
        chemokine is expressed in various types of cells, including immune cells, endothelial cells and epithelial cells. We have developed a novel CCL24 inhibiting product candidate with dual anti-fibrotic and anti-inflammatory activity that modulates the
        complex interplay of both of these inflammatory and fibrotic mechanisms, which drive abnormal states of fibrosis and clinical fibrotic diseases. This innovative approach is being developed for difficult-to-treat rare diseases, also known as orphan
        indications or diseases, such as primary sclerosing cholangitis (&#8220;PSC&#8221;), and systemic sclerosis (&#8220;SSc&#8221;), for which patients have no established disease-modifying or standard-of-care treatment options. We estimate that there are approximately 77
        thousand patients suffering from PSC in the U.S., EU and Japan, representing over a $1 billion market opportunity, and approximately 170 thousand patients suffering from SSc in those same markets, representing over a $1.5 billion market
        opportunity.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">CM-101, our lead clinical product candidate, is a first-in-class humanized monoclonal antibody that attenuates the basic function of the soluble protein CCL24, also known as eotaxin-2, as a regulator
        of major inflammatory and fibrotic pathways. We have demonstrated that CM-101 interferes with the underlying biology of inflammation and fibrosis through a novel and differentiated mechanism of action. We are currently conducting a Phase 2 clinical
        study in PSC, a rare obstructive and cholestatic liver disease. The study is actively recruiting patients in the U.S., Europe and Israel and enrollment is going well. The study design includes a two doses of CM-101 vs placebo (10 or 20mg/kg), as
        well as an open label extension. A topline readout of initial trial results is expected in the second half of 2024.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">In SSc, we suspended initiation of the Phase 2 trial while we focus resources on successfully completing the Phase 2 PSC study.&#160; The CM-101 SSc clinical program is Phase 2-ready and we believe that
        CM-101 could have disease-modifying potential in this poorly treated condition. Although our primary focus is on these two rare indications, we reported topline results from an additional Phase 2 clinical study in patients with liver fibrosis due
        to non-alcoholic steatohepatitis, or NASH, in January of this year.&#160; This trial provided safety and pharmacokinetic (&#8220;PK&#8221;) data and information useful for assessing our current subcutaneous formulation of CM-101. Additionally, the trial measured a
        number of biomarkers that may be relevant to the potential activity of CM-101 in other fibro-inflammatory conditions. The initial trial results showed that the trial met its primary endpoint of safety and tolerability, and that CM-101 demonstrated
        encouraging activity in secondary endpoints that include a range of liver fibrosis biomarkers and physiologic assessments. A more recent secondary analysis confirming and extending these initial results was reported at the 2023 EASL Congress in
        July 2023.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Fibrosis is the abnormal and excessive accumulation of collagen and extracellular matrix, the non-cellular component in all tissues and organs, which provides structural and biochemical support to
        surrounding cells. When present in excessive amounts, collagen and extracellular matrix lead to scarring and thickening of connective tissues, affecting tissue properties and potentially leading to organ dysfunction and failure. Fibrosis can occur
        in many different tissues, including lung, liver, kidney, muscle, skin, and the gastrointestinal tract, resulting in a wide array of progressive fibrotic conditions. Fibrosis and inflammation are intrinsically linked. While a healthy inflammatory
        response is necessary for efficient tissue repair; after disease or injury, an excessive, uncontrolled inflammatory response can lead to tissue fibrosis that in turn can further stimulate inflammatory processes in a fibro-inflammatory vicious
        cycle.&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">6</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Recent Developments</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">&#160;New Executive Appointments and Extension of Cash Runway through Year-End 2024</div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">On June 5, 2023, we announced that Adi Mor, PhD, co-founder and former Chief Executive Officer (CEO), and then Director and Chief Scientific Officer, had been reappointed to the role of CEO,
        replacing&#160;Dale Pfost, PhD.&#160;Sigal Fattal, former Chief Financial Officer (CFO) and then Vice President, Finance, had been reappointed to the role of CFO, replacing&#160;Donald Marvin. Nissim Darvish, MD, PhD, was appointed Chairman of the Board,
        replacing Dr. Pfost. All the appointments were effective&#160;June 1, 2023. We also announced that we were implementing additional cost-reduction measures, which extended&#160; our cash runway from mid-year 2024 to the end of 2024, after the expected topline
        data readout from the Phase 2 CM-101 PSC trial.</div>
      <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Reported Secondary Analyses of CM-101 Phase 2 Liver Fibrosis Trial in NASH Patients</div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">On June 21, 2023, we reported topline results from secondary analyses of its Phase 2a liver fibrosis trial assessing CM-101 in patients with NASH. The results were included in a late-breaking poster
        presentation at the 2023 EASL Congress.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>Overall, the data showed improvements across an additional set of inflammatory and fibrotic biomarkers that are consistent with the clinical results we released in January. Additionally, in NASH
        patients at greater risk of disease progression, CM-101 treatment resulted in a greater biomarker response than in NASH patients with lower risk disease or in placebo-treated patients. The new analyses<font style="font-weight: bold;">&#160;</font>assessed












        additional biomarkers and also used the FibroScan-AST (FAST) score to categorize study patients based on progressive disease risk. The results showed that:</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zcf5a74e5822f483e84eb4fe84bf075d9">

        <tr>
          <td style="width: 5.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 94.88%; vertical-align: top;">
            <div style="line-height: 1.25;">FAST scores were improved in a higher proportion of CM-101-treated patients than in placebo patients.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zcdc453a73e9e4e5e8fb0679fc38775f1">

        <tr>
          <td style="width: 5.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 94.88%; vertical-align: top;">
            <div style="line-height: 1.25;">CM-101-treated patients with higher FAST scores demonstrated greater improvements in key fibro-inflammatory biomarkers than patients with lower FAST scores or placebo patients.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">In these secondary analyses, CM-101-treated patients showed improvements in an additional set of biomarkers associated with active fibrosis and inflammation including AST/ALT ratio,
        Neutrophil-to-Lymphocyte Ratio (NLR), FIB-4, and PRO-C3. Some of these biomarker scores were&#160;further improved in CM-101-treated patients with higher FAST scores. It is noteworthy that as an overall indicator of fibrogenesis and fibrotic disease,
        PRO-C3 may also be viewed as a &#8220;bridge&#8221; to PSC and other anti-fibrotic indications.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Reported Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for PSC</div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">We presented two posters at the 2023 EASL Congress discussing the potential of CM-101 as a novel treatment for PSC. One of the posters reported on a new proteomic study demonstrating a direct
        relationship between the pro-inflammatory, pro-fibrotic activity of CCL24 and PSC disease-related pathways.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>The other poster described the clinical design of our double-blind, placebo-controlled, multiple dose Phase 2 trial of CM-101 in
        PSC patients. These followed a data presentation at the 2023 EASL Biliary Conference in May 2023, reinforcing the proinflammatory role of CCL24 in cholestatic disease.</div>
      <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Published Peer-Reviewed Research Article Demonstrating the Key Role of CCL24 in PSC</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">On June 28, 2023, we reported publication of a peer-reviewed research article in the June issue of the respected journal&#160;&#160;<font style="font-style: italic;">JCI Insight</font>. It was produced through
        collaborations with prominent academic groups and supports the key role of CCL24 in driving the self-perpetuating fibrosis and inflammation that result in the severe liver damage characterizing PSC.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Corporate Information</div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">We were incorporated on September 22, 2011, under the laws of the State of Israel. In March 2021, we changed our name from Anchiano Therapeutics Ltd. to Chemomab Therapeutics Ltd. Our principal
        executive offices are located at Kiryat Atidim, Building 7, Tel Aviv, Israel 6158002, and our phone number is +972-77-331-0156. Our website is:&#160;<font style="font-style: italic;">www.chemomab.com.</font>&#160;</div>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">7</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">RISK <a name="FACTORS"><!--Anchor--></a>FACTORS</div>
    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-indent: 32.4pt; line-height: 1.25;">An investment in our securities involves certain risks. Before investing in our securities, you should carefully consider the risk factors in our most recent Annual Report on Form 10-K, or any
      updates in our Reports on Form 8-K, or, if subsequent to June 30, 2023, Form 6-K, together with all of the other information appearing in this prospectus or incorporated by reference into this prospectus. The risks so described are not the only risks
      facing our company. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. Any of these risks could materially and adversely affect our business, financial condition, results of
      operations and cash flows and could result in a loss of all or part of your investment. In any case, the value of the securities offered by means of this prospectus could decline due to any of these risks, and you may lose all or part of your
      investment.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">8</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">USE <a name="OF"><!--Anchor--></a>OF PROCEEDS</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">&#160;</div>
    <div style="text-indent: 28.35pt; line-height: 1.25;">Unless otherwise set forth in a prospectus supplement, we currently intend to use the net proceeds of any offering of securities for working capital and other general corporate purposes.
      Accordingly, we will have significant discretion in the use of any net proceeds. We may provide additional information on the use of the net proceeds from the sale of the offered securities in an applicable prospectus supplement relating to the
      offered securities.</div>
    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">9</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="CAPITALIZATION"><!--Anchor--></a>CAPITALIZATION</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We intend to include information about our capitalization and indebtedness in prospectus supplements.</div>
    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">10</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFSECURITIES"><!--Anchor--></a>DESCRIPTION OF SECURITIES</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The descriptions of the securities contained in this prospectus, together with the applicable prospectus supplements, summarize the material terms and provisions of the various types of securities that
      we may offer. We will describe in the applicable prospectus supplement relating to any securities the particular terms of the securities offered by that prospectus supplement. If we so indicate in the applicable prospectus supplement, the terms of
      the securities may differ from the terms we have summarized below.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We may sell from time to time, in one or more offerings, ordinary shares,&#160;including ordinary shares represented by ADSs, debt, warrants to purchase ADSs and units comprising any combination of these
      securities.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In this prospectus, we refer to the ordinary shares, ADSs, debt, warrants to purchase ADSs and units that may be offered by us collectively as &#8220;securities.&#8221; The total dollar amount of all securities
      that we may issue under this prospectus will not exceed $200 million.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.</div>
    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">11</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFSHARECAPITAL"><!--Anchor--></a>DESCRIPTION OF SHARE CAPITAL</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">The following descriptions of our share capital and provisions of our amended and restated articles of association are summaries and are qualified by reference to our amended and restated articles of
        association, a copy of which is filed as Exhibit 3.1 hereto.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Registration Number and Purposes of the Company</div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">We are registered with the Israeli Registrar of Companies. Our registration number is 51-4672625.&#160;Our affairs are governed by our amended and restated articles of association, applicable Israeli law
        and the Companies Law. Our purpose as set forth in our amended and restated articles of association is to engage in any lawful act or activity.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Voting Rights</div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">All ordinary shares have identical voting and other rights in all respects.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Transfer of Shares</div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Our fully paid ordinary shares are issued in registered form and may be freely transferred under our amended and restated articles of association, unless the transfer is restricted or prohibited by
        another instrument, applicable law or the rules&#160;of Nasdaq. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our amended and restated articles of association or the laws of the State of
        Israel, except for ownership by nationals of some countries that are, have been, or will be, in a state of war with Israel.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Election of Directors</div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Under our amended and restated articles of association, our board of directors must consist of not less than three (3)&#160;but no more than eleven (11) directors. Pursuant to our amended and restated
        articles of association, each of our directors will be appointed by a simple majority vote of holders of our ordinary shares, participating and voting at an annual general meeting of our shareholders, provided that (i)&#160;in the event of a contested
        election, the method of calculation of the votes and the manner in which the resolutions will be presented to our shareholders at the general meeting shall be determined by our board of directors in its discretion, and (ii)&#160;in the event that our
        board of directors does not or is unable to make a determination on such matter, then the directors will be elected by a majority of the voting power represented at the general meeting in person or by proxy and voting on the election of directors,
        provided that if the number of such nominees exceeds the number of directors to be elected, then as among such nominees the election shall be by a plurality of the votes cast. In addition, our directors are divided into three classes, one class
        being elected each year at the annual general meeting of our shareholders, and shall serve on our board of directors until the third annual general meeting following such election or re-election or until they are removed by a vote of 65% of the
        total voting power of our shareholders at a general meeting of our shareholders or upon the occurrence of certain events, in accordance with the Companies Law and our amended and restated articles of association. In addition, our amended and
        restated articles of association provide that vacancies on our board of directors may be filled by a vote of a simple majority of directors then in office. Any director so appointed will hold office until the next annual general meeting of our
        shareholders for the election of the class of directors in respect of which the vacancy was created, or in the case of a vacancy due to the number of directors being less than the maximum number of directors stated in our amended and restated
        articles of association, until the next annual general meeting of our shareholders for the election of the class of directors to which such director was assigned by our board of directors.</div>
      <div style="text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">12</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Dividend and Liquidation Rights</div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">We may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Companies Law, dividend distributions are determined by the board
        of directors and do not require the approval of the shareholders of a company unless the company&#8217;s articles of association provide otherwise. Our amended and restated articles of association do not require shareholder approval of a dividend
        distribution and provide that dividend distributions may be determined by our board of directors.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to the Companies Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according to our then last reviewed or audited
        financial statements (less the amount of previously distributed dividends, if not reduced from the earnings), provided that the end of the period to which the financial statements relate is not more than six months prior to the date of the
        distribution. If we do not meet such criteria, then we may distribute dividends only with court approval. In each case, we are only permitted to distribute a dividend if our board of directors and, if applicable, the court determines that there is
        no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations as they become due.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to their shareholdings. This right,
        as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-weight: bold;">Exchange Controls</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">There are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the ordinary shares or interest or other payments to
        non-residents of Israel, except for shareholders who are subjects of countries that are, have been, or will be, in a state of war with Israel.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Shareholder Meeting<font style="font-weight: normal;">s</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Under Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year and no later than 15 months after the date of the previous annual general meeting.
        All meetings other than the annual general meeting of shareholders are referred to in our amended and restated articles of association as special general meetings. Our board of directors may call special general meetings of our shareholders
        whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides that our board of directors is required to convene a special general meeting of our shareholders upon the
        written request of (i)&#160;any two or more of our directors, (ii)&#160;one-quarter or more of the serving members of our board of directors or (iii)&#160;one or more shareholders holding, in the aggregate, either (a)&#160;5% or more of our outstanding issued shares
        and 1% or more of our outstanding voting power or (b)&#160;5% or more of our outstanding voting power.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">Under Israeli law, one or more shareholders holding at least 1% of the voting rights at the general meeting of the shareholders may request that the board of directors include a matter in the
          agenda of a general meeting of the shareholders to be convened in the future, provided that it is appropriate to discuss such a matter at the general meeting. Our amended and restated articles of association contain procedural guidelines and
          disclosure items with respect to the submission of shareholder proposals for general meetings.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">13</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25"> <br>
        </div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Subject to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings of shareholders are the shareholders of
        record on a date to be decided by the board of directors, which, as a company listed on an exchange outside Israel, may be between four and 40 days prior to the date of the meeting. Furthermore, the Companies Law requires that resolutions regarding
        the following matters must be passed at a general meeting of shareholders:</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z72d65ab2e9e24c85b71d18528a6a2e08">

        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 93.82%; vertical-align: top;">
            <div style="line-height: 1.25;">amendments to our amended and restated articles of association;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf3f1e73f41c946acb4cd5378b8d92943">

        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 93.82%; vertical-align: top;">
            <div style="line-height: 1.25;">appointment, terms of service or and termination of service of our auditors;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd07ddab520c04c99a58a9c8e77687a76">

        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 93.82%; vertical-align: top;">
            <div style="line-height: 1.25;">appointment of directors, including external directors (if applicable);</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z360e505da74c4f57b6305ddab56d9a90">

        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 93.82%; vertical-align: top;">
            <div style="line-height: 1.25;">approval of certain related party transactions;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7e145ac0ae3b4edcbfafe9b17e75fda7">

        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 93.82%; vertical-align: top;">
            <div style="line-height: 1.25;">increases or reductions of our authorized share capital;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z43097d7f5be74bff868b31358c8ec19b">

        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 93.82%; vertical-align: top;">
            <div style="line-height: 1.25;">a merger; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z0323d58bfc3e4085b3e7e2a135c9794d">

        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 93.82%; vertical-align: top;">
            <div style="line-height: 1.25;">the exercise of our board of directors&#8217; powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">The Companies Law requires that a notice of any annual general meeting or special general meeting be provided to shareholders at least 21 days prior to the meeting and if the agenda of the meeting
        includes, among other things, the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger, notice must be provided at least 35 days prior to the meeting.
        Under the Companies Law, shareholders are not permitted to take action by way of written consent in lieu of a meeting.</div>
      <div style="line-height: 1.25;">&#160;<br>
        <div style="line-height: 1.25; font-weight: bold;">Quorum</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25;">
          <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to our amended and restated articles of association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders
            at a general meeting of shareholders. The quorum required for our general meetings of shareholders consists of at least two shareholders present in person or by proxy who hold or represent between them at least 33&#8531;% of the total outstanding
            voting rights, provided, however, that with respect to any general meeting that was convened pursuant to a resolution adopted by the board of directors and which at the time of such general meeting we qualify as a &#8220;foreign private issuer,&#8221; the
            requisite quorum shall consist of two or more shareholders present in person or by proxy who hold or represent between them at least 25% of the total outstanding voting rights. The requisite quorum shall be present within half an hour of the
            time fixed for the commencement of the general meeting. A general meeting adjourned for lack of a quorum shall be adjourned either to the same day in the next week, at the same time and place, to such day and at such time and place as indicated
            in the notice to such meeting, or to such day and at such time and place as the chairperson of the meeting shall determine. At the reconvened meeting, any number of shareholders present in person or by proxy shall constitute a quorum, unless a
            meeting was called pursuant to a request by our shareholders, in which case the quorum required is one or more shareholders, present in person or by proxy and holding the number of shares required to call the meeting as described above.</div>
          <div style="line-height: 1.25;">&#160;<br>
            <div style="line-height: 1.25; font-weight: bold;">Vote Requirements</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25;">
              <div style="text-indent: 36pt; line-height: 1.25;">Our amended and restated articles of association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by our
                amended and restated articles of association. Under the Companies Law, certain actions require the approval of a special majority, including: (i)&#160;an extraordinary transaction with a controlling shareholder or in which the controlling
                shareholder has a personal interest, (ii)&#160;the terms of employment or other engagement of a controlling shareholder of the company or a controlling shareholder&#8217;s relative (even if such terms are not extraordinary) and (iii)&#160;certain
                additional compensation-related matters. Under our amended and restated articles of association, the alteration of the rights, privileges, preferences or obligations of any class of our shares (to the extent there are classes other than
                ordinary shares) requires the approval of a simple majority of the class so affected (or such other percentage of the relevant class that may be set forth in the governing documents relevant to such class), in addition to a majority of all
                classes of shares voting together as a single class at a shareholder meeting.</div>
              <div style="line-height: 1.25">&#160;</div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Under our amended and restated articles of association, the approval of the holders of at least 65% of the total voting power of our shareholders is generally required to remove any of our directors
        from office, to amend the provision requiring the approval of at least 65% of the total voting power of our shareholders to remove any of our directors from office, or certain other provisions regarding our staggered board, shareholder proposals,
        the size of our board and plurality voting in contested elections. Another exception to the simple majority vote requirement is a resolution for the voluntary winding up, or an approval of a scheme of arrangement or reorganization, of the company
        pursuant to Section&#160;350 of the Companies Law, which requires the approval of holders holding at least 75% of the voting rights represented at the meeting and voting on the resolution.</div>
      <div style="text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">14</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;">&#160;<br>
        <div style="line-height: 1.25; font-weight: bold;">Access to Corporate Records</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25;">
          <div style="text-indent: 36pt; line-height: 1.25;">Under the Companies Law, all shareholders generally have the right to review minutes of our general meetings, our shareholder register (including with respect to material shareholders), our
            articles of association, our financial statements, other documents as provided in the Companies Law and any document we are required by law to file publicly with the Israeli Registrar of Companies or the Israeli Securities Authority. Any
            shareholder who specifies the purpose of its request may request to review any document in our possession that relates to any action or transaction with a related party which requires shareholder approval under the Companies Law. We may deny a
            request to review a document if we determine that the request was not made in good faith, that the document contains a trade secret or a patent or that the document&#8217;s disclosure may otherwise impair our interests.</div>
          <div style="line-height: 1.25;">&#160;
            <div style="line-height: 1.25; font-weight: bold;">Acquisitions under Israeli Law</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25;">
              <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Full Tender Offer</div>
              <div style="line-height: 1.25">&#160;</div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">A person wishing to acquire shares of a public Israeli company who would, as a result, hold over 90% of the target company&#8217;s voting rights or the target company&#8217;s issued and outstanding share capital
        (or of a class thereof), is required by the Companies Law to make a tender offer to all of the company&#8217;s shareholders for the purchase of all of the issued and outstanding shares of the company (or the applicable class). In general, if (a)&#160;the
        shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company (or the applicable class) and the shareholders who accept the offer constitute a majority of the offerees that do not have a
        personal interest in the acceptance of the tender offer or (b)&#160;the shareholders who did not accept the tender offer hold less than 2% of the issued and outstanding share capital of the company (or of the applicable class), all of the shares that
        the acquirer offered to purchase will be transferred to the acquirer by operation of law. A shareholder who had its shares so transferred may petition an Israeli court within six months from the date of acceptance of the full tender offer,
        regardless of whether such shareholder agreed to the offer, to determine whether the tender offer was for less than fair value and whether the fair value should be paid as determined by the court. However, an offeror may provide in the offer that a
        shareholder who accepted the offer will not be entitled to petition the court for appraisal rights as described in the preceding sentence, as long as the offeror and the company disclosed the information required by law in connection with the full
        tender offer. If the full tender offer was not accepted, the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of the company&#8217;s voting rights or the company&#8217;s issued and outstanding share capital (or of
        the applicable class) from shareholders who accepted the tender offer. Shares purchased in contradiction to the full tender offer rules&#160;under the Companies Law will have no rights and will become dormant shares.</div>
      <div style="text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">15</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Special Tender Offer</div>
      <div style="line-height: 1.25">&#160;<br>
      </div>
      <div style="text-indent: 36pt; line-height: 1.25;">The Companies Law provides that, subject to certain exceptions, an acquisition of shares of an Israeli public company must be made by means of a special tender offer if, as a result of the
        acquisition, the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply if there is already another holder of 25% or more of the voting rights in the company. Similarly, the Companies Law
        provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if, as a result of the acquisition, the purchaser would become a holder of more than 45% of the voting rights in the company, if
        there is no other shareholder of the company who holds more than 45% of the voting rights in the company. These requirements do not apply if (i)&#160;the acquisition occurs in the context of a private placement by the company that received shareholder
        approval as a private placement whose purpose is to give the purchaser 25% or more of the voting rights in the company, if there is no person who holds 25% or more of the voting rights in the company or as a private placement whose purpose is to
        give the purchaser 45% of the voting rights in the company, if there is no person who holds 45% of the voting rights in the company, (ii)&#160;the acquisition was from a shareholder holding 25% or more of the voting rights in the company and resulted in
        the purchaser becoming a holder of 25% or more of the voting rights in the company, or (iii)&#160;the acquisition was from a shareholder holding more than 45% of the voting rights in the company and resulted in the purchaser becoming a holder of more
        than 45% of the voting rights in the company. in general, a special tender offer must be extended to all shareholders of a company. A special tender offer may be consummated only if (i)&#160;at least 5% of the voting power attached to the company&#8217;s
        outstanding shares will be acquired by the offeror and (ii)&#160;the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding the purchaser, its controlling shareholders, holders of 25% or more
        of the voting rights in the company and any person having a personal interest in the acceptance of the tender offer, or anyone on their behalf, including any such person&#8217;s relatives and entities under their control).</div>
      <div style="text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">In the event that a special tender offer is made, a company&#8217;s board of directors is required to express its opinion on the advisability of the offer, or may abstain from expressing any opinion if it
        is unable to do so, provided that it gives the reasons for its abstention. The board of directors shall also disclose any personal interest that any of the directors has with respect to the special tender offer or in connection therewith. An office
        holder in a target company who, in his or her capacity as an office holder, performs an action the purpose of which is to cause the failure of an existing or foreseeable special tender offer or to impair the chances of its acceptance, is liable to
        the potential purchaser and shareholders for damages, unless such office holder acted in good faith and had reasonable grounds to believe he or she was acting for the benefit of the company. However, office holders of the target company may
        negotiate with the potential purchaser in order to improve the terms of the special tender offer, and may further negotiate with third parties in order to obtain a competing offer.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">If a special tender offer is accepted, then shareholders who did not respond to or that had objected the offer may accept the offer within four days of the last day set for the acceptance of the
        offer and they will be considered to have accepted the offer from the first day it was made.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">In the event that a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity at the
        time of the offer may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such
        person or entity undertook to effect such an offer or merger in the initial special tender offer.&#160;Shares purchased in contradiction to the special tender offer rules&#160;under the Companies Law will have no rights and will become dormant shares.</div>
      <div style="text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">16</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Merger</div>
        <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;"> <br>
        </div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">The Companies Law permits merger transactions if approved by each party&#8217;s board of directors and, unless certain conditions described under the Companies Law are met, a simple majority of the
        outstanding shares of each party to the merger that are represented and voting on the merger. The board of directors of a merging company is required pursuant to the Companies Law to discuss and determine whether in its opinion there exists a
        reasonable concern that as a result of a proposed merger, the surviving company will not be able to satisfy its obligations towards its creditors, such determination taking into account the financial condition of the merging companies. If the board
        of directors determines that such a concern exists, it may not approve a proposed merger. Following the approval of the board of directors of each of the merging companies, the boards of directors must jointly prepare a merger proposal for
        submission to the Israeli Registrar of Companies.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">For purposes of the shareholder vote of a merging company whose shares are held by the other merging company, or by a person or entity holding 25% or more of the voting rights at the general meeting
        of shareholders of the other merging company, or by a person or entity holding the right to appoint 25% or more of the directors of the other merging company, unless a court rules&#160;otherwise, the merger will not be deemed approved if a majority of
        the shares voted on the matter at the general meeting of shareholders (excluding abstentions) that are held by shareholders other than the other party to the merger, or by any person or entity who holds 25% or more of the voting rights of the other
        party or the right to appoint 25% or more of the directors of the other party, or any one on their behalf including their relatives or corporations controlled by any of them, vote against the merger. In addition, if the non-surviving entity of the
        merger has more than one class of shares, the merger must be approved by each class of shareholders. If the transaction would have been approved but for the separate approval of each class or the exclusion of the votes of certain shareholders as
        provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the valuation of the merging
        companies and the consideration offered to the shareholders. If a merger is with a company&#8217;s controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special
        majority approval that governs all extraordinary transactions with controlling shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">Under the Companies Law, each merging company must deliver to its secured creditors the merger proposal and inform its unsecured creditors of the merger proposal and its content. Upon the request
          of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the
          obligations of the surviving company, and may further give instructions to secure the rights of creditors.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">In addition, a merger may not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger is filed with the Israeli Registrar of Companies and 30 days
          from the date that shareholder approval of both merging companies is obtained.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-weight: bold;">Anti-Takeover Measures</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">The Companies Law allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred rights with respect to
          voting, distributions or other matters and shares having preemptive rights. As of the date of this prospectus, no preferred shares are authorized under our amended and restated articles of association. In the future, if we do authorize, create
          and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders from realizing a
          potential premium over the market value of their ordinary shares. The authorization and designation of a class of preferred shares will require an amendment to our amended and restated articles of association, which requires the prior approval of
          the holders of a majority of the voting power attached to our issued and outstanding shares at a general meeting of our shareholders. The convening of the meeting, the shareholders entitled to participate and the vote required to be obtained at
          such a meeting will be subject to the requirements set forth in the Companies Law and our amended articles of association, as described above in &#8220;&#8212;Shareholder Meetings.&#8221; In addition, as disclosed under &#8220;&#8212;Election of Directors,&#8221; we have a
          classified board structure, which effectively limits the ability of any investor or potential investor or group of investors or potential investors to gain immediate control of our board of directors.</div>
        <div style="text-indent: 36pt; line-height: 1.25;"> <br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">17</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;">&#160;
          <div style="line-height: 1.25; font-weight: bold;">Borrowing Powers</div>
          <div style="line-height: 1.25;">&#160;
            <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to the Companies Law and our amended and restated articles of association, our board of directors may exercise all powers and take all actions that are not required under law or under
              our amended and restated articles of association to be exercised or taken by our shareholders, including the power to borrow money for company purposes.</div>
            <div style="text-indent: 36pt; line-height: 1.25;"> <br>
            </div>
            <div style="line-height: 1.25; font-weight: bold;">Changes in Capital</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25;">
              <div style="text-indent: 36pt; line-height: 1.25;">Our amended and restated articles of association enable us to increase or reduce our share capital. Any such changes are subject to Israeli law and must be approved by a resolution duly
                passed by our shareholders at a general meeting of shareholders. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits,
                require the approval of both our board of directors and an Israeli court.</div>
              <div style="text-indent: 36pt; line-height: 1.25;"> <br>
              </div>
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">Exclusive Forum</div>
                <div style="line-height: 1.25">&#160;</div>
                <div style="line-height: 1.25;">
                  <div style="text-indent: 36pt; line-height: 1.25;">Our amended and restated articles of association provide that unless we consent in writing to the selection of an alternative forum, the United States District Court for the Southern
                    District of New York shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act and/or the Exchange Act. This exclusive forum provision would not apply to suits brought
                    to enforce any liability or duty created by the Exchange Act or Securities Act or any other claim for which the federal courts have exclusive or concurrent jurisdiction. To the extent that any such claims may be based upon federal law
                    claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the
                    Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Although our amended and restated
                    articles of association contains the choice of forum provision described above, it is possible that a court could rule that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable. Our
                    amended and restated articles of association also provide that unless we consent in writing to the selection of an alternative forum, the competent courts in Tel Aviv,&#160;Israel shall be the exclusive forum for any derivative action or
                    proceeding brought on behalf of the Company, any action asserting a breach of a fiduciary duty owed by any of our directors, officers or other employees to the Company or our shareholders or any action asserting a claim arising pursuant
                    to any provision of the Companies Law or the Israeli Securities Law.</div>
                  <div style="line-height: 1.25">&#160;</div>
                  <div style="line-height: 1.25; font-weight: bold;">Transfer Agent and Registrar</div>
                  <div style="line-height: 1.25">&#160;</div>
                  <div style="line-height: 1.25;">
                    <div style="text-indent: 36pt; line-height: 1.25;">The transfer agent and registrar for our ordinary shares is Computershare. Its address is 1290 Avenue of the Americas, 9th Floor, New York, NY 10104, and its telephone number is (212)
                      805-7100.</div>
                    <div style="text-indent: 36pt; line-height: 1.25;"> <br>
                    </div>
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25; font-weight: bold;">Listing</div>
                      <div style="line-height: 1.25; font-weight: bold;"> <br>
                      </div>
                      <div style="line-height: 1.25;">
                        <div style="text-indent: 36pt; line-height: 1.25;">ADSs representing our ordinary shares are listed on Nasdaq under the symbol &#8220;CMMB.&#8221;</div>
                        <div style="line-height: 1.25">&#160;</div>
                        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">18</font></div>
                          <div class="BRPFPageBreak" style="page-break-after: always;">
                            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                        </div>
                        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">DESCRIPTION OF AMERICAN DEPOSITARY SHARES<a name="NDEPOSITARYSHARES"><!--Anchor--></a></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">American Depositary Shares</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The Bank of New York Mellon, as depositary, will register and deliver the ADSs. Each ADS will represent twenty (20) ordinary shares (or a right to receive twenty (20) ordinary shares). Each ADS will
      also represent any other securities, cash or other property which may be held by the depositary. The depositary&#8217;s office at which the ADSs will be administered and its principal executive office are located at 240 Greenwich Street, New York,
      New&#160;York&#160;10286.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">You may hold ADSs either (A)&#160;directly (i)&#160;by having an ADR, which is a certificate evidencing a specific number of ADSs, registered in your name or (ii)&#160;by having uncertificated ADSs registered in your
      name or (B)&#160;indirectly by holding a security entitlement in ADSs through your broker or other financial institution that is a direct or indirect participant in DTC. If you hold ADSs directly, you are a registered ADS holder, also referred to as an
      ADS holder. This description assumes you are an ADS holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of ADS holders described in this section. You should
      consult with your broker or financial institution to find out what those procedures are.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Registered holders of uncertificated ADSs will receive statements from the depositary confirming their holdings.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">As an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. Israeli law governs shareholder rights. The depositary will be the holder of the ordinary
      shares underlying the ADSs. As a registered holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the depositary, ADS holders and all other persons indirectly or beneficially holding ADSs sets out ADS holder rights as well as
      the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of ADR. For directions on how to
      obtain copies of those documents see &#8220;<font style="font-style: italic;">Where You Can Find More Information</font>.&#8221;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Dividends and Other Distributions</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-style: italic;">How will you receive dividends and other distributions on the shares?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The depositary has agreed to pay or distribute to ADS holders the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities, upon payment or
      deduction of its fees and expenses. You will receive these distributions in proportion to the number of ordinary shares the ADSs represent.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">Cash.</font>&#160;&#160;&#160;The depositary will convert any cash dividend or other cash distribution we pay on the ordinary shares into U.S. dollars, if it can do so on a reasonable
      basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS
      holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of the ADS holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Before making a distribution, any withholding taxes or other governmental charges that must be paid will be deducted. See &#8220;Taxation and Government Programs.&#8221; The depositary will distribute only whole
      U.S. dollars and cents and will round fractional cents to the nearest whole cent. If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some or all of the value of the distribution.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">Shares.</font>&#160;&#160;&#160;The depositary may distribute additional ADSs representing any ordinary shares we distribute as a dividend or free distribution. The depositary will
      only distribute whole ADSs. It will sell ordinary shares which would require it to deliver a fraction of an ADS (or ADSs representing those ordinary shares) and distribute the net proceeds in the same way as it does with cash. If the depositary does
      not distribute additional ADSs, the outstanding ADSs will also represent the new shares. The depositary may sell a portion of the distributed ordinary shares (or ADSs representing those ordinary shares) sufficient to pay its fees and expenses in
      connection with that distribution.</div>
    <div style="text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">19</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">Rights to purchase additional shares.</font>&#160;&#160;&#160;If we offer holders of our securities any rights to subscribe for additional ordinary shares or any other rights, the
      depositary may (i)&#160;exercise those rights on behalf of ADS holders, (ii)&#160;distribute those rights to ADS holders or (iii)&#160;sell those rights and distribute the net proceeds to ADS holders, in each case after deduction or upon payment of its fees and
      expenses. To the extent the depositary does not do any of those things, it will allow the rights to lapse.&#160;<font style="font-style: italic;">In that case, you will receive no value for them.</font>&#160;The depositary will exercise or distribute rights
      only if we ask it to and provide satisfactory assurances to the depositary that it is legal to do so. If the depositary will exercise rights, it will purchase the securities to which the rights relate and distribute those securities or, in the case
      of ordinary shares, new ADSs representing the new ordinary shares, to subscribing ADS holders, but only if ADS holders have paid the exercise price to the depositary. U.S. securities laws may restrict the ability of the depositary to distribute
      rights or ADSs or other securities issued on exercise of rights to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.</div>
    <div style="line-height: 1.25;">&#160;&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">Other Distributions.</font>&#160;&#160;&#160;The depositary will send to ADS holders anything else we distribute on deposited securities by any means it thinks is legal, fair and
      practical. If it cannot make the distribution in that way, the depositary will have a choice. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what we
      distributed, in which case ADSs will also represent the newly distributed property. However, the depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is
      legal to make that distribution. The depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution. U.S. securities laws may restrict the ability of the depositary
      to distribute securities to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We have no obligation to register ADSs, ordinary shares, rights
      or other securities under the Securities Act. We also have no obligation to take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. This means that you may not receive the distributions we make on our
      ordinary shares or any value for them if it is illegal or impractical for us to make them available to you.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Deposit, Withdrawal and Cancellation</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-style: italic;">How are ADSs issued?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The depositary will deliver ADSs if you or your broker deposits ordinary shares or evidence of rights to receive ordinary shares with the custodian. Upon payment of its fees and expenses and of any
      taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons that made the deposit.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-style: italic;">How can ADS holders withdraw the deposited securities?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">You may surrender the ADSs for the purpose of withdrawal at the depositary&#8217;s office. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or
      fees, the depositary will deliver the ordinary shares and any other deposited securities underlying the ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at your request, risk and expense, the depositary
      will deliver the deposited securities at its office, if feasible. However, the depositary is not required to accept surrender of ADSs to the extent it would require delivery of a fraction of a deposited share or other securities. The depositary may
      charge you a fee and its expenses for instructing the custodian regarding delivery of deposited securities.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-style: italic;">How do ADS holders interchange between certificated ADSs and uncertificated ADSs?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">You may surrender your ADR to the depositary for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel that ADR and will send to the ADS holder a statement confirming
      that the ADS holder is the registered holder of uncertificated ADSs. Alternatively, upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for certificated
      ADSs, the depositary will execute and deliver to the ADS holder an ADR evidencing those ADSs.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">20</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Voting Rights</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-style: italic;">How do you vote?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">ADS holders may instruct the depositary how to vote the number of deposited ordinary shares their ADSs represent. If we request the depositary to solicit your voting instructions (and we are not
      required to do so), the depositary will notify you of a shareholders&#8217; meeting and send or make voting materials available to you. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the depositary how to
      vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as far as practical, subject to the laws of Israel and the provisions of our articles of association or similar documents, to
      vote or to have its agents vote the ordinary shares or other deposited securities as instructed by ADS holders. If we do not request the depositary to solicit your voting instructions, you can still send voting instructions, and, in that case, the
      depositary may try to vote as you instruct, but it is not required to do so.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Except by instructing the depositary as described above, you won&#8217;t be able to exercise voting rights unless you surrender the ADSs and withdraw the ordinary shares.
        However, you may not know about the meeting enough in advance to withdraw the ordinary shares.</font>&#160;In any event, the depositary will not exercise any discretion in voting deposited securities and it will only vote or attempt to vote as
      instructed.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your shares. In addition, the depositary and its agents are not
      responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that you may not be able to exercise your right to vote and there may be nothing you can do if your ordinary shares are not
      voted as you requested.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In order to give you a reasonable opportunity to instruct the Depositary as to the exercise of voting rights relating to Deposited Securities, if we request the Depositary to act, we agree to give the
      Depositary notice of any such meeting and details concerning the matters to be voted upon at least 45&#160;days in advance of the meeting date.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Fees and Expenses</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z675df8de62104b2991b921c733c65c9f">

        <tr>
          <td style="width: 44.14%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">Persons depositing or withdrawing ordinary shares or<br>
              ADS holders must pay</div>
          </td>
          <td style="width: 0.76%; vertical-align: bottom; padding-bottom: 2px;">
            <div style="line-height: 1.25; font-weight: bold;">&#8203;</div>
          </td>
          <td style="width: 0.76%; vertical-align: bottom; padding-bottom: 2px;">
            <div style="line-height: 1.25; font-weight: bold;">&#8203;</div>
          </td>
          <td style="width: 54.27%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">For</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.14%; vertical-align: top;">
            <div style="line-height: 1.25;">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8203;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8203;</div>
          </td>
          <td style="width: 54.27%; vertical-align: top;">
            <div style="line-height: 1.25;">Issuance of ADSs, including issuances resulting from a distribution of ordinary shares or rights or other property Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.14%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 54.27%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.14%; vertical-align: top;">
            <div style="line-height: 1.25;">$.05 (or less) per ADS</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8203;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8203;</div>
          </td>
          <td style="width: 54.27%; vertical-align: top;">
            <div style="line-height: 1.25;">Any cash distribution to ADS holders</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.14%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 54.27%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.14%; vertical-align: top;">
            <div style="line-height: 1.25;">A fee equivalent to the fee that would be payable if securities distributed to you had been ordinary shares and the ordinary shares had been deposited for issuance of ADSs</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8203;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8203;</div>
          </td>
          <td style="width: 54.27%; vertical-align: top;">
            <div style="line-height: 1.25;">Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.14%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 54.27%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.14%; vertical-align: top;">
            <div style="line-height: 1.25;">$.05 (or less) per ADS per calendar year</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8203;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8203;</div>
          </td>
          <td style="width: 54.27%; vertical-align: top;">
            <div style="line-height: 1.25;">Depositary services</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">21</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z0dff65a7f756418088a2c55c7e540b46">

        <tr>
          <td style="width: 44.14%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">Persons depositing or withdrawing ordinary shares or<br>
              ADS holders must pay</div>
          </td>
          <td style="width: 0.76%; vertical-align: bottom; padding-bottom: 2px;">
            <div style="line-height: 1.25; font-weight: bold;">&#8203;</div>
          </td>
          <td style="width: 0.76%; vertical-align: bottom; padding-bottom: 2px;">
            <div style="line-height: 1.25; font-weight: bold;">&#8203;</div>
          </td>
          <td style="width: 54.27%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">For</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.14%; vertical-align: top;">
            <div style="line-height: 1.25;">Registration or transfer fees</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8203;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8203;</div>
          </td>
          <td style="width: 54.27%; vertical-align: top;">
            <div style="line-height: 1.25;">Transfer and registration of ordinary shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw ordinary shares</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.14%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 54.27%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.14%; vertical-align: top;">
            <div style="line-height: 1.25;">Expenses of the depositary</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8203;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8203;</div>
          </td>
          <td style="width: 54.27%; vertical-align: top;">
            <div style="line-height: 1.25;">Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement)</div>
            <div style="line-height: 1.25;">&#160;</div>
            <div style="line-height: 1.25;">Converting foreign currency to U.S. dollars</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.14%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 54.27%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.14%; vertical-align: top;">
            <div style="line-height: 1.25;">Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or ordinary shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8203;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8203;</div>
          </td>
          <td nowrap="nowrap" style="width: 54.27%; vertical-align: top;">
            <div style="line-height: 1.25;">As necessary</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.14%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 54.27%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.14%; vertical-align: top;">
            <div style="line-height: 1.25;">Any charges incurred by the depositary or its agents for servicing the deposited securities</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8203;</div>
          </td>
          <td style="width: 0.76%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8203;</div>
          </td>
          <td nowrap="nowrap" style="width: 54.27%; vertical-align: top;">
            <div style="line-height: 1.25;">As necessary</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing ordinary shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting
      for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for
      depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash
      distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services
      are paid.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for
      services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency or other service providers that are
      owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The depositary may convert foreign currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as an agent, fiduciary or broker on behalf of any
      other person and earns revenue, including, without limitation, fees and spreads that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made
      under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained in any currency
      conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be most favorable to ADS holders, subject to its obligations under the deposit
      agreement. The methodology used to determine exchange rates used in currency conversions is available upon request.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Payment of Taxes</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">You will be responsible for any taxes or other governmental charges payable on the ADSs or on the deposited securities represented by any of the ADSs. The depositary may refuse to register any transfer
      of the ADSs or allow you to withdraw the deposited securities represented by the ADSs until such taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by the ADSs to pay any taxes owed and you
      will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it
      has paid the taxes.</div>
    <div style="text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">22</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Tender and Exchange Offers; Redemption, Replacement or Cancellation of Deposited Securities</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The depositary will not tender deposited securities in any voluntary tender or exchange offer unless instructed to do by an ADS holder surrendering ADSs and subject to any conditions or procedures the
      depositary may establish.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If deposited securities are redeemed for cash in a transaction that is mandatory for the depositary as a holder of deposited securities, the depositary will call for surrender of a corresponding number
      of ADSs and distribute the net redemption money to the holders of called ADSs upon surrender of those ADSs.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If there is any change in the deposited securities such as a subdivision, combination or other reclassification, or any merger, consolidation, recapitalization or reorganization affecting the issuer of
      deposited securities in which the depositary receives new securities in exchange for or in lieu of the old deposited securities, the depositary will hold those replacement securities as deposited securities under the deposit agreement. However, if
      the depositary decides it would not be lawful and practical to hold the replacement securities because those securities could not be distributed to ADS holders or for any other reason, the depositary may instead sell the replacement securities and
      distribute the net proceeds upon surrender of the ADSs.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If there is a replacement of the deposited securities and the depositary will continue to hold the replacement securities, the depositary may distribute new ADSs representing the new deposited
      securities or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If there are no deposited securities underlying ADSs, including if the deposited securities are cancelled, or if the deposited securities underlying ADSs have become apparently worthless, the
      depositary may call for surrender or of those ADSs or cancel those ADSs upon notice to the ADS holders.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Amendment and Termination</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-style: italic;">How may the deposit agreement be amended?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We may agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes and other
      governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30&#160;days after the
      depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold the ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-style: italic;">How may the deposit agreement be terminated?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The depositary will initiate termination of the deposit agreement if we instruct it to do so. The depositary may initiate termination of the deposit agreement if:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; 90&#160;days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; we delist the ADSs from an exchange on which they were listed and do not list the ADSs on another exchange within a reasonable time;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; we appear to be insolvent or enter insolvency proceedings;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; all or substantially all the value of the deposited securities has been distributed either in cash or in the form of securities;</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">23</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; there are no deposited securities underlying the ADSs or the underlying deposited securities have become apparently worthless; or</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; there has been a replacement of deposited securities.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If the deposit agreement will terminate, the depositary will notify ADS holders at least 90&#160;days before the termination date. At any time after the termination date, the depositary may sell the
      deposited securities. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the pro&#160;rata benefit of the ADS
      holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the termination date.</div>
    <div style="text-indent: 18pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">After the termination date and before the depositary sells, ADS holders can still surrender their ADSs and receive delivery of deposited securities, except that the depositary may refuse to accept a
      surrender for the purpose of withdrawing deposited securities or reverse previously accepted surrenders of that kind if it would interfere with the selling process. The depositary may refuse to accept a surrender for the purpose of withdrawing sale
      proceeds until all the deposited securities have been sold. The depositary will continue to collect distributions on deposited securities, but, after the termination date, the depositary is not required to register any transfer of ADSs or distribute
      any dividends or other distributions on deposited securities to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties under the deposit agreement except as described in this paragraph.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Limitations on Obligations and Liability</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-style: italic;">Limits on our obligations and the obligations of the depositary; Limits on liability to holders of ADSs</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary. We and the depositary:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith and the depositary will not be a fiduciary or have any fiduciary duty to holders of ADSs;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; are not liable if we are or it is prevented or delayed by law or circumstances beyond our or its control from performing our or its obligations under the deposit agreement;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; are not liable if we exercise or it exercises discretion permitted under the deposit agreement;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any
      special, consequential or punitive damages for any breach of the terms of the deposit agreement;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; are not liable for the acts or omissions of any securities depository, clearing agency or settlement system;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person; and</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; the depositary has no duty to make any determinations or provide any information as to our status, or any liability for any tax consequences that may be incurred by ADS holders as a result of owning or holding ADSs or
      any liability for the inability or failure of an ADS holder to obtain the benefit of a foreign tax credit,&#160; reduced rate of withholding or a refund of amounts withheld in respect of tax or any other tax benefit.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances.</div>
    <div style="text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">24</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Requirements for Depositary Actions</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Before the depositary will deliver or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of shares, the depositary may require:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any ordinary shares or other deposited securities;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer books are closed or at any time if the depositary or we think it
      advisable to do so.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Your Right to Receive the Ordinary Shares Underlying the ADSs</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">ADS holders have the right to cancel their ADSs and withdraw the underlying ordinary shares at any time except:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; when temporary delays arise because: (i)&#160;the depositary has closed its transfer books or we have closed our transfer books; (ii)&#160;the transfer of ordinary shares is blocked to permit voting at a shareholders&#8217; meeting;
      or (iii)&#160;we are paying a dividend on our shares;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; when you owe money to pay fees, taxes and similar charges; or</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8226; when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">This right of withdrawal may not be limited by any other provision of the deposit agreement.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Direct Registration System</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In the deposit agreement, all parties to the deposit agreement acknowledge that the Direct Registration System, or DRS, and Profile Modification System, or Profile, will apply to the ADSs. DRS is a
      system administered by DTC that facilitates interchange between registered holding of uncertificated ADSs and holding of security entitlements in ADSs through DTC and a DTC participant. Profile is a feature of DRS that allows a DTC participant,
      claiming to act on behalf of a registered holder of uncertificated ADSs, to direct the depositary to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the
      depositary of prior authorization from the ADS holder to register that transfer.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary will not determine whether the DTC
      participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer and delivery as described in the paragraph above has the actual authority to act on behalf of the ADS holder (notwithstanding any requirements
      under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary&#8217;s reliance on and compliance with instructions received by the depositary through the DRS/Profile system and in accordance with the deposit agreement
      will not constitute negligence or bad faith on the part of the depositary.</div>
    <div style="text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">25</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Shareholder Communications; Inspection of Register of Holders of ADSs</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders of
      deposited securities. The depositary will send you copies of those communications or otherwise make those communications available to you if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of
      contacting those holders about a matter unrelated to our business or the ADSs.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Jury Trial Waiver</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The deposit agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to
      our shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the
      facts and circumstances of that case in accordance with applicable case law.</div>
    <div style="margin-left: 7.55pt; line-height: 1.25;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">26</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFDEBTSECURITI"><!--Anchor--></a>DESCRIPTION OF DEBT SECURITIES</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The following description, together with the additional information we include in any applicable prospectus supplement or free writing prospectus, summarizes certain general terms and provisions of the
      debt securities that we may offer under this prospectus. When we offer to sell a particular series of debt securities, we will describe the specific terms of the series in a supplement to this prospectus. We will also indicate in the supplement to
      what extent the general terms and provisions described in this prospectus apply to a particular series of debt securities.</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We may issue debt securities either separately, or together with, or upon the conversion or exercise of or in exchange for, other securities described in this prospectus. Debt securities may be our
      senior, senior subordinated or subordinated obligations and, unless otherwise specified in a supplement to this prospectus, the debt securities will be our direct, unsecured obligations and may be issued in one or more series.</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The debt securities will be issued under an indenture between us and one or more designated trustees. We have summarized select portions of the indenture below. The summary is not complete. The form of
      the indenture has been filed as an exhibit to the registration statement and you should read the indenture for provisions that may be important to you. In the summary below, we have included references to the section numbers of the indenture so that
      you can easily locate these provisions. Capitalized terms used in the summary and not defined herein have the meanings specified in the indenture.</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">General</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth or determined in the manner provided in a resolution of our board
      of directors, in an officer&#8217;s certificate or by a supplemental indenture. (Section 2.2) The particular terms of each series of debt securities will be described in a prospectus supplement or free writing prospectus relating to such series (including
      any pricing supplement or term sheet).</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We can issue an unlimited amount of debt securities under the indenture that may be in one or more series with the same or various maturities, at par, at a premium, or at a discount. (Sections 2.1 and
      2.2) We will set forth in a prospectus supplement or free writing prospectus (including any pricing supplement or term sheet) relating to any series of debt securities being offered, the aggregate principal amount and the following terms of the debt
      securities, if applicable:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zbabe14cbbe004ecbad6dff9f5f8f4ade">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the title and ranking of the debt securities (including the terms of any subordination provisions);</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z916173122e0c4ed1ab8442cd17813031">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the price or prices (expressed as a percentage of the principal amount) at which we will sell the debt securities;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z77291534710d42469b155b8fd9dfc6b9">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">any limit on the aggregate principal amount of the debt securities;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8a177743722e4864878c8d7ba815a8cb">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the date or dates on which the principal of the securities of the series is payable;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z91fda2d7a1d44556a13a3ff78c65ed68">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates (including any commodity, commodity index, stock exchange index or financial index) at which the debt
              securities will bear interest, the date or dates from which interest will accrue, the date or dates on which interest will commence and be payable and any regular record date for the interest payable on any interest payment date;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z3dd83fb20dbe4808aad06f1fe2d1e75c">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the place or places where principal of, and interest, if any, on the debt securities will be payable (and the method of such payment), where the securities of such series may be surrendered for registration of
              transfer or exchange, and where notices and demands to us in respect of the debt securities may be delivered;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z1276f2f32a214978acf58bec6d7ab20b">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the period or periods within which, the price or prices at which and the terms and conditions upon which we may redeem the debt securities;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">27</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z764535055dc641a8997f592ba5dc1e94">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">any obligation we have to redeem or purchase the debt securities pursuant to any sinking fund or analogous provisions or at the option of a holder of debt securities and the period or periods within which, the
              price or prices at which and in the terms and conditions upon which securities of the series shall be redeemed or purchased, in whole or in part, pursuant to such obligation;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z5c3d89db15af4728a76237865df8e0af">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the dates on which and the price or prices at which we will repurchase debt securities at the option of the holders of debt securities and other detailed terms and provisions of these repurchase obligations;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z3b93ca49ef6b45d4a810e24eb80f0c25">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any integral multiple thereof;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z48e3fd3a20214c2a9145e08f8c7f479e">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">whether the debt securities will be issued in the form of certificated debt securities or global debt securities;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z3373998a6ff4466093f3f47ca2732465">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity date, if other than the principal amount;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z383cd9314a864455871520116ff06aba">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the currency of denomination of the debt securities, which may be United States Dollars or any foreign currency, and if such currency of denomination is a composite currency, the agency or organization, if any,
              responsible for overseeing such composite currency;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zae4b165cf4f94a1fa8439f6e63c4c901">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the designation of the currency, currencies or currency units in which payment of principal of, premium and interest on the debt securities will be made;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z018f28067faf42e0b1f93ffcf0c1af2f">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">if payments of principal of, premium or interest on the debt securities will be made in one or more currencies or currency units other than that or those in which the debt securities are denominated, the manner
              in which the exchange rate with respect to these payments will be determined;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc15e6c303226421bb7fc530ef82b3368">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the manner in which the amounts of payment of principal of, premium, if any, or interest on the debt securities will be determined, if these amounts may be determined by reference to an index based on a currency
              or currencies or by reference to a commodity, commodity index, stock exchange index or financial index;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za65afdb63bf04c08985eed2cd24bab2b">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">any provisions relating to any security provided for the debt securities;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7373ec4732594d529c94608fcfbda322">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">any addition to, deletion of or change in the Events of Default described in this prospectus or in the indenture with respect to the debt securities and any change in the acceleration provisions described in this
              prospectus or in the indenture with respect to the debt securities;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zbf00b5a4161641db86a226e8cc787f51">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">any addition to, deletion of or change in the covenants described in this prospectus or in the indenture with respect to the debt securities;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z5618c06b6f4641ec9b099d5ffe8fb094">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect to the debt securities;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zdf27655cbc8249c38b62eb01760667ff">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the provisions, if any, relating to conversion or exchange of any debt securities of such series, including if applicable, the conversion or exchange price and period, provisions as to whether conversion or
              exchange will be mandatory, the events requiring an adjustment of the conversion or exchange price and provisions affecting conversion or exchange;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zcc01c5292e2547f1a2c5132076c22568">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">any other terms of the debt securities, which may supplement, modify or delete any provision of the indenture as it applies to that series, including any terms that may be required under applicable law or
              regulations or advisable in connection with the marketing of the securities; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z6397d91a002e471fbb41c30a4618f348">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">whether any of our direct or indirect subsidiaries will guarantee the debt securities of that series, including the terms of subordination, if any, of such guarantees. (Section 2.2)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of acceleration of their maturity pursuant to the terms of the
      indenture. We will provide you with information on the federal income tax considerations and other special considerations applicable to any of these debt securities in the applicable prospectus supplement.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If we denominate the purchase price of any of the debt securities in a foreign currency or currencies or a foreign currency unit or units, or if the principal of and any premium and interest on any
      series of debt securities is payable in a foreign currency or currencies or a foreign currency unit or units, we will provide you with information on the restrictions, elections, general tax considerations, specific terms and other information with
      respect to that issue of debt securities and such foreign currency or currencies or foreign currency unit or units in the applicable prospectus supplement.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">28</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Transfer and Exchange</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Each debt security will be represented by either one or more global securities registered in the name of The Depository Trust Company, or the Depositary, or a nominee of the Depositary (we will refer
      to any debt security represented by a global debt security as a &#8220;book-entry debt security&#8221;), or a certificate issued in definitive registered form (we will refer to any debt security represented by a certificated security as a &#8220;certificated debt
      security&#8221;) as set forth in the applicable prospectus supplement. Except as set forth under the heading &#8220;Global Debt Securities and Book-Entry System&#8221; below, book-entry debt securities will not be issuable in certificated form.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Certificated Debt Securities</font>. You may transfer or exchange certificated debt securities at any office we maintain for this purpose in accordance with the terms
      of the indenture. (Section 2.4) No service charge will be made for any transfer or exchange of certificated debt securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection with a
      transfer or exchange. (Section 2.7).</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">You may effect the transfer of certificated debt securities and the right to receive the principal of, premium and interest on certificated debt securities only by surrendering the certificate
      representing those certificated debt securities and either reissuance by us or the trustee of the certificate to the new holder or the issuance by us or the trustee of a new certificate to the new holder.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Global Debt Securities and Book-Entry System</font>. Each global debt security representing book-entry debt securities will be deposited with, or on behalf of, the
      Depositary, and registered in the name of the Depositary or a nominee of the Depositary. Please see &#8220;Global Securities.&#8221;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Covenants</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We will set forth in the applicable prospectus supplement any restrictive covenants applicable to any issue of debt securities. (Article IV)</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">No Protection in the Event of a Change of Control</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Unless we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions which may afford holders of the debt securities protection in the event we have a
      change in control or in the event of a highly leveraged transaction (whether or not such transaction results in a change in control) which could adversely affect holders of debt securities.</div>
    <div style="line-height: 1.25;">&#160;&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Consolidation, Merger and Sale of Assets</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We may not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets to any person, or a successor person, unless:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z6161623152654e53b11bc67faf44f3e2">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">we are the surviving entity or the successor person (if other than Chemomab ) is a corporation, partnership, trust or other entity organized and validly existing under the laws of any U.S. domestic jurisdiction
              or the State of Israel and expressly assumes our obligations on the debt securities and under the indenture; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z2b4556532d4244bc9d7cf7ffd86b1654">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">immediately after giving effect to the transaction, no Default or Event of Default, shall have occurred and be continuing.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Notwithstanding the above, any of our subsidiaries may consolidate with, merge into or transfer all or part of its properties to us. (Section 5.1)</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">29</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Events of Default</div>
    <div style="text-align: justify; text-indent: 24.5pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#8220;Event of Default&#8221; means with respect to any series of debt securities, any of the following:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za88b899e9fb646f1bcf4547cf2da61d2">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">default in the payment of any interest upon any debt security of that series when it becomes due and payable, and continuance of such default for a period of 30 days (unless the entire amount of the payment is
              deposited by us with the trustee or with a paying agent prior to the expiration of the 30-day period);</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z690aadd63bff41d18e03b3fe448b4e6a">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">default in the payment of principal of any security of that series at its maturity;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z0570c7b4066647cf96fcb9ce51cdaaa6">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">default in the performance or breach of any other covenant or warranty by us in the indenture (other than a covenant or warranty that has been included in the indenture solely for the benefit of a series of debt
              securities other than that series), which default continues uncured for a period of 60 days after we receive written notice from the trustee or Chemomab and the trustee receive written notice from the holders of not less than 25% in principal
              amount of the outstanding debt securities of that series as provided in the indenture;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8d31efc0ae0044c29445d51e82652c68">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">certain voluntary or involuntary events of bankruptcy, insolvency or reorganization of Chemomab; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8453a1d9dc034f9a8f7b940141b86faa">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">any other Event of Default provided with respect to debt securities of that series that is described in the applicable prospectus supplement. (Section 6.1)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">No Event of Default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an Event of Default with
      respect to any other series of debt securities. (Section 6.1) The occurrence of certain Events of Default or an acceleration under the indenture may constitute an event of default under certain indebtedness of ours or our subsidiaries outstanding
      from time to time.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We will provide the trustee written notice of any Default or Event of Default within 30 days of becoming aware of the occurrence of such Default or Event of Default, which notice will describe in
      reasonable detail the status of such Default or Event of Default and what action we are taking or propose to take in respect thereof. (Section 6.1)</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If an Event of Default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee or the holders of not less than 25% in principal amount of the
      outstanding debt securities of that series may, by a notice in writing to us (and to the trustee if given by the holders), declare to be due and payable immediately the principal of (or, if the debt securities of that series are discount securities,
      that portion of the principal amount as may be specified in the terms of that series) and accrued and unpaid interest, if any, on all debt securities of that series. In the case of an Event of Default resulting from certain events of bankruptcy,
      insolvency or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, on all outstanding debt securities will become and be immediately due and payable without any declaration or other act on the part of
      the trustee or any holder of outstanding debt securities. At any time after a declaration of acceleration with respect to debt securities of any series has been made, but before a judgment or decree for payment of the money due has been obtained by
      the trustee, the holders of a majority in principal amount of the outstanding debt securities of that series may rescind and annul the acceleration if all Events of Default, other than the non-payment of accelerated principal and interest, if any,
      with respect to debt securities of that series, have been cured or waived as provided in the indenture. (Section 6.2) We refer you to the prospectus supplement relating to any series of debt securities that are discount securities for the particular
      provisions relating to acceleration of a portion of the principal amount of such discount securities upon the occurrence of an Event of Default.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The indenture provides that the trustee may refuse to perform any duty or exercise any of its rights or powers under the indenture unless the trustee receives indemnity satisfactory to it against any
      cost, liability or expense which might be incurred by it in performing such duty or exercising such right or power. (Section 7.1(e)) Subject to certain rights of the trustee, the holders of a majority in principal amount of the outstanding debt
      securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of
      that series. (Section 6.12)</div>
    <div style="text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">30</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">No holder of any debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the indenture or for the appointment of a receiver or trustee, or
      for any remedy under the indenture, unless:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z2279c04fefe54064b0a5113fd17002d8">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">that holder has previously given to the trustee written notice of a continuing Event of Default with respect to debt securities of that series; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za052b595916b40e89526578a19f60080">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the holders of not less than 25% in principal amount of the outstanding debt securities of that series have made written request, and offered indemnity or security satisfactory to the trustee, to the trustee to
              institute the proceeding as trustee, and the trustee has not received from the holders of not less than a majority in principal amount of the outstanding debt securities of that series a direction inconsistent with that request and has failed
              to institute the proceeding within 60 days. (Section 6.7)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Notwithstanding any other provision in the indenture, the holder of any debt security will have an absolute and unconditional right to receive payment of the principal of, premium and any interest on
      that debt security on or after the due dates expressed in that debt security and to institute suit for the enforcement of payment. (Section 6.8)</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The indenture requires us, within 120 days after the end of our fiscal year, to furnish to the trustee a statement as to compliance with the indenture. (Section 4.3) If a Default or Event of Default
      occurs and is continuing with respect to the securities of any series and if it is known to a responsible officer of the trustee, the trustee shall mail to each Securityholder of the securities of that series notice of a Default or Event of Default
      within 90 days after it occurs or, if later, after a responsible officer of the trustee has knowledge of such Default or Event of Default. The indenture provides that the trustee may withhold notice to the holders of debt securities of any series of
      any Default or Event of Default (except in payment on any debt securities of that series) with respect to debt securities of that series if the trustee determines in good faith that withholding notice is in the interest of the holders of those debt
      securities. (Section 7.5)</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Modification and Waiver</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We and the trustee may modify, amend or supplement the indenture or the debt securities of any series without the consent of any holder of any debt security:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z02f9b768545b4351a70bde329ab61fdd">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">to cure any ambiguity, defect or inconsistency;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z963d73c0356b4965839685b3e1c0cd4a">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">to comply with covenants in the indenture described above under the heading &#8220;Consolidation, Merger and Sale of Assets&#8221;;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z909ebf05a99e45ab99e27db42153aa56">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">to provide for uncertificated securities in addition to or in place of certificated securities;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zfea2aefe1ad44165886985983463395f">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">to add guarantees with respect to debt securities of any series or secure debt securities of any series;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z86a4b213557145ff9906859f25286dee">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">to surrender any of our rights or powers under the indenture;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zab22511c38bb4d9688a72c09830c50e1">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">to add covenants or events of default for the benefit of the holders of debt securities of any series;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z349bfcd7b5bc47e2b71402a0728b8997">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">to comply with the applicable procedures of the applicable depositary;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za34d7fe2f8c04f8b9c2b1582d2184d22">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">to make any change that does not adversely affect the rights of any holder of debt securities;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zdc0491e057b84d8aa04ed8051128135b">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">to provide for the issuance of and establish the form and terms and conditions of debt securities of any series as permitted by the indenture;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z9ea20ae5020d4848b437e76f272ea98f">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">to effect the appointment of a successor trustee with respect to the debt securities of any series and to add to or change any of the provisions of the indenture to provide for or facilitate administration by
              more than one trustee; or</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zfd5a3116932c42e88fdd2f5378bb646f">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under the Trust Indenture Act. (Section 9.1)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">31</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">We may also modify and amend the indenture with the consent of the holders of at least a majority in principal amount of the outstanding debt securities of each series affected by the modifications or
      amendments. We may not make any modification or amendment without the consent of the holders of each affected debt security then outstanding if that amendment will:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z997710c693354c488442d70d31d393a7">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">reduce the amount of debt securities whose holders must consent to an amendment, supplement or waiver;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8b8b359da5cd47198c34976e27b48b19">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">reduce the rate of or extend the time for payment of interest (including default interest) on any debt security;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z38d837204d084d96af9325e005b97d80">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">reduce the principal of or premium on or change the fixed maturity of any debt security or reduce the amount of, or postpone the date fixed for, the payment of any sinking fund or analogous obligation with
              respect to any series of debt securities;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z26c61d3d4a7e491fa6d6aa7ed70ae5de">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">reduce the principal amount of discount securities payable upon acceleration of maturity;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z9ee51e8e3e564ed6a4036ae7869ac354">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">waive a default in the payment of the principal of, premium or interest on any debt security (except a rescission of acceleration of the debt securities of any series by the holders of at least a majority in
              aggregate principal amount of the then outstanding debt securities of that series and a waiver of the payment default that resulted from such acceleration);</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z846536485fe24ac0917632416d67f308">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">make the principal of or premium or interest on any debt security payable in currency other than that stated in the debt security;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc97aea4b3b674ff885b0789d7cbf75c3">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">make any change to certain provisions of the indenture relating to, among other things, the right of holders of debt securities to receive payment of the principal of, premium and interest on
              those debt securities and to institute suit for the enforcement of any such payment and to waivers or amendments; or</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z17815cb9090a474aa4c4141561530f5f">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">waive a redemption payment with respect to any debt security. (Section 9.3)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all debt securities of
      that series waive our compliance with provisions of the indenture. (Section 9.2) The holders of a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all the debt securities of such series
      waive any past default under the indenture with respect to that series and its consequences, except a default in the payment of the principal of, premium or any interest on any debt security of that series; provided, however, that the holders of a
      majority in principal amount of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment default that resulted from the acceleration. (Section 6.13)</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Defeasance of Debt Securities and Certain Covenants in Certain Circumstances</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Legal Defeasance</font>. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, we may be discharged from any
      and all obligations in respect of the debt securities of any series (subject to certain exceptions). We will be so discharged upon the irrevocable deposit with the trustee, in trust, of money and/or U.S. government obligations or, in the case of debt
      securities denominated in a single currency other than U.S. Dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their terms, will
      provide money or U.S. government obligations in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal, premium and interest on and
      any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities.</div>
    <div style="text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">32</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">This discharge may occur only if, among other things, we have delivered to the trustee an opinion of counsel stating that we have received from, or there has been published by, the United States
      Internal Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the applicable United States federal income tax law, in either case to the effect that, and based thereon such opinion shall confirm that,
      the holders of the debt securities of that series will not recognize income, gain or loss for United States federal income tax purposes as a result of the deposit, defeasance and discharge and will be subject to United States federal income tax on
      the same amounts and in the same manner and at the same times as would have been the case if the deposit, defeasance and discharge had not occurred. (Section 8.3)</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Defeasance of Certain Covenants</font>. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, upon
      compliance with certain conditions:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z12a31af7175d4a278f6b04a09282eb81">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">we may omit to comply with the covenant described under the heading &#8220;Consolidation, Merger and Sale of Assets&#8221; and certain other covenants set forth in the indenture, as well as any additional covenants which may
              be set forth in the applicable prospectus supplement; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z07ba7b62bb9e4ce59a081f0ab55870d3">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">any omission to comply with those covenants will not constitute a Default or an Event of Default with respect to the debt securities of that series (&#8220;covenant defeasance&#8221;).</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The conditions include:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z549bc7ad5b18470197813a7463179fbe">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">depositing with the trustee money and/or U.S. government obligations or, in the case of debt securities denominated in a single currency other than U.S. Dollars, government obligations of the government that
              issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their terms, will provide money in an amount sufficient in the opinion of a nationally recognized firm of independent public
              accountants or investment bank to pay and discharge each installment of principal of, premium and interest on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in
              accordance with the terms of the indenture and those debt securities; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z44bc84f33fdf4324b2ee7a9a394ff628">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">delivering to the trustee an opinion of counsel to the effect that the holders of the debt securities of that series will not recognize income, gain or loss for United States federal income tax purposes as a
              result of the deposit and related covenant defeasance and will be subject to United States federal income tax on the same amounts and in the same manner and at the same times as would have been the case if the deposit and related covenant
              defeasance had not occurred. (Section 8.4)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">No Personal Liability of Directors, Officers, Employees or Securityholders</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">None of our past, present or future directors, officers, employees or shareholders, as such, will have any liability for any of our obligations under the debt securities or the indenture or for any
      claim based on, or in respect or by reason of, such obligations or their creation. By accepting a debt security, each holder waives and releases all such liability. This waiver and release is part of the consideration for the issue of the debt
      securities. However, this waiver and release may not be effective to waive liabilities under U.S. federal securities laws, and it is the view of the SEC that such a waiver is against public policy.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Governing Law</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The indenture and the debt securities, including any claim or controversy arising out of or relating to the indenture or the securities, will be governed by and construed in accordance with the laws of
      the State of New York.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The indenture will provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably waive, to the fullest extent permitted by applicable law,
      any and all right to trial by jury in any legal proceeding arising out of or relating to the indenture, the debt securities or the transactions contemplated thereby.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The indenture will provide that any legal suit, action or proceeding arising out of or based upon the indenture or the transactions contemplated thereby may be instituted in the federal courts of the
      United States of America located in the City of New York or the courts of the State of New York in each case located in the City of New York, and we, the trustee and the holder of the debt securities (by their acceptance of the debt securities)
      irrevocably submit to the non-exclusive jurisdiction of such courts in any such suit, action or proceeding. The indenture will further provide that service of any process, summons, notice or document by mail (to the extent allowed under any
      applicable statute or rule of court) to such party&#8217;s address set forth in the indenture will be effective service of process for any suit, action or other proceeding brought in any such court. The indenture will further provide that we, the trustee
      and the holders of the debt securities (by their acceptance of the debt securities) irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the courts specified above and irrevocably and
      unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum. (Section 10.10).</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">33</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFWARRANTS"><!--Anchor--></a>DESCRIPTION OF WARRANTS</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We may issue warrants to purchase ADSs. We may issue warrants independently or together with any other securities offered by any prospectus supplement and the warrants may be attached to or separate
      from those securities. We will evidence each series of warrants by warrant certificates that we may issue under a separate agreement. Any series of warrants may be issued under a separate warrant agreement, which may be entered into between us and a
      warrant agent specified in an applicable prospectus supplement relating to a particular series of warrants. Any such warrant agent will act solely as our agent in connection with the warrants of such series and will not assume any obligation or
      relationship of agency or trust with any of the holders of the warrants. We may also choose to act as our own warrant agent. We will set forth further terms of the warrants and any applicable warrant agreements in the applicable prospectus supplement
      relating to the issuance of any warrants, including, where applicable, the following:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc2a6b078283944e0b881f8da7cb2ed68">

        <tr>
          <td style="width: 0.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
            <div style="line-height: 1.25;">&#160;</div>
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.74%; vertical-align: top;">
            <div style="line-height: 1.25;">the title of the warrants;</div>
            <div style="line-height: 1.25;">&#160;</div>
            <div style="line-height: 1.25;">the aggregate number of the warrants;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z24258758c7844e07b0fbed8ab37917d1">

        <tr>
          <td style="width: 0.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.74%; vertical-align: top;">
            <div style="line-height: 1.25;">the number of securities purchasable upon exercise of the warrants;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd32fe3316ef540c08cd54bf4e9d1cf9c">

        <tr>
          <td style="width: 0.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.74%; vertical-align: top;">
            <div style="line-height: 1.25;">the designation and terms of the securities, if any, with which the warrants are issued, and the number of the warrants issued with each such offered security;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zef79041913d74f8394abd65c7bed9658">

        <tr>
          <td style="width: 0.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.74%; vertical-align: top;">
            <div style="line-height: 1.25;">the date, if any, on and after which the warrants and the related securities will be separately transferable;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z59dd86a1ae024f68a151315f7735b2f4">

        <tr>
          <td style="width: 0.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.74%; vertical-align: top;">
            <div style="line-height: 1.25;">the price at which, and form of consideration for which, each security purchasable upon exercise of the warrants may be purchased;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="ze024ddfbb9b44053bd66b7e9f3fb9098">

        <tr>
          <td style="width: 0.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.74%; vertical-align: top;">
            <div style="line-height: 1.25;">the date on which the right to exercise the warrants will commence and the date on which the right will expire;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z3f12d6ad41a4407a9bb888d602e46721">

        <tr>
          <td style="width: 0.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.74%; vertical-align: top;">
            <div style="line-height: 1.25;">if applicable, the date on and after which such warrants and the related securities will be separately transferable;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zbd345afaf2fd4bf2877f69d333292c58">

        <tr>
          <td style="width: 0.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.74%; vertical-align: top;">
            <div style="line-height: 1.25;">information with respect to book-entry procedures, if any;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zade3c327ee744dc9a9af5aac87b21a33">

        <tr>
          <td style="width: 0.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.74%; vertical-align: top;">
            <div style="line-height: 1.25;">if applicable, a discussion of the material Israeli and U.S. income tax considerations applicable to the issuance or exercise of such warrants;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z399be86092ae4f658a95d36e0fb8a3f3">

        <tr>
          <td style="width: 0.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.74%; vertical-align: top;">
            <div style="line-height: 1.25;">the anti-dilution and adjustment of share capital provisions of the warrants, if any;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7ac83cb8732147ed8ad4862d160ff6b9">

        <tr>
          <td style="width: 0.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.74%; vertical-align: top;">
            <div style="line-height: 1.25;">the minimum or maximum amount of the warrants which may be exercised at any one time;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7c0177a3a8a547ca9c5f5dea7baf36eb">

        <tr>
          <td style="width: 0.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.74%; vertical-align: top;">
            <div style="line-height: 1.25;">any circumstances that will cause the warrants to be deemed to be automatically exercised; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z0688777f84ea4bcaaff85077b5818f85">

        <tr>
          <td style="width: 0.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.74%; vertical-align: top;">
            <div style="line-height: 1.25;">any other material terms of the warrants.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Amendments and Supplements to Warrant Agreement</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We and the warrant agent may amend or supplement the warrant agreement for a series of warrants without the consent of the holders of the warrants issued thereunder to effect changes that are not
      inconsistent with the provisions of the warrants and that do not materially and adversely affect the interests of the holders of the warrants.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The description in the applicable prospectus supplement of any warrants we offer will not necessarily be complete and will be qualified in its entirety by reference to the applicable warrant agreement,
      which will be filed with the SEC if we offer warrants. For more information on how you can obtain copies of the applicable warrant agreement if we offer rights, see &#8220;Where You Can Find More Information.&#8221;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">34</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFUNITS"><!--Anchor--></a>DESCRIPTION OF UNITS</div>
    <div style="text-align: center; line-height: 1.25;">&#160; <br>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">We may issue units comprised of one or more of the other securities that may be offered under this prospectus, in any combination. As specified in the applicable prospectus supplement, we may issue
      units consisting of the ADS, debt securities, warrants or any combination of such securities. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the
      rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately at any time, or at any time before a
      specified date. The applicable prospectus supplement will describe:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z3958636e2ae54f748a2da9ed7f91d5fd">

        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">the terms of the units and of the ordinary shares, rights and/or warrants comprising the units, including whether and under what circumstances the securities comprising the units may be traded separately;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">a description of the terms of any unit agreement governing the units or any arrangement with an agent that may act on our behalf in connection with the unit offering;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">a description of the provisions for the payment, settlement, transfer or exchange of the units; and</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">any material provisions of the governing unit agreement that differ from those described above.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The description in the applicable prospectus supplement of any units we offer will not necessarily be complete and will be qualified in its entirety by reference to the applicable units agreement,
      which will be filed with the SEC if we offer units. For more information on how you can obtain copies of the applicable units agreement if we offer units, see &#8220;Where You Can Find More Information.&#8221;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">35</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; margin-left: 3.6pt; line-height: 1.25; font-weight: bold;"><a name="PLANOFDISTRIBUTION"><!--Anchor--></a>PLAN OF DISTRIBUTION</div>
    <div style="text-align: center; margin-left: 3.6pt; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We may sell the securities in one or more of the following ways (or in any combination) from time to time:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za5543acc51c44ce28de9dd28daa1f1ce">

        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">through underwriters or dealers;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">directly to a limited number of purchasers or to a single purchaser;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">through agents; or</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">through any other method permitted by applicable law and described in the applicable prospectus supplement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The distribution of our securities may be carried out, from time to time, in one or more transactions, including:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z09813c52efc0489b913efe870fb82a63">

        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">block transactions and transactions on the Nasdaq Capital Market or any other organized market where the securities may be traded;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">purchases by a broker-dealer as principal and resale by the broker-dealer for its own account pursuant to a prospectus supplement;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">ordinary brokerage transactions and transactions in which a broker-dealer solicits purchasers;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">sales &#8220;at the market&#8221; into an existing trading market; or</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">sales in other ways not involving market makers or established trading markets, including direct sales to purchasers.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">A prospectus supplement or supplements (and any related free writing prospectus that we or the selling shareholders may authorize to be provided to you) will describe the terms of the offering of the
      securities, including, to the extent applicable:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z40ee533184f340f2a078174544d395af">

        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">the name or names of any underwriters, dealers or agents;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">the method of distribution;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">the public offering price or purchase price and the proceeds to us from that sale;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">the expenses of the offering;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">any discounts or commissions to be allowed or paid to the underwriters, dealers or agents;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">all other items constituting underwriting compensation and the discounts and commissions to be allowed or paid to dealers, if any; and</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.81%; vertical-align: top;">
            <div style="line-height: 1.25;">any other information regarding the distribution of the securities that we believe to be material.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Underwriters may offer and sell the securities at a fixed price or prices, which may be changed, or from time to time at market prices prevailing at the time of sale, at prices related to prevailing
      market prices or at negotiated prices. We may, from time to time, authorize agents acting on a best or reasonable efforts basis as our agents to solicit or receive offers to purchase the securities upon the terms and conditions as are set forth in
      the applicable prospectus supplement. In connection with the sale of securities, underwriters or agents may be deemed to have received compensation from us in the form of underwriting discounts or commissions and may also receive commissions from
      purchasers of securities for whom they may act as agent. Underwriters may sell securities to or through dealers, and dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from
      the purchasers for whom they may act as agent.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Underwriters, dealers and agents who participate in the distribution of securities and their controlling persons may be entitled, under agreements that may be entered into with us to indemnification by
      us against certain liabilities, including liabilities under the Securities Act, or to contribution with respect to payments that the underwriters, dealers or agents and their controlling persons may be required to make in respect of those
      liabilities.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We may also make direct sales through subscription rights distributed to our existing shareholders on a pro rata basis, which may or may not be transferable. In any distribution of subscription rights
      to our shareholders, if all of the underlying securities are not subscribed for, we may then sell the unsubscribed securities directly to third parties or may engage the services of one or more underwriters, dealers or agents, including standby
      underwriters, to sell the unsubscribed securities to third parties.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Certain persons participating in an offering may engage in over-allotment, stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act
      that stabilize, maintain or otherwise affect the price of the offered securities. If any such activities will occur, they will be described in the applicable prospectus supplement.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">36</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="ENFORCEMENTOFCIVILLIABILI"><!--Anchor--></a>ENFORCEMENT OF CIVIL LIABILITIES</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">We are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in this prospectus, substantially all of whom
        reside outside the United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets and substantially all of our directors and officers are located outside the United States, any judgment
        obtained in the United States against us or any of our directors and officers may not be collectible within the United States.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">We have irrevocably appointed Chemomab Therapeutics, Inc. as our agent to receive service of process in any action against us in any U.S. federal or state court arising out of this offering or any
        purchase or sale of securities in connection with this offering. The address of our agent is One Kendall Square, Building 1400E, Suite 14-105, Cambridge, MA 02139.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">We have been informed by our legal counsel in Israel, Meitar | Law Offices, that it may be difficult to initiate an action with respect to U.S. securities law in original actions instituted in Israel
        or obtain a judgement based on the civil liability provisions of the U.S. federal securities laws. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate
        forum to hear such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must
        be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure may also be governed by Israeli law.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Subject to specified time limitations and legal procedures, Israeli courts may enforce a United States judgment in a civil matter which, subject to certain exceptions, is non-appealable, including a
        judgment based upon the civil liability provisions of the Securities Act or the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided that, among other things:</div>
      <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z492d238ac3a1403abb25b96bd48ddbfd">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the judgment is obtained after due process before a court of competent jurisdiction, according to the laws of the state in which the judgment is given and the rules of private international law prevailing in
              Israel;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="margin-left: 72pt; line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z6de0e94922e24b5aa5ca99bc6dc23c2a">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the prevailing law of the foreign state in which the judgment is rendered allows for the enforcement of judgments of Israeli courts;</div>
          </td>
        </tr>

    </table>
    <div style="margin-left: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za4514ac409064fd1a7b52a970215c392">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">adequate service of process has been effected and the defendant has had a reasonable opportunity to be heard and to present his or her evidence;</div>
          </td>
        </tr>

    </table>
    <div style="margin-left: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc18b3cf4c24c4abbbb2f92ffff2fc1cb">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the judgment is not contrary to public policy of Israel, and the enforcement of the civil liabilities set forth in the judgment is not likely to impair the security or sovereignty of Israel;</div>
          </td>
        </tr>

    </table>
    <div style="margin-left: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z21528e4e4f6a4fc689f8585feddfcb7a">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the judgment was not obtained by fraud and does not conflict with any other valid judgment in the same matter between the same parties;</div>
          </td>
        </tr>

    </table>
    <div style="margin-left: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7c85c78e7ea342378060c25022616b57">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">an action between the same parties in the same matter was not pending in any Israeli court at the time at which the lawsuit was instituted in the foreign court; and</div>
          </td>
        </tr>

    </table>
    <div style="margin-left: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z866431a416ed494aa9891cb4fc8e8fdf">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the judgment is enforceable according to the laws of Israel and according to the law of the foreign state in which the relief was granted.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25;">If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred out of Israel. The usual
        practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment,
        but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual
        statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.</div>
    </div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">37</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="EXPENSES"><!--Anchor--></a>EXPENSES</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The following table sets forth the expenses (other than underwriting discounts and commissions or agency fees and other items constituting underwriters&#8217; or agents&#8217; compensation, if any) expected to be
      incurred by us in connection with a possible offering of securities registered under this registration statement.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za99619faa7d24880af8acbc03754ee93">

        <tr>
          <td style="width: 86.67%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">SEC registration fee</div>
          </td>
          <td style="width: 0.81%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9.91%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">9,621</div>
          </td>
          <td style="width: 1.41%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 86.67%; vertical-align: bottom;">
            <div style="line-height: 1.25;">FINRA filing fee</div>
          </td>
          <td style="width: 0.81%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 9.91%; vertical-align: bottom; text-align: right;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">3,140</div>
          </td>
          <td style="width: 1.41%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 86.67%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Depositary and Transfer agent&#8217;s fees</div>
          </td>
          <td style="width: 0.81%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 9.91%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">*</div>
          </td>
          <td style="width: 1.41%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 86.67%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Printing and engraving expenses</div>
          </td>
          <td style="width: 0.81%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 9.91%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">*</div>
          </td>
          <td style="width: 1.41%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 86.67%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Legal fees and expenses</div>
          </td>
          <td style="width: 0.81%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 9.91%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">*</div>
          </td>
          <td style="width: 1.41%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 86.67%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Accounting fees and expenses</div>
          </td>
          <td style="width: 0.81%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 9.91%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">*</div>
          </td>
          <td style="width: 1.41%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 86.67%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Miscellaneous</div>
          </td>
          <td style="width: 0.81%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 9.91%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="text-align: right; line-height: 1.25;">*</div>
          </td>
          <td style="width: 1.41%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 86.67%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.81%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 9.91%; vertical-align: bottom;">&#160;</td>
          <td style="width: 1.41%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 86.67%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Total</div>
          </td>
          <td style="width: 0.81%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 4px double;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9.91%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 4px double;">
            <div style="text-align: right; line-height: 1.25;">*</div>
          </td>
          <td style="width: 1.41%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc71b23cdb6ac4f638a83e986b11e4e8c">

        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: top;">
            <div style="line-height: 1.25;">*</div>
          </td>
          <td style="width: 98.06%; vertical-align: top;">
            <div style="line-height: 1.25;">Estimated fees and expenses are not presently known. If required, to be provided by a prospectus supplement or as an exhibit to a Report on Form 6-K that is incorporated by reference into this prospectus.</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">38</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="LEGALMATTERS"><!--Anchor--></a>LEGAL MATTERS</div>
    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The validity of the securities offered by this prospectus will be passed upon by&#160;Meitar | Law Offices, Ramat Gan, Israel. Cooley LLP, New York, New York, will pass upon certain matters of U.S. federal
      and New York law.&#160; Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">39</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="EXPERTS"><!--Anchor--></a>EXPERTS</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">
          <div style="text-indent: 36pt; line-height: 1.25;">The consolidated financial statements of Chemomab Therapeutics Ltd. as of December 31, 2022 and 2021, and for each of the years in the two-year period ended December 31, 2022, and as of December
            31, 2021 and 2020, and for each of the years in the two-year period ended December 31, 2021, have been incorporated by reference herein in reliance upon the report of Somekh Chaikin, a member firm of KPMG International, independent registered
            public accounting firm incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.</div>
        </div>
      </div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">40</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="WHEREYOUCANFINDMOREINFORM"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION OF INFORMATION BY REFERENCE</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The SEC allows us to incorporate by reference the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information
      incorporated by reference is considered to be part of this registration statement, and later information filed with the SEC will update and supersede this information. We hereby incorporate by reference into this registration statement the following
      documents previously filed with the SEC:</div>
    <div style="text-indent: 18pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za99721d3faea4ad5bf6afa383b91ea37">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the Company&#8217;s Annual Reports on&#160;<a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323001041/0001178913-23-001041-index.htm">Form&#160;10-K</a>&#160;for the&#160;years ended December&#160;31, 2022 and December 31,
              2021 filed with the SEC on March&#160;20, 2023 (the &#8220;2022 Annual Report&#8221;) and March 30, 2022, respectively;</div>
            <div style="line-height: 1.25;"> <br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the Company&#8217;s Current Reports on Form 8-K filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000010/0001178913-23-000010-index.htm">January 3, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000147/0001178913-23-000147-index.htm">January 11, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000670/0001178913-23-000670-index.htm">February












                21, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000679/0001178913-23-000679-index.htm">February 21, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323001809/0001178913-23-001809-index.htm">May 11, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323002136/0001178913-23-002136-index.htm">June 5,
                2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323002225/0001178913-23-002225-index.htm">June 16, 2023</a>, and Reports on Form 6-K furnished with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323002362/0001178913-23-002362-index.htm">July 3, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323002732/0001178913-23-002732-index.htm">August
                8, 2023</a> and <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323002860/0001178913-23-002860-index.htm">August 14, 2023</a>; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z0e1de9bdb0e44bbba5c4f21b7e736e4f">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the description of our share capital, which is set forth in&#160;Exhibit 4.1&#160;of the 2022 Annual Report, and as may be further updated or amended in any amendment or report filed for such purpose, including&#160;<a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_4-1.htm"><u>Exhibit 4.1</u></a>&#160;to our 2022 Annual Report on Form 10-K for the year ended December 31, 2022.</div>
          </td>
        </tr>

    </table>
    <div style="text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">We are also incorporating by reference all subsequent Annual Reports on Form 20-F that we file with the SEC and those of our Reports on Form 6-K that we furnish to the SEC that we specifically identify
      in such form or in any applicable prospectus supplement as being incorporated by reference into this prospectus or such prospectus supplement after the date hereof and prior to the completion of an offering of securities under this prospectus.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">We have filed a registration statement on Form&#160;F-3 to register the issuance and the resale of the securities described elsewhere in this prospectus. This prospectus is a part of that registration
      statement. As permitted by SEC rules, this prospectus does not contain all of the information included in the registration statement and the accompanying exhibits and schedules we file with the SEC. You may refer to the registration statement and the
      exhibits and schedules for more information about us and our securities.</div>
    <div style="text-indent: 18pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Information and statements contained in this prospectus or any annex to this prospectus are qualified in all respects by reference to the copy of the relevant contract or other annex filed as an
      exhibit to the registration statement of which this prospectus forms a part.</div>
    <div style="text-indent: 18pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Statements made in this prospectus concerning the contents of any contract, agreement or other document are not complete descriptions of all terms of these documents. If a document has been filed as an
      exhibit to the registration statement, we refer you to the copy of the document that has been filed for a complete description of its terms. Each statement in this prospectus relating to a document filed as an exhibit is qualified in all respects by
      the filed exhibit. You should read this prospectus and the documents that we have filed as exhibits to the registration statement of which this prospectus is a part in their entirety.</div>
    <div style="text-indent: 18pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We are subject to the informational requirements of the Exchange Act. Accordingly, we will be required to file reports and other information with the SEC, including annual reports on Form&#160;20-F and
      reports on Form&#160;6-K. The SEC maintains an internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.</div>
    <div style="text-indent: 18pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We are a &#8220;foreign private issuer&#8221; as defined in Rule&#160;3b-4 under the Securities Exchange Act of 1934, or the Exchange Act. As a result, our proxy solicitations are not subject to the disclosure and
      procedural requirements of Regulation 14A under the Exchange Act and transactions in our equity securities by our officers and directors are exempt from Section&#160;16 of the Exchange Act. In addition, we are not required under the Exchange Act to file
      periodic reports and financial statements as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. We publish annually an annual report filed on Form&#160;20-F containing financial statements that have been
      examined and reported on, with an opinion expressed by, a registered public accounting firm. We prepare our annual financial statements in United States dollars and in accordance with accounting principles generally accepted in the United States, or
      U.S. GAAP. If there is any inconsistency between the information in this prospectus and in any post-effective amendment to the Form&#160;F-3 of which this prospectus is a part, or in any prospectus supplement, you should rely on the information in the
      post-effective amendment or prospectus supplement, as relevant. You should read this prospectus and any post-effective amendment or prospectus supplement together with the additional information contained in documents listed above under the heading
      &#8220;Where You Can Find More Information; Incorporation of Information by Reference.&#8221; The registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us, the securities
      offered under this prospectus, and our other outstanding securities. The registration statement, including the exhibits, can be read at the SEC&#8217;s website mentioned above under &#8220;Where You Can Find More Information; Incorporation of Information by
      Reference.&#8221;</div>
    <div style="text-indent: 18pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We will provide to each person, including any beneficial owner, to whom this prospectus is delivered, a copy of any or all the information that has been incorporated by reference in this prospectus but
      not delivered with this prospectus (and any exhibits specifically incorporated in such information), at no cost, upon written or oral request to us at the following address:</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">Chemomab Therapeutics Ltd.</div>
      <div style="line-height: 1.25;">Attention: Chief Financial Officer</div>
      <div style="line-height: 1.25;">Kiryat Atidim, Building 7,</div>
      <div style="line-height: 1.25;">Tel Aviv</div>
      <div style="line-height: 1.25;">6158002</div>
      <div style="line-height: 1.25;">Israel</div>
      <div style="margin-left: 54pt; line-height: 1.25;">&#160;</div>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">You may also obtain information about us by visiting our website at <font style="font-style: italic;">www.chemomab.com</font>. Information contained in our website is not part of this prospectus.</div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 18pt; line-height: 1.25;">&#160;</div>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">We have not authorized anyone to give any information or make any representation about their companies that is different from, or in addition to, that contained in this prospectus or in any of the
      materials that have been incorporated in this prospectus. Therefore, if anyone does give you information of this sort, you should not rely on it. If you are in a jurisdiction where offers to exchange or sell, or solicitations of offers to exchange or
      purchase, the securities offered by this prospectus or the solicitation of proxies is unlawful, or if you are a person to whom it is unlawful to direct these types of activities, then the offer presented in this prospectus does not extend to you. The
      information contained in this prospectus speaks only as of the date of this prospectus unless the information specifically indicates that another date applies. You should read all information supplementing this prospectus.</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">41</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><font style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(255, 0, 0); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;"><br style="line-height: 1.25;">
      </font> </div>
    <font style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(255, 0, 0); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;"> </font>
    <div style="line-height: 1.25; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(255, 0, 0); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
    <font style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(255, 0, 0); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;"> </font>
    <div style="line-height: 1.25; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(255, 0, 0); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;">
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">The information in this prospectus supplement is not complete and may be changed. We may not sell these securities until the registration statement
          filed with the Securities and Exchange Commission is effective. This prospectus supplement is not an offer to sell these securities, and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not
          permitted.</div>
      </div>
    </div>
    <font style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(255, 0, 0); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;"> </font>
    <div style="line-height: 1.25; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(255, 0, 0); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
    <font style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(255, 0, 0); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;"> </font>
    <div style="text-align: center; line-height: 1.25; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(255, 0, 0); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;">
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">SUBJECT TO COMPLETION, DATED OCTOBER 16, 2023</div>
      </div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">PROSPECTUS SUPPLEMENT</div>
    <div style="text-align: center; line-height: 1.25;">
      <div style="text-align: left; line-height: 1.25;">(To Prospectus dated&#160; &#160; &#160; &#160; &#160; &#160; &#160; , 2023)</div>
      <img width="253" height="132" src="image0.jpg">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Up to $2,863,664</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">American Depositary Shares</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We have entered into a Sales Agreement (the &#8220;Sales Agreement&#8221;), with Roth Capital Partners, LLC, (&#8220;Roth&#8221;), relating to American Depositary Shares, each representing twenty (20) ordinary shares, no par
      value, of the Company, (the &#8220;ADSs&#8221;), offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell the ADSs having an aggregate offering price of up to $2,863,664<font style="font-weight: bold;">&#160;</font>million from time to time through or to Roth, as the sales agent or principal.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Sales of the ADSs, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under
      the Securities Act of 1933, as amended, or the Securities Act. Roth will act as sales agent or principal on a best efforts basis and use commercially reasonable efforts to sell on our behalf all of the ADSs requested to be sold by us, consistent with
      its normal trading and sales practices, on mutually agreed terms between Roth and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">ADSs representing our ordinary shares are traded on the Nasdaq Capital Market under the symbol &#8220;CMMB.&#8221; On October 11, 2023, the closing price of ADSs as reported by the Nasdaq Capital Market was $0.87
      per ADS.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Roth will be entitled to compensation under the terms of the Sales Agreement at a commission rate of 3.0% of the aggregate gross sales price per share sold. In connection with the sale of the ADSs on
      our behalf, Roth will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act and the compensation of Roth will be deemed to be underwriting commissions or discounts.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">As of October 11, 2023, the aggregate market value of outstanding ADSs held by non-affiliates (&#8220;public float&#8221;) was approximately $12.8 million, based on 11,824,512 ADSs outstanding as of October
          11, 2023, of which 11,254,490 ADSs were held by non-affiliates, and a per ADS price of $1.14 based on the closing sale price of such ADS on September 5, 2023. As of the date hereof, we have sold or offered 772,900 ADSs for a total of
          approximately $1.4 million pursuant to General Instruction I.B.5 of Form F-3 during the prior 12 calendar month period that ends on and includes the date hereof. Pursuant to General Instruction I.B.5 of Form F-3, in no event may we offer
          securities pursuant to this prospectus supplement and the accompanying prospectus with an aggregate offering price of more than one-third of the aggregate market value of ADSs held by non-affiliates in any twelve-month period, for as long as the
          aggregate market value of the ADSs held by non-affiliates is less than $75,000,000. If, subsequent to the date of this prospectus supplement, the aggregate market value of our outstanding ADSs held by non-affiliates equals or exceeds $75,000,000,
          then the one-third limitation on sales will not apply to additional sales made pursuant to this prospectus supplement and the accompanying prospectus.&#160;</div>
      </div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in this
      prospectus supplement, the accompanying prospectus and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus supplement as described on page SP-22 of this
      prospectus supplement.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is
      truthful or complete. Any representation to the contrary is a criminal offense.</div>
    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: normal; font-variant: normal; text-transform: none;">Roth Capital Partners</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; margin-left: 3.6pt; line-height: 1.25; font-weight: bold;">
      <div style="line-height: 1.25; font-weight: bold;">The date of this prospectus supplement is&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; , 2023</div>
    </div>
    <div style="text-align: center; margin-left: 3.6pt; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; margin-right: 5.75pt; margin-left: 5.75pt; line-height: 1.25; font-weight: bold;">Table of Contents</div>
    <div style="text-align: center; margin-right: 5.75pt; margin-left: 5.75pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="ze20420676493466f854a5b1e5723605f">

        <tr>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Page</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#SUPPLEMENT"><u>ABOUT THIS PROSPECTUS</u><u> </u>SUPPLEMENT</a></div>
          </td>
          <td style="width: 12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">SP-1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;"><a href="#WARD-LOOKINGSTATEMENTS"><u>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</u></a></div>
          </td>
          <td rowspan="1" style="width: 12%; vertical-align: top; text-align: center; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">SP-3</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 88%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 12%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#PROSPECTUSSUPPLEMENTSUMMA"><u>PROSPECTUS SUMMARY</u></a></div>
          </td>
          <td style="width: 12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">SP-5</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#THEOFFERING"><u>THE OFFERING</u></a></div>
          </td>
          <td style="width: 12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">SP-7</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#RISKFACTORS"><u>RISK FACTORS</u></a></div>
          </td>
          <td style="width: 12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">SP-8</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#CAPITALIZATION2">CAPITALIZATION</a></div>
          </td>
          <td style="width: 12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">SP-9</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#USEOFPROCEEDS"><u>REASONS FOR THE OFFER AND USE OF PROCEEDS</u></a></div>
          </td>
          <td style="width: 12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">SP-10</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#MATERIALTAXCONSIDERATIONS"><u>MATERIAL TAX CONSIDERATIONS</u></a></div>
          </td>
          <td style="width: 12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">SP-11</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#DILUTION"><u>DILUTION</u></a></div>
          </td>
          <td style="width: 12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">SP-19</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#PLANOFDISTRIBUTION2"><u>PLAN OF DISTRIBUTION</u></a></div>
          </td>
          <td style="width: 12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">SP-20</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#ENFORCEMENTOFCI2VILLIABILI"><u>ENFORCEMENT OF CIVIL LIABILITIES</u></a></div>
          </td>
          <td style="width: 12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">SP-21</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#LEGALM2ATTERS"><u>LEGAL MATTERS</u></a></div>
          </td>
          <td style="width: 12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">SP-22</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top;"> <br>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#LEGALM2ATTERS"><u>EXPERTS</u></a></div>
          </td>
          <td style="width: 12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">SP-22</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top;"> <br>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#LEGALM2ATTERS"><u>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</u></a></div>
          </td>
          <td style="width: 12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">SP-22</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top;"> <br>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#LEGALM2ATTERS"><u>WHERE YOU CAN FIND MORE INFORMATION</u></a></div>
          </td>
          <td style="width: 12%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">SP-22</div>
          </td>
        </tr>

    </table>
    &#160;
    <div style="text-align: center; margin-right: 5.75pt; margin-left: 5.75pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%SP - %%-->
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">ABOUT THIS PROSPECTUS SUPPLEMENT<a name="SUPPLEMENT"><!--Anchor--></a></div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">This prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a &#8220;shelf&#8221; registration
      process.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">This document comprises two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and also adds to and updates information contained in the
      accompanying base prospectus and the documents incorporated by reference herein. The second part, the accompanying base prospectus, gives more general information, some of which may not apply to this offering. Generally, when we refer to this
      &#8220;prospectus&#8221; or &#8220;prospectus supplement,&#8221; we are referring to the sales agreement prospectus and the accompanying base prospectus combined. Before buying any of the ADSs that we are offering, we urge you to carefully read this prospectus, the
      accompanying base prospectus, any free writing prospectus that we have authorized for use in connection with this offering, and the information incorporated by reference as described under the headings &#8220;Where You Can Find More Information;
      Incorporation of Information by Reference&#8221; in this prospectus. These documents contain important information that you should consider when making your investment decision.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">This prospectus describes the terms of this offering of ADSs and also adds to and updates information contained in the documents incorporated by reference into this prospectus. To the extent there is a
      conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference that was filed with the SEC before the date of this prospectus, on the other hand, you should rely
      on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example, a document incorporated by reference into this prospectus&#8212;the statement in the
      document having the later date modifies or supersedes the earlier statement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for
      the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such
      representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">We have not, and Roth has not, authorized anyone to provide you with information different than or inconsistent with the information contained in or incorporated by reference into this prospectus or in
      any free writing prospectus that we have authorized for use in connection with this offering. We and the sales agent take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We
      are not, and Roth is not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus and the documents incorporated by reference into this
      prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents, regardless of the time of delivery of those respective documents. Our
      business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus, the documents incorporated by reference into this prospectus, and any free writing prospectus that we have
      authorized for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you to in the section of this prospectus titled
      &#8220;Where You Can Find More Information; Incorporation of Information by Reference.&#8221;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">We are offering to sell, and seeking offers to buy, ADSs only in jurisdictions where offers and sales are permitted. The distribution of this prospectus and the offering of the ADSs in certain
      jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the ADSs and the distribution of this
      prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in
      which it is unlawful for such person to make such an offer or solicitation.</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">For investors outside the United States: We have not done anything that would permit the offering or possession or distribution of this prospectus supplement in any jurisdiction where action for that
      purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus supplement must inform themselves about, and observe any restrictions relating to, the offering of the securities
      described herein and the distribution of this prospectus supplement outside the United States.</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We are a company incorporated under the laws of the State of Israel. Under the rules of the SEC, we are currently eligible for treatment as a &#8220;foreign private issuer.&#8221; As a foreign private issuer, we
      are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, as amended.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In this prospectus, unless otherwise indicated, &#8220;Chemomab Therapeutics,&#8221; &#8220;Chemomab,&#8221; &#8220;the Company,&#8221; &#8220;our company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Chemomab Therapeutics Ltd. and its wholly owned
      subsidiary, Chemomab Ltd.</div>
    <div style="text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">SP - 1</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">In addition, as used in this prospectus, unless the context otherwise requires:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z9c6fd38dd35d449192bf954d1353fcb1">

        <tr>
          <td style="width: 3%; vertical-align: middle;">
            <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 93.82%; vertical-align: top;">
            <div style="line-height: 1.25;">references to &#8220;ordinary shares,&#8221; &#8220;our shares&#8221; and similar expressions refer to the Company&#8217;s ordinary shares, no nominal (par) value;</div>
          </td>
        </tr>

    </table>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z97dadcabf4ff41cea2d306e8e6f860e4">

        <tr>
          <td style="width: 3%; vertical-align: middle;">
            <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 93.82%; vertical-align: top;">
            <div style="line-height: 1.25;">references to &#8220;ADS&#8221; refer to the American Depositary Shares listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;CMMB,&#8221; each representing twenty (20) ordinary shares;</div>
          </td>
        </tr>

    </table>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zacc4aed6bc364a819af041e89b1ea4aa">

        <tr>
          <td style="width: 3%; vertical-align: middle;">
            <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 93.82%; vertical-align: top;">
            <div style="line-height: 1.25;">references to &#8220;dollars,&#8221; &#8220;U.S. dollars&#8221; and &#8220;$&#8221; are to U.S. Dollars;</div>
          </td>
        </tr>

    </table>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="ze823b417ac3045718b72664ca4a3d499">

        <tr>
          <td style="width: 3%; vertical-align: middle;">
            <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 93.82%; vertical-align: top;">
            <div style="line-height: 1.25;">references to &#8220;NIS&#8221; are to New Israeli Shekels;</div>
          </td>
        </tr>

    </table>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z32ca7bc15274429f9321ee79ebd772be">

        <tr>
          <td style="width: 3%; vertical-align: middle;">
            <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 93.82%; vertical-align: top;">
            <div style="line-height: 1.25;">references to the &#8220;SEC&#8221; are to the U.S. Securities and Exchange Commission; and</div>
          </td>
        </tr>

    </table>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z491b3afc132645b193c755ace6f5ed29">

        <tr>
          <td style="width: 3%; vertical-align: middle;">
            <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 93.82%; vertical-align: top;">
            <div style="line-height: 1.25;">references to the &#8220;Merger&#8221; refer to the merger involving Anchiano Therapeutics Ltd. and Chemomab Ltd., whereby a wholly owned subsidiary of Anchiano Therapeutics Ltd. merged with and into Chemomab Ltd., with
              Chemomab Ltd. surviving as a wholly owned subsidiary of Anchiano Therapeutics Ltd. Upon consummation of the Merger, Anchiano Therapeutics Ltd. changed its name to &#8220;Chemomab Therapeutics Ltd.&#8221; and the business conducted by Chemomab Ltd. became
              primarily the business conducted by the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">You should rely only on the information contained or incorporated by reference in this prospectus or any &#8220;free writing prospectus&#8221; we may authorize to be delivered to you. We have
      not authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information appearing in this prospectus and the documents
      incorporated by reference herein and therein are accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed since those dates.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">This prospectus shall not constitute an offer or solicitation by anyone in any jurisdiction in which such offer or solicitation is not authorized or in which the person making such
      offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation.</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">SP - 2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">&#160;<font style="font-weight: bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS<a name="WARD-LOOKINGSTATEMENTS"><!--Anchor--></a></font></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">This prospectus, any prospectus supplement and the information incorporated by reference in this prospectus and any prospectus supplement contain forward-looking statements within the meaning of
      Section 27A of the Securities Act, and Section 21E of the Exchange Act of 1934, as amended, or the Exchange Act, that involve substantial risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our
      management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from
      results and outcomes discussed in the forward-looking statements.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 20.35pt; line-height: 1.25;">All statements other than present and historical facts and conditions contained in this prospectus, any prospectus supplement and the information incorporated by reference in this prospectus and any
      prospectus supplement including statements regarding our future results of operations and financial positions, business strategy, plans and our objectives for future operations, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221;
      &#8220;continue&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;ongoing,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will&#8221; and &#8220;would,&#8221; or the negative of these and similar expressions identify forward-looking statements.
      Forward-looking statements include, but are not limited to, statements about:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zef1aef036bef43afb55c62fc73026b65">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we have incurred significant losses since inception and anticipate that we will continue to incur increasing levels of operating losses over the next several&#160;years and for the foreseeable future;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze65098faafc34542a87b64b1ea1feeaa">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we are unable to predict the extent of any future losses or when we will become profitable, if at all;&#160;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z74c0d75e0a8941ebb1b1b8461274ff6c">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>even if we become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z83f2de018f7143ccaeca8f11fa4801d1">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we have a limited operating history and funding, which may make it difficult to evaluate our prospects and likelihood of success;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3ba2b5c6d66d4c50902b3909a7451648">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>our business is highly dependent on the success of our lead product candidate, CM-101, and any other product candidates that we advance into clinical studies;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1671ba27337b41209b344d49a3b195cb">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>all of our programs will require significant additional clinical development;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z551f72ca1ad64a879d9080e52517751c">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>our&#160;central objective is to design and develop targeted treatments for inflammation and fibrosis with an initial focus on the antagonism of CCL24 signaling, which is known to regulate fibrotic and inflammatory processes;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9f28f82c447a4b7894ce08f69e2a6740">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>while several studies are currently underway, our approach in the area of fibrotic diseases is novel and unproven and may not result in marketable products;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z54a33eb4a3f24575a76302bffdcb832d">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>the successful completion of clinical studies is a prerequisite to submitting a marketing application to the FDA and similar marketing applications to comparable foreign regulatory authorities, for each product candidate and, consequently,
              the ultimate approval and commercial marketing of any product candidates;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z28716f2f56024fe7a310f039c3346963">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we may experience negative or inconclusive results, which may result in us deciding, or regulators requiring us, to conduct additional clinical studies or trials or abandon some or all of its product development programs, which could have
              a material adverse effect on our business;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z86fafa8b2f2e482fa010e9545f35faef">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we may encounter difficulties enrolling patients in our clinical studies, including due to the continuing effects of the COVID-19 pandemic, or other public health emergencies and related clinical development activities could be delayed or
              otherwise adversely affected;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z79b70765914f4b9fa6ec7f67f7dc0b9e">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>our ongoing and future clinical studies may reveal significant adverse events or immunogenicity-related responses and may result in a safety profile that could delay or prevent regulatory approval or market acceptance of our product
              candidate;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za1b6fffb48064222b0c4ee7d2fa0bfcd">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for CM-101 or any other product
              candidates, our business will be substantially harmed;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za37a19cb6dc24051803921d68467a331">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>if we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and our business will be harmed;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc318cec7d9fb4ce3b74f505d3fe1d05f">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than us;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0a46ca751b34440abc35d3f2fb3b416a">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we have been granted Orphan Drug Designation for CM-101 in connection with three indications and may seek Orphan Drug Designation for other indications or product candidates, and we may be unable to maintain the benefits associated with
              Orphan Drug Designation, including the potential for market exclusivity, and may not receive Orphan Drug Designation for other indications or for its other product candidates;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zffe294328cc049238a1f42dcc61f9c2b">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we expect to experience significant growth in the number of our employees over time and the scope of our operations, particularly in the areas of product candidate development, regulatory affairs and sales and marketing;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z133851226f814243a98ad8ad5e93144f">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we will therefore need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations;</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">SP - 3</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z09f4c22b2a8b40869abe29cb08272fc5">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>if we are unable to protect our patents or other proprietary rights, or if we infringe the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z865d8cae9a334b5db11284b93b5e85bd">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb393fe8a7b4d45feba3d94d6cce2e672">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>risks related to our operations in Israel could materially adversely impact our business, financial condition and results of operations;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4711740cbfa74e2aba2c85612dbf498a">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>our principal executive offices are located in Israel and certain of our product candidates may be manufactured at third-party facilities located in Europe. In addition, our business strategy includes potentially expanding internationally
              if any of its product candidates receives regulatory approval;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd430b1585c83438381a76366648a3bf7">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>holders of ADSs may not have the same voting rights as the holders of our ordinary shares and may not receive voting materials in time to be able to exercise their right to vote;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za906df94d3af4b518618c120ece89760">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z84c7f09e1c1a4dad972d1cf680304351">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we are entitled to amend the deposit agreement and to change the rights of ADS holders under the terms of such agreement, or to terminate the deposit agreement, without the prior consent of the ADS holders;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za79257fb90884871b8dc1e31bf6e5096">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action; and</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2065d2ea910c473c9fa1d218764c3e21">

        <tr>
          <td style="width: 20.35pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>we presently anticipate that we will be classified as a passive foreign investment company, which could result in adverse U.S. federal income tax consequences to U.S. Holders of our ordinary shares.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 20.35pt; line-height: 1.25;">As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus, any prospectus supplement and the information incorporated by reference in this prospectus
      and any prospectus supplement will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should
      not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements,
      whether as a result of new information, future events or otherwise, except as required by law.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 20.35pt; line-height: 1.25;">You should read this prospectus supplement and the information incorporated by reference in this prospectus supplement completely and with the understanding that our actual future results may be
      materially different from what we expect. We qualify all of our forward- looking statements by these cautionary statements.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 20.35pt; line-height: 1.25;">This prospectus supplement and the information incorporated by reference in this prospectus supplement may contain market data and industry forecasts that were obtained from industry publications.
      These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we believe the market position, market opportunity and market size information included in this prospectus supplement
      and the information incorporated by reference in this prospectus supplement is generally reliable, such information is inherently imprecise.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 20.35pt; line-height: 1.25;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date
      the statements were made, and while we believed such information formed a reasonable basis for such statements at the time they were made, such information may be limited or incomplete, and our statements should not be read to indicate that we have
      conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">SP - 4</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%5%SP - %%-->
    <div style="line-height: 1.25;">
      <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
        <div>&#160;
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROSPECTUS SUPPLEMENT SUMMARY</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25; font-style: italic;">This summary provides an overview of selected information contained elsewhere or incorporated by reference in this prospectus supplement and does not contain all of the
            information you should consider before investing in our securities. You should carefully read the prospectus, the applicable prospectus supplement and any related free writing prospectus, the information incorporated by reference herein and the
            registration statement of which this prospectus is a part in their entirety before investing in our securities, including the information discussed under &#8220;Risk Factors&#8221; in this prospectus and the documents incorporated by reference and our
            financial statements and related notes that are incorporated by reference in this prospectus.</div>
          <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">Our Business</div>
          <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          <div style="line-height: 1.25;">
            <div style="text-indent: 36pt; line-height: 1.25;">Chemomab is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet needs. Based on the
              unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple
              severe and life-threatening fibrotic and inflammatory diseases.</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;">&#160;</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-indent: 36pt; line-height: 1.25;">Chemomab has pioneered the therapeutic targeting of CCL24, a chemokine that promotes various types of cellular processes that regulate inflammatory and fibrotic activities through the CCR3
              receptor. The chemokine is expressed in various types of cells, including immune cells, endothelial cells and epithelial cells. We have developed a novel CCL24 inhibiting product candidate with dual anti-fibrotic and anti-inflammatory
              activity that modulates the complex interplay of both of these inflammatory and fibrotic mechanisms, which drive abnormal states of fibrosis and clinical fibrotic diseases. This innovative approach is being developed for difficult-to-treat
              rare diseases, also known as orphan indications or diseases, such as primary sclerosing cholangitis (&#8220;PSC&#8221;), and systemic sclerosis (&#8220;SSc&#8221;), for which patients have no established disease-modifying or standard-of-care treatment options. We
              estimate that there are approximately 77 thousand patients suffering from PSC in the U.S., EU and Japan, representing over a $1 billion market opportunity, and approximately 170 thousand patients suffering from SSc in those same markets,
              representing over a $1.5 billion market opportunity.</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;">&#160;</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-indent: 36pt; line-height: 1.25;">CM-101, our lead clinical product candidate, is a first-in-class humanized monoclonal antibody that attenuates the basic function of the soluble protein CCL24, also known as eotaxin-2, as a
              regulator of major inflammatory and fibrotic pathways. We have demonstrated that CM-101 interferes with the underlying biology of inflammation and fibrosis through a novel and differentiated mechanism of action. We are currently conducting a
              Phase 2 clinical study in PSC, a rare obstructive and cholestatic liver disease. The study is actively recruiting patients in the U.S., Europe and Israel and enrollment is going well. The study design includes a two doses of CM-101 vs placebo
              (10 or 20mg/kg), as well as an open label extension. A topline readout of initial trial results is expected in the second half of 2024.</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;">&#160;</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-indent: 36pt; line-height: 1.25;">In SSc, Chemomab has suspended initiation of the Phase 2 trial while it focuses resources on successfully completing the Phase 2 PSC study. The CM-101 SSc clinical program is Phase 2-ready and
              the Company believes that CM-101 could have disease-modifying potential in this poorly treated condition. Although our primary focus is on these two rare indications, The Company reported topline results from an additional Phase 2 clinical
              study in patients with liver fibrosis due to non-alcoholic steatohepatitis, or NASH, in January of this year. This trial provided safety and pharmacokinetic (&#8220;PK&#8221;) data and information useful for assessing the Company&#8217;s current subcutaneous
              formulation of CM-101. Additionally, the trial measured a number of biomarkers that may be relevant to the potential activity of CM-101 in other fibro-inflammatory conditions. The initial trial results showed that the trial met its primary
              endpoint of safety and tolerability, and that CM-101 demonstrated encouraging activity in secondary endpoints that include a range of liver fibrosis biomarkers and physiologic assessments. A more recent secondary analysis confirming and
              extending these initial results was reported at the 2023 EASL Congress in July 2023.</div>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-indent: 36pt; line-height: 1.25;">Fibrosis is the abnormal and excessive accumulation of collagen and extracellular matrix, the non-cellular component in all tissues and organs, which provides structural and biochemical support
              to surrounding cells. When present in excessive amounts, collagen and extracellular matrix lead to scarring and thickening of connective tissues, affecting tissue properties and potentially leading to organ dysfunction and failure. Fibrosis
              can occur in many different tissues, including lung, liver, kidney, muscle, skin, and the gastrointestinal tract, resulting in a wide array of progressive fibrotic conditions. Fibrosis and inflammation are intrinsically linked. While a
              healthy inflammatory response is necessary for efficient tissue repair; after disease or injury, an excessive, uncontrolled inflammatory response can lead to tissue fibrosis that in turn can further stimulate inflammatory processes in a
              fibro-inflammatory vicious cycle.</div>
          </div>
        </div>
        <div>&#160;</div>
      </div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">SP - 5</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;
      <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
        <div>&#160;
          <div style="line-height: 1.25; font-weight: bold;">Recent Developments</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">New Executive Appointments and Extension of Cash Runway through Year-End 2024</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">On June 5, 2023, Chemomab announced that Adi Mor, PhD, co-founder and former Chief Executive Officer (CEO), and then Director and Chief Scientific Officer, had been reappointed to the role of
            CEO, replacing Dale Pfost, PhD. Sigal Fattal, former Chief Financial Officer (CFO) and then Vice President, Finance, had been reappointed to the role of CFO, replacing Donald Marvin. Nissim Darvish, MD, PhD, was appointed Chairman of the Board,
            replacing Dr. Pfost. All the appointments were effective June 1, 2023. The Company also announced that it was implementing additional cost-reduction measures, which extended its cash runway from mid-year 2024 to the end of 2024, after the
            expected topline data readout from the Phase 2 CM-101 PSC trial.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Reported Secondary Analyses of CM-101 Phase 2 Liver Fibrosis Trial in NASH Patients</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">On June 21, 2023, Chemomab reported topline results from secondary analyses of its Phase 2a liver fibrosis trial assessing CM-101 in patients with NASH. The results were included in a
            late-breaking poster presentation at the 2023 EASL Congress.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>Overall, the data showed improvements across an additional set of inflammatory and fibrotic biomarkers that are consistent with the clinical results Chemomab released in
            January. Additionally, in NASH patients at greater risk of disease progression, CM-101 treatment resulted in a greater biomarker response than in NASH patients with lower risk disease or in placebo-treated patients. The new analyses<font style="font-weight: bold;">&#160;</font>assessed additional biomarkers and also used the FibroScan-AST (FAST) score to categorize study patients based on progressive disease risk. The results showed that:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 10.25%; vertical-align: top;">
                  <div style="text-indent: 36pt; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.75%; vertical-align: top;">
                  <div style="line-height: 1.25;">FAST scores were improved in a higher proportion of CM-101-treated patients than in placebo patients.</div>
                </td>
              </tr>

          </table>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 10.25%; vertical-align: top;">
                  <div style="text-indent: 36pt; line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.75%; vertical-align: top;">
                  <div style="line-height: 1.25;">CM-101-treated patients with higher FAST scores demonstrated greater improvements in key fibro-inflammatory biomarkers than patients with lower FAST scores or placebo patients.</div>
                </td>
              </tr>

          </table>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">In these secondary analyses, CM-101-treated patients showed improvements in an additional set of biomarkers associated with active fibrosis and inflammation including AST/ALT ratio,
            Neutrophil-to-Lymphocyte Ratio (NLR), FIB-4, and PRO-C3. Some of these biomarker scores were further improved in CM-101-treated patients with higher FAST scores. It is noteworthy that as an overall indicator of fibrogenesis and fibrotic
            disease, PRO-C3 may also be viewed as a &#8220;bridge&#8221; to PSC and other anti-fibrotic indications.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;<font style="font-weight: bold; font-style: italic;">Reported Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for PSC</font></div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The Company presented two posters at the 2023 EASL Congress discussing the potential of CM-101 as a novel treatment for PSC. One of the posters reported on a new proteomic study demonstrating a
            direct relationship between the pro-inflammatory, pro-fibrotic activity of CCL24 and PSC disease-related pathways.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>The other poster described the clinical design of Chemomab&#8217;s double-blind, placebo-controlled, multiple dose Phase 2
            trial of CM-101 in PSC patients. These followed a data presentation at the 2023 EASL Biliary Conference in May 2023, reinforcing the proinflammatory role of CCL24 in cholestatic disease.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Published Peer-Reviewed Research Article Demonstrating the Key Role of CCL24 in PSC</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-indent: 36pt; line-height: 1.25;">On June 28, 2023, Chemomab reported publication of a peer-reviewed research article in the June issue of the respected journal&#160;<font style="font-style: italic;">JCI Insight</font>. It was
            produced through collaborations with prominent academic groups and supports the key role of CCL24 in driving the self-perpetuating fibrosis and inflammation that result in the severe liver damage characterizing PSC.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">Corporate Information</div>
          <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We were incorporated on September 22, 2011, under the laws of the State of Israel. In March 2021, we changed our name from Anchiano Therapeutics Ltd. to Chemomab Therapeutics Ltd. Our principal
            executive offices are located at Kiryat Atidim, Building 7, Tel Aviv, Israel 6158002, and our phone number is +972-77-331-0156. Our website is:&#160;<font style="font-style: italic;">www.chemomab.com.</font>&#160;The information contained on, or that can
            be accessed through, our website is not part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.</div>
        </div>
        <div>&#160;</div>
      </div>
    </div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <br>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 6</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
        <div>&#160;</div>
        <div>
          <div style="text-align: center;"><font style="font-weight: bold;">&#160;THE OFFERING</font> </div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8f0e4f5699864773a5e104f7945945de">

              <tr>
                <td style="vertical-align: top;">
                  <div style="line-height: 1.25; font-weight: bold;">Securities offered by us</div>
                </td>
                <td style="width: 1.02%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 65.32%; vertical-align: top;">
                  <div style="line-height: 1.25;">ADSs, each representing twenty (20) ordinary shares, no par value, having an aggregate offering price of up to $2,863,664.</div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 1.02%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 65.32%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align: top;">
                  <div style="text-align: justify; text-indent: 0.2pt; line-height: 1.25; font-weight: bold;">ADSs to be outstanding immediately after this offering</div>
                </td>
                <td style="width: 1.02%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 65.32%; vertical-align: top;">
                  <div style="line-height: 1.25;">Up to 15,114,280 ADSs, assuming sales of 3,291,568 ADSs in this offering at an offering price of $0.87 per ADS, the sale price of&#160;ADSs on the Nasdaq Captial Market on October 11, 2023. The actual number of
                    ADSs issued will vary depending on the sales price under this offering.</div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 1.02%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 65.32%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align: top;">
                  <div style="line-height: 1.25; font-weight: bold;">Plan of Distribution</div>
                </td>
                <td style="width: 1.02%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 65.32%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#8220;At the market offering&#8221; that may be made from time to time through or to Roth, as sales agent or principal. See &#8220;Plan of Distribution.&#8221;</div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 1.02%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 65.32%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align: top;">
                  <div style="line-height: 1.25; font-weight: bold;">Use of Proceeds</div>
                </td>
                <td style="width: 1.02%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 65.32%; vertical-align: top;">
                  <div style="line-height: 1.25;">We intend to use the net proceeds from this offering for continued clinical development of our product candidates, research activities, and for other general corporate purposes. See &#8220;Reasons for the Offer
                    and Use of Proceeds&#8221; on page SP-10 of this prospectus.</div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 1.02%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 65.32%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align: top;">
                  <div style="line-height: 1.25; font-weight: bold;">Risk Factors</div>
                </td>
                <td style="width: 1.02%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 65.32%; vertical-align: top;">
                  <div style="line-height: 1.25;">Investing in our securities involves significant risks. See the information under the heading &#8220;Risk Factors&#8221; beginning on page SP-4 of this prospectus and in the documents incorporated by reference into
                    this prospectus for a discussion of factors you should carefully consider before deciding to invest in our securities.</div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 1.02%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 65.32%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align: top;">
                  <div style="line-height: 1.25; font-weight: bold;">Nasdaq Capital Market symbol</div>
                </td>
                <td style="width: 1.02%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 65.32%; vertical-align: top;">
                  <div style="line-height: 1.25;">ADSs representing our ordinary shares are listed for trading on the Nasdaq Capital Market under the symbol &#8220;CMMB.&#8221;</div>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="vertical-align: top;">&#160;</td>
                <td rowspan="1" style="width: 1.02%; vertical-align: top;">&#160;</td>
                <td rowspan="1" style="width: 65.32%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td rowspan="1" style="vertical-align: top;">
                  <div style="line-height: 1.25; font-weight: bold;">Depositary</div>
                </td>
                <td rowspan="1" style="width: 1.02%; vertical-align: top;">&#160;</td>
                <td rowspan="1" style="width: 65.32%; vertical-align: top;">
                  <div style="line-height: 1.25;">The Bank of New York Mellon</div>
                </td>
              </tr>
              <tr>
                <td style="width: 33.72%; vertical-align: top;"><br>
                </td>
                <td colspan="2" style="vertical-align: top;">
                  <div style="line-height: 1.25;"><br>
                  </div>
                </td>
              </tr>

          </table>
          <div style="text-indent: 36pt; line-height: 1.25;">The information above is based on 11,822,712 ADSs outstanding as of October 11, 2023, and excludes the following:</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc279fa6b7c0244dcbb625ecb634404ae">

              <tr>
                <td style="width: 2.17%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 2.17%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 95.67%; vertical-align: top;">
                  <div style="line-height: 1.25;">1,642,058 ADSs issuable upon the exercise of outstanding options to purchase ADSs, at a weighted average exercise price of $3.24 per ADS;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.17%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 2.17%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 95.67%; vertical-align: top;">
                  <div style="line-height: 1.25;">an aggregate 760,888 ADSs reserved for future issuance under the 2015 Share Incentive Plan (the &#8220;2015 Plan&#8221;) and the 2017 Equity-Based Incentive Plan (the &#8220;2017 Plan&#8221;, and together with the 2015 Plan, the
                    &#8220;Share Incentive Plans&#8221;), as of October 11, 2023, as well as any automatic increases in the number of ADSs reserved for future issuance under the 2017 Plan; and</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.17%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 2.17%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 95.67%; vertical-align: top;">
                  <div style="line-height: 1.25;">261,929 ADSs issuable upon the exercise of outstanding warrants to purchase ADSs at a weighted average exercise price of $17.35 per share, which warrants are expected to remain outstanding at the
                    consummation of this offering.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">To the extent that options and warrants outstanding as of October 11, 2023 may be exercised, investors purchasing our securities in this offering may experience further dilution.</div>
          <div style="text-indent: 36pt; line-height: 1.25;"> <br>
          </div>
        </div>
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="THEOFFERING"><!--Anchor--></a><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 7</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="RISKFACTORS"><!--Anchor--></a>RISK FACTORS</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Investing in the ADSs may involve a high degree of risk. Before making an investment in our securities, you should carefully read all of the information contained in this prospectus supplement, the
      accompanying prospectus and in the documents incorporated by reference herein, including the risk factors contained in our then-most recent Annual Report on Form 10-K or 20-F, as applicable, and any updates to those risk factors in our reports on
      Form 6-K incorporated by reference in this prospectus,&#160;together with all of the other information appearing in this prospectus supplement or incorporated by reference into the accompanying prospectus, in light of your particular investment objectives
      and financial circumstances. For a discussion of risk factors that you should carefully consider before deciding to purchase the ADSs, please review the additional risk factors disclosed below and the information under the heading &#8220;Risk Factors&#8221; in
      the accompanying prospectus. In addition, please read &#8220;About this Prospectus Supplement&#8221; and &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; in this prospectus supplement, where we describe additional uncertainties associated with our business
      and the forward-looking statements included or incorporated by reference in this prospectus supplement and the accompanying prospectus. The risks and uncertainties described below are not the only risks facing us. Please note that additional risks
      not currently known to us or that we currently deem immaterial also may adversely affect our business, results of operations, financial condition and prospects. Our business, financial condition, results of operations and prospects could be
      materially and adversely affected by these risks, and you may lose all or part of your original investment.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Risks Related to our Securities and this Offering</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Our management will have broad discretion in the use of the net proceeds we receive in this offering and might not apply the proceeds in ways that increase the
      value of your investment.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Our management and board of directors will have broad discretion over the use of our net proceeds from this offering, and you will be relying on their judgment regarding the application of these
      proceeds, which can be different from that contemplated at the time of this offering. Our management and board of directors might not apply our net proceeds in ways that ultimately increase the value of your investment and we might not be able to
      yield a significant return, if any, on any investment of these net proceeds. Our failure to apply these funds effectively could have a material adverse effect on our business, delay the development of our products and cause the price of our ordinary
      shares to decline.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Because we do not intend to declare cash dividends on our ordinary shares in the foreseeable future, shareholders must rely on appreciation of the value of the
      ADSs for any return on their investment and may not receive any funds without selling the ADSs.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We have never declared or paid cash dividends on our ordinary shares and do not anticipate declaring or paying any cash dividends in the foreseeable future. As a result, we expect that only
      appreciation of the price of the ADSs, if any, will provide a return to investors in this offering for the foreseeable future. In addition, because we do not pay cash dividends, if our shareholders want to receive funds in respect of the ADSs, they
      must sell the ADSs to do so.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">You may experience future dilution as a result of future equity offerings.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In order to raise additional capital, we expect to in the future offer additional ADSs or other securities convertible into or exchangeable for ADSs. We cannot assure you that we will be able to sell
      shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights
      superior to existing shareholders. The price per share at which we sell additional ADSs or other securities convertible into or exchangeable for the ADSs in future transactions may be higher or lower than the price per share in this offering.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Future sales of ADSs, or the perception that such sales could occur, may cause the prevailing market price of the ADSs to
        decrease.</font>&#160;</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We cannot predict the effect, if any, that future issuances or sales of our securities, this offering or the availability of our securities for future issuance or sale, will have
        on the market price of the ADSs. Subject to the completion of this offering, we will have sold a substantial number of ADSs. Any sales of such ADSs in the public market or otherwise, or the perception that such issuances or sales could occur, could
        reduce the prevailing market price for the ADSs, as well as make future sales of equity securities by us less attractive or even not feasible.</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">&#160;<font style="font-weight: bold; font-style: italic;">The actual number of ADSs we will sell under the Sales Agreement, at any one time or in total, is uncertain.</font></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Subject to certain limitations in the Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement notice at any time throughout the term of the Sales Agreement.
      The number of shares that are sold after delivering a placement notice will fluctuate based on the market price of the ADSs during the sales period and limits we set. Because the price per ADS of each ADS sold will fluctuate based on the market price
      of the ADSs during the sales period, it is not possible at this stage to predict the number of shares that will be ultimately issued.</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;"><font style="font-style: italic;">The ADSs offered hereby will be sold in</font>&#160;&#8220;<font style="font-style: italic;">at the market offerings,</font>&#8221;&#160;<font style="font-style: italic;">and investors who buy ADSs at different times will likely pay different prices.</font></div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Investors who purchase ADSs in this offering at different times will likely pay different prices, and so may experience different levels of dilution and different outcomes in their
      investment results. We will have discretion, subject to market demand, to vary the timing, prices, and number of shares sold in this offering. In addition, subject to the final determination by our board of directors, there is no minimum or maximum
      sales price for ADSs to be sold in this offering. Investors may experience a decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Risks Related to Chemomab&#8217;s Incorporation and Location in Israel</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Conditions in Israel, including the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israel&#8217;s war against them, may affect
          our operations</div>
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Because&#160; part of our operations are conducted in Israel, our business and operations are directly affected by economic, political, geopolitical and military conditions in
          Israel. Since the establishment of the State of Israel in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries and terrorist organizations active in the region. These conflicts have involved missile
          strikes, hostile infiltrations and terrorism against civilian targets in various parts of Israel, which have negatively affected business conditions in Israel.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also
          launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of
          civilians and soldiers. Following the attack, Israel&#8217;s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The intensity and duration of Israel&#8217;s current war against Hamas is difficult to predict, as are such war&#8217;s economic implications on the Company&#8217;s business and operations and
          on Israel's economy in general.</div>
      </div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 8</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="CAPITALIZATION2"><!--Anchor--></a>CAPITALIZATION</div>
    <div style="line-height: 1.25">&#160;&#160; </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following table sets forth our cash, cash equivalents and short-term bank deposits, and our capitalization as of June 30, 2023:</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf55e1452dd7d4e738d86d9c2081cab07">

        <tr>
          <td style="width: 2.01%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.02%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 1.02%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 95.94%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">on an actual basis; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z4f86554095f34e3b8d87000297161aa7">

        <tr>
          <td style="width: 2.01%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.02%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 1.02%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 95.94%; vertical-align: top;">
            <div style="line-height: 1.25;">on an as adjusted basis to give effect to the sale of 3,291,568 ADSs in this offering, at an assumed public offering price of $0.87 per ADS, and after deducting the estimated underwriting discounts and
              commissions and estimated offering expenses payable by us.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The information set forth in the following table should be read in conjunction with, and is qualified in its entirety by, reference to our audited and unaudited financial
        statements and the notes thereto incorporated by reference into this prospectus supplement and the accompanying base prospectus.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" id="zf3e53e4a1c6f436a8297c54a6ae4e342" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 75.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 0.96%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 22.09%; vertical-align: bottom;" colspan="6">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">As of June 30 , 2023</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 75.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 0.96%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 22.09%; vertical-align: bottom; border-bottom: #000000 2px solid;" colspan="6">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">(in thousands)(unaudited)</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 75.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 0.96%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 10.08%; vertical-align: bottom; border-bottom: #000000 2px solid;" colspan="2">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Actual</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 10.06%; vertical-align: bottom; border-bottom: #000000 2px solid;" colspan="2">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">As Adjusted</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 75.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 0.96%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 22.09%; vertical-align: bottom;" colspan="6">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 75.97%; vertical-align: top; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">Cash and cash equivalents and short-term bank deposits</div>
              </td>
              <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 1.12%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 4px double;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td nowrap="nowrap" style="width: 8.96%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 4px double;">
                <div style="text-align: right; line-height: 1.25;">26,663</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 1.12%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 4px double;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 8.94%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 4px double;">
                <div style="text-align: right; line-height: 1.25;">29,253</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 75.97%; vertical-align: top;">
                <div style="line-height: 1.25;">Shareholders&#8217; equity</div>
              </td>
              <td style="width: 0.96%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1.12%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 8.96%; vertical-align: bottom;">
                <div style="text-align: right; line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1.12%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 8.94%; vertical-align: bottom;">
                <div style="text-align: right; line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 75.97%; vertical-align: top; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">Ordinary Shares, no par value - Authorized: 650,000,000 ordinary shares as of June 30, 2023</div>
              </td>
              <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 1.12%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 8.96%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="text-align: right; line-height: 1.25;">&#8212;</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 1.12%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 8.94%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="text-align: right; line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 75.97%; vertical-align: top;">
                <div style="line-height: 1.25;">Issued and outstanding: 248,058,700 ordinary shares issued and outstanding actual;&#160; 313,890,060 ordinary shares issued and outstanding as adjusted</div>
              </td>
              <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 1.12%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 8.96%; vertical-align: bottom;">
                <div style="text-align: right; line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 1.12%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 8.94%; vertical-align: bottom;">
                <div style="text-align: right; line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 75.97%; vertical-align: top; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">Additional paid-in capital</div>
              </td>
              <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 1.12%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 8.96%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="text-align: right; line-height: 1.25;">103,751</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 1.12%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 8.94%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="text-align: right; line-height: 1.25;">106,341</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 75.97%; vertical-align: top;">
                <div style="line-height: 1.25;">Treasury stock at cost: 11,640,460 ordinary shares issued and outstanding</div>
              </td>
              <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 1.12%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 8.96%; vertical-align: bottom;">
                <div style="text-align: right; line-height: 1.25;">(1,218</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">)</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 1.12%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 8.94%; vertical-align: bottom;">
                <div style="text-align: right; line-height: 1.25;">(1,218</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">)</div>
              </td>
            </tr>
            <tr>
              <td style="width: 75.97%; vertical-align: top; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">Accumulated deficit</div>
              </td>
              <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 1.12%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 8.96%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="text-align: right; line-height: 1.25;">(80,542</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">)</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 1.12%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 8.94%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
                <div style="text-align: right; line-height: 1.25;">(80,542</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">)</div>
              </td>
            </tr>
            <tr>
              <td style="width: 75.97%; vertical-align: top;">
                <div style="line-height: 1.25;">Total shareholders&#8217; equity</div>
              </td>
              <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 1.12%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td nowrap="nowrap" style="width: 8.96%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="text-align: right; line-height: 1.25;">21,991</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 1.12%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td nowrap="nowrap" style="width: 8.94%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="text-align: right; line-height: 1.25;">24,581</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 75.97%; vertical-align: top; background-color: #CCEEFF;">
                <div style="line-height: 1.25;"><font style="font-weight: bold;">Total liabilities and shareholders&#8217; equity</font>&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 0.96%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 1.12%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td nowrap="nowrap" style="width: 8.96%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="text-align: right; line-height: 1.25;">28,849</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td nowrap="nowrap" style="width: 1.12%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td nowrap="nowrap" style="width: 8.94%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="text-align: right; line-height: 1.25;">31,439</div>
              </td>
              <td nowrap="nowrap" style="width: 0.97%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;"> <br>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The information above is based on 11,820,912 ADSs outstanding as of June 30, 2023, and does not account for the following:</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z13d5b8f2b7244135989aaae1793f3e3e">

        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.41%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 97.86%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">1,642,058 ADSs issuable upon the exercise of outstanding options to purchase ADSs, as of October 11, 2023, at a weighted average exercise price of $3.24 per ADS;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.41%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.86%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.41%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 97.86%; vertical-align: top;">
            <div style="line-height: 1.25;">an aggregate of 760,888 ADSs reserved for future issuance under our Share Incentive Plans, as of October 11, 2023, as well as any automatic increases in the number of ADSs reserved for future issuance under the
              2017 Plan; and</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.41%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.86%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.41%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 97.86%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">261,929 ADSs issuable upon the exercise of outstanding warrants to purchase ADSs at a weighted average exercise price of $17.35 per ADS, which warrants are expected to remain outstanding at
              the consummation of this offering.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">To the extent that options and warrants outstanding may be exercised, investors purchasing our securities in this offering may experience further dilution.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 9</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="USEOFPROCEEDS"><!--Anchor--></a>USE OF PROCEEDS</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 28.35pt; line-height: 1.25;">We currently expect to use the net proceeds from this offering for continued clinical development of our product candidates,&#160;research activities, and for other general corporate purposes. We have
      not determined the amount of net proceeds to be used specifically for the foregoing purposes. This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. Amounts and timing
      of our actual expenditures will depend upon a number of factors, including our sales, marketing and commercialization efforts, regulatory approval and demand for our product candidates, operating costs, among other factors. Accordingly, our
      management will have flexibility in applying the net proceeds from this offering. An investor will not have the opportunity to evaluate the economic, financial or other information on which we base our decisions on how to use the proceeds.</div>
    <div style="text-indent: 28.35pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 28.35pt; line-height: 1.25;">Pending use of the net proceeds, we intend to invest any proceeds in a variety of capital preservation instruments, including short-term deposits and interest-bearing instruments.</div>
    <div style="text-indent: 28.35pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 28.35pt; line-height: 1.25;">Based on our planned use of the net proceeds from this offering and our existing cash, cash equivalents and short-term bank deposits, we estimate that this financing will enable us to advance our
      clinical development programs for PSC. We are likely to need to secure additional financing to complete those programs. We continue to manage our cash runway and believe additional capital will be available when required. We have based this estimate
      on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect. In any event, we will require additional funding to complete the clinical development of, and commercialize, our future
      therapeutic candidates. We may satisfy our future cash needs through the sale of equity securities, debt financings, working capital lines of credit, corporate collaborations or license agreements, grant funding, interest income earned on invested
      cash balances or a combination of one or more of these sources.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 10</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="MATERIALTAXCONSIDERATIONS"><!--Anchor--></a>MATERIAL TAX CONSIDERATIONS</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The following is a brief summary of certain material tax consequences concerning the ownership and disposition of our securities by purchasers or holders of our securities. Because parts of this
      discussion are based on new or existing tax or other legislation that has not been subject to judicial or administrative interpretation, there can be no assurance that the views expressed herein will be accepted by the tax or other authorities in
      question. The summary below does not address all of the tax consequences that may be relevant to all purchasers or holders of our securities in light of each purchaser&#8217;s or holder&#8217;s particular circumstances and specific tax treatment. For example,
      the summary below does not address the tax treatment of residents of Israel and traders in securities who are subject to specific tax regimes. As individual circumstances may differ, holders of our securities should consult their own tax advisors as
      to United States, Israeli or other tax consequences of the purchase, ownership and disposition of our securities. This discussion is not intended, nor should it be construed, as legal or professional tax advice and it is not exhaustive of all
      possible tax considerations. Each individual should consult his or her own tax or legal advisor.</div>
    <div style="text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 11</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">CERTAIN MATERIAL ISRAELI TAX CONSEQUENCES</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Taxation of Capital Gains Applicable to Non-Israeli Shareholders</div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Israeli law generally imposes a capital gains tax on the sale of securities of an Israeli company, including securities traded on the TASE, on a recognized stock exchange outside Israel (such as
        Nasdaq) or on a regulated market (which includes a system through which securities are traded pursuant to rules prescribed by the competent authority in the relevant jurisdiction) in or outside Israel, a Recognized Exchange. The capital gains tax
        rate applicable to individuals upon the sale of such securities is such individual&#8217;s capital gain tax rate of 25%, or 30% with respect to an individual who meets the definition of a &#8216;Substantial Shareholder&#8217; on the date of the sale of the
        securities or at any time during the 12 months period preceding such date (or claims a deduction for interest and linkage differences expenses in connection with the purchase and holding of such shares). A &#8216;Substantial Shareholder&#8217; is defined as a
        person who, either alone or together with another person who collaborates with such person on a permanent basis , holds, directly or indirectly, at least 10% of any of the &#8220;means of control&#8221; of a company (including, among other things, the right to
        receive profits of the company, voting rights, the right to receive the company&#8217;s liquidation proceeds and the right to appoint a director).</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Notwithstanding the foregoing, dealers in securities in Israel are taxed at regular tax rates applicable to business income (a corporate tax rate for a corporation and a marginal tax rate of up to
        47% for an individual in 2022, excluding excess tax as discussed below) unless contrary provisions in a relevant tax treaty applies.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">With respect to corporate investors, capital gain tax equal to the corporate tax rate (23% starting in 2018) will be imposed on the sale of our traded shares, unless contrary provisions in a relevant
        tax treaty applies.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Generally, a non-Israeli resident (whether an individual or a corporation) who derives capital gains from the sale of shares in an Israeli resident company purchased upon or after the registration of
        the shares on the TASE or on a regulated market outside of Israel (such as Nasdaq) will generally be exempt from Israeli capital gains tax, provided, among other things, that the shares were not held through a permanent establishment that the
        non-Israeli tax resident investor maintains in Israel.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">However, non-Israeli resident corporations will not be entitled to the foregoing exemption if Israeli residents, whether directly or indirectly: (i) hold more than 25% of any of the means of control
        in such non-Israeli corporation or (ii) are the beneficiaries of, or are entitled to, 25% or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly. Such exemption is not applicable to a person whose gains
        from selling or otherwise disposing of the shares are deemed to be business income. In addition, persons paying consideration for shares, including purchasers of shares, Israeli securities dealers effecting a transaction, or a financial institution
        through which securities being sold are held, are generally required to withhold tax at source upon the sale of publicly traded securities at a rate of 25% for individuals and at the corporate tax rate (23% starting 2018) for corporations.
        Shareholders may be required to demonstrate that they are exempt from tax on their capital gains by providing a valid certificate from the Israel Tax Authority allowing for an exemption from withholding tax at source at the time of sale.
        Specifically, in transactions involving a sale of all of the shares of an Israeli resident company, in the form of a merger or otherwise, the Israel Tax Authority may require from shareholders who are not liable for Israeli tax to sign declarations
        in forms specified by this authority or obtain a specific exemption from the Israel Tax Authority to confirm their status as non-Israeli resident, and, in the absence of such declarations or exemptions, may require the purchaser of the shares to
        withhold taxes at source.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Income Taxes on Dividend Distribution to Non-Israeli Shareholders</div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Non-Israeli residents (whether individuals or corporations) are generally subject to Israeli income tax on the receipt of dividends paid on our ordinary shares at the rate of 25%, unless relief is
        provided under the provisions of an applicable tax treaty between Israel and the shareholder&#8217;s country of residence (provided that a certificate from the Israel Tax Authority allowing for a reduced withholding tax rate or a tax exemption is
        obtained in advance). With respect to a person who is a Substantial Shareholder at the time of receiving the dividend or on any time during the preceding 12 months, the applicable tax rate is 30%.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">In principle, non-Israeli residents (whether individuals or corporations) are generally subject to Israeli withholding tax on the receipt of dividends paid for publicly traded shares at the rate of
        25% and at the rate of 30% on dividends paid to Substantial Shareholders. However, so long as the shares are registered with a Nominee Company, which is a company incorporated to be a holder of record and distribution agent of publicly traded or
        other securities in accordance with the Israeli Securities Law, the shares are generally subject to Israeli withholding tax at a rate of 25% (whether or not the recipient is a substantial shareholder), unless a different rate is provided under an
        applicable tax treaty (provided that a certificate from the Israel Tax Authority allowing for a reduced withholding tax rate is obtained in advance).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">The distribution of dividends to non-Israeli residents (either individuals or corporations) from income derived from the Company&#8217;s Approved Enterprises or Benefited Enterprises during the applicable
        benefits period is subject to withholding tax at a rate of 15% subject to the receipt in advance of a valid certificate from the Israel Tax Authority allowing for a reduced tax rate, 15%, or such lower rate as may be. We cannot assure you that we
        will designate the profits that we may distribute in a way that will reduce shareholders&#8217; tax liability.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">A non-resident of Israel who has dividend and/or capital income derived from or accrued in Israel, from which the full amount of tax was withheld, is generally exempt from the duty to file tax
        returns in Israel in respect of such income, provided that: (i) such income was not derived from a business conducted in Israel by the taxpayer; (ii) the taxpayer has no other taxable sources of income in Israel with respect to which a tax return
        is required to be filed; and (iii) the taxpayer is not obligated to pay excess tax (as further explained below).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 12</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"></div>
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">U.S. Israel Tax Treaty</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">The Convention between the Government of the State of Israel and the Government of the United States of America with Respect to Taxes on Income (the &#8220;Treaty&#8221;) is generally effective as of January
          1, 1995. Under the Treaty, the maximum Israeli withholding tax on dividends paid to a holder of our ordinary shares who is a Treaty U.S. Resident (as defined below) is generally 25%. However, for dividends not generated by an Approved Enterprise,
          Benefited Enterprise or Preferred Enterprises and paid to a U.S. corporation holding 10% or more of the outstanding voting capital throughout the tax year in which the dividend is distributed as well as during the previous tax year, the maximum
          rate of withholding tax is generally 12.5%, provided that not more than 25% of the gross income of the Israeli resident paying corporation for such preceding year consists of certain types of dividends and interest. Notwithstanding the foregoing,
          dividends distributed from income attributed to an Approved Enterprise, Benefited Enterprise or Preferred Enterprise are not entitled to such reduction under such tax treaty but are subject to withholding tax at the rate of 15% or 20% for such a
          United States corporate shareholder, provided that the conditions related to the holding of 10% of our voting capital and to our gross income for the previous year (as set forth in the previous sentence) are met. The aforementioned rates under
          the Treaty would not apply if the dividend income is derived through a permanent establishment of the U.S. resident in Israel.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to the Treaty, the sale, exchange or disposition of our ordinary shares by a person who qualifies as a resident of the United States within the meaning of the Treaty that holds the shares as
        a capital asset, and who is entitled to claim the benefits afforded to such residents under the Treaty a (&#8220;Treaty U.S. Resident&#8221;) generally will not be subject to the Israeli capital gains tax unless,&#160;<font style="font-style: italic;">inter alia</font>:
        (i) such Treaty U.S. Resident holds, directly or indirectly, shares representing 10% or more of the voting power of the Company during any part of the 12-month period preceding such sale, exchange or disposition subject to certain conditions; (ii)
        the capital gain arising from such sale, exchange or disposition can be attributable to a permanent establishment of the shareholder maintained in Israel, under certain terms; (iii) such U.S. resident is an individual and was present in Israel for
        a period or periods aggregating to 183 days or more during the relevant taxable year; (iv) the capital gains arising from such sale, exchange or disposition is attributed to real estate located in Israel, or (v) the capital gain arising from such
        sale, exchange or disposition is attributed to royalties. A sale, exchange or disposition of our ordinary shares by a Treaty U.S. Resident who holds, directly or indirectly, shares representing 10% or more of the voting power of the Company at any
        time during such preceding 12-month period would not be exempt under the Treaty from such Israeli tax; however, under the Treaty, U.S. Resident would be permitted to claim a credit for such taxes against U.S. federal income tax imposed on any gain
        from such sale, exchange or disposition, under the circumstances and subject to the limitations specified in the Treaty and U.S. domestic law.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Excess Tax</div>
      <div style="line-height: 1.25;">&#160;
        <div style="text-indent: 36pt; line-height: 1.25;">Individuals who are subject to tax in Israel are also currently subject to an additional tax at a rate of 3% on annual income exceeding NIS 663,240 for 2022, which amount is linked to the annual
          change in the Israeli Consumer Price Index, including, but not limited to, dividends, interest and capital gain.</div>
        <div style="text-indent: 36pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 13</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">General</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The following discussion describes the material U.S. federal income tax consequences relating to the ownership and disposition of our ADSs by U.S. Holders (as defined below). This discussion applies to
      U.S. Holders that purchase ADSs pursuant to this offering and hold such ordinary shares as capital assets within the meaning of Section 1221 of the U.S. Internal Revenue Code of 1986, as amended, or the Code. This discussion is based on the Code,
      U.S. Treasury regulations promulgated thereunder and administrative and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject to change, possibly with retroactive effect. This discussion does not address
      all of the U.S. federal income tax consequences that may be relevant to specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special treatment under U.S. federal income tax law (such as banks, financial
      institutions, insurance companies, broker-dealers and traders in securities, commodities or currencies, persons that generally mark their securities to market for U.S. federal income tax purposes, tax-exempt entities, retirement plans, individual
      retirement accounts or other tax deferred accounts, regulated investment companies, real estate investment trusts, certain former citizens or residents of the United States, persons who hold ordinary shares as part of a &#8220;straddle,&#8221; &#8220;hedge,&#8221;
      &#8220;conversion transaction,&#8221; &#8220;synthetic security&#8221; or integrated investment, persons who received their ordinary shares as compensation or otherwise in connection with the performance of services, persons that have a &#8220;functional currency&#8221; other than the
      U.S. dollar, persons that own or are treated for tax purposes as owning directly, indirectly or through attribution 10% or more of our shares by vote or value, persons who are subject to special tax accounting under Section 451(b) of the Code,
      corporations that accumulate earnings to avoid U.S. federal income tax, partnerships and other pass-through entities and arrangements that are classified as partnerships for U.S. federal income tax purposes, and investors in such pass-through
      entities, and any holders that are not U.S. Holders). This discussion does not address any U.S. state or local or non-U.S. tax consequences,&#160; any U.S. federal estate, gift or alternative minimum tax consequences, or any tax consequences under the
      Medicare provisions of the Code. This discussion assumes that each obligation in the deposit agreement and in any related agreement is performed in accordance with its terms and that, therefore, beneficial owners of the ADSs should be treated as the
      owners of the underlying ordinary shares for U.S. federal income tax purposes.&#160; Accordingly, the terms &#8220;ordinary shares&#8221; and &#8220;ADS&#8221; are used interchangeably in this discussion.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">As used in this discussion, the term &#8220;U.S. Holder&#8221; means a beneficial owner of ordinary shares that is, for U.S. federal income tax purposes, (1) an individual who is a citizen or resident of the
      United States, (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia, (3) an estate the income of
      which is subject to U.S. federal income tax regardless of its source or (4) a trust (x) with respect to which a court within the United States is able to exercise primary supervision over its administration and one or more United States persons have
      the authority to control all of its substantial decisions or (y) that has elected under applicable U.S. Treasury regulations to be treated as a domestic trust for U.S. federal income tax purposes.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds ordinary shares, the U.S. federal income tax consequences relating to an investment in the ordinary
      shares will depend in part upon the status and activities of such entity or arrangement and the particular partner. Any such entity or arrangement should consult its own tax advisor regarding the U.S. federal income tax consequences applicable to it
      and its partners of the purchase, ownership and disposition of ordinary shares.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">Persons considering an investment in ordinary shares should consult their own tax advisors as to the particular tax consequences applicable to them relating to the purchase,
      ownership and disposition of ordinary shares, including the applicability of U.S. federal, state and local tax laws and non-U.S. tax laws.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Passive Foreign Investment Company Consequences</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In general, a corporation organized outside the United States will be treated as a passive foreign investment company, or PFIC, for any taxable year in which either (1) at least 75% of its gross income
      is &#8220;passive income&#8221;, the PFIC income test, or (2) on average at least 50% of its assets, determined on a quarterly basis, are assets that produce passive income or are held for the production of passive income, the PFIC asset test. Passive income for
      this purpose generally includes, among other things, dividends, interest, royalties, rents, and gains from the sale or exchange of property that gives rise to passive income. Assets that produce or are held for the production of passive income
      generally include cash, even if held as working capital or raised in a public offering, marketable securities, and other assets that may produce passive income. Generally, in determining whether a non-U.S. corporation is a PFIC, a proportionate share
      of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Our status as a PFIC will depend on the nature and composition of our income and the nature, composition and value of our assets (which may be determined based on the fair market value of each asset,
      with the value of goodwill and going concern value being determined in large part by reference to the market value of our common shares, which may be volatile). Based upon the value of our assets, including any goodwill and the nature and composition
      of our income, we believe that we were classified as a PFIC for the taxable year ended December 31, 2022. Furthermore, we presently anticipate that we will be classified as a PFIC for the current taxable year ending December 31, 2023 based upon the
      expected value of our assets, including goodwill, and the expected nature and composition of our income and assets. Our status as a PFIC is a fact-intensive determination made on an annual basis after the end of each taxable year. Even if we
      determine that we are not a PFIC for a taxable year, there can be no assurance that the IRS will agree with our conclusion and that the IRS would not successfully challenge our position. Our U.S. counsel expresses no opinion with respect to our PFIC
      status for any period.</div>
    <div style="text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 14</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Subject to the discussion below relating to the making of a QEF election or a mark-to-market election by a U.S. Holder, if we are a PFIC in any taxable year during which a U.S. Holder owns ordinary
      shares, the U.S. Holder could be liable for additional taxes and interest charges under the &#8220;PFIC excess distribution regime&#8221; upon (1) a distribution paid during a taxable year that is greater than 125% of the average annual distributions paid in the
      three preceding taxable years, or, if shorter, the U.S. Holder&#8217;s holding period for the ordinary shares, and (2) any gain recognized on a sale, exchange or other disposition, including a pledge, of the ordinary shares, whether or not we continue to
      be a PFIC. Under the PFIC excess distribution regime, the tax on such distribution or gain would be determined by allocating the distribution or gain ratably over the U.S. Holder&#8217;s holding period for ordinary shares. The amount allocated to the
      current taxable year (i.e., the year in which the distribution occurs or the gain is recognized) and any year prior to the first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year. The amount
      allocated to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations, as applicable, to ordinary income for each such taxable year, and an interest charge, generally applicable to underpayments of
      tax, will be added to the tax.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If we are a PFIC for any year during which a U.S. Holder holds ordinary shares, we must generally continue to be treated as a PFIC by that holder for all succeeding years during which the U.S. Holder
      holds the ordinary shares, unless we cease to meet the requirements for PFIC status and the U.S. Holder makes a &#8220;deemed sale&#8221; election with respect to the ordinary shares. If the election is made, the U.S. Holder will be deemed to sell the ordinary
      shares it holds at their fair market value on the last day of the last taxable year in which we qualified as a PFIC, and any gain recognized from such deemed sale would be taxed under the PFIC excess distribution regime. After the deemed sale
      election, the U.S. Holder&#8217;s ordinary shares would not be treated as shares of a PFIC unless we subsequently become a PFIC.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If we are a PFIC for any taxable year during which a U.S. Holder holds ordinary shares and one of our non-U.S. corporate subsidiaries is also a PFIC (i.e., a lower-tier PFIC), such U.S. Holder would be
      treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC and would be taxed under the PFIC excess distribution regime on distributions by the lower-tier PFIC and on gain from the disposition of shares of the lower-tier
      PFIC even though such U.S. Holder would not receive the proceeds of those distributions or dispositions. Each U.S. Holder is advised to consult its tax advisors regarding the application of the PFIC rules to our non-U.S. subsidiaries.</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In general, if we are determined to be a PFIC, a U.S. Holder may avoid application of the PFIC tax consequences described above in respect to our ordinary shares by making a timely QEF election (if
      eligible to do so) to include in income its pro rata share of our net capital gains (as long-term capital gain) and other earnings and profits (as ordinary income), on a current basis, in each case whether or not distributed, in the taxable year of
      the U.S. Holder in which or with which our taxable year ends. A U.S. Holder generally may make a separate election to defer the payment of taxes on undistributed income inclusions under the QEF rules, but if deferred, any such taxes will be subject
      to an interest charge. It should be noted that dividends paid by a PFIC would generally not qualify for the preferred capital gains rates discussed below. The QEF election is made on a shareholder-by-shareholder basis and, once made, can be revoked
      only with the consent of the IRS.</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">A U.S. Holder generally makes a QEF election by attaching a completed IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund), including
      the information provided in a PFIC annual information statement, to a timely filed U.S. federal income tax return for the tax year to which the election relates. Retroactive QEF elections generally may be made only by filing a protective statement
      with such return and if certain other conditions are met or with the consent of the IRS. U.S. Holders should consult their own tax advisors regarding the availability and tax consequences of a retroactive QEF election under their particular
      circumstances.</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In order to comply with the requirements of a QEF election, a U.S. Holder must receive a PFIC annual information statement from us. If we determine we are a PFIC for any taxable year, we will endeavor
      to provide to a U.S. Holder such information as the IRS may require, including a PFIC annual information statement, in order to enable the U.S. Holder to make and maintain a QEF election. However, there is no assurance that we will have timely
      knowledge of our status as a PFIC in the future or of the required information to be provided.</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If a U.S. Holder has made a QEF election with respect to our ordinary shares, and the special tax and interest charge rules do not apply to such shares (because of a timely QEF election for our first
      taxable year as a PFIC in which the U.S. Holder holds (or is deemed to hold) such shares), any gain recognized on the sale of our&#160; ordinary shares generally will be taxable as capital gain and no interest charge will be imposed under the PFIC rules.
      As discussed above, U.S. Holders of a QEF are currently taxed on their pro rata shares of its earnings and profits, whether or not distributed. In such case, a subsequent distribution of such earnings and profits that were previously included in
      income generally should not be taxable as a dividend to such U.S. Holders. The tax basis of a U.S. Holder&#8217;s shares in a QEF will be increased by amounts that are included in income, and decreased by amounts distributed but not taxed as dividends,
      under the above rules.</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 15</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Alternatively, if we are a PFIC, a U.S. Holder will not be subject to tax under the PFIC excess distribution regime on distributions or gain recognized on ordinary shares if such U.S. Holder makes a
      valid &#8220;mark-to-market&#8221; election for our ordinary shares. A mark-to-market election is available to a U.S. Holder only for &#8220;marketable stock.&#8221; Our ordinary shares will be marketable stock as long as they remain listed on The Nasdaq Capital Market and
      are regularly traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. If a mark-to-market election is in effect, a U.S. Holder generally would take into account, as ordinary income for each taxable year of the
      U.S. holder, the excess of the fair market value of ordinary shares held at the end of such taxable year over the adjusted tax basis of such ordinary shares. The U.S. Holder would also take into account, as an ordinary loss each year, the excess of
      the adjusted tax basis of such ordinary shares over their fair market value at the end of the taxable year, but only to the extent of the excess of amounts previously included in income over ordinary losses deducted as a result of the mark-to-market
      election. The U.S. Holder&#8217;s tax basis in ordinary shares would be adjusted to reflect any income or loss recognized as a result of the mark-to-market election. Any gain from a sale, exchange or other disposition of ordinary shares in any taxable year
      in which we are a PFIC would be treated as ordinary income and any loss from such sale, exchange or other disposition would be treated first as ordinary loss (to the extent of any net mark-to-market gains previously included in income) and thereafter
      as capital loss.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">A mark-to-market election will not apply to ordinary shares for any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable year in which we become
      a PFIC. Such election will not apply to any non-U.S. subsidiaries that we may organize or acquire in the future. Accordingly, a U.S. Holder may continue to be subject to tax under the PFIC excess distribution regime with respect to any lower-tier
      PFICs that we may organize or acquire in the future notwithstanding the U.S. Holder&#8217;s mark-to-market election for the ordinary shares.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Each U.S. person that is an investor of a PFIC is generally required to file an annual information return on IRS Form 8621 containing such information as the U.S. Treasury Department may require. The
      failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the statute of limitations with respect to U.S. federal income tax.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">The U.S. federal income tax rules relating to PFICs are very complex. Prospective U.S. investors are strongly urged to consult their own tax advisors with respect to the impact of
      PFIC status on the purchase, ownership and disposition of ordinary shares, the consequences to them of an investment in a PFIC, any elections available with respect to the ordinary shares and the IRS information reporting obligations with respect to
      the purchase, ownership and disposition of ordinary shares of a PFIC.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Distributions</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Subject to the discussion above under &#8220;&#8212;Passive Foreign Investment Company Consequences,&#8221; a U.S. Holder that receives a distribution with respect to ordinary shares generally will be required to
      include the gross amount of such distribution (before reduction for any Israeli withholding taxes withheld therefrom) in gross income as a dividend when actually or constructively received to the extent of the U.S. Holder&#8217;s pro rata share of our
      current and/or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution received by a U.S. Holder is not a dividend because it exceeds the U.S. Holder&#8217;s pro rata share of our current and
      accumulated earnings and profits, it will be treated first as a tax-free return of capital and reduce (but not below zero) the adjusted tax basis of the U.S. Holder&#8217;s ordinary shares. To the extent the distribution exceeds the adjusted tax basis of
      the U.S. Holder&#8217;s ordinary shares, the remainder will be taxed as capital gain. Because we may not account for our earnings and profits in accordance with U.S. federal income tax principles, U.S. Holders should expect all distributions to be reported
      to them as dividends. Such dividends will not be eligible for the &#8220;dividends received&#8221; deduction generally allowed to corporate shareholders with respect to dividends received from U.S. corporations.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Dividends paid to non-corporate U.S. Holders by a &#8220;qualified foreign corporation&#8221; are eligible for taxation at a reduced capital gains rate rather than the marginal tax rates generally applicable to
      ordinary income provided that certain requirements are met. However, if we are a PFIC for the taxable year in which the dividend is paid or the preceding taxable year (see discussion above under &#8220;&#8212;Passive Foreign Investment Company Consequences&#8221;), we
      will not be treated as a qualified foreign corporation, and therefore the reduced capital gains tax rate described above will not apply. Each U.S. Holder is advised to consult its tax advisors regarding the availability of the reduced tax rate on
      dividends with regard to its particular circumstances.</div>
    <div style="text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 16</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">A non-United States corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to
      be a qualified foreign corporation (a) if it is eligible for the benefits of a comprehensive tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which
      includes an exchange of information provision, or (b) with respect to any dividend it pays on ordinary shares that are readily tradable on an established securities market in the United States. Further, the IRS has determined that the Treaty is
      satisfactory for purposes of the qualified dividend rules and that it includes an exchange of information provision. Therefore, subject to the discussion above under &#8220;&#8212;Passive Foreign Investment Company Consequences,&#8221; if the Treaty is applicable,
      such dividends will generally be &#8220;qualified dividend income&#8221; in the hands of individual U.S. Holders, provided that certain conditions are met.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Distributions on ordinary shares that are treated as dividends generally will constitute income from sources outside the United States for foreign tax credit purposes and generally will constitute
      passive category income. Subject to applicable limitations, some of which vary depending upon a U.S. Holder&#8217;s particular circumstances, Israeli income taxes withheld from dividends on our common shares at a rate not exceeding the rate provided by the
      Treaty (assuming such U.S. Holder is eligible for the benefits of the Treaty) will be creditable against the U.S. Holder&#8217;s U.S. federal income tax liability. The rules governing foreign tax credits are complex and U.S. Holders should consult their
      tax advisers regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes, including any Israeli income tax, in computing their
      taxable income, subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Sale, Exchange or Other Disposition of Ordinary Shares</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Subject to the discussion above under &#8220;&#8212;Passive Foreign Investment Company Consequences,&#8221; a U.S. Holder generally will recognize capital gain or loss for U.S. federal income tax purposes upon the sale,
      exchange or other disposition of ordinary shares in an amount equal to the difference, if any, between the amount realized (i.e., the amount of cash plus the fair market value of any property received) on the sale, exchange or other disposition and
      such U.S. Holder&#8217;s adjusted tax basis in the ordinary shares. Such capital gain or loss generally will be long-term capital gain taxable at a reduced rate for non-corporate U.S. Holders or long-term capital loss if, on the date of sale, exchange or
      other disposition, the ordinary shares were held by the U.S. Holder for more than one year. Any capital gain of a non-corporate U.S. Holder that is not long-term capital gain is taxed at ordinary income rates. The deductibility of capital losses is
      subject to limitations. Any gain or loss recognized from the sale or other disposition of ordinary shares will generally be gain or loss from sources within the United States for U.S. foreign tax credit purposes.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Disposition of Foreign Currency</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">U.S. Holders are urged to consult their tax advisors regarding the tax consequences of receiving, converting or disposing of any non-U.S. currency received as dividends on ordinary shares or on the
      sale or retirement of ordinary shares.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 17</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Information Reporting and Backup Withholding</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">U.S. Holders may be required to file certain U.S. information reporting returns with the IRS with respect to an investment in ordinary shares, including, among others, IRS Form 8938 (Statement of
      Specified Foreign Financial Assets). As described above under &#8220;Passive Foreign Investment Company Consequences,&#8221; each U.S. Holder who is a shareholder of a PFIC must file an annual report containing certain information. U.S. Holders paying more than
      $100,000 for ordinary shares may be required to file IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) reporting this payment. Substantial penalties may be imposed upon a U.S. Holder that fails to comply with the
      required information reporting.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Dividends on and proceeds from the sale or other disposition of ordinary shares may be reported to the IRS unless the U.S. Holder establishes a basis for exemption. Backup withholding (currently at a
      rate of 24%) may apply to amounts subject to reporting if the holder (1) fails to provide an accurate United States taxpayer identification number or otherwise establish a basis for exemption, or (2) is described in certain other categories of
      persons. However, U.S. Holders that are corporations generally are excluded from these information reporting and backup withholding tax rules. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules
      generally will be allowed as a refund or a credit against a U.S. Holder&#8217;s U.S. federal income tax liability if the required information is furnished by the U.S. Holder on a timely basis to the IRS.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">U.S. Holders should consult their own tax advisors regarding the backup withholding tax and information reporting rules.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN ORDINARY SHARES IN LIGHT OF THE INVESTOR&#8217;S OWN CIRCUMSTANCES.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 18</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DILUTION"><!--Anchor--></a>DILUTION</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If you invest in the ADSs in this offering, your ownership interest will be immediately diluted to the extent of the difference between the public offering price per share and the as adjusted net
      tangible book value per ADS after this offering. Net tangible book value per ADS is calculated by subtracting our total liabilities from our total tangible assets, which is total assets, and dividing this amount by the number of ADSs outstanding. Our
      net tangible book value as of June 30, 2023 (unaudited) was approximately $22 million, or $1.86 per ADS.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">After giving effect to the sale of 3,306,559&#160; ADSs in this offering at an assumed public offering price of&#160;$0.87&#160; per ADSs, which was the closing sale price of the ADSs on the Nasdaq Capital Market
        on October 11, 2023, and after deducting commissions and other estimated offering expenses payable by us, our as adjusted net tangible book value as of June 30, 2023 would have been approximately $24,581 million, or $1.63 per ADS. This amount
        represents an immediate decrease in the net tangible book value of $0.23 per ADS to our existing shareholders and an immediate and increase in net tangible book value of $0.76 per ADS to new investors purchasing ADSs in this offering. The following
        table illustrates this per share dilution:</div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z9f0130c33fc94527b69a1d162f3d5c31">

        <tr>
          <td style="width: 73.93%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Assumed offering price per ADS</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 9.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">0.87</div>
          </td>
          <td style="width: 0.95%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 73.93%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Net tangible book value per ADS as of June 30, 2023</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9.94%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">1.86</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 9.94%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.95%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 73.93%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Decrease in net tangible book value per ADS attributable to new investors</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">(0.23)</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 9.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.95%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 73.93%; vertical-align: bottom;">
            <div style="line-height: 1.25;">As adjusted net tangible book value per ADS after this offering</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 9.94%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9.94%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">1.63</div>
          </td>
          <td style="width: 0.95%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 73.93%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Net increase in net tangible book per ADS to new investors in this offering</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 9.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.2%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td style="width: 9.94%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">0.76</div>
          </td>
          <td style="width: 0.95%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">The table above assumes for illustrative purposes that an aggregate of 3,291,568 ADSs are sold at a price of $0.87 per ADS, the closing sales price of ADSs on the Nasdaq Capital Market on October 11,
        2023, for aggregate gross proceeds of approximately $2.9 million. The shares sold in this offering, if any, will be sold from time to time at various prices.</div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The information above is based on 11,820,912 ADSs outstanding as of June 30, 2023, and excludes the following:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z2a6d6b181f8740109fbd79228d32b8a5">

        <tr>
          <td style="width: 2.17%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.17%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95.67%; vertical-align: top;">
            <div style="line-height: 1.25;">1,642,058 ADSs issuable upon the exercise of outstanding options to purchase ADSs, as of October 11, 2023 at a weighted average exercise price of $3.24 per ADS;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.17%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.17%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95.67%; vertical-align: top;">
            <div style="line-height: 1.25;">an aggregate 760,888 ADSs reserved for future issuance under our Share Incentive Plans, as of October 11, 2023, as well as any automatic increases in the number of common shares reserved for future issuance under
              the 2017 Plan; and</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.17%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.17%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95.67%; vertical-align: top;">
            <div style="line-height: 1.25;">261,929 ADSs issuable upon the exercise of outstanding warrants to purchase ADSs at a weighted average exercise price of $17.35 per share, which warrants are expected to remain outstanding at the consummation of
              this offering.</div>
          </td>
        </tr>

    </table>
    <div style="text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">To the extent that options and warrants outstanding as of October 11, 2023 may be exercised, investors purchasing our securities in this offering may experience further dilution.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 19</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="PLANOFDISTRIBUTION2"><!--Anchor--></a>PLAN OF DISTRIBUTION</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We have entered into a Sales Agreement (the &#8220;Sales Agreement&#8221;) with Roth, under which we may offer and sell the ADSs having an aggregate gross sales price of up to $2,863,664<font style="font-weight: bold;">&#160;</font>million from time to time through or to Roth acting as sales agent or principal. The Sales Agreement has been filed as an exhibit to the registration statement on Form F-3 of which this prospectus forms a part.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Roth may sell the ADSs by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as
      defined in Rule 415(a)(4) promulgated under the Securities Act. We may instruct Roth not to sell the ADSs if the sales cannot be effected at or above the price designated by us from time to time. We or Roth may suspend the offering of the ADSs upon
      notice and subject to other conditions.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We will pay Roth commissions, in cash, for its services in acting as agent in the sale of the ADSs. Roth will be entitled to compensation at a fixed commission rate of 3.0% of the aggregate gross sales
      price per ADS sold. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We have also agreed to
      reimburse Roth for certain specified expenses, including the fees and disbursements of its legal counsel in an amount not to exceed $50,000, an amount not to exceed $5,000 in the aggregate per quarter&#160;in connection with the ongoing diligence arising
      from the transactions contemplated by the sales agreement, and $10,000 for each amendment or replacement of the prospectus supplement. We have also agreed to pay Roth an advisory fee of $25,000.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">We estimate that the total expenses for the offering, excluding compensation and reimbursements payable to Roth under the terms of the Sales Agreement, will be approximately $113,000.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Settlement for sales of ADSs will occur on the second trading day following the date on which any sales are made, or on some other date that is agreed upon by us and Roth in connection with a
      particular transaction, in return for payment of the net proceeds to us. Sales of the ADSs as contemplated in this prospectus will be settled through the facilities of The Depository Trust Company or by such other means as we and Roth may agree upon.
      There is no arrangement for funds to be received in an escrow, trust or similar arrangement.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Roth will use its commercially reasonable efforts, consistent with its sales and trading practices, to solicit offers to purchase the ADSs under the terms and subject to the conditions set forth in the
      Sales Agreement. In connection with the sale of the ADSs on our behalf, Roth will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act and the compensation of Roth will be deemed to be underwriting commissions or discounts. We
      have agreed to provide indemnification and contribution to Roth against certain civil liabilities, including liabilities under the Securities Act.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The offering of the ADSs pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement as permitted therein. We and Roth&#160; may each terminate the Sales Agreement at any time
      upon ten days&#8217; prior notice.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Roth and its affiliates may in the future provide various investment banking, commercial banking and other financial services for us and our affiliates, for which services they may in the future
      receive customary fees.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">This prospectus, and any supplement thereto, in electronic format may be made available on a website maintained by Roth and Roth may distribute this prospectus, any supplement thereto, electronically.</div>
    <div style="text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Roth&#8217;s address is 888 San Clemente Drive, Suite 4000, Newport Beach, CA, 92660.</div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 20</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="ENFORCEMENTOFCI2VILLIABILI"><!--Anchor--></a>ENFORCEMENT OF CIVIL LIABILITIES</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">We are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in this prospectus, substantially all of whom
        reside outside the United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets and substantially all of our directors and officers are located outside the United States, any judgment
        obtained in the United States against us or any of our directors and officers may not be collectible within the United States.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">We have irrevocably appointed Chemomab Therapeutics, Inc. as our agent to receive service of process in any action against us in any U.S. federal or state court arising out of this offering or any
        purchase or sale of securities in connection with this offering. The address of our agent is One Kendall Square, Building 1400E, Suite 14-105, Cambridge, MA 02139.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">We have been informed by our legal counsel in Israel, Meitar | Law Offices, that it may be difficult to initiate an action with respect to U.S. securities law in original actions instituted in Israel
        or obtain a judgement based on the civil liability provisions of the U.S. federal securities laws. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate
        forum to hear such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must
        be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure may also be governed by Israeli law.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Subject to specified time limitations and legal procedures, Israeli courts may enforce a United States judgment in a civil matter which, subject to certain exceptions, is non-appealable, including a
        judgment based upon the civil liability provisions of the Securities Act or the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided that, among other things:</div>
      <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z73b9f491691742339f98123180c4c1b2">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the judgment is obtained after due process before a court of competent jurisdiction, according to the laws of the state in which the judgment is given and the rules of private international law prevailing in
              Israel;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="margin-left: 72pt; line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z00000eb778344764a7e625eeb2ecd047">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the prevailing law of the foreign state in which the judgment is rendered allows for the enforcement of judgments of Israeli courts;</div>
          </td>
        </tr>

    </table>
    <div style="margin-left: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z93e471771a5e4ff09db843c278f756f6">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">adequate service of process has been effected and the defendant has had a reasonable opportunity to be heard and to present his or her evidence;</div>
          </td>
        </tr>

    </table>
    <div style="margin-left: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf94b06c2b4714dadb0cc96cefa760848">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the judgment is not contrary to public policy of Israel, and the enforcement of the civil liabilities set forth in the judgment is not likely to impair the security or sovereignty of Israel;</div>
          </td>
        </tr>

    </table>
    <div style="margin-left: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc0340f38b28d4c2090054d08ee8f8316">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the judgment was not obtained by fraud and does not conflict with any other valid judgment in the same matter between the same parties;</div>
          </td>
        </tr>

    </table>
    <div style="margin-left: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc65d34b976ee441bb4aa75c056247626">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">an action between the same parties in the same matter was not pending in any Israeli court at the time at which the lawsuit was instituted in the foreign court; and</div>
          </td>
        </tr>

    </table>
    <div style="margin-left: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z89e26f5dc7264f959dfe20643281614f">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">&#160;</td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">the judgment is enforceable according to the laws of Israel and according to the law of the foreign state in which the relief was granted.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25;">If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred out of Israel. The usual
        practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment,
        but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual
        statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.</div>
      <div style="text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 21</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXPENSES</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25;">The following are the estimated expenses related to the filing of the registration statement of which this prospectus supplement forms a part, all of which will be paid by us.</div>
      <div style="text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-indent: 36pt; line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="zb3a2a706ddb64d9a9f0569d0c8472e41" class="cfttable">

            <tr>
              <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 88%;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">SEC registration fee</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">$</div>
              </td>
              <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">-</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 88%;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">FINRA filing fee</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">-</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 88%;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Depositary and Transfer agent&#8217;s fees</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">32,915</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 88%;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Printing and engraving expenses</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">1,000</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 88%;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Legal fees and expenses</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">25,000</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 88%;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Accounting fees and expenses</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">41,985</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 88%; padding-bottom: 2px;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Miscellaneous</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">-</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 88%;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 88%; padding-bottom: 4px;">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Total</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1" class="cftcurrcell">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">$</div>
              </td>
              <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1" class="cftnumcell">
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">100,900</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="LEGALM2ATTERS"><!--Anchor--></a>LEGAL MATTERS</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The validity of the securities offered by this prospectus will be passed upon by&#160;Meitar | Law Offices, Ramat Gan, Israel. Cooley LLP, New York, New York, will pass upon certain matters of U.S. federal
      and New York law. Certain legal matters will be passed upon for Roth by Duane Morris LLP, New York, New York.&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXPERTS</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">The consolidated financial statements of Chemomab Therapeutics Ltd. as of December 31, 2022 and 2021, and for each of the years in the two-year period ended December 31, 2022, and as of December
          31, 2021 and 2020, and for each of the years in the two-year period ending December 31, 2021, have been incorporated by reference herein in reliance upon the report of Somekh Chaikin, a member firm of KPMG International, independent registered
          public accounting firm incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.</div>
      </div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION OF INFORMATION BY REFERENCE</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The SEC allows us to incorporate by reference the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information
      incorporated by reference is considered to be part of this registration statement, and later information filed with the SEC will update and supersede this information. We hereby incorporate by reference into this registration statement the following
      documents previously filed with the SEC:</div>
    <div style="text-indent: 18pt; line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 3.33%; vertical-align: top;">&#160;</td>
            <td style="width: 1.66%; vertical-align: top;">
              <div style="line-height: 1.25;">&#9679;</div>
            </td>
            <td style="width: 95%; vertical-align: top;">
              <div style="line-height: 1.25;">the Company&#8217;s Annual Reports on&#160;<a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323001041/0001178913-23-001041-index.htm">Form&#160;10-K</a>&#160;for the&#160;years ended December&#160;31, 2022 and December 31,
                2021 filed with the SEC on March&#160;20, 2023 (the &#8220;2022 Annual Report&#8221;) and March 30, 2022, respectively;</div>
              <div style="line-height: 1.25;"> <br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 3.33%; vertical-align: top;">&#160;</td>
            <td style="width: 1.66%; vertical-align: top;">
              <div style="line-height: 1.25;">&#9679;</div>
            </td>
            <td style="width: 95%; vertical-align: top;">
              <div style="line-height: 1.25;">the Company&#8217;s Current Reports on Form 8-K filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000010/0001178913-23-000010-index.htm">January 3, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000147/0001178913-23-000147-index.htm">January 11, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000670/0001178913-23-000670-index.htm">February












                  21, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000679/0001178913-23-000679-index.htm">February 21, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323001809/0001178913-23-001809-index.htm">May 11, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323002136/0001178913-23-002136-index.htm">June
                  5, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323002225/0001178913-23-002225-index.htm">June 16, 2023</a>, and Reports on Form 6-K furnished with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323002362/0001178913-23-002362-index.htm">July 3, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323002732/0001178913-23-002732-index.htm">August
                  8, 2023</a> and <a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323002860/0001178913-23-002860-index.htm">August 14, 2023</a>; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 3.33%; vertical-align: top;">&#160;</td>
            <td style="width: 1.66%; vertical-align: top;">
              <div style="line-height: 1.25;">&#9679;</div>
            </td>
            <td style="width: 95%; vertical-align: top;">
              <div style="line-height: 1.25;">the description of our share capital, which is set forth in&#160;Exhibit 4.1&#160;of the 2022 Annual Report, and as may be further updated or amended in any amendment or report filed for such purpose, including&#160;<a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_4-1.htm"><u>Exhibit 4.1</u></a>&#160;to our 2022 Annual Report on Form 10-K for the year ended December 31, 2022.</div>
            </td>
          </tr>

      </table>
      <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;We are also incorporating by reference all subsequent Annual Reports on Form 20-F that we file with the SEC and those of our Reports on Form 6-K that we furnish to the SEC that we specifically
      identify in such form or in any applicable prospectus supplement as being incorporated by reference into this prospectus or such prospectus supplement after the date hereof and prior to the completion of an offering of securities under this
      prospectus.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">We have filed a registration statement on Form&#160;F-3 to register the issuance and the resale of the securities described elsewhere in this prospectus. This prospectus is a part of that registration
      statement. As permitted by SEC rules, this prospectus does not contain all of the information included in the registration statement and the accompanying exhibits and schedules we file with the SEC. You may refer to the registration statement and the
      exhibits and schedules for more information about us and our securities.</div>
    <div style="text-indent: 18pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Information and statements contained in this prospectus or any annex to this prospectus are qualified in all respects by reference to the copy of the relevant contract or other annex filed as an
      exhibit to the registration statement of which this prospectus forms a part.</div>
    <div style="text-indent: 18pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Statements made in this prospectus concerning the contents of any contract, agreement or other document are not complete descriptions of all terms of these documents. If a document has been filed as an
      exhibit to the registration statement, we refer you to the copy of the document that has been filed for a complete description of its terms. Each statement in this prospectus relating to a document filed as an exhibit is qualified in all respects by
      the filed exhibit. You should read this prospectus and the documents that we have filed as exhibits to the registration statement of which this prospectus is a part in their entirety.</div>
    <div style="text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 22</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 18pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We are subject to the informational requirements of the Exchange Act. Accordingly, we will be required to file reports and other information with the SEC, including annual reports on Form&#160;20-F and
      reports on Form&#160;6-K. The SEC maintains an internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.</div>
    <div style="text-indent: 18pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We are a &#8220;foreign private issuer&#8221; as defined in Rule&#160;3b-4 under the Securities Exchange Act of 1934, or the Exchange Act. As a result, our proxy solicitations are not subject to the disclosure and
      procedural requirements of Regulation 14A under the Exchange Act and transactions in our equity securities by our officers and directors are exempt from Section&#160;16 of the Exchange Act. In addition, we are not required under the Exchange Act to file
      periodic reports and financial statements as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. We publish annually an annual report filed on Form&#160;20-F containing financial statements that have been
      examined and reported on, with an opinion expressed by, a registered public accounting firm. We prepare our annual financial statements in United States dollars and in accordance with accounting principles generally accepted in the United States, or
      U.S. GAAP. If there is any inconsistency between the information in this prospectus and in any post-effective amendment to the Form&#160;F-3 of which this prospectus is a part, or in any prospectus supplement, you should rely on the information in the
      post-effective amendment or prospectus supplement, as relevant. You should read this prospectus and any post-effective amendment or prospectus supplement together with the additional information contained in documents listed above under the heading
      &#8220;Where You Can Find More Information; Incorporation of Information by Reference.&#8221; The registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us, the securities
      offered under this prospectus, and our other outstanding securities. The registration statement, including the exhibits, can be read at the SEC&#8217;s website mentioned above under &#8220;Where You Can Find More Information; Incorporation of Information by
      Reference.&#8221;</div>
    <div style="text-indent: 18pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We will provide to each person, including any beneficial owner, to whom this prospectus is delivered, a copy of any or all the information that has been incorporated by reference in this prospectus but
      not delivered with this prospectus (and any exhibits specifically incorporated in such information), at no cost, upon written or oral request to us at the following address:</div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 18pt; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">Chemomab Therapeutics Ltd.</div>
      <div style="line-height: 1.25;">Attention: Chief Financial Officer</div>
      <div style="line-height: 1.25;">Kiryat Atidim, Building 7,</div>
      <div style="line-height: 1.25;">Tel Aviv</div>
      <div style="line-height: 1.25;">6158002</div>
      <div style="line-height: 1.25;">Israel</div>
      <div style="margin-left: 54pt; line-height: 1.25;">&#160;</div>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">You may also obtain information about us by visiting our website at <font style="font-style: italic;">www.chemomab.com</font>. Information contained in our website is not part of this prospectus.</div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 18pt; line-height: 1.25;">&#160;</div>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">We have not authorized anyone to give any information or make any representation about their companies that is different from, or in addition to, that contained in this prospectus or in any of the
      materials that have been incorporated in this prospectus. Therefore, if anyone does give you information of this sort, you should not rely on it. If you are in a jurisdiction where offers to exchange or sell, or solicitations of offers to exchange or
      purchase, the securities offered by this prospectus or the solicitation of proxies is unlawful, or if you are a person to whom it is unlawful to direct these types of activities, then the offer presented in this prospectus does not extend to you. The
      information contained in this prospectus speaks only as of the date of this prospectus unless the information specifically indicates that another date applies. You should read all information supplementing this prospectus.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" class="BRPFPageNumber">SP - 23</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;"><img width="253" height="132" src="image0.jpg">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Up to $2,863,664</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">American Depositary Shares</div>
    <div style="line-height: 1.25;">&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: center; margin-left: 3.6pt; line-height: 1.25;">PROSPECTUS SUPPLEMENT</div>
    <div style="text-align: center; margin-left: 3.6pt; line-height: 1.25;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; margin-left: 3.6pt; line-height: 1.25;">&#160;</div>
    </div>
    <div style="text-align: center; margin-left: 3.6pt; line-height: 1.25; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: normal; font-variant: normal; text-transform: none;">Roth Capital Partners</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; margin-left: 3.6pt; line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div><br>
    <div style="line-height: 1.25;"></div>
    <div style="text-align: center; margin-left: 3.6pt; line-height: 1.25; font-weight: bold;">PART II</div>
    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; margin-left: 3.6pt; line-height: 1.25; font-weight: bold;">INFORMATION NOT REQUIRED IN PROSPECTUS</div>
    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Item 8. Indemnification of Directors and Officers.</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Under the Israeli Companies Law 5759-1999, or the Companies Law, an Israeli company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may
        exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of
        association. Our articles of association include such a provision. An Israeli company may not exculpate a director from liability arising out of a prohibited dividend or distribution to shareholders.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Under the Companies Law, an Israeli company may indemnify an office holder in respect of the following liabilities and expenses incurred for acts performed by him or her as an office holder, pursuant
        to an undertaking made either in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification (ours contain such a provision):</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z591456e9e6504b2d995ec93727e92c7c">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">a financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s award approved by a court. However, if an undertaking to indemnify an office
              holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to
              indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the above-mentioned foreseen events and amount or criteria;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd48e4df65ede44ecbddf382df7ee7208">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder: (i) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such
              investigation or proceeding, provided that (A) no indictment was filed against such office holder as a result of such investigation or proceeding; and (B) no financial liability, such as a criminal penalty, was imposed upon him or her as a
              substitute for the criminal proceeding as a result of such investigation or proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (ii) in
              connection with a monetary sanction; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z393710a418084eff9f9279b40a13cd3b">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or
              in connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder, or certain compensation payments
              made to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of the Israeli Securities Law 5728-1968, or the Israeli Securities Law.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Under the Companies Law, an Israeli company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder if and to the extent provided
        in the company&#8217;s articles of association:</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7cac2a29565a445ea711eeacee52c64c">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zce39154f7d1241bf8242a374788956a4">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">a breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z41734ab5e2334c8a8f015027fe6f585e">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">a financial liability imposed on the office holder in favor of a third party.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%II - %%-->
      <div style="line-height: 1.25;"> <br>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd323607944074d52a9c05029569938bf">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">a financial liability imposed in an administrative proceeding on the office holder in favor of a third party harmed by a breach, pursuant to certain provisions of the Israeli Securities Law.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zaff8baa86700428d95182c5f0d8b8052">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">expenses, including reasonable litigation expenses and legal fees, incurred by the office holder as a result of an administrative proceeding instituted against him or her, pursuant to certain provisions of the
              Israeli Securities Law.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Under the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zb5f6e77d5f1942a180f5e354ee4b0ed0">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to
              believe that the act would not harm the company;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zddc6e898ede748d2a7e5b8fe580d0e3c">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">a breach of duty of care committed intentionally or recklessly, excluding a breach arising solely out of the negligent conduct of the office holder;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z62b10361078444bc95ca1022c207dcac">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">an act or omission committed with intent to derive illegal personal benefit; or</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z95110b45b4544ea1b599ea0509c49289">

        <tr>
          <td style="width: 3.33%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.66%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="line-height: 1.25;">a civil or administrative fine or forfeit levied against the office holder.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Our articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by the Companies Law and the Israeli Securities Law.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Under the Companies Law, exculpation, indemnification and insurance for office holders in a public company must be approved by the compensation committee and the board of directors, and, with respect
        to certain office holders or under certain circumstances, also by the shareholders. We have obtained the foregoing approvals with respect to our office holders, and have entered into agreements with each of our office holders exculpating them to
        the fullest extent permitted by law and by our articles of association, and undertaking to indemnify them to the fullest extent permitted by law and our articles of association. This indemnification is limited to events determined as foreseeable by
        the board of directors based on our activities, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">The maximum indemnification amount to be set forth in such agreements is limited to an amount equal to the higher of $40 million, 25% of our total shareholders&#8217; equity as reflected in our most recent
        consolidated financial statements prior to the date on which the indemnity payment is made and 10% of our total market capitalization calculated based on the average closing price of ordinary shares over the 30 trading&#160;days prior to the actual
        payment, multiplied by the total number of our issued and outstanding shares as of the date of the payment (other than indemnification for an offering of securities to the public, including by a shareholder in a secondary offering, in which case
        the maximum indemnification amount is limited to the gross proceeds raised by us and/or any selling shareholder in such public offering). The maximum amount set forth in such agreements is in addition to any amount paid (if paid) under insurance
        and/or by a third-party pursuant to an indemnification arrangement.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">We have obtained directors&#8217; and officers&#8217; liability insurance for the benefit of our office holders and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest
        extent permitted by the Companies Law.</div>
      <div style="text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">II - 2</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="margin-left: 7.55pt; line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Item 9. Exhibits.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">The following exhibits are filed herewith:</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXHIBIT INDEX</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z6b134d1519ae4ab0a78f7fdb9f9ba99b">

        <tr>
          <td style="width: 9.38%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46.21%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td colspan="7" style="width: 30.97%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Incorporation by Reference</div>
          </td>
          <td style="width: 0.73%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.24%; vertical-align: middle;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.38%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-weight: bold;">Exhibit No.</div>
          </td>
          <td style="width: 0.73%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46.21%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Description</div>
          </td>
          <td style="width: 0.73%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.75%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Form</div>
          </td>
          <td style="width: 0.73%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.92%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">File No.</div>
          </td>
          <td style="width: 0.73%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.63%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Exhibit<br>
              No.</div>
          </td>
          <td style="width: 0.73%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.45%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Filing<br>
              Date</div>
          </td>
          <td style="width: 0.73%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.24%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Filed<br>
              /Furnished</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.38%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">1.1***</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46.21%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Form of Underwriting Agreement.</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.75%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.92%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.63%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.45%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.24%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.38%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_1-2.htm">1.2</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: top;"> <a href="exhibit_1-2.htm"><br>
            </a> </td>
          <td style="width: 46.21%; vertical-align: top;">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><a href="exhibit_1-2.htm">Sales Agreement, dated October 16, 2023, by and between the Registrant and&#160;Roth Capital Partners, LLC</a></div>
            </div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.75%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.92%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.63%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.45%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.24%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">*</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.38%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921037294/tm219877d1_ex3-1.htm">3.1</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);"> <br>
          </td>
          <td style="width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921037294/tm219877d1_ex3-1.htm">Amended and Restated Articles of Association of Chemomab Therapeutics Ltd.</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.75%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">8-K</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.92%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">001-38807</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.63%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">3.1</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.45%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">March 17, 2021</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.24%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.38%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_4-1.htm">4.1</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: top;"> <br>
          </td>
          <td style="width: 46.21%; vertical-align: bottom;">
            <div style="line-height: 1.25;"><a href="exhibit_4-1.htm">Form of Indenture.</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.75%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.92%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.63%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.45%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.24%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">*</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.38%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">4.2***</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Form of Note</div>
          </td>
          <td style="width: 0.73%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.75%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.92%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.63%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.45%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.24%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.38%; vertical-align: top;">
            <div style="line-height: 1.25;">4.3***</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46.21%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Form of Warrant</div>
          </td>
          <td style="width: 0.73%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.75%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.92%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.63%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.45%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.24%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.38%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">4.4***</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Form of Warrant Agreement</div>
          </td>
          <td style="width: 0.73%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.75%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.92%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.63%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.45%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.24%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.38%; vertical-align: top;">
            <div style="line-height: 1.25;">4.5***</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46.21%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Form of Unit Agreement</div>
          </td>
          <td style="width: 0.73%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.75%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.92%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.63%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.45%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.24%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.38%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;"><a href="exhibit_5-1.htm">5.1</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);"> <br>
          </td>
          <td style="width: 46.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;"><a href="exhibit_5-1.htm">Opinion of Meitar | Law Offices</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.75%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.92%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.63%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.45%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.24%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">**</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.38%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_5-2.htm">5.2</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: top;"> <br>
          </td>
          <td style="width: 46.21%; vertical-align: bottom;">
            <div style="line-height: 1.25;"><a href="exhibit_5-2.htm">Opinion of Cooley LLP</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.75%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.92%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.63%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.45%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.24%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">**</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.38%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;"><a href="exhibit_23-1.htm">23.1</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;"><a href="exhibit_23-1.htm">&#160;</a></div>
          </td>
          <td style="width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;"><a href="exhibit_23-1.htm">Consent of Somekh Chaikin, a member of KPMG International, independent registered accounting firm for
                Chemomab Therapeutics Ltd.</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.75%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.92%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.63%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.45%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.24%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">*</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.38%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_5-1.htm">23.2</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: top;"> <a href="exhibit_5-1.htm"><br>
            </a> </td>
          <td style="width: 46.21%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_5-1.htm">Consent of Meitar | Law Offices. (included in Exhibit 5.1)</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.75%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.92%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.63%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.45%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.24%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">**</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.38%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;"><a href="exhibit_5-2.htm">23.3</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);"> <a href="exhibit_5-2.htm"><br>
            </a> </td>
          <td style="width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;"><a href="exhibit_5-2.htm">Consent of Cooley LLP (included in Exhibit 5.2)</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.75%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.92%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.63%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.45%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.24%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">**</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.38%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="#PowerofAttorney">24.1</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: top;"> <br>
          </td>
          <td style="width: 46.21%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="#PowerofAttorney">Power of Attorney (included on the signature page hereto)</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.75%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.92%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.63%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.45%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.24%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">**</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.38%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;"><a href="exhibit_107.htm">107</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);"> <br>
          </td>
          <td style="width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;"><a href="exhibit_107.htm">Calculation of Registration Fee</a></div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.75%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.92%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.63%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.45%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.73%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.24%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25;">*</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zbb8a406e2fd8448a98cc890b51a07d1b">

        <tr>
          <td style="width: 3.33%; vertical-align: top;">
            <div style="line-height: 1.25;">*</div>
          </td>
          <td style="vertical-align: top;">
            <div style="line-height: 1.25;">Filed herewith.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3.33%; vertical-align: top;">
            <div style="line-height: 1.25;">**</div>
          </td>
          <td style="vertical-align: top;">
            <div style="line-height: 1.25;">Furnished herewith.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="vertical-align: top;">
            <div style="line-height: 1.25;">***</div>
          </td>
          <td style="width: 96.39%; vertical-align: top;">
            <div style="line-height: 1.25;">To be filed by amendment or incorporated by reference in connection with the offering of the securities.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3.33%; vertical-align: top;">
            <div style="line-height: 1.25;">&#8224;</div>
          </td>
          <td style="vertical-align: top;">
            <div style="line-height: 1.25;">Schedules and Exhibits omitted pursuant to Regulation S-K Item 601(b)(2). The Registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">Certain agreements filed as exhibits to this registration statement contain representations and warranties that the parties thereto made to each other. These representations and warranties have been made solely for the
        benefit of the other parties to such agreements and may have been qualified by certain information that has been disclosed to the other parties to such agreements and that may not be reflected in such agreements. In addition, these representations
        and warranties may be intended as a way of allocating risks among parties if the statements contained therein prove to be incorrect, rather than as actual statements of fact. Accordingly, there can be no reliance on any such representations and
        warranties as characterizations of the actual state of facts. Moreover, information concerning the subject matter of any such representations and warranties may have changed since the date of such agreements.</div>
      <div style="line-height: 1.25;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">II - 3</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Item 10. Undertakings.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z4084a225961f4dfc916feb03044a6c26">

        <tr>
          <td style="width: 2.67%; vertical-align: top;">
            <div style="line-height: 1.25;">(a)</div>
          </td>
          <td style="width: 97.33%; vertical-align: top;">
            <div style="line-height: 1.25;">The undersigned registrant hereby undertakes:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z0f562c57cf114cadbe8c2b2a44e9c5cd">

        <tr>
          <td style="width: 1.08%; vertical-align: top;">
            <div style="margin-left: 9pt">
              <div style="margin-left: 9pt">
                <div style="margin-left: 9pt">&#160;</div>
              </div>
            </div>
          </td>
          <td style="width: 2.82%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(1)</div>
          </td>
          <td style="width: 96.1%; vertical-align: top;">
            <div style="line-height: 1.25;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7b006be090684b3288de102731a1bd4d">

        <tr>
          <td style="width: 3.02%; vertical-align: top;">
            <div style="margin-left: 9pt">
              <div style="margin-left: 9pt">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt">
                      <div style="margin-left: 9pt">
                        <div style="margin-left: 9pt">&#160;</div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </td>
          <td style="width: 2.28%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(i)</div>
          </td>
          <td style="width: 94.7%; vertical-align: top;">
            <div style="line-height: 1.25;">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="ze9ed9b6c57e544b1b221695898913249">

        <tr>
          <td style="width: 2.68%; vertical-align: top;">
            <div style="margin-left: 9pt">
              <div style="margin-left: 9pt">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt">
                      <div style="margin-left: 9pt">
                        <div style="margin-left: 9pt">&#160;</div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </td>
          <td style="width: 2.95%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(ii)</div>
          </td>
          <td style="width: 94.37%; vertical-align: top;">
            <div style="line-height: 1.25;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate,
              represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not
              exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in
              volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zad12f2cff4d6404c9684d8c345e2efab">

        <tr>
          <td style="width: 2.68%; vertical-align: middle;">
            <div style="line-height: 1.25; margin-left: 63pt;">&#160;</div>
          </td>
          <td style="width: 2.95%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(iii)</div>
          </td>
          <td style="width: 94.37%; vertical-align: top;">
            <div style="line-height: 1.25;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;&#160;</div>
            <div style="line-height: 1.25; font-style: italic;">&#160;</div>
            <div style="line-height: 1.25;"><font style="font-style: italic;">provided, however</font>, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective
              amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration
              statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z95a5f98f16594f4cbbc4b22b4337cf10">

        <tr>
          <td style="width: 1.08%; vertical-align: top;">
            <div style="margin-left: 9pt">
              <div style="margin-left: 9pt">
                <div style="margin-left: 9pt">&#160;</div>
              </div>
            </div>
          </td>
          <td style="width: 2.82%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(2)</div>
          </td>
          <td style="width: 96.1%; vertical-align: top;">
            <div style="line-height: 1.25;">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered
              therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd62e56b9a57644f6ba5ff2ede33854a2">

        <tr>
          <td style="width: 1.08%; vertical-align: top;">
            <div style="margin-left: 9pt">
              <div style="margin-left: 9pt">
                <div style="margin-left: 9pt">&#160;</div>
              </div>
            </div>
          </td>
          <td style="width: 2.82%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(3)</div>
          </td>
          <td style="width: 96.1%; vertical-align: top;">
            <div style="line-height: 1.25;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zfcc8cd8e23554a48b0e256fa9c73968d">

        <tr>
          <td style="width: 1.08%; vertical-align: top;">
            <div style="margin-left: 9pt">
              <div style="margin-left: 9pt">
                <div style="margin-left: 9pt">&#160;</div>
              </div>
            </div>
          </td>
          <td style="width: 2.82%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(4)</div>
          </td>
          <td style="width: 96.1%; vertical-align: top;">
            <div style="line-height: 1.25;">To file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form&#160;20-F&#160;at the start of any delayed offering or throughout a continuous offering.
              Financial statements and information otherwise required by Section&#160;10(a)(3) of the Act need not be furnished, provided, that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required
              pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with respect to
              registration statements on Form&#160;F-3,&#160;a post-effective amendment need not be filed to include financial statements and information required by Section&#160;10(a)(3) of the Act or Rule&#160;3-19&#160;of this chapter if such financial statements and
              information are contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Form&#160;F-3.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="ze8626d2931d14aa8af1acedbb337ff8d">

        <tr>
          <td style="width: 1.08%; vertical-align: top;">
            <div style="margin-left: 9pt">
              <div style="margin-left: 9pt">
                <div style="margin-left: 9pt">&#160;</div>
              </div>
            </div>
          </td>
          <td style="width: 2.82%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(5)</div>
          </td>
          <td style="width: 96.1%; vertical-align: top;">
            <div style="line-height: 1.25;">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z02840c96c3a549e2bad7cd34e4fa68d9">

        <tr>
          <td style="width: 3.02%; vertical-align: top;">
            <div style="margin-left: 9pt">
              <div style="margin-left: 9pt">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt">
                      <div style="margin-left: 9pt">
                        <div style="margin-left: 9pt">&#160;</div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </td>
          <td style="width: 2.28%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(i)</div>
          </td>
          <td style="width: 94.7%; vertical-align: top;">
            <div style="line-height: 1.25;">If the registrant is relying on Rule 430B:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; text-align: center;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd2af9148cbb54f91bc7e4e734ff3d5a2">

        <tr>
          <td style="width: 4.15%; vertical-align: top;">
            <div style="margin-left: 9pt">
              <div style="margin-left: 9pt">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt">
                      <div style="margin-left: 9pt">
                        <div style="margin-left: 9pt">
                          <div style="margin-left: 9pt">
                            <div style="margin-left: 9pt">
                              <div style="margin-left: 9pt">&#160;</div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </td>
          <td style="width: 3.35%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(A)</div>
          </td>
          <td style="width: 92.5%; vertical-align: top;">
            <div style="line-height: 1.25;">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration
              statement; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">II - 4</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"> <br>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z186a255932a04262bfc5a676a5f57526">

        <tr>
          <td style="width: 4.21%; vertical-align: top;">
            <div style="margin-left: 9pt">
              <div style="margin-left: 9pt">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt">
                      <div style="margin-left: 9pt">
                        <div style="margin-left: 9pt">
                          <div style="margin-left: 9pt">
                            <div style="margin-left: 9pt">
                              <div style="margin-left: 9pt">&#160;</div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </td>
          <td style="width: 3.21%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(B)</div>
          </td>
          <td style="width: 92.57%; vertical-align: top;">
            <div style="line-height: 1.25;">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule&#160;415(a)(1)(i), (vii) or
              (x)&#160;for the purpose of providing the information required by Section&#160;10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first
              used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter,
              such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to
              be the initial&#160;<font style="font-style: italic;">bona fide</font>&#160;offering thereof;&#160;<font style="font-style: italic;">provided</font>,&#160;<font style="font-style: italic;">however</font>, that no statement made in a registration statement or
              prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with
              a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to
              such effective date;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z0da0d0bff4a84e7ea49555b470ce2f08">

        <tr>
          <td style="width: 1.08%; vertical-align: top;">
            <div style="margin-left: 9pt">
              <div style="margin-left: 9pt">
                <div style="margin-left: 9pt">&#160;</div>
              </div>
            </div>
          </td>
          <td style="width: 2.82%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(6)</div>
          </td>
          <td style="width: 96.1%; vertical-align: top;">
            <div style="line-height: 1.25;">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a
              primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser
              by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z05b74eb9d3fa41cca096dfe7876dde54">

        <tr>
          <td style="width: 3.02%; vertical-align: top;">
            <div style="margin-left: 9pt">
              <div style="margin-left: 9pt">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt">
                      <div style="margin-left: 9pt">
                        <div style="margin-left: 9pt">&#160;</div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </td>
          <td style="width: 2.28%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(i)</div>
          </td>
          <td style="width: 94.7%; vertical-align: top;">
            <div style="line-height: 1.25;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za2458b2322cf4a4fb828aa22a8e8dcd4">

        <tr>
          <td style="width: 3.02%; vertical-align: top;">
            <div style="margin-left: 9pt">
              <div style="margin-left: 9pt">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt">
                      <div style="margin-left: 9pt">
                        <div style="margin-left: 9pt">&#160;</div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </td>
          <td style="width: 2.28%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(ii)</div>
          </td>
          <td style="width: 94.7%; vertical-align: top;">
            <div style="line-height: 1.25;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd3de0afff4d84fa184f9537a8f58509d">

        <tr>
          <td style="width: 3.02%; vertical-align: top;">
            <div style="margin-left: 9pt">
              <div style="margin-left: 9pt">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt">
                      <div style="margin-left: 9pt">
                        <div style="margin-left: 9pt">&#160;</div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </td>
          <td style="width: 2.28%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(iii)</div>
          </td>
          <td style="width: 94.7%; vertical-align: top;">
            <div style="line-height: 1.25;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant;
              and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7b52a8f11e3146169774cce6c45b5f84">

        <tr>
          <td style="width: 3.02%; vertical-align: top;">
            <div style="margin-left: 9pt">
              <div style="margin-left: 9pt">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt">
                      <div style="margin-left: 9pt">
                        <div style="margin-left: 9pt">&#160;</div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </td>
          <td style="width: 2.28%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(iv)</div>
          </td>
          <td style="width: 94.7%; vertical-align: top;">
            <div style="line-height: 1.25;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc523e150650b4597ac5bbc3c056785d5">

        <tr>
          <td style="width: 2.82%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(b)</div>
          </td>
          <td style="width: 97.18%; vertical-align: top;">
            <div style="line-height: 1.25;">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or
              Section&#160;15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the
              registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial&#160;<font style="font-style: italic;">bona
                fide</font>&#160;offering thereof.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z2af01f8e2a674d9498a45df248c4e844">

        <tr>
          <td style="width: 2.67%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(c)</div>
          </td>
          <td style="width: 97.33%; vertical-align: top;">
            <div style="line-height: 1.25;">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or
              otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event
              that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or
              proceeding), is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent,
              submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z732f742ef2924cf9a10fb641e83b09ab">

        <tr>
          <td style="width: 2.82%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">(d)</div>
          </td>
          <td style="width: 97.18%; vertical-align: top;">
            <div style="line-height: 1.25;">The undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a)&#160;of Section&#160;310 of the Trust Indenture Act in
              accordance with the rules and regulations prescribed by the SEC under Section&#160;305(b)(2) of the Trust Indenture Act.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">II - 5</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURES</div>
    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-indent: 32.4pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has
        duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tel Aviv, Israel, on October 16, 2023.</div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z163702425bbe4bcf9b13c0e39050a19f">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="line-height: 1.25;">CHEMOMAB THERAPEUTICS LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-style: italic;">/s/ Adi Mor</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">Name:</div>
          </td>
          <td style="width: 46%; vertical-align: top;">
            <div style="line-height: 1.25;">Adi Mor</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">Title:</div>
          </td>
          <td style="width: 46%; vertical-align: top;">
            <div style="line-height: 1.25;">Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">II - 6</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="PowerofAttorney"><!--Anchor--></a>Power of Attorney</div>
    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-indent: 32.4pt; line-height: 1.25;">KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints Adi Mor and Sigal Fattal, jointly and severally, his or her true and lawful
      attorneys-in-fact and agents with full powers of substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all supplements amendments (including post-effective amendments) to this Registration Statement, and
      to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each
      and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their
      substitute or substitutes, may lawfully do or cause to be done by virtue thereof.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 32.4pt; line-height: 1.25;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z3747f62b9e6848acb4cbd394a4c88002">

        <tr>
          <td style="width: 26.05%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-weight: bold;">Signature</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Title</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Date</div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom;" rowspan="1">&#160;</td>
          <td style="width: 1%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 56.92%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 1%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 15.03%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-style: italic;">/s/ Adi Mor</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">Chief Executive Officer and Director</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top; text-align: center;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">October 16, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Adi Mor</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">(principal executive officer)</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-style: italic;">/s/ Sigal Fattal</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">Chief Financial Officer</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">October 16, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Sigal Fattal</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">(principal financial and accounting officer)</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-style: italic;">/s/ Nissim Darvish</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">Chairman of the Board of Directors</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">October 16, 2023</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Nissim Darvish</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-style: italic;">/s/ Jill Quigley</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">Director</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">October 16, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Jill Quigley</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: bottom;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: bottom;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-style: italic;">/s/ Claude Nicaise</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">Director</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">October 16, 2023</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Claude Nicaise</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-style: italic;">/s/ Alan Moses</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">Director</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">October 16, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Alan Moses</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-style: italic;">/s/ Neil Cohen</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">Director</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">October 16, 2023</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 26.05%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Neil Cohen</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 56.92%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 15.03%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">II - 7</font> </div>
    <div style="text-align: center; line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"> </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25">&#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1
<SEQUENCE>2
<FILENAME>exhibit_1-2.htm
<DESCRIPTION>EXHIBIT 1.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="text-align: right; line-height: 1.25;"><u><font style="font-weight: bold;">Exhibit 1.2</font></u><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">Chemomab Therapeutics Ltd.</font><br>
      American Depositary Shares</div>
    <div style="text-align: center; line-height: 1.25;">Each Representing 20 Ordinary Shares</div>
    <div style="text-align: center; line-height: 1.25;">(no par value)</div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>Sales Agreement</u></div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: right; text-indent: 36pt; line-height: 1.25;">October 16, 2023</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Roth Capital Partners, LLC</div>
    <div style="text-align: justify; line-height: 1.25;">888 San Clemente Drive, Suite 400</div>
    <div style="text-align: justify; line-height: 1.25;">Newport Beach, CA 92660</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Ladies and Gentlemen:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">Chemomab Therapeutics Ltd., a company organized under the laws of Israel (the &#8220;<font style="font-weight: bold;"><u>Company</u></font>&#8221;), confirms its agreement (this &#8220;<font style="font-weight: bold;"><u>Agreement</u></font>&#8221;)



      with Roth Capital Partners, LLC (the &#8220;<font style="font-weight: bold;"><u>Agent</u></font>&#8221;), as follows:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue
      and sell through the Agent, American Depositary Shares (the &#8220;<font style="font-weight: bold;"><u>ADSs</u></font>&#8221; and the &#8220;<font style="font-weight: bold;"><u>Placement Shares</u></font>&#8221;), each representing twenty (20) of the Company&#8217;s ordinary
      shares, no par value per share (the &#8220;<font style="font-weight: bold;"><u>Ordinary Shares</u></font>&#8221;); provided, however, that in no event shall the Company issue or sell through the Agent such number or dollar amount of Placement Shares that would
      (a) exceed the number or dollar amount of ADSs registered on the effective Registration Statement (defined below) pursuant to which the offering of such Placement Shares is being made, (b) exceed the number of authorized but unissued Ordinary Shares
      or ADSs (less Ordinary Shares or ADSs issuable upon exercise, conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company&#8217;s authorized capital stock), (c) exceed the number or dollar amount of ADSs
      permitted to be sold under Form F-3 (including General Instruction I.B.5 thereof, if applicable) or (d) exceed the number or dollar amount of ADSs for which the Company has filed a Prospectus Supplement (defined below) (the lesser of (a), (b), (c)
      and (d), the &#8220;<font style="font-weight: bold;"><u>Maximum Amount</u></font>&#8221;). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in this <u>Section 1</u> on the number
      or dollar amount of ADSs issued and sold under this Agreement shall be the sole responsibility of the Company, and Agent shall have no obligation in connection with such compliance. The offer and sale of ADSs through the Agent will be effected
      pursuant to the Registration Statement (as defined below) to be filed by the Company and which will have been declared effective by the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold;"><u>Commission</u></font>&#8221;), although
      nothing in this Agreement shall be construed as requiring the Company to use the Registration Statement (as defined below) to issue the ADSs. The ADSs are to be issued pursuant to that certain deposit agreement (the &#8220;<font style="font-weight: bold;"><u>Deposit



          Agreement</u></font>&#8221;), dated as of February 14, 2019, among the Company, the Bank of New York Mellon as depositary (the &#8220;<font style="font-weight: bold;"><u>Depositary</u></font>&#8221;), and the holders and beneficial owners from time to time of the
      ADSs. Each ADS will represent the right to receive twenty Ordinary Shares deposited pursuant to the Deposit Agreement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;The Company will file, in accordance with the provisions of the Securities Act of 1933, as amended (the &#8220;<font style="font-weight: bold;"><u>Securities Act</u></font>&#8221;) and the
      rules and regulations thereunder (the &#8220;<font style="font-weight: bold;"><u>Securities Act Regulations</u></font>&#8221;), with the Commission a registration statement on Form F-3, including a base prospectus, relating to certain securities, including the
      Placement Shares to be issued from time to time by the Company pursuant to this Agreement, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934,
      as amended (the &#8220;<font style="font-weight: bold;"><u>Exchange Act</u></font>&#8221;), and the rules and regulations thereunder. The Company has prepared a prospectus or a prospectus supplement to the base prospectus included as part of such registration
      statement, which prospectus or prospectus supplement relates to the Placement Shares to be issued from time to time by the Company pursuant to this Agreement (the &#8220;<font style="font-weight: bold;"><u>Prospectus Supplement</u></font>&#8221;). The Company
      will furnish to the Agent, for use by the Agent, copies of the prospectus included as part of such registration statement, as supplemented, by the Prospectus Supplement, relating to the Placement Shares to be issued from time to time by the Company.
      The Company may file one or more additional registration statements from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable (which shall be a Prospectus Supplement), with respect to the
      Placement Shares to be issued pursuant to this Agreement. Except where the context otherwise requires, such registration statement(s), including all documents filed as part thereof or incorporated by reference therein, and including any information
      contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act Regulations and deemed to be a part of such registration statement pursuant to Rule 430B of the Securities Act
      Regulations, is herein called the &#8220;<font style="font-weight: bold;"><u>Registration Statement</u></font>.&#8221; The base prospectus or base prospectuses, including all documents incorporated therein by reference, included in the Registration Statement, as
      it may be supplemented, if necessary, by the Prospectus Supplement, in the form in which such prospectus or prospectuses and/or Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to Rule 424(b) under the
      Securities Act Regulations, together with the then issued Issuer Free Writing Prospectus(es) (if any), is herein called the &#8220;<font style="font-weight: bold;"><u>Prospectus</u></font>.&#8221; The Company has filed with the Commission a registration
      statement on Form F-6, as amended (File No. 333-229522) relating to the ADSs. Such registration statement, as amended, including the financial statements, exhibits and schedules thereto, in the form in which it became effective under the Securities
      Act is called the &#8220;<font style="font-weight: bold;"><u>F-6 Registration Statement</u></font>.&#8221;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">Any reference herein to the Registration Statement, the F-6 Registration Statement, any Prospectus Supplement, Prospectus or any Issuer Free Writing Prospectus (defined below) shall be deemed to refer
      to and include the documents, if any, incorporated by reference therein (the &#8220;<font style="font-weight: bold;"><u>Incorporated Documents</u></font>&#8221;), including, unless the context otherwise requires, the documents, if any, filed as exhibits to such
      Incorporated Documents. Any reference herein to the terms &#8220;amend,&#8221; &#8220;amendment&#8221; or &#8220;supplement&#8221; with respect to the Registration Statement, the F-6 Registration Statement, any Prospectus Supplement, the Prospectus or any Issuer Free Writing Prospectus
      shall be deemed to refer to and include the filing of any document under the Exchange Act on or after the most-recent effective date of the Registration Statement or the F-6 Registration Statement, or the date of the Prospectus Supplement, Prospectus
      or such Issuer Free Writing Prospectus, as the case may be, and incorporated therein by reference. For purposes of this Agreement, all references to the Registration Statement, the F-6 Registration Statement, the Prospectus or to any amendment or
      supplement thereto shall be deemed to include the most recent copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval system, or if applicable, the Interactive Data Electronic Application system when used by
      the Commission (collectively, &#8220;<font style="font-weight: bold;"><u>EDGAR</u></font>&#8221;).</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Placements</u>. Each time that the Company wishes to issue and sell Placement Shares hereunder (each, a &#8220;<font style="font-weight: bold;"><u>Placement</u></font>&#8221;), it will
      notify the Agent by email notice (or other method mutually agreed to by the parties) of the number of Placement Shares to be issued, the time period during which sales are requested to be made, any limitation on the number of Placement Shares that
      may be sold in any one day and any minimum price below which sales may not be made (a &#8220;<font style="font-weight: bold;"><u>Placement Notice</u></font>&#8221;), which Placement Notice shall be substantially in the form attached hereto as <u>Schedule 1</u>.
      The Placement Notice shall originate from any of the individuals from the Company set forth on <u>Schedule 3</u> (with a copy to each of the other individuals from the Company listed on such schedule<u>)</u>, and shall be addressed to each of the
      individuals from the Agent set forth on <u>Schedule 3</u>, as such <u>Schedule 3</u> may be amended from time to time in accordance with the terms of this Agreement. The Placement Notice shall be effective unless and until (i) the Agent declines to
      accept the terms contained therein for any reason, in its sole discretion, (ii) the entire amount of the Placement Shares thereunder has been sold, (iii) the Company amends, supersedes, suspends or terminates the Placement Notice or (iv) this
      Agreement has been terminated under the provisions of <u>Section 12</u>. The amount of any discount, commission or other compensation to be paid by the Company to Agent in connection with the sale of the Placement Shares shall be calculated in
      accordance with the terms set forth in <u>Schedule 2</u>. It is expressly acknowledged and agreed that neither the Company nor the Agent will have any obligation whatsoever with respect to a Placement or any Placement Shares unless and until the
      Company delivers a Placement Notice to the Agent and the Agent does not decline (and the Company does not suspend or terminate in accordance with the terms of this Agreement) such Placement Notice pursuant to the terms set forth above, and then only
      upon the terms specified therein and herein. In the event of a conflict between the terms of this Agreement and the terms of a Placement Notice, the terms of the Placement Notice will control.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Sale of Placement Shares by the Agent</u>. Subject to the provisions of <u>Section 5(a)</u>, the Agent, for the period specified in the Placement Notice, will use its
      commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Capital Market (the &#8220;<font style="font-weight: bold;"><u>Exchange</u></font>&#8221;),



      to sell the Placement Shares up to the amount specified in, and otherwise in accordance with the terms of, such Placement Notice. The Agent will provide written confirmation to the Company no later than the opening of the Trading Day (as defined
      below) immediately following the Trading Day on which it has made sales of Placement Shares hereunder setting forth the number of Placement Shares sold on such day, the compensation payable by the Company to the Agent pursuant to <u>Section 2</u>
      with respect to such sales, and the Net Proceeds (as defined below) payable to the Company, with an itemization of the deductions made by the Agent (as set forth in <u>Section 5(b)</u>) from the gross proceeds that it receives from such sales.
      Subject to the terms of the Placement Notice, the Agent may sell Placement Shares by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act Regulations, including sales made directly on
      or through the Exchange or any other existing trading market for the ADSs, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or any other method permitted by law. &#8220;<u>Trading



        Day</u>&#8221; means any day on which ADSs are traded on the Exchange.</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Suspension of Sales</u>. The Company or the Agent may, upon notice to the other party in writing (including by email correspondence to each of the individuals of the other party set
      forth on <u>Schedule 3</u>, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable facsimile transmission or
      email correspondence to each of the individuals of the other party set forth on <u>Schedule 3</u>), suspend any sale of Placement Shares (a &#8220;<font style="font-weight: bold;"><u>Suspension</u></font>&#8221;); <font style="font-style: italic;">provided</font>,
      <font style="font-style: italic;">however</font>, that such Suspension shall not affect or impair any party&#8217;s obligations with respect to any Placement Shares sold hereunder prior to the receipt of such notice. While a Suspension is in effect any
      obligation under <u>Sections 7(l)</u>, <u>7(m)</u>, and <u>7(n)</u> with respect to the delivery of certificates, opinions, or comfort letters to the Agent, shall be waived. Each of the parties agrees that no such notice under this <u>Section 4</u>
      shall be effective against any other party unless it is made to one of the individuals named on <u>Schedule 3</u> hereto, as such Schedule may be amended from time to time in accordance with the terms of this Agreement.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Sale and Delivery to the Agent; Settlement</u>.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Sale of Placement Shares</u><font style="font-style: italic;">. </font>On the basis of the representations and warranties herein contained and subject to the terms and conditions
      herein set forth, upon the Agent&#8217;s acceptance of the terms of a Placement Notice, and unless the sale of the Placement Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this Agreement, the
      Agent, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell such Placement Shares up to the amount specified,
      and otherwise in accordance with the terms of such Placement Notice. The Company acknowledges and agrees that (i) there can be no assurance that the Agent will be successful in selling Placement Shares, (ii) the Agent will incur no liability or
      obligation to the Company or any other person or entity if it does not sell Placement Shares for any reason other than a failure by the Agent to use its commercially reasonable efforts consistent with its normal trading and sales practices and
      applicable law and regulations to sell such Placement Shares as required under this Agreement and (iii) the Agent shall be under no obligation to purchase Placement Shares on a principal basis pursuant to this Agreement, except as otherwise agreed by
      the Agent and the Company.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Settlement of Placement Shares</u><font style="font-style: italic;">. </font>Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement
      Shares will occur on the second (2nd) Trading Day (or such earlier day as is industry practice for regular-way trading) following the date on which such sales are made (each, a &#8220;<font style="font-weight: bold;"><u>Settlement Date</u></font>&#8221;). The
      Agent shall notify the Company of each sale of Placement Shares no later than the opening of the Trading Day immediately following the Trading Day on which it has made sales of Placement Shares hereunder. The amount of proceeds to be delivered to the
      Company on a Settlement Date against receipt of the Placement Shares sold (the &#8220;<font style="font-weight: bold;"><u>Net Proceeds</u></font>&#8221;) will be equal to the aggregate sales price received by the Agent, after deduction for (i) the Agent&#8217;s
      commission, discount or other compensation for such sales payable by the Company pursuant to <u>Section 2</u> hereof, and (ii) any transaction fees imposed by any Governmental Authority in respect of such sales.</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Delivery of Placement Shares</u>. On or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the Placement Shares being sold
      by crediting the Agent&#8217;s or its designee&#8217;s account (provided the Agent shall have given the Company written notice of such designee at least one Trading Day prior to the Settlement Date) at The Depository Trust Company through its Deposit and
      Withdrawal at Custodian System or by such other means of delivery as may be mutually agreed upon by the parties hereto which in all cases shall be freely tradable, transferable, registered shares in good deliverable form. On each Settlement Date, the
      Agent will deliver the related Net Proceeds in same day funds to an account designated by the Company on, or prior to, the Settlement Date. The Company agrees that if the Company, or its transfer agent (if applicable), defaults in its obligation to
      deliver Placement Shares on a Settlement Date, then in addition to and in no way limiting the rights and obligations set forth in <u>Section 10(a)</u> hereto, it will (i) hold the Agent harmless against any loss, claim, damage, or expense (including
      reasonable and documented legal fees and expenses), as incurred, arising out of or in connection with such default by the Company or its transfer agent (if applicable) and (ii) pay to the Agent (without duplication) any commission, discount, or other
      compensation to which it would otherwise have been entitled absent such default.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Denominations; Registration</u><font style="font-style: italic;">. </font>Certificates for the Placement Shares, if any, shall be in such denominations and registered in such
      names as the Agent may request in writing at least one full Business Day (as defined below) before the Settlement Date. The certificates for the Placement Shares, if any, will be made available by the Company for examination and packaging by the
      Agent in The City of New York not later than noon (New York time) on the Business Day prior to the Settlement Date.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Limitations on Offering Size</u><font style="font-style: italic;">. </font>Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares if,
      after giving effect to the sale of such Placement Shares, the aggregate gross sales proceeds of Placement Shares sold pursuant to this Agreement would exceed the lesser of (A) together with all sales of Placement Shares under this Agreement, the
      Maximum Amount and (B) the amount authorized from time to time to be issued and sold under this Agreement by the Company&#8217;s board of directors, a duly authorized committee thereof or a duly authorized executive committee, and notified to the Agent in
      writing. Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares pursuant to this Agreement at a price lower than the minimum price authorized from time to time by the Company&#8217;s board of directors, a duly
      authorized committee thereof or a duly authorized executive committee. Further, under no circumstances shall the Company cause or permit the aggregate offering amount of Placement Shares sold pursuant to this Agreement to exceed the Maximum Amount.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">4</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Representations and Warranties of the Company</u>. The Company represents and warrants to, and agrees with Agent that as of the date of this Agreement and as of each Applicable Time
      (as defined below), unless such representation, warranty or agreement specifies a different time:</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Registration Statement and Prospectus</u>. The Company and the transactions contemplated by this Agreement meet the requirements for and comply with the applicable conditions set
      forth in Form F-3 (including General Instructions I.A and I.B) under the Securities Act. The Registration Statement has been or will be filed with the Commission and will be declared effective by the Commission under the Securities Act prior to the
      issuance of any Placement Notices by the Company. The Prospectus Supplement will name the Agent as the agent in the section entitled &#8220;Plan of Distribution.&#8221; The Company has not received, and has no notice of, any order of the Commission preventing or
      suspending the use of the Registration Statement, or threatening or instituting proceedings for that purpose. The Registration Statement and the offer and sale of Placement Shares as contemplated hereby meet the requirements of Rule 415 under the
      Securities Act and comply in all material respects with said Rule. Any statutes, regulations, contracts or other documents that are required to be described in the Registration Statement or the Prospectus or to be filed as exhibits to the
      Registration Statement have been so described or filed. Copies of the Registration Statement, the Prospectus, and any such amendments or supplements and all documents incorporated by reference therein that were filed with the Commission on or prior
      to the date of this Agreement have been delivered, or are available through EDGAR, to Agent and its counsel. The Company has not distributed and, prior to the later to occur of each Settlement Date and completion of the distribution of the Placement
      Shares, will not distribute any offering material in connection with the offering or sale of the Placement Shares other than the Registration Statement and the Prospectus and any Issuer Free Writing Prospectus (as defined below) to which the Agent
      has consented. The ADSs are registered pursuant to Section 12(b) of the Exchange Act and are currently listed on the Exchange under the trading symbol &#8220;CMMB.&#8221; The Company has taken no action designed to, or likely to have the effect of, terminating
      the registration of the ADSs under the Exchange Act, delisting the ADSs from the Exchange, nor has the Company received any notification that the Commission or the Exchange is contemplating terminating such registration or listing. To the Company&#8217;s
      knowledge (following due inquiry), it is in compliance with all applicable listing requirements of the Exchange.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Misstatement or Omission</u>. The Registration Statement, when it became or becomes effective, and the Prospectus, and any amendment or supplement thereto, on the date of such
      Prospectus or amendment or supplement, conformed and will conform in all material respects with the requirements of the Securities Act. At each Settlement Date, the Registration Statement and the Prospectus, as of such date, will conform in all
      material respects with the requirements of the Securities Act. The Registration Statement, when it became or becomes effective, did not, and will not, contain an untrue statement of a material fact or omit to state a material fact required to be
      stated therein or necessary to make the statements therein not misleading. The Prospectus and any amendment and supplement thereto, on the date thereof and at each Applicable Time (defined below), did not or will not include an untrue statement of a
      material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. The documents incorporated by reference in the Prospectus or any Prospectus Supplement
      did not, and any further documents filed and incorporated by reference therein will not, when filed with the Commission, contain an untrue statement of a material fact or omit to state a material fact required to be stated in such document or
      necessary to make the statements in such document, in light of the circumstances under which they were made, not misleading. The foregoing shall not apply to statements in, or omissions from, any such document made in reliance upon, and in conformity
      with, information furnished to the Company by Agent specifically for use in the preparation thereof.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">5</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Conformity with Securities Act and Exchange Act</u>. The Registration Statement, the Prospectus, any Issuer Free Writing Prospectus or any amendment or supplement thereto, and the
      documents incorporated by reference in the Registration Statement, the Prospectus or any amendment or supplement thereto, when such documents were or are filed with the Commission under the Securities Act or the Exchange Act or became or become
      effective under the Securities Act, as the case may be, conformed or will conform in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>F-6 Registration Statement</u>. The F-6 Registration Statement and any amendments thereto, in respect of the Placement Shares has been filed with the Commission; such registration
      statement in the form heretofore delivered to the Agent and has been declared effective by the Commission; no stop order suspending the effectiveness of such registration statement has been issued and, to the knowledge of the Company, no proceeding
      for that purpose has been initiated or threatened by the Commission (the various parts of such registration statement, including all exhibits thereto, each as amended at the time such part of the registration statement became effective; as of the
      applicable effective date of the F-6 Registration Statement and any post-effective amendment thereto, the F-6 Registration Statement and any such post-effective amendment complied and as of each Applicable Time, complied and will comply in all
      material respects with the applicable requirements of the Securities Act, and did not and as of each Applicable Time, did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
      or necessary in order to make the statements therein not misleading.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Financial Information</u>. The consolidated financial statements of the Company included or incorporated by reference in the Registration Statement, the Prospectus and the Issuer
      Free Writing Prospectuses, if any, together with the related notes and schedules, present fairly, in all material respects, the consolidated financial position of the Company and the Subsidiaries (as defined below) as of the dates indicated and the
      consolidated results of operations, cash flows and changes in stockholders&#8217; equity of the Company for the periods specified and have been prepared in compliance with the requirements of the Securities Act and Exchange Act and in conformity with GAAP
      (as defined below) applied on a consistent basis during the periods involved; the other financial and statistical data with respect to the Company and the Subsidiaries (as defined below) contained or incorporated by reference in the Registration
      Statement, the Prospectus and the Issuer Free Writing Prospectuses, if any, are accurately and fairly presented and prepared on a basis consistent with the financial statements and books and records of the Company; there are no financial statements
      (historical or pro forma) that are required to be included or incorporated by reference in the Registration Statement, or the Prospectus that are not included or incorporated by reference as required; the Company and the Subsidiaries (as defined
      below) do not have any material liabilities or obligations, direct or contingent (including any off-balance sheet obligations), not described in the Registration Statement (excluding the exhibits thereto), and the Prospectus; and all disclosures
      contained or incorporated by reference in the Registration Statement, the Prospectus and the Issuer Free Writing Prospectuses, if any, regarding &#8220;non-GAAP financial measures&#8221; (as such term is defined by the rules and regulations of the Commission)
      comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities Act, to the extent applicable. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration
      Statement and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">6</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Conformity with EDGAR Filing</u>. The Prospectus delivered to Agent for use in connection with the sale of the Placement Shares pursuant to this Agreement will be identical to
      the versions of the Prospectus created to be transmitted to the Commission for filing via EDGAR, except to the extent permitted by Regulation S-T.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Organization</u>. The Company and each of its Subsidiaries are duly organized, validly existing as a corporation and in good standing (where such concept is applicable) under the
      laws of their respective jurisdictions of organization. The Company and each of its Subsidiaries are duly licensed or qualified as a foreign corporation for transaction of business and in good standing (where such concept is applicable) under the
      laws of each other jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses requires such license or qualification, and have all corporate power and authority necessary to own or hold their
      respective properties and to conduct their respective businesses as described in the Registration Statement and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or
      in the aggregate, have a material adverse effect or would reasonably be expected to have a material adverse effect on or affecting the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders&#8217;
      equity or results of operations of the Company and the Subsidiaries taken as a whole, or prevent or materially interfere with consummation of the transactions contemplated hereby (a &#8220;<font style="font-weight: bold;"><u>Material Adverse Effect</u></font>&#8221;).The




      Company is not designated as a &#8220;breaching company&#8221; (within the meaning of the Israeli Companies Law, 5759-1999 and the rules and regulations promulgated thereunder, the &#8220;<font style="font-weight: bold;"><u>Companies Law</u></font>&#8221;) by the Registrar
      of Companies of the State of Israel (the &#8220;<font style="font-weight: bold;"><u>Israeli Registrar</u></font>&#8221;) nor has a proceeding been instituted by the Registrar of Companies in Israel for the dissolution of the Company or each of its Subsidiaries.
      The certificate of incorporation and articles of association and other organizational documents of the Company comply with the requirements of applicable law of its jurisdiction of incorporation and are in full force and effect.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Subsidiaries</u>. The subsidiaries set forth on <u>Schedule 4</u> (collectively, the &#8220;<font style="font-weight: bold;"><u>Subsidiaries</u></font>&#8221;), are the Company&#8217;s only
      significant subsidiaries (as such term is defined in Rule 1-02 of Regulation S-X promulgated by the Commission). Except as set forth in the Registration Statement and in the Prospectus, the Company owns, directly or indirectly, all of the equity
      interests of the Subsidiaries free and clear of any lien, charge, security interest, encumbrance, right of first refusal or other restriction, and all the equity interests of the Subsidiaries are validly issued and are fully paid, nonassessable and
      free of preemptive and similar rights. No Subsidiary is currently prohibited, directly or indirectly, from paying any dividends to the Company, from making any other distribution on such Subsidiary&#8217;s capital stock, from repaying to the Company any
      loans or advances to such Subsidiary from the Company or from transferring any of such Subsidiary&#8217;s property or assets to the Company or any other Subsidiary of the Company.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">7</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Violation or Default</u>. Neither the Company nor any of its Subsidiaries is (i) in violation of its charter or by-laws or similar organizational documents; (ii) in default,
      and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or
      other agreement or instrument to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound or to which any of the property or assets of the Company or any of its Subsidiaries are subject; or
      (iii) in violation of any law or statute or any judgment, order, rule or regulation of any Governmental Authority, except, in the case of each of clauses (ii) and (iii) above, for any such violation or default that would not, individually or in the
      aggregate, have a Material Adverse Effect. To the Company&#8217;s knowledge, no other party under any material contract or other agreement to which it or any of its Subsidiaries is a party is in default in any respect thereunder where such default would
      have a Material Adverse Effect.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Material Adverse Change</u>. Subsequent to the respective dates as of which information is given in the Registration Statement, the Prospectus and the Free Writing
      Prospectuses, if any (including any document deemed incorporated by reference therein), there has not been (i) any Material Adverse Effect or the occurrence of any development that the Company reasonably expects will result in a Material Adverse
      Effect, (ii) any transaction which is material to the Company and the Subsidiaries taken as a whole, (iii) any obligation or liability, direct or contingent (including any off-balance sheet obligations), incurred by the Company or any Subsidiary,
      which is material to the Company and the Subsidiaries taken as a whole, (iv) any material change in the capital stock or outstanding long-term indebtedness of the Company or any of its Subsidiaries or (v) any dividend or distribution of any kind
      declared, paid or made on the capital stock of the Company or any Subsidiary, other than in each case above in the ordinary course of business or as otherwise disclosed in the Registration Statement or Prospectus (including any document deemed
      incorporated by reference therein).</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Capitalization</u>. The issued and outstanding shares of capital stock of the Company (i) have been validly issued, are fully paid and nonassessable and, (ii) other than as
      disclosed in the Registration Statement or the Prospectus, are not subject to any preemptive rights, rights of first refusal or similar rights and (iii) were issued in compliance with the Companies Law and the Israeli Securities Law 5728-1968 (the &#8220;<font style="font-weight: bold;">Israeli Securities Law</font>&#8221;). The Company has an authorized, issued and outstanding and fully diluted capitalization as set forth in the Registration Statement and the Prospectus as of the dates referred to therein
      (other than the grant of additional options under the Company&#8217;s existing stock option plans, or changes in the number of outstanding Ordinary Shares or ADSs of the Company due to the issuance of shares upon the exercise or conversion of securities
      exercisable for, or convertible into, Ordinary Shares or ADSs outstanding on the date hereof) and such authorized capital stock conforms to the description thereof set forth in the Registration Statement and the Prospectus. The description of the
      securities of the Company in the Registration Statement and the Prospectus is complete and accurate in all material respects. Except as disclosed in or contemplated by the Registration Statement or the Prospectus, as of the date referred to therein,
      the Company does not have any outstanding options to purchase, or any rights or warrants to subscribe for, or any securities or obligations convertible into, or exchangeable for, or any contracts or commitments to issue or sell, any shares of capital
      stock or other securities.</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Authorization; Enforceability</u>. The Company has full legal right, power and authority to enter into this Agreement and perform the transactions contemplated hereby. This
      Agreement has been duly authorized, executed and delivered by the Company and is a legal, valid and binding agreement of the Company enforceable in accordance with its terms, except to the extent that enforceability may be limited by bankruptcy,
      insolvency, reorganization, moratorium or similar laws affecting creditors&#8217; rights generally and by general equitable principles.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">8</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Authorization of Placement Shares</u>. The Placement Shares, when issued and delivered pursuant to the terms approved by the board of directors of the Company and, when the Ordinary
      Shares underlying the Placement Shares are issued and delivered and paid for as provided herein, such shares will be duly and validly issued, will be fully paid and nonassessable and will conform in all material respects to the descriptions thereof
      in the Registration Statement and the Prospectus; and the issuance of the Placement Shares is not subject to any preemptive or similar rights (save for those granted under applicable law). The Ordinary Shares underlying the Placement Shares may be
      freely deposited by the Company with the Depositary against issuance of the ADSs; the ADSs to be sold by the Company, when issued and delivered against payment thereof, will be freely transferable by the Company to or for the account of the Agent and
      (to the extent described in the Prospectus) the initial purchasers thereof; and there are no restrictions on subsequent transfers of the ADSs under the laws of Israel or the United States except as disclosed or incorporated by reference in the
      Registration Statement and the Prospectus under &#8220;Description of Share Capital,&#8221; and &#8220;Description of American Depositary Shares&#8221;.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Deposit Agreement</u>. The Deposit Agreement has been duly authorized by the Company and delivered in accordance with its terms by each of the parties thereto, and constitutes a
      valid and legally binding agreement of the Company enforceable against the Company in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization or similar laws affecting the enforcement of
      creditors&#8217; rights generally or by equitable principles relating to enforceability.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Consents Required</u>. No consent, approval, authorization, order, registration or qualification of or with any Governmental Authority is required for the execution, delivery
      and performance by the Company of this Agreement, the issuance and sale by the Company of the Placement Shares, except for such consents, approvals, authorizations, orders and registrations or qualifications as may be required under applicable state
      securities laws or by the by-laws and rules of the Financial Industry Regulatory Authority (&#8220;<font style="font-weight: bold;"><u>FINRA</u></font>&#8221;) or the Exchange in connection with the sale of the Placement Shares by the Agent.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Preferential Rights</u>. Except as set forth in the Registration Statement and the Prospectus, (i) no person, as such term is defined in Rule 1-02 of Regulation S-X promulgated
      under the Securities Act (each, a &#8220;<font style="font-weight: bold;"><u>Person</u></font>&#8221;), has the right, contractual or otherwise, to cause the Company or any of its Subsidiaries to issue or sell to such Person any Ordinary Shares or ADSs or shares
      of any other capital stock or other securities of the Company or any of its Subsidiaries, (ii) no Person has any preemptive rights, resale rights, rights of first refusal, rights of co-sale, or any other rights (whether pursuant to a &#8220;poison pill&#8221;
      provision or otherwise) to purchase any Ordinary Shares or ADSs or shares of any other capital stock or other securities of the Company or any of its Subsidiaries, (iii) no Person has the right to act as an underwriter or as a financial advisor to
      the Company or any of its Subsidiaries in connection with the offer and sale of Ordinary Shares or ADSs, and (iv) no Person&#160; has the right, contractual or otherwise, to require the Company or any of its Subsidiaries to register under the Securities
      Act any Ordinary Shares or ADSs or shares of any other capital stock or other securities of the Company or any of its Subsidiaries, or to include any such shares or other securities in the Registration Statement or the offering contemplated thereby,
      whether as a result of the filing or effectiveness of the Registration Statement or the sale of the Placement Shares as contemplated thereby or otherwise.</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(q)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Independent Public Accounting Firm</u>. Somekh Chaikin, a member firm of KPMG International (the &#8220;<font style="font-weight: bold;"><u>Accountant</u></font>&#8221;), whose report on the
      consolidated financial statements of the Company is filed with the Commission as part of the Company&#8217;s most recent Annual Report on Form 20-F or Form 10-K, as applicable, filed with the Commission and incorporated by reference into the Registration
      Statement and the Prospectus, are and, during the periods covered by their report, were an independent registered public accounting firm within the meaning of the Securities Act and the Public Company Accounting Oversight Board (United States). To
      the Company&#8217;s knowledge, the Accountant is not in violation of the auditor independence requirements of the Sarbanes-Oxley Act of 2002 (the &#8220;<font style="font-weight: bold;"><u>Sarbanes-Oxley Act</u></font>&#8221;) with respect to the Company.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">9</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Enforceability of Agreements</u>. All agreements between the Company and third parties expressly referenced in the Prospectus are legal, valid and binding obligations of the
      Company enforceable in accordance with their respective terms, except to the extent that (i) enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#8217; rights generally and by general
      equitable principles and (ii) the indemnification provisions of certain agreements may be limited by federal or state securities laws or public policy considerations in respect thereof.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(s)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Litigation</u>. Except as set forth in the Registration Statement or the Prospectus, there are no actions, suits or proceedings by or before any Governmental Authority
      pending, nor, to the Company&#8217;s knowledge, any audits or investigations by or before any Governmental Authority to which the Company or a Subsidiary is a party or to which any property of the Company or any of its Subsidiaries is the subject that,
      individually or in the aggregate, would have a Material Adverse Effect and, to the Company&#8217;s knowledge, no such actions, suits, proceedings, audits or investigations are threatened or contemplated by any Governmental Authority or threatened by
      others; and (i) there are no current or pending audits or investigations, actions, suits or proceedings by or before any Governmental Authority that are required under the Securities Act to be described in the Prospectus that are not so described;
      and (ii) there are no contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement that are not so filed.</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(t)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Consents and Permits</u>. Except as disclosed in the Registration Statement and the Prospectus, the Company and its Subsidiaries have made all filings, applications and
      submissions required by, possesses and is operating in compliance with, all approvals, licenses, certificates, certifications, clearances, consents, grants, exemptions, marks, notifications, orders, permits and other authorizations issued by, the
      appropriate federal, state or foreign Governmental Authority (including, without limitation, the United States Food and Drug Administration (the &#8220;<font style="font-weight: bold;"><u>FDA</u></font>&#8221;), the United States Drug Enforcement Administration
      or any other foreign, federal, state, provincial, court or local government or regulatory authorities including self-regulatory organizations engaged in the regulation of clinical trials, pharmaceuticals, biologics or biohazardous substances or
      materials) necessary for the ownership or lease of their respective properties or to conduct its businesses as described in the Registration Statement and the Prospectus (collectively, &#8220;<font style="font-weight: bold;"><u>Permits</u></font>&#8221;), except
      for such Permits the failure of which to possess, obtain or make the same would not have a Material Adverse Effect; the Company and its Subsidiaries are in compliance with the terms and conditions of all such Permits, except where the failure to be
      in compliance would not have a Material Adverse Effect; all of the Permits are valid and in full force and effect, except where any invalidity, individually or in the aggregate, would not be reasonably expected to have a Material Adverse Effect; and
      neither the Company nor any of its Subsidiaries has received any written notice relating to the limitation, revocation, cancellation, suspension, modification or non-renewal of any such Permit which, singly or in the aggregate, if the subject of an
      unfavorable decision, ruling or finding, would have a Material Adverse Effect, or has any reason to believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course. To the extent required by applicable
      laws and regulations of the FDA, the Company or the applicable Subsidiary has submitted to the FDA an Investigational New Drug Application or amendment or supplement thereto for each clinical trial it has conducted or sponsored or is conducting or
      sponsoring; all such submissions were in material compliance with applicable laws and rules and regulations when submitted and no material deficiencies have been asserted by the FDA with respect to any such submissions.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">10</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(u)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Regulatory Filings</u>. Except as disclosed in the Registration Statement and the Prospectus, neither the Company nor any of its Subsidiaries has failed to file with the
      applicable Governmental Authorities (including, without limitation, the FDA, the Israeli Securities Authority, or any foreign, federal, state, provincial or local Governmental Authority performing functions similar to those performed by the FDA) any
      required filing, declaration, listing, registration, report or submission, except for such failures that, individually or in the aggregate, would not have a Material Adverse Effect; except as disclosed in the Registration Statement and the
      Prospectus, all such filings, declarations, listings, registrations, reports or submissions were in compliance with applicable laws when filed and no deficiencies have been asserted by any applicable regulatory authority with respect to any such
      filings, declarations, listings, registrations, reports or submissions, except for any deficiencies that, individually or in the aggregate, would not have a Material Adverse Effect. The Company and its Subsidiaries have operated and currently is, in
      all material respects, in compliance with the United States Federal Food, Drug, and Cosmetic Act, all applicable rules and regulations of the FDA and other federal, state, local and foreign Governmental Authority exercising comparable authority. The
      Company has no knowledge of any studies, tests or trials not described in the Prospectus the results of which reasonably call into question in any material respect the results of the Company's and its Subsidiaries' studies, tests and trials described
      in the Prospectus.</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Intellectual Property</u>. Except as disclosed in the Registration Statement and the Prospectus, the Company and its Subsidiaries own, possess, license or have other rights to use
      all foreign and domestic patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology, Internet domain names, know-how and other intellectual
      property (collectively, the &#8220;<font style="font-weight: bold;"><u>Intellectual Property</u></font>&#8221;), necessary for the conduct of their respective businesses as now conducted and planned to be conducted except to the extent that the failure to own,
      possess, license or otherwise hold adequate rights to use such Intellectual Property would not, individually or in the aggregate, have a Material Adverse Effect. Except as disclosed in the Registration Statement and the Prospectus (i) there are no
      rights of third parties to any such Intellectual Property owned by the Company and its Subsidiaries; (ii) to the Company&#8217;s knowledge, there is no infringement by third parties of any such Intellectual Property; (iii) there is no pending or, to the
      Company&#8217;s knowledge, threatened action, suit, proceeding or claim by others challenging the Company&#8217;s and its Subsidiaries&#8217; rights in or to any such Intellectual Property, and the Company is unaware of any facts which could form a reasonable basis
      for any such action, suit, proceeding or claim; (iv) there is no pending or, to the Company&#8217;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property; (v) there is no
      pending or, to the Company&#8217;s knowledge, threatened action, suit, proceeding or claim by others that the Company and its Subsidiaries infringe or otherwise violate any patent, trademark, copyright, trade secret or other proprietary rights of others;
      (vi) to the Company&#8217;s knowledge (after due inquiry), there is no third-party U.S. patent or published U.S. patent application which contains claims for which an Interference Proceeding (as defined in 35 U.S.C. &#167; 135) has been commenced against any
      patent or patent application described in the Prospectus as being owned by or licensed to the Company; and (vii) the Company and its Subsidiaries have complied with the terms of each agreement pursuant to which Intellectual Property has been licensed
      to the Company or such Subsidiary, and all such agreements are in full force and effect, except, in the case of any of clauses (i)-(vii) above, for any such infringement by third parties or any such pending or threatened suit, action, proceeding or
      claim as would not, individually or in the aggregate, result in a Material Adverse Effect.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">11</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(w)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Clinical and other Studies</u>. The preclinical, clinical and other studies tests and trials described in the Prospectus were, and, if still pending, are being conducted in all
      material respects in accordance with the Permits, experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by
      the Company and its Subsidiaries and the Company or, as applicable, its Subsidiaries received all informed consents required pursuant thereto; the descriptions of such studies, tests and trials, and the results thereof, contained in the Prospectus
      are accurate and complete in all material respects; the Company is not aware of any tests, studies or trials not described in the Prospectus, the results of which reasonably call into question the results of the tests, studies and trials described in
      the Prospectus; and the Company (or any of its Subsidiaries) has not received any written notice or correspondence from the FDA or any foreign, state or local Governmental Authority exercising comparable authority or any institutional review board or
      comparable authority requiring the termination, suspension, clinical hold or material modification of any tests, studies or trials.</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Market Capitalization</u>. At the time the Registration Statement was or will be originally declared effective, and at the time the Company&#8217;s most recent Annual Report on Form
      10-K or 20-F, as applicable, was filed with the Commission, the Company met or will meet the then applicable requirements for the use of Form F-3 under the Securities Act, including, but not limited to, General Instruction I.B.5 of Form F-3. As of
      the close of trading on the Exchange on September 5, 2023, the aggregate market value of the outstanding voting and non-voting common equity (as defined in Securities Act Rule 405) of the Company held by persons other than affiliates of the Company
      (pursuant to Securities Act Rule 144, those that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the Company)&#160; (the &#8220;<font style="font-weight: bold;"><u>Non-Affiliate Shares</u></font>&#8221;),



      was approximately $12.9 million (calculated by multiplying (x) the highest price at which the common equity of the Company closed on the Exchange during the 60 days prior to the date of this Agreement times (y) the number of Non-Affiliate Shares).
      The Company is not a shell company (as defined in Rule 405 under the Securities Act) and has not been a shell company for at least 12 calendar months previously and if it has been a shell company at any time previously, has filed current Form 10
      information (as defined in Instruction I.B.5 of Form F-3) with the Commission at least 12 calendar months previously reflecting its status as an entity that is not a shell company.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(y)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Material Defaults</u>. Neither the Company nor any of the Subsidiaries has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more
      long-term leases, which defaults, individually or in the aggregate, would have a Material Adverse Effect. The Company has not filed a report pursuant to Section 13(a) or 15(d) of the Exchange Act since the filing of its last Annual Report on Form
      20-F or Form 10-K, as applicable, indicating that it (i) has failed to pay any dividend or sinking fund installment on preferred stock or (ii) has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more
      long-term leases, which defaults, individually or in the aggregate, would have a Material Adverse Effect.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(z)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Certain Market Activities</u>. Neither the Company, nor any of the Subsidiaries, nor any of their respective directors, officers or controlling persons has taken, directly or
      indirectly, any action designed, or that has constituted or might reasonably be expected to cause or result in, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any security of the Company to facilitate the sale
      or resale of the Placement Shares. The Company has not engaged and will not engage in any form of solicitation, advertising or other action constituting an offer or a sale under the Israeli Securities Law, 5728-1968, as amended (the &#8220;<font style="font-weight: bold;"><u>Israeli Securities Law</u></font>&#8221;), and the regulations promulgated thereunder in connection with the transactions contemplated hereby which would require the publication of a prospectus in the State of Israel under
      the laws of the State of Israel.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">12</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(aa)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Broker/Dealer Relationships</u>. Neither the Company nor any of the Subsidiaries (i) is required to register as a &#8220;broker&#8221; or &#8220;dealer&#8221; in accordance with the provisions of the
      Exchange Act or (ii) directly or indirectly through one or more intermediaries, controls or is a &#8220;person associated with a member&#8221; or &#8220;associated person of a member&#8221; (within the meaning set forth in the FINRA Manual).</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(bb)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Reliance</u>. The Company has not relied upon the Agent or legal counsel for the Agent for any legal, tax or accounting advice in connection with the offering and sale of the
      Placement Shares.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(cc)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Taxes</u>. The Company and each of its Subsidiaries have filed all federal, state, local and foreign tax returns which have been required to be filed and paid all taxes shown
      thereon through the date hereof, to the extent that such taxes have become due and are not being contested in good faith, except where the failure to so file or pay would not have a Material Adverse Effect. Except as otherwise disclosed in or
      contemplated by the Registration Statement or the Prospectus, no tax deficiency has been determined adversely to the Company or any of its Subsidiaries which has had, or would have, individually or in the aggregate, a Material Adverse Effect. The
      Company has no knowledge of any federal, state, local, foreign or other governmental tax deficiency, penalty or assessment which has been or might be asserted or threatened against it which would have a Material Adverse Effect.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(dd)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Title to Real and Personal Property</u>. Except as set forth in the Registration Statement or the Prospectus, the Company and its Subsidiaries have good and marketable title (and
      where applicable, in fee simple) to all items of real property owned by them, good and valid title to all personal property described in the Registration Statement or Prospectus as being owned by them, in each case free and clear of all liens,
      encumbrances and claims, except those matters that (i) do not materially interfere with the use made and proposed to be made of such property by the Company and any of its Subsidiaries or (ii) would not, individually or in the aggregate, have a
      Material Adverse Effect. Any real or personal property described in the Registration Statement or Prospectus as being leased by the Company and any of its Subsidiaries is held by them under valid, existing and enforceable leases, except those that
      (A) do not materially interfere with the use made or proposed to be made of such property by the Company or any of its Subsidiaries or (B) would not be reasonably expected, individually or in the aggregate, to have a Material Adverse Effect. Each of
      the properties of the Company and its Subsidiaries complies with all applicable codes, laws and regulations (including, without limitation, building and zoning codes, laws and regulations and laws relating to access to such properties), except if and
      to the extent disclosed in the Registration Statement or Prospectus or except for such failures to comply that would not, individually or in the aggregate, reasonably be expected to interfere in any material respect with the use made and proposed to
      be made of such property by the Company and its Subsidiaries or otherwise have a Material Adverse Effect. None of the Company or its subsidiaries has received from any Governmental Authorities any notice of any condemnation of, or zoning change
      affecting, the properties of the Company and its Subsidiaries, and the Company knows of no such condemnation or zoning change which is threatened, except for such that would not reasonably be expected to interfere in any material respect with the use
      made and proposed to be made of such property by the Company and its Subsidiaries or otherwise have a Material Adverse Effect, individually or in the aggregate.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(ee)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Environmental Laws</u>. Except as set forth in the Registration Statement or the Prospectus, the Company and its Subsidiaries (i) are in compliance with any and all applicable
      federal, state, local and foreign laws, rules, regulations, decisions and orders relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#8220;<font style="font-weight: bold;"><u>Environmental Laws</u></font>&#8221;); (ii) have received and are in compliance with all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses as
      described in the Registration Statement and the Prospectus; and (iii) have not received notice of any actual or potential liability for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants
      or contaminants, except, in the case of any of clauses (i), (ii) or (iii) above, for any such failure to comply or failure to receive required permits, licenses, other approvals or liability as would not, individually or in the aggregate, have a
      Material Adverse Effect.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">13</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(ff)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Disclosure Controls</u>. The Company and each of its Subsidiaries maintain systems of internal accounting controls compliant with all applicable Laws (including the Israeli
      Securities Law and the Exchange Act) and sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management&#8217;s general or specific authorizations; (ii) transactions are recorded as necessary to permit
      preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization; and (iv)
      the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company&#8217;s internal control over financial reporting is effective and the Company
      is not aware of any material weaknesses in its and its Subsidiaries internal control over financial reporting (other than as set forth in the Prospectus). Since the date of the latest audited financial statements of the Company included in the
      Prospectus, there has been no change in the Company&#8217;s nor in its Subsidiaries internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s or such Subsidiary internal control over
      financial reporting (other than as set forth in the Prospectus). The Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15) for the Company (and any applicable Subsidiary) and designed such
      disclosure controls and procedures to ensure that material information relating to the Company and each of its Subsidiaries is made known to the certifying officers by others within those entities, particularly during the period in which the
      Company&#8217;s Annual Report on Form 20-F or Current Report on Form 6-K containing unaudited quarterly financial statements, as the case may be, is being prepared. The Company&#8217;s certifying officers have evaluated the effectiveness of the Company&#8217;s
      disclosure controls and procedures as of a date within 90 days prior to the filing date of the Form 20-F or Form 10-K, as applicable, for the fiscal year most recently ended (such date, the <font style="font-weight: bold;">&#8220;<u>Evaluation Date</u></font>&#8221;).



      The Company presented in its Form 20-F or Form 10-K, as applicable, for the fiscal year most recently ended the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of
      the Evaluation Date and the disclosure controls and procedures are effective. Since the Evaluation Date, there have been no significant changes in the Company&#8217;s internal controls (as such term is defined in Item 307(b) of Regulation S-K under the
      Securities Act) or, to the Company&#8217;s knowledge, in other factors that could significantly affect the Company&#8217;s internal controls.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(gg)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Sarbanes-Oxley</u>. There is and has been no failure on the part of the Company or any of the Company&#8217;s directors or officers, in their capacities as such, to comply in all
      material respects with any applicable provisions of the Sarbanes-Oxley Act and the rules and regulations promulgated thereunder. Each of the principal executive officer and the principal financial officer of the Company (or each former principal
      executive officer of the Company and each former principal financial officer of the Company as applicable) has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports, schedules, forms,
      statements and other documents required to be filed by it or furnished by it to the Commission. For purposes of the preceding sentence, &#8220;principal executive officer&#8221; and &#8220;principal financial officer&#8221; shall have the meanings given to such terms in the
      Sarbanes-Oxley Act.</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(hh)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Finder&#8217;s Fees</u>. Neither the Company nor any of the Subsidiaries has incurred any liability for any finder&#8217;s fees, brokerage commissions or similar payments in connection with the
      transactions herein contemplated, except as may otherwise exist with respect to Agent pursuant to this Agreement.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">14</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Labor Disputes</u>. No labor disturbance by or dispute with employees of the Company or any of its Subsidiaries exists or, to the knowledge of the Company, is threatened which
      would result in a Material Adverse Effect.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(jj)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Investment Company Act</u>. Neither the Company nor any of the Subsidiaries is or, after giving effect to the offering and sale of the Placement Shares, will be an &#8220;investment
      company&#8221; or an entity &#8220;controlled&#8221; by an &#8220;investment company,&#8221; as such terms are defined in the Investment Company Act of 1940, as amended (the &#8220;<font style="font-weight: bold;"><u>Investment Company Act</u></font>&#8221;).</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(kk)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Operations</u>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record keeping and reporting
      requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the rules and regulations thereunder and any related or
      similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Authority (collectively, the &#8220;<font style="font-weight: bold;"><u>Money Laundering Laws</u></font>&#8221;); and no action, suit or proceeding by or before any
      Governmental Authority involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(ll)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Off-Balance Sheet Arrangements</u>. There are no transactions, arrangements and other relationships between and/or among the Company, and/or any of its affiliates and any
      unconsolidated entity, including, but not limited to, any structural finance, special purpose or limited purpose entity (each, an &#8220;<font style="font-weight: bold;"><u>Off-Balance Sheet Transaction</u></font>&#8221;) that could reasonably be expected to
      affect materially the Company&#8217;s liquidity or the availability of or requirements for its capital resources, including those Off-Balance Sheet Transactions described in the Commission&#8217;s Statement about Management&#8217;s Discussion and Analysis of Financial
      Conditions and Results of Operations (Release Nos. 33-8056; 34-45321; FR-61), required to be described in the Prospectus which have not been described as required.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(mm)&#160;&#160;&#160;&#160;&#160; <u>Underwriter Agreements</u>. The Company is not a party to any agreement with an agent or underwriter for any other &#8220;at the market&#8221; or continuous equity transaction.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(nn)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>ERISA &amp; Other Plans</u>. To the knowledge of the Company, each material employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act
      of 1974, as amended (&#8220;<font style="font-weight: bold;"><u>ERISA</u></font>&#8221;) or Section 102 of the Israeli Income Tax Ordinance (the "<font style="font-weight: bold;">Israeli Code</font>"), that is maintained, administered or contributed to by the
      Company or any of its affiliates for employees or former employees of the Company and any of its Subsidiaries has been maintained in material compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations,
      including but not limited to ERISA and the Internal Revenue Code of 1986, as amended (the &#8220;<font style="font-weight: bold;"><u>Code</u></font>&#8221;) as well as the Israeli Code; no prohibited transaction, within the meaning of Section 406 of ERISA or
      Section 4975 of the Code, and no breach of Section 102 of the Israeli Code has occurred which would result in a material liability to the Company with respect to any such plan excluding transactions effected pursuant to a statutory or administrative
      exemption; and for each such plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no &#8220;accumulated funding deficiency&#8221; as defined in Section 412 of the Code has been incurred, whether or not waived, and the
      fair market value of the assets of each such plan (excluding for these purposes accrued but unpaid contributions) exceeds the present value of all benefits accrued under such plan determined using reasonable actuarial assumptions.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">15</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(oo)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Forward-Looking Statements</u>. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) (a &#8220;<font style="font-weight: bold;"><u>Forward-Looking Statement</u></font>&#8221;) contained in the Registration Statement and the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(pp)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Agent Purchases</u>. The Company acknowledges and agrees that Agent has informed the Company that the Agent may, to the extent permitted under the Securities Act and the Exchange
      Act, purchase and sell Ordinary Shares or ADSs for its own account while this Agreement is in effect, <font style="font-style: italic;">provided</font>, that (i) no such purchase or sales shall take place while a Placement Notice is in effect
      (except to the extent the Agent may engage in sales of Placement Shares purchased or deemed purchased from the Company as a &#8220;riskless principal&#8221; or in a similar capacity) and (ii) the Company shall not be deemed to have authorized or consented to any
      such purchases or sales by the Agent.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(qq)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Margin Rules</u>. Neither the issuance, sale and delivery of the Placement Shares nor the application of the proceeds thereof by the Company as described in the Registration
      Statement and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(rr)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Insurance</u>. The Company and each of its Subsidiaries carry, or are covered by, insurance in such amounts and covering such risks as the Company and each of its Subsidiaries
      reasonably believe are adequate for the conduct of their respective properties and businesses and as is customary for companies engaged in similar businesses in similar industries.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(ss)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Improper Practices</u>. (i) Neither the Company nor the Subsidiaries, nor any director, officer, or employee of the Company or any Subsidiary nor, to the Company&#8217;s knowledge,
      any agent, affiliate or other person acting on behalf of the Company or any Subsidiary has, in the past five years, made any unlawful contributions to any candidate for any political office (or failed fully to disclose any contribution in violation
      of applicable law) or made any contribution or other payment to any official of, or candidate for, any federal, state, municipal, or foreign office or other person charged with similar public or quasi-public duty in violation of any applicable law or
      of the character required to be disclosed in the Prospectus; (ii) no relationship, direct or indirect, exists between or among the Company or any Subsidiary or any affiliate of any of them, on the one hand, and the directors, officers and
      stockholders of the Company or any Subsidiary, on the other hand, that is required by the Securities Act to be described in the Registration Statement and the Prospectus that is not so described; (iii) no relationship, direct or indirect, exists
      between or among the Company or any Subsidiary or any affiliate of them, on the one hand, and the directors, officers, or stockholders of the Company or any Subsidiary, on the other hand, that is required by the rules of FINRA or the Israeli
      Securities Law to be described in the Registration Statement and the Prospectus that is not so described; (iv) except as described in the Registration Statement and the Prospectus, there are no material outstanding loans or advances or material
      guarantees of indebtedness by the Company or any Subsidiary to or for the benefit of any of their respective officers or directors or any of the members of the families of any of them; and (v) the Company has not offered, or caused any placement
      agent to offer, Ordinary Shares or ADSs to any person with the intent to influence unlawfully (A) a customer or supplier of the Company or any Subsidiary to alter the customer&#8217;s or supplier&#8217;s level or type of business with the Company or any
      Subsidiary or (B) a trade journalist or publication to write or publish favorable information about the Company or any Subsidiary or any of their respective products or services, and, (vi) neither the Company nor any Subsidiary nor any director,
      officer or employee of the Company or any Subsidiary nor, to the Company&#8217;s knowledge, any agent, affiliate or other person acting on behalf of the Company or any Subsidiary has (A) violated or is in violation of any applicable provision of the U.S.
      Foreign Corrupt Practices Act of 1977, as amended, or any other applicable anti-bribery or anti-corruption law (collectively, &#8220;<font style="font-weight: bold;">Anti-Corruption Laws</font>&#8221;), (B) promised, offered, provided, attempted to provide or
      authorized the provision of anything of value, directly or indirectly, to any person for the purpose of obtaining or retaining business, influencing any act or decision of the recipient, or securing any improper advantage; or (C) made any payment of
      funds of the Company or any Subsidiary or received or retained any funds in violation of any Anti-Corruption Laws.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">16</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(tt)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Status Under the Securities Act</u>. The Company is not an ineligible issuer as defined in Rule 405 under the Securities Act at the times specified in Rules 164 and 433 under the
      Securities Act in connection with the offering of the Placement Shares.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(uu)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Misstatement or Omission in an Issuer Free Writing Prospectus</u>. Each Issuer Free Writing Prospectus, as of its issue date and as of each Applicable Time (as defined in <u>Section




        23</u> below), did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any incorporated document deemed to be a
      part thereof that has not been superseded or modified. The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus based upon and in conformity with written information furnished to the Company by the
      Agent specifically for use therein.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(vv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Conflicts</u>. Neither the execution of this Agreement, nor the issuance, offering or sale of the Placement Shares, nor the consummation of any of the transactions contemplated
      herein and therein, nor the compliance by the Company with the terms and provisions hereof and thereof will conflict with, or will result in a breach of, any of the terms and provisions of, or has constituted or will constitute a default under, or
      has resulted in or will result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its Subsidiaries pursuant to the terms of any contract or other agreement to which the Company or any
      of its Subsidiaries may be bound or to which any of the property or assets of the Company or any of its Subsidiaries is subject, except (i) such conflicts, breaches or defaults as may have been waived and (ii) such conflicts, breaches and defaults
      that would not have a Material Adverse Effect; nor will such action result (x) in any violation of the provisions of the organizational or governing documents of the Company or any of its Subsidiaries, or (y) in any material violation of the
      provisions of any statute or any order, rule or regulation applicable to the Company or any of its Subsidiaries or of any Governmental Authority having jurisdiction over the Company or any of its Subsidiaries.</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(ww)&#160;&#160;&#160;&#160;&#160;&#160; <u>Sanctions</u>. (i) The Company represents that, neither the Company nor any of its Subsidiaries (collectively, the &#8220;<font style="font-weight: bold;"><u>Entity</u></font>&#8221;) or any
      director, officer, employee, agent, affiliate or representative of the Entity, is a government, individual, or entity (in this paragraph (ww), &#8220;<font style="font-weight: bold;"><u>Person</u></font>&#8221;) that is, or is owned or controlled by a Person
      that is:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; margin-left: 72pt; line-height: 1.25;">(A) the subject of any sanctions administered or enforced by the U.S. Department of Treasury&#8217;s Office of Foreign Assets Control (&#8220;<font style="font-weight: bold;"><u>OFAC</u></font>&#8221;),



      the United Nations Security Council, the European Union, His Majesty&#8217;s Treasury, or other relevant sanctions authorities, including, without limitation, designation on OFAC&#8217;s Specially Designated Nationals and Blocked Persons List or OFAC&#8217;s Foreign
      Sanctions Evaders List (as amended, collectively, &#8220;<font style="font-weight: bold;"><u>Sanctions</u></font>&#8221;), nor</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; margin-left: 72pt; line-height: 1.25;">(B) located, organized or resident in a country or territory that is the subject of Sanctions that broadly prohibit dealings with that country or territory (including, without
      limitation, Cuba, Iran, North Korea, Sudan, Syria and the Crimea Region of the Ukraine) (the &#8220;<font style="font-weight: bold;">Sanctioned Countries</font>&#8221;)).</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">17</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(ii) The Entity represents and covenants that it will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary,
      joint venture partner or other Person:</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 12pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; margin-left: 72pt; line-height: 1.25;">(A) to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of
      Sanctions or is a Sanctioned Country; or</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; margin-left: 72pt; line-height: 1.25;">(B) in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or
      otherwise).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(iii) The Entity represents and covenants that, except as detailed in the Registration Statement and the Prospectus, for the past 5 years, it has not engaged in, is not now engaging in, and will not
      engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions or is or was a Sanctioned Country.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 12pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(xx)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Stock Transfer Taxes</u>. On each Settlement Date, all stock transfer or other taxes (other than income taxes) which are required to be paid in connection with the sale and transfer
      of the Placement Shares to be sold hereunder will be, or will have been, fully paid or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(yy)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Stamp Tax</u>. No Israeli stamp or other Israeli issuance or transfer taxes or similar Israeli issuance or transfer duties and assuming that the Agent is not otherwise subject to
      taxation in Israel due to Israeli tax residence, the existence of a permanent establishment in Israel, a fixed place of business in Israel or any business activity of the Agent in Israel, no capital gains, income, withholding or other taxes are
      payable in Israel by or on behalf of the Agent in connection with the sale and delivery by the Company of the Placement Shares to or for the account of the Agent or the sale and delivery by the Agent of the Placement Shares to the purchasers thereof.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(zz)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Compliance with Laws</u>. Each of the Company and its Subsidiaries: (A) is and at all times has been in compliance with all statutes, rules, or regulations applicable to the
      ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company or its
      Subsidiaries (&#8220;<font style="font-weight: bold;"><u>Applicable Laws</u></font>&#8221;), except as could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect; (B) has not received any FDA Form 483, notice of
      adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any other Governmental Authority alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances,
      authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (&#8220;<font style="font-weight: bold;"><u>Authorizations</u></font>&#8221;); (C) possesses all material Authorizations and such Authorizations are valid and in
      full force and effect and are not in material violation of any term of any such Authorizations; (D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental
      Authority or third party alleging that any product operation or activity is in violation of any Applicable Laws or Authorizations and has no knowledge that any such Governmental Authority or third party is considering any such claim, litigation,
      arbitration, action, suit, investigation or proceeding; (E) has not received notice that any Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any
      such Governmental Authority is considering such action; (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any
      Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were corrected or supplemented by a
      subsequent submission); and (G) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post sale warning, &#8220;dear
      healthcare provider&#8221; letter, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to the Company&#8217;s knowledge, no third party has initiated, conducted or intends to
      initiate any such notice or action.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">18</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(aaa)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Statistical and Market-Related Data</u>. The statistical, demographic and market-related data included in the Registration Statement and Prospectus are based on or derived from
      sources that the Company believes to be reliable and accurate or represent the Company&#8217;s good faith estimates that are made on the basis of data derived from such sources.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(bbb)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Cybersecurity &amp; Protection of Personal Data</u>. The Company and its subsidiaries&#8217; information technology assets and equipment, computers, systems, networks, hardware,
      software, websites, applications, and databases (collectively, &#8220;<font style="font-weight: bold;"><u>IT Systems</u></font>&#8221;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the
      business of the Company as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable
      physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data,
      including all &#8220;Personal Data&#8221; (defined below) and all sensitive, confidential or regulated data (&#8220;<font style="font-weight: bold;"><u>Confidential Data</u></font>&#8221;) used in connection with their businesses. &#8220;<font style="font-weight: bold;"><u>Personal



          Data</u></font>&#8221; includes (i) a natural person&#8217;s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver&#8217;s license number, passport number, credit card number, bank
      information, or customer or account number; (ii) any information which would qualify as &#8220;personally identifying information&#8221; under the Federal Trade Commission Act, as amended; (iii) &#8220;personal data&#8221; as defined by GDPR or applicable Israeli laws; (iv)
      any information which would qualify as &#8220;protected health information&#8221; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#8220;<font style="font-weight: bold;"><u>HIPAA</u></font>&#8221;); (v) any &#8220;personal information&#8221; as defined by the California Consumer Privacy Act (&#8220;<font style="font-weight: bold;"><u>CCPA</u></font>&#8221;); and (vi) any other piece of information that allows the
      identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&#8217;s health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of or
      accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its Subsidiaries are
      presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the
      privacy and security of IT Systems, Confidential Data (including confidential data of third parties), and Personal Data and to the protection of such IT Systems, Confidential Data, and Personal Data from unauthorized use, access, misappropriation or
      modification.</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(ccc)&#160;&#160;&#160;&#160;&#160;&#160; <u>Compliance with Data Privacy Laws</u>. The Company and its subsidiaries are, and at all prior times were, in compliance in all material respects with all applicable state and federal
      data privacy and security laws and regulations, including without limitation HIPAA, CCPA, and the European Union General Data Protection Regulation (&#8220;<font style="font-weight: bold;"><u>GDPR</u></font>&#8221;) (EU 2016/679) (collectively, the &#8220;<font style="font-weight: bold;"><u>Privacy Laws</u></font>&#8221;). To ensure compliance with the Privacy Laws, the Company has in place, complies with, and takes appropriate steps to ensure compliance in all material respects with their policies and
      procedures relating to data privacy and security and the collection, storage, use, processing, disclosure, handling, and analysis of Personal Data and Confidential Data (the &#8220;<font style="font-weight: bold;"><u>Policies</u></font>&#8221;). The Company has
      at all times made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have been inaccurate or in violation of any applicable laws and
      regulatory rules or requirements in any material respect. The Company further certifies that neither it nor any subsidiary: (i) has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of
      the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective
      action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">19</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(ddd)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Emerging Growth Company Status</u>. The Company is an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act (an &#8220;<font style="font-weight: bold;"><u>Emerging
          Growth Company</u></font>&#8221;).</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(eee)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Stabilization</u>. The Company has not taken, nor will it take, directly or indirectly, any action designed to, or which might reasonably be expected to cause or result in, or which
      has constituted or which might reasonably be expected to constitute, the stabilization or manipulation of the price of the ADSs or any security of the Company to facilitate the sale or resale of any of the Placement Shares. The Company has not
      engaged and will not engage in any form of solicitation, advertising or other action constituting an offer or a sale under the Israeli Securities Law, and the regulations promulgated thereunder in connection with the transactions contemplated hereby
      which would require the publication of a prospectus in the State of Israel under the laws of the State of Israel.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(fff)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Governmental Grants</u>. Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its Subsidiary has received any
      grant from the Israel Innovation Authority of the Ministry of Economy and Industry of the State of Israel (formerly known as the Office of the Chief Scientist) (the &#8220;<font style="font-weight: bold;"><u>IIA</u></font>&#8221;) or any other Israeli
      governmental or regulatory authority, including the Investment Center of the Ministry of Economy and Industry of the State of Israel. Neither the Company nor its Subsidiary has received any notice denying, revoking or modifying any &#8220;Approved
      Enterprise,&#8221; &#8220;Benefited Enterprise,&#8221; &#8220;Preferred Enterprise,&#8221; &#8220;Preferred Technology Enterprise&#8221; or &#8220;Special Preferred Technology Enterprise&#8221; status or benefits with respect to any of the Company&#8217;s facilities or operations (collectively and together
      with the grants approved or received by the IIA, the &#8220;<font style="font-weight: bold;"><u>Governmental Grant</u></font>&#8221;). No event has occurred, and no circumstance or condition exists, that would reasonably be expected to give rise to or serve as
      the basis for (i) the annulment, revocation, withdrawal, suspension, cancellation, recapture or modification of the Governmental Grant, (ii) the imposition of any material limitation on the Governmental Grant or (iii) a requirement that the Company
      return or refund any benefits provided under the Governmental Grant. All information supplied by the Company with respect to the applications or notifications relating to Governmental Grant was true, correct and complete in all material respects when
      supplied to the appropriate authorities.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(ggg)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Choice of Law</u>. The choice of laws of the State of New York as the governing law of this Agreement is a valid choice of law under the laws of the State of Israel. The Company
      has the power to submit and, pursuant to Section 18 of this Agreement, has validly and irrevocably submitted to the personal jurisdiction of each Specified Court (as defined below) and to the exclusive jurisdiction of any court sitting therein.
      Subject to the conditions and qualifications set forth in the Registration Statement and the Prospectus, a final and conclusive judgment against the Company for a definitive sum of money entered by any court in the United States may be enforced by an
      Israeli court. Neither the Company nor its properties or assets has immunity under the State of Israel, U.S. federal or New York state law from any legal action, suit or proceeding, from the giving of any relief in any such legal action, suit or
      proceeding, from set-off or counterclaim, from the jurisdiction of the State of Israel, U.S. federal or New York state court, from service of process, attachment upon or prior to judgment, or attachment in aid of execution of judgment, or from
      execution of a judgment, or other legal process or proceeding for the giving of any relief or for the enforcement of a judgment, in any such court with respect to their respective obligations, liabilities or any other matter under or arising out of
      or in connection herewith; and, to the extent that the Company or any of its properties, assets or revenues may have or may hereafter become entitled to any such right of immunity in any such court in which proceedings arising out of, or relating to
      the transactions contemplated by this Agreement, may at any time be commenced, the Company has, pursuant to this Agreement, waived, and it will waive such right to the extent permitted by law.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">20</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">Any certificate signed by an officer of the Company and delivered to the Agent or to counsel for the Agent pursuant to or in connection with this Agreement shall be deemed to be a representation and
      warranty by the Company, as applicable, to the Agent as to the matters set forth therein.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Covenants of the Company</u>. The Company covenants and agrees with Agent that:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Registration Statement Amendments</u>. After the date of this Agreement and during any period in which a Prospectus relating to any Placement Shares is required to be delivered by
      Agent under the Securities Act (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or similar rule), (i) the Company will notify the Agent promptly of the time when any subsequent
      amendment to the Registration Statement or the F-6 Registration Statement, other than documents incorporated by reference, has been filed with the Commission and/or has become effective or any subsequent supplement to the Prospectus has been filed
      and of any request by the Commission for any amendment or supplement to the Registration Statement, the F-6 Registration Statement or the Prospectus or for additional information, (ii) the Company will prepare and file with the Commission, promptly
      upon the Agent&#8217;s reasonable request, any amendments or supplements to the Registration Statement, the F-6 Registration Statement or the Prospectus that, in the Agent&#8217;s reasonable opinion, may be necessary or advisable in connection with the
      distribution of the Placement Shares by the Agent (<font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that the failure of the Agent to make such request shall not relieve the Company of any
      obligation or liability hereunder, or affect the Agent&#8217;s right to rely on the representations and warranties made by the Company in this Agreement and <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">further</font>,
      that the only remedy the Agent shall have with respect to the failure to make such filing shall be to cease making sales under this Agreement until such amendment or supplement is filed); (iii) the Company will not file any amendment or supplement to
      the Registration Statement, the F-6 Registration Statement or the Prospectus relating to the Placement Shares or a security convertible into the Placement Shares unless a copy thereof has been submitted to Agent within a reasonable period of time
      before the filing and the Agent has not objected thereto (<font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that the failure of the Agent to make such objection shall not relieve the Company of any
      obligation or liability hereunder, or affect the Agent&#8217;s right to rely on the representations and warranties made by the Company in this Agreement and <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">further</font>,
      that the only remedy the Agent shall have with respect to the failure by the Company to obtain such consent shall be to cease making sales under this Agreement) and the Company will furnish to the Agent at the time of filing thereof a copy of any
      document that upon filing is deemed to be incorporated by reference into the Registration Statement, the F-6 Registration Statement or the Prospectus, except for those documents available via EDGAR; and (iv) the Company will cause each amendment or
      supplement to the Prospectus to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act or, in the case of any document to be incorporated therein by reference, to be filed with the
      Commission as required pursuant to the Exchange Act, within the time period prescribed (the determination to file or not file any amendment or supplement with the Commission under this <u>Section 7(a)</u>, based on the Company&#8217;s reasonable opinion
      or reasonable objections, shall be made exclusively by the Company).</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">21</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Notice of Commission Stop Orders</u>. The Company will advise the Agent, promptly after it receives notice or obtains knowledge thereof, of the issuance or threatened issuance by
      the Commission of any stop order suspending the effectiveness of the Registration Statement or the F-6 Registration Statement, of the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction, or of the
      initiation or threatening of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal if such a stop order should be issued. The Company
      will advise the Agent promptly after it receives any request by the Commission for any amendments to the Registration Statement or the F-6 Registration Statement or any amendment or supplements to the Prospectus or any Issuer Free Writing Prospectus
      or for additional information related to the offering of the Placement Shares or for additional information related to the Registration Statement, the F-6 Registration Statement, the Prospectus or any Issuer Free Writing Prospectus.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Delivery of Prospectus; Subsequent Changes</u>. During any period in which a Prospectus relating to the Placement Shares is required to be delivered by the Agent under the
      Securities Act with respect to the offer and sale of the Placement Shares, (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or similar rule), the Company will comply with all
      requirements imposed upon it by the Securities Act, as from time to time in force, and to file on or before their respective due dates all reports and any definitive proxy or information statements required to be filed by the Company with the
      Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange Act. If the Company has omitted any information from the Registration Statement pursuant to Rule 430B under the Securities Act, it will use its
      commercially reasonable efforts to comply with the provisions of and make all requisite filings with the Commission pursuant to said Rule 430B and to notify the Agent promptly of all such filings if not available on EDGAR. If during such period any
      event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then
      existing, not misleading, or if during such period it is necessary to amend or supplement the Registration Statement, the F-6 Registration Statement or the Prospectus to comply with the Securities Act, the Company will promptly notify the Agent to
      suspend the offering of Placement Shares during such period and the Company will promptly amend or supplement the Registration Statement, the F-6 Registration Statement or the Prospectus (at the expense of the Company) so as to correct such statement
      or omission or effect such compliance; provided, however, that the Company may delay any such amendment or supplement if, in the reasonable judgment of the Company, it is in the interests of the Company to do so, and shall promptly provide the Agent
      with a written notice to that affect setting forth with reasonable details the grounds for such judgment. Until such time as the Company shall have corrected such misstatement or omission or effected such compliance, the Company shall not instruct
      the Agent to resume the offering of Placement Shares.</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Listing of Placement Shares</u>. Prior to the date of the first Placement Notice, the Company will use its reasonable best efforts to cause the Placement Shares to be listed on the
      Exchange.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">22</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Delivery of Registration Statement and Prospectus</u>. The Company will furnish to the Agent and its counsel (at the expense of the Company) copies of the Registration Statement,
      the F-6 Registration Statement, the Prospectus (including all documents incorporated by reference therein) and all amendments and supplements to the Registration Statement, the F-6 Registration Statement or the Prospectus that are filed with the
      Commission during any period in which a Prospectus relating to the Placement Shares is required to be delivered under the Securities Act (including all documents filed with the Commission during such period that are deemed to be incorporated by
      reference therein), in each case as soon as reasonably practicable and in such quantities as the Agent may from time to time reasonably request and, at the Agent&#8217;s request, will also furnish copies of the Prospectus to each exchange or market on
      which sales of the Placement Shares may be made; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that the Company shall not be required to furnish any document (other than the Prospectus) to the
      Agent to the extent such document is available on EDGAR.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Earning Statement</u>. The Company will make generally available to its security holders as soon as practicable, but in any event not later than 15 months after the end of the
      Company&#8217;s current fiscal quarter, an earning statement covering a 12-month period that satisfies the provisions of Section 11(a) and Rule 158 of the Securities Act.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Use of Proceeds</u>. The Company will use the Net Proceeds as described in the Prospectus in the section entitled &#8220;Use of Proceeds.&#8221;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Notice of Other Sales</u>. Without the prior written consent of the Agent, the Company will not, directly or indirectly, offer to sell, sell, contract to sell, grant any option to
      sell or otherwise dispose of any Ordinary Shares or ADSs (other than the Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Ordinary Shares or ADSs, warrants or any rights to purchase or acquire,
      Ordinary Shares or ADSs during the period beginning on the fifth (5<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) Trading Day immediately prior to the date on which any Placement Notice is delivered to Agent hereunder and ending on the fifth (5<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) Trading Day immediately
      following the final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice (or, if the Placement Notice has been terminated or suspended prior to the sale of all Placement Shares covered by a Placement Notice, the
      date of such suspension or termination); and will not directly or indirectly in any other &#8220;at the market&#8221; or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any ADS (other than the
      Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Ordinary Shares or ADSs, warrants or any rights to purchase or acquire, Ordinary Shares or ADSs prior to the sixtieth (60<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) day
      immediately following the termination of this Agreement; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that such restrictions will not be required in connection with the Company&#8217;s issuance or
      sale of (i) Ordinary Shares, ADSs, options to purchase Ordinary Shares or ADSs or Ordinary Shares or ADSs issuable upon the exercise of options, pursuant to any employee or director stock option or benefits plan, stock ownership plan or dividend
      reinvestment plan (but not Ordinary Shares or ADSs subject to a waiver to exceed plan limits in its dividend reinvestment plan) of the Company whether now in effect or hereafter implemented, (ii) ADSs issuable upon conversion of securities or the
      exercise of warrants, options or other rights in effect or outstanding, and disclosed in filings by the Company available on EDGAR or otherwise in writing to the Agent and (iii) Ordinary Shares, ADSs or securities convertible into or exchangeable for
      Ordinary Shares or ADSs as consideration for mergers, acquisitions, other business combinations or strategic alliances occurring after the date of this Agreement which are not issued for capital raising purposes.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">23</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Change of Circumstances</u>. The Company will, at any time during the pendency of a Placement Notice advise the Agent promptly after it shall have received notice or obtained
      knowledge thereof, of any information or fact that would, to the Company&#8217;s knowledge, alter or affect in any material respect any opinion, certificate, letter or other document required to be provided to the Agent pursuant to this Agreement.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Due Diligence Cooperation</u>. The Company will cooperate with any reasonable due diligence review conducted by the Agent or its representatives in connection with the
      transactions contemplated hereby, including, without limitation, providing information and making available documents and senior corporate officers, during regular business hours and at the Company&#8217;s principal offices, as the Agent may reasonably
      request.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Required Filings Relating to Placement of Placement Shares</u>. The Company agrees that on such dates as the Securities Act shall require, the Company will (i) file a prospectus
      supplement with the Commission under the applicable paragraph of Rule 424(b) under the Securities Act (each and every filing date under Rule 424(b), a &#8220;<font style="font-weight: bold;"><u>Filing Date</u></font>&#8221;), which prospectus supplement will set
      forth, within the relevant period, the amount of Placement Shares sold through the Agent, the Net Proceeds to the Company and the compensation payable by the Company to the Agent with respect to such Placement Shares, and (ii) deliver such number of
      copies of each such prospectus supplement to each exchange or market on which such sales were effected as may be required by the rules or regulations of such exchange or market; provided, however, that no such filing shall be required if the Company
      shall have disclosed such information in its most recent periodic report filed pursuant the Exchange Act, and such disclosure is sufficient pursuant to the Exchange Act.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Representation Dates; Certificate</u>. (1) Prior to the date of the first Placement Notice and (2) each time the Company:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="margin-left: 36pt; line-height: 1.25;">(i) files the Prospectus relating to the Placement Shares or amends or supplements (other than a prospectus supplement relating solely to an offering of securities other than the Placement Shares) the
      Registration Statement or the Prospectus relating to the Placement Shares by means of a post-effective amendment, sticker, or supplement but not by means of incorporation of documents by reference into the Registration Statement or the Prospectus
      relating to the Placement Shares;</div>
    <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="margin-left: 36pt; line-height: 1.25;">(ii) files an annual report on Form 20-F under the Exchange Act (including any Form 20-F/A containing amended financial information or a material amendment to the previously filed Form 20-F);</div>
    <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="margin-left: 36pt; line-height: 1.25;">(iii) files a current report on Form 6-K containing unaudited quarterly financial statements under the Exchange Act; or</div>
    <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="margin-left: 36pt; line-height: 1.25;">(iv) files a current report on Form 6-K containing amended financial information under the Exchange Act (each date of filing of one or more of the documents referred to in clauses (i) through (iv)
      shall be a &#8220;<font style="font-weight: bold;"><u>Representation Date</u></font>&#8221;);</div>
    <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">the Company shall furnish the Agent (but in the case of clause (iv) above only if the Agent reasonably determines that the information contained in such Form 6-K is material) with a certificate dated the Representation
      Date, in the form and substance satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent, modified, as necessary, to relate to the Registration Statement and the Prospectus as amended or
      supplemented. The requirement to provide a certificate under this <u>Section 7(l)</u> shall be waived for any Representation Date occurring at a time a Suspension is in effect, which waiver shall continue until the earlier to occur of the date the
      Company delivers instructions for the sale of Placement Shares hereunder (which for such calendar quarter shall be considered a Representation Date) and the next occurring Representation Date. Notwithstanding the foregoing, if the Company
      subsequently decides to sell Placement Shares following a Representation Date when a Suspension was in effect and did not provide the Agent with a certificate under this <u>Section 7(l)</u>, then before the Company delivers the instructions for the
      sale of Placement Shares or the Agent sells any Placement Shares pursuant to such instructions, the Company shall provide the Agent with a certificate in conformity with this <u>Section 7(l)</u> dated as of the date that the instructions for the
      sale of Placement Shares are issued.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">24</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Legal Opinions</u>. (1) Prior to the date of the first Placement Notice and (2) within five (5) Trading Days of each Representation Date with respect to which the Company is
      obligated to deliver a certificate pursuant to <u>Section 7(l)(i)</u> for which no waiver is applicable and excluding the date of this Agreement, the Company shall cause to be furnished to the Agent (i) a written opinion and negative assurance
      letter of Meitar (&#8220;<font style="font-weight: bold;"><u>Israeli Company Counsel</u></font>&#8221;), (ii) a written opinion of Cooley LLP (&#8220;<font style="font-weight: bold;"><u>US Company Counsel</u></font>&#8221;), and (iii) a written opinion of Emmet, Marvin
      &amp; Martin, LLP, counsel to the Depositary (&#8220;<font style="font-weight: bold;"><u>Depositary Counsel</u></font>&#8221;), or in each case, other counsel satisfactory to the Agent, in form and substance satisfactory to Agent and its counsel, substantially
      similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented; further, within five (5) Trading Days of each Representation
      Date with respect to which the Company is obligated to deliver a certificate pursuant to <u>Section 7(l)(ii)-(iv)</u> for which no waiver is applicable and excluding the date of this Agreement, the Company shall cause to be furnished to the Agent a
      negative assurance letter of <u>Israeli Company Counsel </u>in form and substance satisfactory to the Agent and its counsel; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">further</font>, that in lieu of each
      such opinion or negative assurance letter for subsequent periodic filings under the Exchange Act, counsel may furnish the Agent with a letter (a &#8220;<font style="font-weight: bold;"><u>Reliance Letter</u></font>&#8221;) to the effect that the Agent may rely
      on a prior opinion or negative assurance letter delivered under this <u>Section 7(m)</u> to the same extent as if it were dated the date of such letter (except that statements in such prior opinion shall be deemed to relate to the Registration
      Statement and the Prospectus as amended or supplemented as of the date of the Reliance Letter).</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Comfort Letter</u>. (1) Prior to the date of the first Placement Notice and (2) within five (5) Trading Days of each Representation Date with respect to which the Company is
      obligated to deliver a certificate pursuant to <u>Section 7(l)</u> for which no waiver is applicable and excluding the date of this Agreement, the Company shall cause its independent registered public accounting firm to furnish the Agent letters
      (the &#8220;<font style="font-weight: bold;"><u>Comfort Letters</u></font>&#8221;), dated the date the Comfort Letter is delivered, which shall meet the requirements set forth in this <u>Section 7(n)</u>; <font style="font-style: italic;">provided</font>, that
      if requested by the Agent, the Company shall cause a Comfort Letter to be furnished to the Agent within ten (10) Trading Days of the date of occurrence of any material transaction or event, including the restatement of the Company&#8217;s financial
      statements. The Comfort Letter from the Company&#8217;s independent registered public accounting firm shall be in a form and substance satisfactory to the Agent, (i) confirming that they are an independent registered public accounting firm within the
      meaning of the Securities Act and the PCAOB, (ii) stating, as of such date, the conclusions and findings of such firm with respect to the financial information and other matters ordinarily covered by accountants&#8217; &#8220;comfort letters&#8221; to underwriters in
      connection with registered public offerings (the first such letter, the &#8220;<font style="font-weight: bold;"><u>Initial Comfort Letter</u></font>&#8221;) and (iii) updating the Initial Comfort Letter with any information that would have been included in the
      Initial Comfort Letter had it been given on such date and modified as necessary to relate to the Registration Statement and the Prospectus, as amended and supplemented to the date of such letter.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">25</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Market Activities</u>. The Company will not, directly or indirectly, (i) take any action designed to cause or result in, or that constitutes or might reasonably be expected to
      constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of ADSs or (ii) sell, bid for, or purchase Ordinary Shares or ADSs in violation of Regulation M, or pay anyone any compensation
      for soliciting purchases of the Placement Shares other than the Agent.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Investment Company Act</u>. The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it nor any of its Subsidiaries will be or become, at any
      time prior to the termination of this Agreement, required to register as an &#8220;investment company,&#8221; as such term is defined in the Investment Company Act.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(q)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Offer to Sell</u>. Other than an Issuer Free Writing Prospectus approved in advance by the Company and the Agent in its capacity as agent hereunder, neither the Agent nor the
      Company (including its agents and representatives, other than the Agent in its capacity as such) will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule 405 under the Securities Act), required to be filed
      with the Commission, that constitutes an offer to sell or solicitation of an offer to buy Placement Shares hereunder.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Blue Sky and Other Qualifications</u><font style="font-style: italic;">. </font>The Company will use its commercially reasonable efforts, in cooperation with the Agent, to
      qualify the Placement Shares for offering and sale, or to obtain an exemption for the Placement Shares to be offered and sold, under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Agent may
      designate and to maintain such qualifications and exemptions in effect for so long as required for the distribution of the Placement Shares (but in no event for less than one year from the date of this Agreement); <font style="font-style: italic;">provided</font>,
      <font style="font-style: italic;">however</font>, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so
      qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject. In each jurisdiction in which the Placement Shares have been so qualified or exempt, the Company will file such
      statements and reports as may be required by the laws of such jurisdiction to continue such qualification or exemption, as the case may be, in effect for so long as required for the distribution of the Placement Shares (but in no event for less than
      one year from the date of this Agreement).</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(s)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Sarbanes-Oxley Act</u>. The Company and the Subsidiaries will maintain and keep accurate books and records reflecting their assets and maintain internal accounting controls in a
      manner designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and including those
      policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company, (ii) provide reasonable assurance that transactions are
      recorded as necessary to permit the preparation of the Company&#8217;s consolidated financial statements in accordance with generally accepted accounting principles, (iii) that receipts and expenditures of the Company are being made only in accordance with
      management&#8217;s and the Company&#8217;s directors&#8217; authorization, and (iv) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on its
      financial statements. The Company and the Subsidiaries will maintain such controls and other procedures, including, without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act, and the applicable regulations thereunder that
      are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s
      rules and forms, including, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the
      Company&#8217;s management, including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and to ensure that material information
      relating to the Company or the Subsidiaries is made known to them by others within those entities, particularly during the period in which such periodic reports are being prepared.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">26</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(t)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Secretary&#8217;s Certificate; Further Documentation</u>. Prior to the date of the first Placement Notice, the Company shall deliver to the Agent a certificate of the Secretary of the
      Company and attested to by an executive officer of the Company, dated as of such date, certifying as to (i) the Certificate of Incorporation of the Company, (ii) the By-laws of the Company, (iii) the resolutions of the Board of Directors of the
      Company authorizing the execution, delivery and performance of this Agreement and the issuance of the Placement Shares and (iv) the incumbency of the officers duly authorized to execute this Agreement and the other documents contemplated by this
      Agreement. Within five (5) Trading Days of each Representation Date, the Company shall have furnished to the Agent such further information, certificates and documents as the Agent may reasonably request.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(u)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Emerging Growth Company Status</u>. The Company will promptly notify the Agent if the Company ceases to be an Emerging Growth Company at any time during the term of this
      Agreement.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">8.&#160;&#160;&#160;&#160;&#160;&#8239;&#160;&#160;&#160;&#160;&#160;&#160; <u>Payment of Expenses</u>. The Company will pay all expenses incident to the performance of its obligations under this Agreement, including (i) the preparation and filing of the
      Registration Statement, including any fees required by the Commission, and the printing or electronic delivery of the Prospectus as originally filed and of each amendment and supplement thereto, in such number as the Agent shall deem necessary, (ii)
      the printing and delivery to the Agent of this Agreement and such other documents as may be required in connection with the offering, purchase, sale, issuance or delivery of the Placement Shares, (iii) the preparation, issuance and delivery of the
      certificates, if any, for the Placement Shares to the Agent, including any stock or other transfer taxes and any capital duties, stamp duties or other duties or taxes payable upon the sale, issuance or delivery of the Placement Shares to the Agent,
      (iv) the fees and disbursements of the counsel, accountants and other advisors to the Company, (v) the fees and expenses of Agent for the fees and expenses of the counsel to the Agent (x) payable upon the execution of this Agreement, in an amount not
      to exceed $50,000 in connection with the execution of this Agreement, (y) in connection with quarterly diligence arising from the transactions contemplated by this Agreement in an amount not to exceed $5,000 per quarter and (z) the reasonable out of
      pocket expenses&#160; in an amount not to exceed $10,000 for each amendment or replacement of the Prospectus, (vi) the qualification or exemption of the Placement Shares under state securities laws in accordance with the provisions of <u>Section 7(r)</u>
      hereof, including filing fees, but excluding fees of the Agent&#8217;s counsel, (vii) the printing and delivery to the Agent of copies of any Permitted Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto in such
      number as the Agent shall deem necessary, (viii) the preparation, printing and delivery to the Agent of copies of the blue sky survey, (ix) the fees and expenses of the Depositary, the transfer agent and the registrar for the Ordinary Shares or the
      ADSs (x) the filing and other fees incident to any review by FINRA of the terms of the sale of the Placement Shares including the fees of the Agent&#8217;s counsel (subject to the cap, set forth in clause (v) above), and (xi) the fees and expenses incurred
      in connection with the listing of the Placement Shares on the Exchange.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">27</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">&#160;</font>9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Conditions to Agent&#8217;s Obligations</u>. The obligations of the Agent hereunder with respect to a Placement will be
      subject to the continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due performance by the Company of its obligations hereunder, to the completion by the Agent of a due diligence review
      satisfactory to it in its reasonable judgment, and to the continuing satisfaction (or waiver by the Agent in its sole discretion) of the following additional conditions:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Registration Statements Effective</u>. The Registration Statement and the F-6 Registration Statement shall have become effective and shall be available for the (i) resale of all
      Placement Shares issued to the Agent and not yet sold by the Agent and (ii) sale of all Placement Shares contemplated to be issued by any Placement Notice.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Material Notices</u>. None of the following events shall have occurred and be continuing: (i) receipt by the Company of any request for additional information from the
      Commission or any other federal, state or foreign Governmental Authority during the period of effectiveness of the Registration Statement or the F-6 Registration Statement, the response to which would require any post-effective amendments or
      supplements to the Registration Statement, the F-6 Registration Statement or the Prospectus; (ii) the issuance by the Commission or any other federal, state or foreign Governmental Authority of any stop order suspending the effectiveness of the
      Registration Statement or the F-6 Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of
      any of the Placement Shares for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or (iv) the occurrence of any event that makes any material statement made in the Registration Statement or the Prospectus
      or any material document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires the making of any changes in the Registration Statement, the Prospectus or documents so that, in the case of the
      Registration Statement, it will not contain an untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading and, that in the case of the Prospectus, it
      will not contain an untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Misstatement or Material Omission</u>. Agent shall not have advised the Company that the Registration Statement or Prospectus, or any amendment or supplement thereto, contains
      an untrue statement of fact that in the Agent&#8217;s reasonable opinion is material, or omits to state a fact that in the Agent&#8217;s reasonable opinion is material and is required to be stated therein or is necessary to make the statements therein not
      misleading.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Material Changes</u>. Except as contemplated in the Prospectus, or disclosed in the Company&#8217;s reports filed with the Commission, there shall not have been any material adverse
      change in the authorized capital stock of the Company or any Material Adverse Effect or any development that would cause a Material Adverse Effect, or a downgrading in or withdrawal of the rating assigned to any of the Company&#8217;s securities (other
      than asset backed securities) by any rating organization or a public announcement by any rating organization that it has under surveillance or review its rating of any of the Company&#8217;s securities (other than asset backed securities), the effect of
      which, in the case of any such action by a rating organization described above, in the reasonable judgment of the Agent (without relieving the Company of any obligation or liability it may otherwise have), is so material as to make it impracticable
      or inadvisable to proceed with the offering of the Placement Shares on the terms and in the manner contemplated in the Prospectus.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">28</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Legal Opinions</u>. The Agent shall have received the opinion letters of Israeli Company Counsel, US Company Counsel and Depositary Counsel required to be delivered pursuant to <u>Section



        7(m) </u>on or before the date on which such delivery of such opinion letters is required pursuant to <u>Section 7(m)</u>.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Comfort Letter</u>. The Agent shall have received the Comfort Letter required to be delivered pursuant to <u>Section 7(n)</u> on or before the date on which such delivery of
      such Comfort Letter is required pursuant to <u>Section 7(n)</u>.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Representation Certificate</u>. The Agent shall have received the certificate required to be delivered pursuant to <u>Section 7(l)</u> on or before the date on which delivery of
      such certificate is required pursuant to <u>Section 7(l)</u>.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Suspension</u>. Trading in the ADSs shall not have been suspended on the Exchange and the ADSs shall not have been delisted from the Exchange.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Other Materials</u>. On each date on which the Company is required to deliver a certificate pursuant to <u>Section 7(l)</u>, the Company shall have furnished to the Agent such
      appropriate further information, opinions, certificates, letters and other documents as the Agent may reasonably request. All such opinions, certificates, letters and other documents will be in compliance with the provisions hereof.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Securities Act Filings Made</u>. All filings with the Commission required by Rule 424 under the Securities Act to have been filed prior to the issuance of any Placement Notice
      hereunder shall have been made within the applicable time period prescribed for such filing by Rule 424.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Approval for Listing</u>. The Placement Shares shall either have been (i) approved for listing on the Exchange, subject only to notice of issuance, or (ii) the Company shall have
      filed an application for listing of the Placement Shares on the Exchange at, or prior to, the issuance of any Placement Notice and the Exchange shall have reviewed such application and not provided any objections thereto.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>FINRA</u>. If applicable, FINRA shall have raised no objection to the terms of this offering and the amount of compensation allowable or payable to the Agent as described in the
      Prospectus.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Termination Event</u>. There shall not have occurred any event that would permit the Agent to terminate this Agreement pursuant to <u>Section 12(a)</u>.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Indemnification and Contribution</u>.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Company Indemnification</u>. The Company agrees to indemnify and hold harmless the Agent, its affiliates and their respective partners, members, directors, officers, employees,
      counsels and agents and each person, if any, who controls the Agent or any affiliate within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act as follows:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; against any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, arising out of or based upon any untrue statement or alleged untrue
      statement of a material fact contained in the Registration Statement or the F-6 Registration Statement (or any amendment thereto), or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the
      statements therein not misleading, or arising out of any untrue statement or alleged untrue statement of a material fact included in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), or the
      omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">29</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; against any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, to the extent of the aggregate amount paid in settlement of any litigation,
      or any investigation or proceeding by any Governmental Authority, commenced or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; <font style="font-style: italic;">provided</font> that (subject to <u>Section 10(d)</u> below) any such settlement is effected with the written consent of the Company, which consent shall not unreasonably be delayed or withheld; and</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; against any and all expense whatsoever, as incurred (including the fees and disbursements of counsel), reasonably incurred in investigating, preparing or defending against any
      litigation, or any investigation or proceeding by any Governmental Authority, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission (whether or not a
      party), to the extent that any such expense is not paid under (i) or (ii) above,</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising
      out of any untrue statement or omission or alleged untrue statement or omission made solely in reliance upon and in conformity with the Agent Information (as defined below).</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Agent Indemnification</u>. Agent agrees to indemnify and hold harmless the Company and its directors and each officer of the Company who signed the Registration Statement, and
      each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the indemnity contained in <u>Section
        10(a)</u>, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendments thereto), the Prospectus (or any amendment or supplement thereto) or
      any Issuer Free Writing Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with information relating to the Agent and furnished to the Company in writing by the Agent expressly for use therein. The Company hereby
      acknowledges that the only information that the Agent has furnished to the Company expressly for use in the Registration Statement, the Prospectus or any Issuer Free Writing Prospectus (or any amendment or supplement thereto) are the statements set
      forth in the seventh and eighth paragraphs under the caption &#8220;Plan of Distribution&#8221; in the Prospectus (the &#8220;<font style="font-weight: bold;"><u>Agent Information</u></font>&#8221;).</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Procedure</u>. Any party that proposes to assert the right to be indemnified under this <u>Section 10</u> will, promptly after receipt of notice of commencement of any action
      against such party in respect of which a claim is to be made against an indemnifying party or parties under this <u>Section 10</u>, notify each such indemnifying party of the commencement of such action, enclosing a copy of all papers served, but
      the omission so to notify such indemnifying party will not relieve the indemnifying party from (i) any liability that it might have to any indemnified party otherwise than under this <u>Section 10</u> and (ii) any liability that it may have to any
      indemnified party under the foregoing provision of this <u>Section 10</u> unless, and only to the extent that, such omission results in the forfeiture of substantive rights or defenses by the indemnifying party. If any such action is brought against
      any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying party will be entitled to participate in and, to the extent that it elects by delivering written notice to the indemnified party promptly after
      receiving notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly notified, to assume the defense of the action, with counsel reasonably satisfactory to the indemnified party, and after
      notice from the indemnifying party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to the indemnified party for any other legal expenses except as provided below and except for the reasonable
      costs of investigation subsequently incurred by the indemnified party in connection with the defense. The indemnified party will have the right to employ its own counsel in any such action, but the fees, expenses and other charges of such counsel
      will be at the expense of such indemnified party unless (1) the employment of counsel by the indemnified party has been authorized in writing by the indemnifying party, (2) the indemnified party has reasonably concluded (based on advice of counsel)
      that there may be legal defenses available to it or other indemnified parties that are different from or in addition to those available to the indemnifying party, (3) a conflict or potential conflict exists (based on advice of counsel to the
      indemnified party) between the indemnified party and the indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified party) or (4) the indemnifying party has not
      in fact employed counsel to assume the defense of such action or counsel reasonably satisfactory to the indemnified party, in each case, within a reasonable time after receiving notice of the commencement of the action; in each of which cases the
      reasonable fees, disbursements and other charges of counsel will be at the expense of the indemnifying party or parties. It is understood that the indemnifying party or parties shall not, in connection with any proceeding or related proceedings in
      the same jurisdiction, be liable for the fees, disbursements and other charges of more than one separate firm (plus local counsel) admitted to practice in such jurisdiction at any one time for all such indemnified party or parties. All such fees,
      disbursements and other charges will be reimbursed by the indemnifying party promptly as they are incurred. An indemnifying party will not, in any event, be liable for any settlement of any action or claim effected without its written consent (such
      consent not to be unreasonably withheld or delayed). No indemnifying party shall, without the prior written consent of each indemnified party, settle or compromise or consent to the entry of any judgment in any pending or threatened claim, action or
      proceeding relating to the matters contemplated by this <u>Section 10</u> (whether or not any indemnified party is a party thereto), unless such settlement, compromise or consent (1) includes an express and unconditional release of each indemnified
      party, in form and substance reasonably satisfactory to such indemnified party, from all liability arising out of such litigation, investigation, proceeding or claim and (2) does not include a statement as to or an admission of fault, culpability or
      a failure to act by or on behalf of any indemnified party.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">30</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Settlement Without Consent if Failure to Reimburse</u><font style="font-style: italic;">. </font>If an indemnified party shall have requested an indemnifying party to reimburse
      the indemnified party for reasonable fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by <u>Section 10(a)(ii)</u> effected without its written consent if (1) such
      settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (2) such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement being
      entered into and (3) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Contribution. In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing paragraphs of this <u>Section 10</u>
      is applicable in accordance with its terms but for any reason is held to be unavailable or insufficient from the Company or the Agent, the Company and the Agent will contribute to the total losses, claims, liabilities, expenses and damages (including
      any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding or any claim asserted) to which the Company and the Agent may be subject in such proportion as
      shall be appropriate to reflect the relative benefits received by the Company on the one hand and the Agent on the other hand. The relative benefits received by the Company on the one hand and the Agent on the other hand shall be deemed to be in the
      same proportion as the total net proceeds from the sale of the Placement Shares (before deducting expenses) received by the Company bear to the total compensation received by the Agent from the sale of Placement Shares on behalf of the Company. If,
      but only if, the allocation provided by the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion as is appropriate to reflect not only the relative benefits referred to in the
      foregoing sentence but also the relative fault, if any, of the Company, on the one hand, and the Agent, on the other hand, with respect to the statements or omission that resulted in such loss, claim, liability, expense or damage, or action in
      respect thereof, as well as any other relevant equitable considerations with respect to such offering. Such relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or
      omission or alleged omission to state a material fact relates to information supplied by the Company or the Agent, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such statement or
      omission. The Company and the Agent agree that it would not be just and equitable if contributions pursuant to this <u>Section 10(e)</u> were to be determined by pro rata allocation or by any other method of allocation that does not take into
      account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, liability, expense, or damage, or action in respect thereof, referred to above in this <u>Section 10(e)</u>
      shall be deemed to include, for the purpose of this <u>Section 10(e)</u>, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim to the extent consistent with
      <u>Section 10(c)</u> hereof. Notwithstanding the foregoing provisions of this <u>Section 10(e)</u>, the Agent shall not be required to contribute any amount in excess of the commissions received by it under this Agreement and no person found guilty
      of fraudulent misrepresentation (within the meaning of <u>Section 11(f)</u> of the Securities Act) will be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this <u>Section 10(e)</u>,
      any person who controls a party to this Agreement within the meaning of the Securities Act, any affiliates of the Agent and any officers, directors, partners, employees or agents of the Agent or any of its affiliates, will have the same rights to
      contribution as that party, and each director of the Company and each officer of the Company who signed the Registration Statement will have the same rights to contribution as the Company, subject in each case to the provisions hereof. Any party
      entitled to contribution, promptly after receipt of notice of commencement of any action against such party in respect of which a claim for contribution may be made under this <u>Section 10(e)</u>, will notify in writing any such party or parties
      from whom contribution may be sought, but the omission to so notify will not relieve that party or parties from whom contribution may be sought from any other obligation it or they may have under this <u>Section 10(e)</u> except to the extent that
      the failure to so notify such other party materially prejudiced the substantive rights or defenses of the party from whom contribution is sought. Except for a settlement entered into pursuant to the last sentence of <u>Section 10(c)</u> hereof, no
      party will be liable for contribution with respect to any action or claim settled without its written consent if such consent is required pursuant to <u>Section 10(c)</u> hereof.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">31</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Representations and Agreements to Survive Delivery</u>. The indemnity and contribution agreements contained in <u>Section 10</u> of this Agreement and all representations and
      warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as of their respective dates, regardless of (i) any investigation made by or on behalf of the Agent, any controlling persons, or the Company (or any of their
      respective officers, directors, employees or controlling persons), (ii) delivery and acceptance of the Placement Shares and payment therefor or (iii) any termination of this Agreement.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Termination</u>.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Agent may terminate this Agreement, by notice to the Company, as hereinafter specified at any time (1) if there has been, since the time of execution of this Agreement or since
      the date as of which information is given in the Prospectus, any change, or any development or event involving a prospective change, in the condition, financial or otherwise, or in the business, properties, earnings, results of operations or
      prospects of the Company and its Subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business, which individually or in the aggregate, in the sole judgment of the Agent is material and adverse and makes it
      impractical or inadvisable to market the Placement Shares or to enforce contracts for the sale of the Placement Shares, (2) if there has occurred any material adverse change in the financial markets in the United States or the international financial
      markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or pandemic or any change or development involving a prospective change in national or international political, financial or economic conditions, in each case the
      effect of which is such as to make it, in the judgment of the Agent, impracticable or inadvisable to market the Placement Shares or to enforce contracts for the sale of the Placement Shares, (3) if trading in the ADSs has been suspended or limited by
      the Commission or the Exchange, or if trading generally on the Exchange has been suspended or limited, or minimum prices for trading have been fixed on the Exchange, (4) if any suspension of trading of any securities of the Company on any exchange or
      in the over-the-counter market shall have occurred and be continuing, (5) if a major disruption of securities settlements or clearance services in the United States shall have occurred and be continuing, or (6) if a banking moratorium has been
      declared by either U.S. Federal or New York authorities. Any such termination shall be without liability of any party to any other party except that the provisions of <u>Section 8</u> (Payment of Expenses), <u>Section 10</u> (Indemnification and
      Contribution), <u>Section 11</u> (Representations and Agreements to Survive Delivery), <u>Section 17</u> (Governing Law and Time; Waiver of Jury Trial) and <u>Section 18</u> (Consent to Jurisdiction) hereof shall remain in full force and effect
      notwithstanding such termination. If the Agent elects to terminate this Agreement as provided in this <u>Section 12(a)</u>, the Agent shall provide the required notice as specified in <u>Section 13</u> (Notices).</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall have the right, by giving ten (10) days notice as hereinafter specified to terminate this Agreement in its sole discretion at any time after the date of this
      Agreement. Any such termination shall be without liability of any party to any other party except that the provisions of <u>Section 8</u>, <u>Section 10</u>, <u>Section 11</u>, <u>Section 17</u> and <u>Section 18</u> hereof shall remain in full
      force and effect notwithstanding such termination.</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Agent shall have the right, by giving ten (10) days notice as hereinafter specified to terminate this Agreement in its sole discretion at any time after the date of this
      Agreement. Any such termination shall be without liability of any party to any other party except that the provisions of <u>Section 8</u>, <u>Section 10</u>, <u>Section 11</u>, <u>Section 17</u> and <u>Section 18</u> hereof shall remain in full
      force and effect notwithstanding such termination.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Agreement shall remain in full force and effect unless terminated pursuant to <u>Sections 12(a)</u>, <u>(b)</u>, or <u>(c)</u> above or otherwise by mutual agreement of the
      parties; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that any such termination by mutual agreement shall in all cases be deemed to provide that <u>Section 8</u>, <u>Section 10</u>, <u>Section



        11</u>, <u>Section 17</u> and <u>Section 18</u> shall remain in full force and effect.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Any termination of this Agreement shall be effective on the date specified in such notice of termination; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that such termination shall not be effective until the close of business on the date of receipt of such notice by the Agent or the Company, as the case may be. If such termination shall occur prior to the Settlement Date
      for any sale of Placement Shares, such Placement Shares shall settle in accordance with the provisions of this Agreement.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">32</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Notices</u>. All notices or other communications required or permitted to be given by any party to any other party pursuant to the terms of this Agreement shall be in writing, unless
      otherwise specified, and if sent to the Agent, shall be delivered to:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">Roth Capital Partners, LLC</div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">888 San Clemente</div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">Newport Beach, CA 92660</div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">Fax No.: (949) 720-7227</div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">Attention: Managing Director</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">with a copy (which shall not constitute notice) to:</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">Duane Morris LLP</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">1540 Broadway</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">New York, NY 10036</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">Attn: Dean M. Colucci</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;">E-mail: dmcolucci@duanemorris.com</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; line-height: 1.25;">and if to the Company, shall be delivered to:</div>
    <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">Chemomab Therapeutics Ltd.</div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">Kiryat Atidim, Building 7</div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">Tel Aviv 6158002, Israel</div>
    <div style="margin-left: 72pt; line-height: 1.25;">Attention: Adi Mor</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">with a copy (which shall not constitute notice) to:</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">Meitar Law Offices</div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">16 Abba Hillel Silver Road</div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">Ramat Gan 5250608, Israel</div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">Attention: David S. Glatt, Adv.</div>
    <div style="text-align: justify; margin-left: 72pt; line-height: 1.25;">Email: dglatt@meitar.com</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">Each party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose. Each such notice or other communication
      shall be deemed given (i) when delivered personally or by verifiable facsimile transmission (with an original to follow) on or before 4:30 p.m., New York City time, on a Business Day or, if such day is not a Business Day, on the next succeeding
      Business Day, (ii) on the next Business Day after timely delivery to a nationally-recognized overnight courier and (iii) on the Business Day actually received if deposited in the U.S. mail (certified or registered mail, return receipt requested,
      postage prepaid). For purposes of this Agreement, &#8220;<font style="font-weight: bold;"><u>Business Day</u></font>&#8221; shall mean any day on which the Exchange and commercial banks in the City of New York are open for business.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">An electronic communication (&#8220;<font style="font-weight: bold;"><u>Electronic Notice</u></font>&#8221;) shall be deemed written notice for purposes of this Section 13 if sent to the electronic mail address
      specified by the receiving party under separate cover. Electronic Notice shall be deemed received at the time the party sending Electronic Notice receives verification of receipt by the receiving party. Any party receiving Electronic Notice may
      request and shall be entitled to receive the notice on paper, in a nonelectronic form (&#8220;<font style="font-weight: bold;"><u>Nonelectronic Notic</u>e</font>&#8221;) which shall be sent to the requesting party within ten (10) days of receipt of the written
      request for Nonelectronic Notice.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">33</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Successors and Assigns</u>. This Agreement shall inure to the benefit of and be binding upon the Company and the Agent and their respective successors and the parties referred to
      in Section 10 hereof. References to any of the parties contained in this Agreement shall be deemed to include the successors and permitted assigns of such party. Nothing in this Agreement, express or implied, is intended to confer upon any party
      other than the parties hereto or their respective successors and permitted assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. Neither party may assign its
      rights or obligations under this Agreement without the prior written consent of the other party; provided, however, that the Agent may assign its rights and obligations hereunder to an affiliate thereof without obtaining the Company&#8217;s consent.
      Without limitation to the above, all of the Company's representations herein and any opinion provided by any of its counsels and auditors may be relied upon also by such successors, assignees, and the Agent's counsels.</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Adjustments for Stock Splits</u>. The parties acknowledge and agree that all share-related numbers contained in this Agreement shall be adjusted to take into account any stock
      split, stock dividend or similar event effected with respect to the Placement Shares.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Entire Agreement; Amendment; Severability; Waiver</u>. This Agreement (including all schedules and exhibits attached hereto and Placement Notices issued pursuant hereto)
      constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term hereof may
      be amended except pursuant to a written instrument duly executed by the Company and the Agent specifically noting that it shall serve as an amendment to this Agreement. In the event that any one or more of the provisions contained herein, or the
      application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal and
      enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the
      remainder of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement. No implied waiver by a party shall arise in the absence of a waiver in writing signed by such party. No failure or
      delay in exercising any right, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any right, power, or privilege
      hereunder.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">17.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;"><u>GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL</u>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW
        YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE OF NEW YORK. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY HEREBY IRREVOCABLY
        WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</font></div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">18.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;"><u>CONSENT TO JURISDICTION</u>. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE
        CITY OF NEW YORK, BOROUGH OF MANHATTAN (THE &#8220;SPECIFIED COURTS&#8221;), FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY TRANSACTION CONTEMPLATED HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR
        PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM OR THAT THE VENUE OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY
        HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED) TO SUCH PARTY AT THE ADDRESS IN
        EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY
        MANNER PERMITTED BY LAW.</font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">34</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">19.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Agent for Service of Process</u>. The Company hereby appoints Chemomab Therapeutics, Inc., with offices at One Kendall Square, Building 1400E Suite 14-105 Cambridge, MA 02139, as
      its agent for service of process in any suit, action or proceeding and agrees that service of process in any such suit, action or proceeding may be made upon it at the office of such agent. The Company waives, to the fullest extent permitted by law,
      any other requirements of or objections to personal jurisdiction with respect thereto. The Company represents and warrants that such agent has agreed to act as the Company&#8217;s agent for service of process, and the Company agrees to take any and all
      action, including the filing of any and all documents and instruments, that may be necessary to continue such appointment in full force and effect. In the event that Chemomab Therapeutics, Inc. is unable to serve as such agent, the Company hereby
      agrees to maintain the uninterrupted designation of an authorized agent upon whom process may be served in any such suit, action or proceeding and agrees to notify the Agent of the name and address of any such future authorized agent. Service of any
      process, summons, notice or document by mail to such party&#8217;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any
      objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any
      such court has been brought in an inconvenient forum.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">20.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Judgment Currency</u>. The obligations of the Company pursuant to this Agreement in respect of any sum due to the Agent or any indemnitee pursuant to Section 10(a) (&#8220;Agent
      Indemnitee&#8221;) shall, notwithstanding any judgment in a currency other than United States dollars, not be discharged until the first business day, following receipt by the Agent or any Agent Indemnitee of any sum adjudged to be so due in such other
      currency, on which such Agent or Agent Indemnitee may in accordance with normal banking procedures purchase United States dollars with such other currency. If the United States dollars so purchased are less than the sum originally due to such Agent
      or Agent Indemnitee in United States dollars hereunder, the Company agrees as a separate obligation and notwithstanding any such judgment, to indemnify such Agent or Agent Indemnitee against such loss. If the United States dollars so purchased are
      greater than the sum originally due to such Agent or Agent Indemnitee hereunder, the Agent agrees to pay, or to cause such Agent Indemnitee to pay, to the Company, an amount equal to the excess of the dollars so purchased over the sum originally due
      to such Agent or Agent Indemnitee hereunder.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">35</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">21.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Withholding</u>. All payments made or deemed to be made by the Company under this Agreement, if any, will be made without withholding or deduction for or on account of any present
      or future taxes, duties, assessments or governmental charges of whatever nature (other than taxes on net income) imposed or levied by or on behalf of the State of Israel or any political subdivision or any taxing authority thereof or therein unless
      the Company is or becomes required by law to withhold or deduct such taxes, duties, assessments or other governmental charges. In such event, the Company will pay such additional amounts as will result, after such withholding or deduction, in the
      receipt by the Agent each Agent Indemnitee, as the case may be, of the amounts that would otherwise have been receivable in respect thereof.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">22.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Counterparts</u>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same
      instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile or electronic transmission.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">23.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Construction</u>. The section and exhibit headings herein are for convenience only and shall not affect the construction hereof. References herein to any law, statute, ordinance,
      code, regulation, rule or other requirement of any Governmental Authority shall be deemed to refer to such law, statute, ordinance, code, regulation, rule or other requirement of any Governmental Authority as amended, reenacted, supplemented or
      superseded in whole or in part and in effect from time to time and also to all rules and regulations promulgated thereunder.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">24.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Permitted Free Writing Prospectuses</u>. The Company represents, warrants and agrees that, unless it obtains the prior written consent of the Agent, and the Agent represents,
      warrants and agrees that, unless it obtains the prior written consent of the Company, it has not made and will not make any offer relating to the Placement Shares that would constitute an Issuer Free Writing Prospectus, or that would otherwise
      constitute a &#8220;free writing prospectus,&#8221; as defined in Rule 405, required to be filed with the Commission. Any such free writing prospectus consented to by the Agent or by the Company, as the case may be, is hereinafter referred to as a &#8220;Permitted
      Free Writing Prospectus.&#8221; The Company represents and warrants that it has treated and agrees that it will treat each Permitted Free Writing Prospectus as an &#8220;issuer free writing prospectus,&#8221; as defined in Rule 433, and has complied and will comply
      with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely filing with the Commission where required, legending and record keeping. For the purposes of clarity, the parties hereto agree that all free
      writing prospectuses, if any, listed in <u>Exhibit 24</u> hereto are Permitted Free Writing Prospectuses.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">25.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Absence of Fiduciary Relationship</u>. The Company acknowledges and agrees that:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the Agent is acting solely as agent in connection with the public offering of the Placement Shares and in connection with each transaction contemplated by this Agreement and the
      process leading to such transactions, and no fiduciary or advisory relationship between the Company or any of its respective affiliates, stockholders (or other equity holders), creditors or employees or any other party, on the one hand, and the
      Agent, on the other hand, has been or will be created in respect of any of the transactions contemplated by this Agreement, irrespective of whether or not the Agent has advised or is advising the Company on other matters, and the Agent has no
      obligation to the Company with respect to the transactions contemplated by this Agreement except the obligations expressly set forth in this Agreement;</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; it is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated by this Agreement;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">36</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; neither the Agent nor its affiliates have provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated by this Agreement and it has consulted
      its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; it is aware that the Agent and its affiliates are engaged in a broad range of transactions which may involve interests that differ from those of the Company and the Agent and its
      affiliates have no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary, advisory or agency relationship or otherwise; and</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; it waives, to the fullest extent permitted by law, any claims it may have against the Agent or its affiliates for breach of fiduciary duty or alleged breach of fiduciary duty in
      connection with the sale of Placement Shares under this Agreement and agrees that the Agent and its affiliates shall not have any liability (whether direct or indirect, in contract, tort or otherwise) to it in respect of such a fiduciary duty claim
      or to any person asserting a fiduciary duty claim on its behalf or in right of it or the Company, employees or creditors of Company.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">26.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Definitions</u>. As used in this Agreement, the following terms have the respective meanings set forth below:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;"><u>Applicable Time</u></font>&#8221; means (i) each Representation Date, (ii) the time of each sale of any Placement Shares pursuant to this Agreement and (iii) each
      Settlement Date.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;"><u>Governmental Authority</u></font>&#8221; means (i) any federal, provincial, state, local, municipal, national or international government or governmental authority,
      regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court, tribunal, arbitrator or arbitral body (public or private); (ii) any self-regulatory organization; or (iii) any political
      subdivision of any of the foregoing, in the United States of America, Israel or elsewhere.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;"><u>Issuer Free Writing Prospectus</u></font>&#8221; means any &#8220;issuer free writing prospectus,&#8221; as defined in Rule 433, relating to the Placement Shares that (1) is required
      to be filed with the Commission by the Company, (2) is a &#8220;road show&#8221; that is a &#8220;written communication&#8221; within the meaning of Rule 433(d)(8)(i) whether or not required to be filed with the Commission, or (3) is exempt from filing pursuant to Rule
      433(d)(5)(i) because it contains a description of the Placement Shares or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form
      retained in the Company&#8217;s records pursuant to Rule 433(g) under the Securities Act Regulations.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;"><u>Rule 164</u></font>,&#8221; &#8220;<font style="font-weight: bold;"><u>Rule 172</u></font>,&#8221; &#8220;<font style="font-weight: bold;"><u>Rule 405</u></font>,&#8221; &#8220;<font style="font-weight: bold;"><u>Rule 415</u></font>,&#8221; &#8220;<font style="font-weight: bold;"><u>Rule 424</u></font>,&#8221; &#8220;<font style="font-weight: bold;"><u>Rule 424(b)</u></font>,&#8221; &#8220;<font style="font-weight: bold;"><u>Rule 430B</u></font>,&#8221; and &#8220;<font style="font-weight: bold;"><u>Rule 433</u></font>&#8221; refer to such rules under the Securities Act Regulations.</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">All references in this Agreement to financial statements and schedules and other information that is &#8220;contained,&#8221; &#8220;included&#8221; or &#8220;stated&#8221; in the Registration Statement, the F-6 Registration Statement or
      the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information that is incorporated by reference in the Registration Statement or the Prospectus, as the
      case may be.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">All references in this Agreement to the Registration Statement, the F-6 Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy
      filed with the Commission pursuant to EDGAR; all references in this Agreement to any Issuer Free Writing Prospectus (other than any Issuer Free Writing Prospectuses that, pursuant to Rule 433, are not required to be filed with the Commission) shall
      be deemed to include the copy thereof filed with the Commission pursuant to EDGAR; and all references in this Agreement to &#8220;supplements&#8221; to the Prospectus shall include, without limitation, any supplements, &#8220;wrappers&#8221; or similar materials prepared in
      connection with any offering, sale or private placement of any Placement Shares by the Agent outside of the United States.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">[<font style="font-weight: bold; font-style: italic;">Signature Page Follows</font>]</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">37</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">If the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a
      binding agreement between the Company and the Agent.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z22e9b66800e44823a5c9edeb91fb5f52" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 47.87%; vertical-align: top;">&#160;</td>
          <td style="width: 52.13%; vertical-align: top;" colspan="3">
            <div style="line-height: 1.25;">Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.87%; vertical-align: top;">&#160;</td>
          <td style="width: 52.13%; vertical-align: top;" colspan="3">&#160;</td>
        </tr>
        <tr>
          <td style="width: 47.87%; vertical-align: top;">&#160;</td>
          <td style="width: 52.13%; vertical-align: top;" colspan="3">
            <div style="line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD. &#160; &#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.87%; vertical-align: top;">&#160;</td>
          <td style="width: 52.13%; vertical-align: top;" colspan="3">&#160;</td>
        </tr>
        <tr>
          <td style="width: 47.87%; vertical-align: bottom;">&#160;</td>
          <td style="width: 3.4%; vertical-align: bottom;">
            <div style="text-align: justify; line-height: 1.25;">By:</div>
          </td>
          <td style="width: 48.73%; vertical-align: bottom; border-bottom: #000000 2px solid;" colspan="2">
            <div style="line-height: 1.25;">/s/ <font style="font-style: italic;">Adi Mor</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.87%; vertical-align: top;">&#160;</td>
          <td style="width: 3.4%; vertical-align: top;">&#160;</td>
          <td style="width: 6.86%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Name:&#160;</div>
          </td>
          <td style="width: 41.87%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Adi Mor</div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.87%; vertical-align: bottom;">&#160;</td>
          <td style="width: 3.4%; vertical-align: bottom;">&#160;</td>
          <td style="width: 6.86%; vertical-align: bottom;">
            <div style="text-align: justify; line-height: 1.25;">Title:</div>
          </td>
          <td style="width: 41.87%; vertical-align: bottom;">
            <div style="text-align: justify; line-height: 1.25;">Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="za6c1489137d344d281b7887de22a8bc1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 47.86%; vertical-align: top;">&#160;</td>
          <td style="width: 52.14%; vertical-align: top;" colspan="3">
            <div style="line-height: 1.25;">ACCEPTED as of the date first-above written:</div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.86%; vertical-align: top;">&#160;</td>
          <td style="width: 52.14%; vertical-align: top;" colspan="3">&#160;</td>
        </tr>
        <tr>
          <td style="width: 47.86%; vertical-align: top;">&#160;</td>
          <td style="width: 52.14%; vertical-align: top;" colspan="3">
            <div style="line-height: 1.25; font-weight: bold;">ROTH CAPITAL PARTNERS, LLC &#160; &#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.86%; vertical-align: top;">&#160;</td>
          <td style="width: 52.14%; vertical-align: top;" colspan="3">&#160;</td>
        </tr>
        <tr>
          <td style="width: 47.86%; vertical-align: bottom;">&#160;</td>
          <td style="width: 3.41%; vertical-align: bottom;">
            <div style="text-align: justify; line-height: 1.25;">By:</div>
          </td>
          <td style="width: 48.73%; vertical-align: bottom; border-bottom: #000000 2px solid;" colspan="2">
            <div style="line-height: 1.25;">/s/ <font style="font-style: italic;">Aaron M Gurewitz</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.86%; vertical-align: top;">&#160;</td>
          <td style="width: 3.41%; vertical-align: top;">&#160;</td>
          <td style="width: 6.86%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Name:&#160;</div>
          </td>
          <td style="width: 41.87%; vertical-align: top;">
            <div style="line-height: 1.25;">Aaron M Gurewitz</div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.86%; vertical-align: bottom;">&#160;</td>
          <td style="width: 3.41%; vertical-align: bottom;">&#160;</td>
          <td style="width: 6.86%; vertical-align: bottom;">
            <div style="text-align: justify; line-height: 1.25;">Title:</div>
          </td>
          <td style="width: 41.87%; vertical-align: bottom;">
            <div style="line-height: 1.25;">President and Head of Investment Banking</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="ze5b0ee795abf4a8ba8f787a51f5621a1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 100%; vertical-align: bottom;">
              <div style="line-height: 1.25;"><br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">38</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SCHEDULE 1</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Form of Placement Notice</div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="zb35900c237844fb587d8f91217a2ced4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7.69%; vertical-align: top;">&#160;</td>
          <td style="width: 8%; vertical-align: top;">
            <div style="line-height: 1.25;">From:</div>
          </td>
          <td style="width: 84%; vertical-align: top;">
            <div style="line-height: 1.25;">Chemomab Therapeutics Ltd.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.69%; vertical-align: top;">&#160;</td>
          <td style="width: 8%; vertical-align: top;">
            <div style="line-height: 1.25;">To:</div>
          </td>
          <td style="width: 84%; vertical-align: top;">
            <div style="line-height: 1.25;">Roth Capital Partners, LLC<br>
              Attention: [&#8226;]</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.69%; vertical-align: top;">&#160;</td>
          <td style="width: 8%; vertical-align: top;">
            <div style="line-height: 1.25;">Subject:</div>
          </td>
          <td style="width: 84%; vertical-align: top;">
            <div style="line-height: 1.25;">Placement Notice</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.69%; vertical-align: top;">&#160;</td>
          <td style="width: 8%; vertical-align: top;">
            <div style="line-height: 1.25;">Date:</div>
          </td>
          <td style="width: 84%; vertical-align: top;">
            <div style="line-height: 1.25;">[&#8226;], 20[&#8226;]</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Ladies and Gentlemen:</div>
    <div style="line-height: 1.25">&#160;
      <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to the terms and subject to the conditions contained in the Sales Agreement between Chemomab Therapeutics
        Ltd, a company organized under the laws of Israel (the &#8220;<font style="font-weight: bold;"><u>Company</u></font>&#8221;), and Roth Capital Partners, LLC (&#8220;<font style="font-weight: bold;"><u>Agent</u></font>&#8221;), dated October 16, 2023, the Company hereby requests that the Agent sell up to [&#8226;] of the Company&#8217;s ADSs, at a minimum market price of $[&#8226;] per share, during
        the time period beginning [month, day, time] and ending [month, day, time].</div>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;"><br>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">39</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SCHEDULE 2</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Compensation</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">The Company shall pay to the Agent in cash, upon each sale of Placement Shares pursuant to this Agreement, an amount equal to 3.0% of the aggregate gross proceeds from each sale of Placement Shares.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">40</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SCHEDULE 3</div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Notice Parties</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><u>The Company</u></div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Adi Mor (adimor@chemomab.com)</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><u>The Agent</u></div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z14b6e1e77d32431d98269b0330321053">

          <tr>
            <td style="width: 15%;">
              <div>
                <div style="line-height: 1.25;">Benjamin Bowen&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
                </div>
                <div style="line-height: 1.25;">Lou Ellis&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
                </div>
                <div style="line-height: 1.25;">Nazan Akdeniz <br>
                </div>
              </div>
            </td>
            <td style="width: 85%; text-align: left; vertical-align: top;">
              <div>bbowen@roth.com</div>
              <div>LEllis@roth.com </div>
              <div>NAkdeniz@roth.com </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; line-height: 1.25;">
      <div style="line-height: 1.25;">With a copy to RothECM@roth.com</div>
    </div>
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">41</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div><br>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SCHEDULE 4</div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Subsidiaries</div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Incorporated by reference to Exhibit 8.1 of the Company&#8217;s most recently filed Form 20-F or Exhibit 21.1 of the Company&#8217;s most recently filed Form 10-K, as applicable.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">42</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Form of Representation Date Certificate Pursuant to Section 7(l)</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25;">
      <div style="text-align: left; text-indent: 36pt; line-height: 1.25;">The undersigned, the duly qualified and elected [name &amp; title executive officer], of Chemomab Therapeutics Ltd., a
        company organized under the laws of Israel (the &#8220;<u>Company</u>&#8221;), does hereby certify in such capacity and on behalf of the Company, pursuant to <u>Section 7(l)</u> of the Sales Agreement, dated October 16, 2023 (the &#8220;<u>Sales Agreement</u>&#8221;),
        between the Company and Roth Capital Partners, LLC, that to the best of the knowledge of the undersigned:</div>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(i) The representations and warranties of the Company in <u>Section 6</u> of the Sales Agreement are true and correct on and as of the date hereof with the same force and effect as if expressly made
      on and as of the date hereof, except for those representations and warranties that speak solely as of a specific date and which were true and correct as of such date; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that such representations and warranties also shall be qualified by the disclosure included or incorporated by reference in the Registration Statement and Prospectus; and</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(ii) The Company has complied in all material respects with all agreements and satisfied all conditions on its part to be performed or satisfied pursuant to the Sales Agreement at or prior to the date
      hereof.</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Capitalized terms used herein without definition shall have the respective meanings given to such terms in the Sales Agreement.</div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z1f114dc473d54038b4ee1bc2769a744b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;" colspan="2">
            <div style="line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD. &#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">By:</div>
          </td>
          <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Name:&#160;&#160;</div>
          </td>
          <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Title:</div>
          </td>
          <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Date: [&#8226;], 2023</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">43</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>Exhibit 24</u></div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Permitted Free Writing Prospectus</div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">None.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
  </div>
  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">44</font>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>exhibit_4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div> <br>
    </div>
    <div>
      <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 4.1</u></div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">INDENTURE</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">Dated as of ___________, 20___</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">[_________]</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">Trustee</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">TABLE OF CONTENTS</div>
      <div style="text-align: right; line-height: 1.25; font-weight: bold;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z9c74c612d0ce409a99264d9d6151340e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Page</div>
            </td>
          </tr>
          <tr>
            <td style="width: 92.86%; vertical-align: top; background-color: #CCEEFF;" colspan="2">
              <div style="line-height: 1.25;">ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">1</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 1.1.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">Definitions</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">1</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 1.2.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Other Definitions</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">3</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 1.3.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">Incorporation by Reference of Trust Indenture Act</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">4</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 1.4.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Rules of Construction</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">4</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 92.86%; vertical-align: top; background-color: #CCEEFF;" colspan="2">
              <div style="line-height: 1.25;">ARTICLE II. THE SECURITIES</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">4</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 2.1.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">Issuable in Series</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">4</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 2.2.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Establishment of Terms of Series of Securities</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">5</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 2.3.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">Execution and Authentication</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">6</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 2.4.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Registrar and Paying Agent</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">7</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 2.5.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">Paying Agent to Hold Money in Trust</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">8</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 2.6.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Securityholder Lists</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">8</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 2.7.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">Transfer and Exchange</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">8</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 2.8.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Mutilated, Destroyed, Lost and Stolen Securities</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">9</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 2.9.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">Outstanding Securities</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">9</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 2.10.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Treasury Securities</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">10</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 2.11.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">Temporary Securities</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">10</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 2.12.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Cancellation</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">10</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 2.13.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">Defaulted Interest</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">10</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 2.14.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Global Securities</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">10</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 2.15.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">CUSIP Numbers</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">12</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 92.86%; vertical-align: top;" colspan="2">
              <div style="line-height: 1.25;">ARTICLE III. REDEMPTION</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">12</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 3.1.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Notice to Trustee</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">12</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 3.2.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">Selection of Securities to be Redeemed</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">12</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 3.3.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Notice of Redemption</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">12</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 3.4.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">Effect of Notice of Redemption</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">13</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 3.5.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Deposit of Redemption Price</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">13</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 3.6.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">Securities Redeemed in Part</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">13</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 92.86%; vertical-align: top;" colspan="2">
              <div style="line-height: 1.25;">ARTICLE IV. COVENANTS</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">13</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 4.1.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Payment of Principal and Interest</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">13</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 4.2.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">SEC Reports</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">14</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 4.3.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Compliance Certificate</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">14</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 4.4.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">Stay, Extension and Usury Laws</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">14</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 92.86%; vertical-align: top;" colspan="2">
              <div style="line-height: 1.25;">ARTICLE V. SUCCESSORS</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">14</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 5.1.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">When Company May Merge, Etc</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">14</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 5.2.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">Successor Corporation Substituted</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">15</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 92.86%; vertical-align: top;" colspan="2">
              <div style="line-height: 1.25;">ARTICLE VI. DEFAULTS AND REMEDIES</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">15</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 6.1.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Events of Default</div>
            </td>
            <td style="width: 7.14%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">15</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 6.2.</div>
            </td>
            <td style="width: 79.14%; vertical-align: top;">
              <div style="line-height: 1.25;">Acceleration of Maturity; Rescission and Annulment</div>
            </td>
            <td style="width: 7.14%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">16</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">i</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z83e4c9ab61ec421d9577bfdf3ae28799" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 6.3.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Collection of Indebtedness and Suits for Enforcement by Trustee</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">17</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 6.4.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Trustee May File Proofs of Claim</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">17</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 6.5.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Trustee May Enforce Claims Without Possession of Securities</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">18</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 6.6.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Application of Money Collected</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">18</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 6.7.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Limitation on Suits</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">18</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 6.8.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Unconditional Right of Holders to Receive Principal and Interest</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">19</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 6.9.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Restoration of Rights and Remedies</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">19</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 6.10.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Rights and Remedies Cumulative</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">19</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 6.11.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Delay or Omission Not Waiver</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">19</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 6.12.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Control by Holders</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">20</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 6.13.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Waiver of Past Defaults</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">20</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 6.14.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Undertaking for Costs</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">20</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 92.88%; vertical-align: top;" colspan="2">
              <div style="line-height: 1.25;">ARTICLE VII. TRUSTEE</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">20</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 7.1.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Duties of Trustee</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">20</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 7.2.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Rights of Trustee</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">21</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 7.3.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Individual Rights of Trustee</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">22</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 7.4.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Trustee&#8217;s Disclaimer</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">22</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 7.5.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Notice of Defaults</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">23</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 7.6.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Reports by Trustee to Holders</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">23</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 7.7.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Compensation and Indemnity</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">23</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 7.8.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Replacement of Trustee</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">24</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 7.9.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Successor Trustee by Merger, Etc</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">24</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 7.10.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Eligibility; Disqualification</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">24</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 7.11.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Preferential Collection of Claims Against Company</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">24</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 92.88%; vertical-align: top; background-color: #CCEEFF;" colspan="2">
              <div style="line-height: 1.25;">ARTICLE VIII. SATISFACTION AND DISCHARGE; DEFEASANCE</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">25</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 8.1.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Satisfaction and Discharge of Indenture</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">25</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 8.2.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Application of Trust Funds; Indemnification</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">26</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 8.3.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Legal Defeasance of Securities of any Series</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">26</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 8.4.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Covenant Defeasance</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">27</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 8.5.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Repayment to Company</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">28</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 8.6.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Reinstatement</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">28</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 92.88%; vertical-align: top; background-color: #CCEEFF;" colspan="2">
              <div style="line-height: 1.25;">ARTICLE IX. AMENDMENTS AND WAIVERS</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">29</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 9.1.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Without Consent of Holders</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">29</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 9.2.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">With Consent of Holders</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">29</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 9.3.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Limitations</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">30</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 9.4.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Compliance with Trust Indenture Act</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">30</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 9.5.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Revocation and Effect of Consents</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">30</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 9.6.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Notation on or Exchange of Securities</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">31</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 9.7.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Trustee Protected</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">31</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">ii</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z8ca386c55d8640acb1c28574b5273d1e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 92.88%; vertical-align: top; background-color: #CCEEFF;" colspan="2">
              <div style="line-height: 1.25;">ARTICLE X. MISCELLANEOUS</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">31</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 10.1.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Trust Indenture Act Controls</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">31</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 10.2.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Notices</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">31</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 10.3.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Communication by Holders with Other Holders</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">32</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 10.4.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Certificate and Opinion as to Conditions Precedent</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">32</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 10.5.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Statements Required in Certificate or Opinion</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">32</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 10.6.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Rules by Trustee and Agents</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">33</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 10.7.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Legal Holidays</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">33</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 10.8.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">No Recourse Against Others</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">33</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 10.9.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Counterparts</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">33</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 10.10.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Governing Law; Waiver of Jury Trial; Consent to Jurisdiction</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">33</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 10.11.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">No Adverse Interpretation of Other Agreements</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">34</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 10.12.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Successors</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">34</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 10.13.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Severability</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">34</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 10.14.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Table of Contents, Headings, Etc</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">34</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 10.15.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Securities in a Foreign Currency</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">34</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 10.16.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Judgment Currency</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">35</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 10.17.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Force Majeure</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">35</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 92.88%; vertical-align: top;" colspan="2">
              <div style="line-height: 1.25;">ARTICLE XI. SINKING FUNDS</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">36</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 11.1.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Applicability of Article</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">36</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top;">
              <div style="line-height: 1.25;">Section 11.2.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top;">
              <div style="line-height: 1.25;">Satisfaction of Sinking Fund Payments with Securities</div>
            </td>
            <td style="width: 7.12%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">36</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.73%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Section 11.3.</div>
            </td>
            <td style="width: 79.16%; vertical-align: top; background-color: #CCEEFF;">
              <div style="line-height: 1.25;">Redemption of Securities for Sinking Fund</div>
            </td>
            <td style="width: 7.12%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">36</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">iii</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">Reconciliation and tie between Trust Indenture Act of 1939 and<br>
        Indenture, dated as of ____________, 20 __</div>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z85445cac141e4ea7b2f440d5645ad0a5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#167; 310(a)(1)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">7.10</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">(a)(2)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">7.10</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(a)(3)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Not Applicable</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">(a)(4)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">Not Applicable</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(a)(5)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">7.10</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">(b)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">7.10</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#167; 311(a)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">7.11</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">(b)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">7.11</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(c)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Not Applicable</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">&#167; 312(a)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">2.6</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(b)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">10.3</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">(c)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">10.3</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#167; 313(a)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">7.6</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">(b)(1)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">7.6</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(b)(2)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">7.6</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">(c)(1)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">7.6</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(d)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">7.6</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">&#167; 314(a)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">4.2, 10.5</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(b)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Not Applicable</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">(c)(1)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">10.4</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(c)(2)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">10.4</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">(c)(3)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">Not Applicable</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(d)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Not Applicable</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">(e)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">10.5</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(f)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Not Applicable</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">&#167; 315(a)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">7.1</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(b)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">7.5</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">(c)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">7.1</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(d)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">7.1</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">(e)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">6.14</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#167; 316(a)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">2.10</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">(a)(1)(A)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">6.12</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(a)(1)(B)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">6.13</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">(b)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">6.8</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#167; 317(a)(1)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">6.3</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">(a)(2)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">6.4</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(b)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">2.5</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;">
              <div style="line-height: 1.25;">&#167; 318(a)</div>
            </td>
            <td style="width: 50.02%; vertical-align: top;">
              <div style="line-height: 1.25;">10.1</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">Note: This reconciliation and tie shall not, for any purpose, be deemed to be part of the Indenture.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">iv</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25;">Indenture dated as of __________, 20__ between Chemomab Therapeutics Ltd., a company incorporated under the laws of
        Israel (&#8220;<font style="font-style: italic;">Company</font>&#8221;), and [______] (&#8220;<font style="font-style: italic;">Trustee</font>&#8221;).</div>
      <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25;">Each party agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders
        of the Securities issued under this Indenture.</div>
      <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">ARTICLE&#160;I.<br>
        DEFINITIONS AND INCORPORATION BY REFERENCE</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="line-height: 1.25;">Section&#160;1.1.&#160;<u>Definitions</u>.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Additional
          Amounts</font>&#8221; means any additional amounts which are required hereby or by any Security, under circumstances specified herein or therein, to be paid by the Company in respect of certain taxes imposed on Holders specified herein or therein and
        which are owing to such Holders.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Affiliate</font>&#8221;
        of any specified person means any other person directly or indirectly controlling or controlled by or under common control with such specified person. For the purposes of this definition, &#8220;control&#8221; (including, with correlative meanings, the terms
        &#8220;controlled by&#8221; and &#8220;under common control with&#8221;), as used with respect to any person, shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such person, whether through the
        ownership of voting securities or by agreement or otherwise.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Agent</font>&#8221;
        means any Registrar, Paying Agent or Notice Agent.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Board of
          Directors</font>&#8221; means the board of directors of the Company or any duly authorized committee thereof.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Board Resolution</font>&#8221;
        means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been adopted by the Board of Directors or pursuant to authorization by the Board of Directors and to be in full force and effect on the date of
        the certificate and delivered to the Trustee.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Business Day</font>&#8221;
        means any day except a Saturday, Sunday or a legal holiday in The City of New York, New York (or in connection with any payment, the place of payment) on which banking institutions are authorized or required by law, regulation or executive order to
        close.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Capital Stock</font>&#8221;
        means any and all shares, interests, participations, rights or other equivalents (however designated) of corporate stock.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Company</font>&#8221;
        means the party named as such above until a successor replaces it and thereafter means the successor.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Company Order</font>&#8221;
        means a written order signed in the name of the Company by an Officer.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Corporate Trust
          Office</font>&#8221; means the office of the Trustee at which at any particular time its corporate trust business related to this Indenture shall be principally administered.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Default</font>&#8221;
        means any event which is, or after notice or passage of time or both would be, an Event of Default.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Depositary</font>&#8221;
        means, with respect to the Securities of any Series issuable or issued in whole or in part in the form of one or more Global Securities, the person designated as Depositary for such Series by the Company, which Depositary shall be a clearing agency
        registered under the Exchange Act; and if at any time there is more than one such person, &#8220;Depositary&#8221; as used with respect to the Securities of any Series shall mean the Depositary with respect to the Securities of such Series.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: center; line-height: 1.25;"><br>
      </div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Discount Security</font>&#8221;
        means any Security that provides for an amount less than the stated principal amount thereof to be due and payable upon declaration of acceleration of the maturity thereof pursuant to Section&#160;6.2.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Dollars</font>&#8221;
        and &#8220;<font style="font-style: italic;">$</font>&#8221; means the currency of The United States of America.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Exchange Act</font>&#8221;
        means the Securities Exchange Act of 1934, as amended.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Foreign Currency</font>&#8221;
        means any currency or currency unit issued by a government other than the government of The United States of America.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Foreign
          Government Obligations</font>&#8221; means, with respect to Securities of any Series that are denominated in a Foreign Currency, direct obligations of, or obligations guaranteed by, the government that issued or caused to be issued such currency for
        the payment of which obligations its full faith and credit is pledged and which are not callable or redeemable at the option of the issuer thereof.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;"><font style="font-style: italic;">&#8220;GAAP&#8221;</font>&#160;means
        generally accepted accounting principles in the United States of America set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of
        the Financial Accounting Standards Board or in such other statements by such other entity as have been approved by a significant segment of the accounting profession, which are in effect as of the date of determination.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Global Security</font>&#8221;
        or &#8220;<font style="font-style: italic;">Global Securities</font>&#8221; means a Security or Securities, as the case may be, in the form established pursuant to Section&#160;2.2 evidencing all or
        part of a Series of Securities, issued to the Depositary for such Series or its nominee, and registered in the name of such Depositary or nominee.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Holder</font>&#8221; or
        &#8220;<font style="font-style: italic;">Securityholder</font>&#8221; means a person in whose name a Security is registered.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Indenture</font>&#8221;
        means this Indenture as amended or supplemented from time to time and shall include the form and terms of particular Series of Securities established as contemplated hereunder.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">interest</font>&#8221;
        with respect to any Discount Security which by its terms bears interest only after Maturity, means interest payable after Maturity.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Maturity</font>,&#8221;
        when used with respect to any Security, means the date on which the principal of such Security becomes due and payable as therein or herein provided, whether at the Stated Maturity or by declaration of acceleration, call for redemption or
        otherwise.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Officer</font>&#8221;
        means the Chief Executive Officer, the Chief Financial Officer, the General Counsel, the Treasurer or any Assistant Treasurer, the Secretary or any Assistant Secretary, and any Vice President of the Company.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Officer&#8217;s
          Certificate</font>&#8221; means a certificate signed by any Officer.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Opinion of
          Counsel</font>&#8221; means a written opinion of legal counsel who is acceptable to the Trustee. The counsel may be an employee of or counsel to the Company. The opinion may contain customary limitations, conditions and exceptions.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">person</font>&#8221;
        means any individual, corporation, partnership, joint venture, association, limited liability company, joint-stock company, trust, unincorporated organization or government or any agency or political subdivision thereof.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">principal</font>&#8221;
        of a Security means the principal of the Security plus, when appropriate, the premium, if any, on, and any Additional Amounts in respect of, the Security.</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Responsible
          Officer</font>&#8221; means any officer of the Trustee in its Corporate Trust Office having responsibility for administration of this Indenture and also means, with respect to a particular corporate trust matter, any other officer to whom any corporate
        trust matter is referred because of his or her knowledge of and familiarity with a particular subject.</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div>&#160;<br>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">SEC</font>&#8221;
          means the Securities and Exchange Commission.</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Securities</font>&#8221;
          means the debentures, notes or other debt instruments of the Company of any Series authenticated and delivered under this Indenture.</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Series</font>&#8221;
          or &#8220;<font style="font-style: italic;">Series of Securities</font>&#8221; means each series of debentures, notes or other debt instruments of the Company created pursuant to Sections&#160;2.1 and
          2.2 hereof.</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Stated Maturity</font>&#8221;
          when used with respect to any Security, means the date specified in such Security as the fixed date on which the principal of such Security or interest is due and payable.</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Subsidiary</font>&#8221;
          of any specified person means any corporation, association or other business entity of which more than 50% of the total voting power of shares of Capital Stock entitled (without regard to the occurrence of any contingency) to vote in the election
          of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by such person or one or more of the other Subsidiaries of that person or a combination thereof.</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">TIA</font>&#8221;
          means the Trust Indenture Act of 1939 (15 U.S. Code &#167;&#167; 77aaa-77bbbb) as in effect on the date of this Indenture;&#160;<u>provided</u>,&#160;<u>however</u>, that in the event the Trust Indenture Act of 1939 is amended after such date, &#8220;TIA&#8221; means, to the extent required by any such amendment, the Trust Indenture Act as so
          amended.</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Trustee</font>&#8221;
          means the person named as the &#8220;Trustee&#8221; in the first paragraph of this instrument until a successor Trustee shall have become such pursuant to the applicable provisions of this Indenture, and thereafter &#8220;Trustee&#8221; shall mean or include each person
          who is then a Trustee hereunder, and if at any time there is more than one such person, &#8220;Trustee&#8221; as used with respect to the Securities of any Series shall mean the Trustee with respect to Securities of that Series.</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">U.S. Government
            Obligations</font>&#8221; means securities which are direct obligations of, or guaranteed by, The United States of America for the payment of which its full faith and credit is pledged and which are not callable or redeemable at the option of the
          issuer thereof, and shall also include a depositary receipt issued by a bank or trust company as custodian with respect to any such U.S. Government Obligation or a specific payment of interest on or principal of any such U.S. Government
          Obligation held by such custodian for the account of the holder of a depositary receipt,&#160;<font style="font-style: italic;">provided</font>&#160;that (except as required by law) such
          custodian is not authorized to make any deduction from the amount payable to the holder of such depositary receipt from any amount received by the custodian in respect of the U.S. Government Obligation evidenced by such depositary receipt.</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;1.2.&#160;<u>Other Definitions</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z619ed8c70fcb4d7d9579dfa2a6917ed9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 81.89%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="line-height: 1.25; font-weight: bold;">Term</div>
              </td>
              <td style="width: 1.35%; vertical-align: bottom;">
                <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
              </td>
              <td style="width: 13.94%; vertical-align: bottom; border-bottom: #000000 2px solid;" colspan="2">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Defined In Section</div>
              </td>
              <td style="width: 2.82%; vertical-align: bottom;">
                <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 81.89%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#8220;<font style="font-style: italic;">Bankruptcy Law</font>&#8221;</div>
              </td>
              <td style="width: 1.35%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1.47%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 12.47%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="text-align: right; line-height: 1.25;">6.1</div>
              </td>
              <td style="width: 2.82%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">(f)</div>
              </td>
            </tr>
            <tr>
              <td style="width: 81.89%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#8220;Currency Rates&#8221;</div>
              </td>
              <td style="width: 1.35%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1.47%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 12.47%; vertical-align: bottom;">
                <div style="text-align: right; line-height: 1.25;">10.5</div>
              </td>
              <td style="width: 2.82%; vertical-align: bottom;">
                <div style="line-height: 1.25;">(d)</div>
              </td>
            </tr>
            <tr>
              <td style="width: 81.89%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#8220;<font style="font-style: italic;">Custodian</font>&#8221;</div>
              </td>
              <td style="width: 1.35%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1.47%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 12.47%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="text-align: right; line-height: 1.25;">6.1</div>
              </td>
              <td style="width: 2.82%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">(f)</div>
              </td>
            </tr>
            <tr>
              <td style="width: 81.89%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#8220;<font style="font-style: italic;">Event of Default,</font>&#8221;</div>
              </td>
              <td style="width: 1.35%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1.47%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 12.47%; vertical-align: bottom;">
                <div style="text-align: right; line-height: 1.25;">6.1</div>
              </td>
              <td style="width: 2.82%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 81.89%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#8220;<font style="font-style: italic;">Judgment Currency</font>&#8221;</div>
              </td>
              <td style="width: 1.35%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1.47%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 12.47%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="text-align: right; line-height: 1.25;">10.5</div>
              </td>
              <td style="width: 2.82%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">(d)</div>
              </td>
            </tr>
            <tr>
              <td style="width: 81.89%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#8220;<font style="font-style: italic;">Legal Holiday</font>&#8221;</div>
              </td>
              <td style="width: 1.35%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1.47%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 12.47%; vertical-align: bottom;">
                <div style="text-align: right; line-height: 1.25;">10.5</div>
              </td>
              <td style="width: 2.82%; vertical-align: bottom;">
                <div style="line-height: 1.25;">(d)</div>
              </td>
            </tr>
            <tr>
              <td style="width: 81.89%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#8220;<font style="font-style: italic;">New York Banking Day</font>&#8221;</div>
              </td>
              <td style="width: 1.35%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1.47%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 12.47%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="text-align: right; line-height: 1.25;">10.5</div>
              </td>
              <td style="width: 2.82%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">(d)</div>
              </td>
            </tr>
            <tr>
              <td style="width: 81.89%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#8220;<font style="font-style: italic;">Notice Agent</font>&#8221;</div>
              </td>
              <td style="width: 1.35%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1.47%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 12.47%; vertical-align: bottom;">
                <div style="text-align: right; line-height: 1.25;">2.2.23</div>
              </td>
              <td style="width: 2.82%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 81.89%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#8220;<font style="font-style: italic;">Registrar</font>&#8221;</div>
              </td>
              <td style="width: 1.35%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1.47%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 12.47%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="text-align: right; line-height: 1.25;">2.2.23</div>
              </td>
              <td style="width: 2.82%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 81.89%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#8220;<font style="font-style: italic;">Required Currency</font>&#8221;</div>
              </td>
              <td style="width: 1.35%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1.47%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 12.47%; vertical-align: bottom;">
                <div style="text-align: right; line-height: 1.25;">10.5</div>
              </td>
              <td style="width: 2.82%; vertical-align: bottom;">
                <div style="line-height: 1.25;">(d)</div>
              </td>
            </tr>
            <tr>
              <td style="width: 81.89%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#8220;<font style="font-style: italic;">Specified Courts</font>&#8221;</div>
              </td>
              <td style="width: 1.35%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1.47%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 12.47%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="text-align: right; line-height: 1.25;">10.5</div>
              </td>
              <td style="width: 2.82%; vertical-align: bottom; background-color: #CCEEFF;">
                <div style="line-height: 1.25;">(d)</div>
              </td>
            </tr>
            <tr>
              <td style="width: 81.89%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#8220;<font style="font-style: italic;">successor person</font>&#8221;</div>
              </td>
              <td style="width: 1.35%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 1.47%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
              <td style="width: 12.47%; vertical-align: bottom;">
                <div style="text-align: right; line-height: 1.25;">5.1</div>
              </td>
              <td style="width: 2.82%; vertical-align: bottom;">
                <div style="line-height: 1.25;">&#160;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-align: center; line-height: 1.25;"><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;1.3.&#160;<u>Incorporation by Reference of Trust
              Indenture Act</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">Whenever this Indenture refers to a provision of the TIA, the provision is incorporated by reference in and made
          a part of this Indenture. The following TIA terms used in this Indenture have the following meanings:</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Commission</font>&#8221;
          means the SEC.</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">indenture
            securities</font>&#8221; means the Securities.</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">indenture
            security holder</font>&#8221; means a Securityholder.</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">indenture to be
            qualified</font>&#8221; means this Indenture.</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">indenture
            trustee</font>&#8221; or &#8220;<font style="font-style: italic;">institutional trustee</font>&#8221; means the Trustee.</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">obligor</font>&#8221;
          on the indenture securities means the Company and any successor obligor upon the Securities.</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">All other terms used in this Indenture that are defined by the TIA, defined by TIA reference to another statute
          or defined by SEC rule under the TIA and not otherwise defined herein are used herein as so defined.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;1.4.&#160;<u>Rules of Construction</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">Unless the context otherwise requires:</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">(a)&#160;a term has the meaning assigned to it;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;an accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">(c)&#160;&#8220;<font style="font-style: italic;">or</font>&#8221;
          is not exclusive;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">(d)&#160;words in the singular include the plural, and in the plural include the singular; and</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">(e)&#160;provisions apply to successive events and transactions.</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">ARTICLE&#160;II.<br>
          THE SECURITIES</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;2.1.&#160;<u>Issuable in Series</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The aggregate principal amount of Securities that may be authenticated and delivered under this Indenture is
          unlimited. The Securities may be issued in one or more Series. All Securities of a Series shall be identical except as may be set forth or determined in the manner provided in a Board Resolution, a supplemental indenture or an Officer&#8217;s
          Certificate detailing the adoption of the terms thereof pursuant to authority granted under a Board Resolution. In the case of Securities of a Series to be issued from time to time, the Board Resolution, Officer&#8217;s Certificate or supplemental
          indenture detailing the adoption of the terms thereof pursuant to authority granted under a Board Resolution may provide for the method by which specified terms (such as interest rate, maturity date, record date or date from which interest shall
          accrue) are to be determined. Securities may differ between Series in respect of any matters, provided that all Series of Securities shall be equally and ratably entitled to the benefits of the Indenture.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">4</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;2.2.&#160;<u>Establishment of Terms of Series of
              Securities</u>.</div>
        <div style="margin-left: 35.45pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">At or prior to the issuance of any Securities within a Series, the following shall be established (as to the Series
          generally, in the case of Subsection&#160;2.2.1 and either as to such Securities within the Series or as to the Series generally in the case of Subsections&#160;2.2.2 through 2.2.23) by or pursuant to a Board Resolution, and set forth or determined in the
          manner provided in a Board Resolution, supplemental indenture hereto or Officer&#8217;s Certificate:</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.1.&#160;the title (which shall distinguish the Securities of that particular Series from the Securities of any
          other Series) and ranking (including the terms of any subordination provisions) of the Series;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.2.&#160;the price or prices (expressed as a percentage of the principal amount thereof) at which the Securities of
          the Series will be issued;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.3.&#160;any limit upon the aggregate principal amount of the Securities of the Series which may be authenticated
          and delivered under this Indenture (except for Securities authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities of the Series pursuant to Section&#160;2.7, 2.8, 2.11, 3.6 or 9.6);</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.4.&#160;the date or dates on which the principal of the Securities of the Series is payable;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.5.&#160;the rate or rates (which may be fixed or variable) per annum or, if applicable, the method used to
          determine such rate or rates (including, but not limited to, any commodity, commodity index, stock exchange index or financial index) at which the Securities of the Series shall bear interest, if any, the date or dates from which such interest,
          if any, shall accrue, the date or dates on which such interest, if any, shall commence and be payable and any regular record date for the interest payable on any interest payment date;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.6.&#160;the place or places where the principal of and interest, if any, on the Securities of the Series shall be
          payable, where the Securities of such Series may be surrendered for registration of transfer or exchange and where notices and demands to or upon the Company in respect of the Securities of such Series and this Indenture may be delivered, and the
          method of such payment, if by wire transfer, mail or other means;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.7.&#160;if applicable, the period or periods within which, the price or prices at which and the terms and
          conditions upon which the Securities of the Series may be redeemed, in whole or in part, at the option of the Company;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.8.&#160;the obligation, if any, of the Company to redeem or purchase the Securities of the Series pursuant to any
          sinking fund or analogous provisions or at the option of a Holder thereof and the period or periods within which, the price or prices at which and the terms and conditions upon which Securities of the Series shall be redeemed or purchased, in
          whole or in part, pursuant to such obligation;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.9.&#160;the dates, if any, on which and the price or prices at which the Securities of the Series will be
          repurchased by the Company at the option of the Holders thereof and other detailed terms and provisions of such repurchase obligations;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.10.&#160;if other than denominations of $1,000 and any integral multiple thereof, the denominations in which the
          Securities of the Series shall be issuable;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.11.&#160;the forms of the Securities of the Series and whether the Securities will be issuable as Global
          Securities;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: center; line-height: 1.25;"><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">5</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.12.&#160;if other than the principal amount thereof, the portion of the principal amount of the Securities of the
          Series that shall be payable upon declaration of acceleration of the maturity thereof pursuant to Section&#160;6.2;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.13.&#160;the currency of denomination of the Securities of the Series, which may be Dollars or any Foreign
          Currency, and if such currency of denomination is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.14.&#160;the designation of the currency, currencies or currency units in which payment of the principal of and
          interest, if any, on the Securities of the Series will be made;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.15.&#160;if payments of principal of or interest, if any, on the Securities of the Series are to be made in one or
          more currencies or currency units other than that or those in which such Securities are denominated, the manner in which the exchange rate with respect to such payments will be determined;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.16.&#160;the manner in which the amounts of payment of principal of or interest, if any, on the Securities of the
          Series will be determined, if such amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.17.&#160;the provisions, if any, relating to any security provided for the Securities of the Series;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.18.&#160;any addition to, deletion of or change in the Events of Default which applies to any Securities of the
          Series and any change in the right of the Trustee or the requisite Holders of such Securities to declare the principal amount thereof due and payable pursuant to Section&#160;6.2;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.19.&#160;any addition to, deletion of or change in the covenants set forth in Articles&#160;IV or V which applies to
          Securities of the Series;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.20.&#160;any Depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with
          respect to Securities of such Series if other than those appointed herein;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.21.&#160;the provisions, if any, relating to conversion or exchange of any Securities of such Series, including if
          applicable, the conversion or exchange price, the conversion or exchange period, provisions as to whether conversion or exchange will be mandatory, at the option of the Holders thereof or at the option of the Company, the events requiring an
          adjustment of the conversion price or exchange price and provisions affecting conversion or exchange if such Series of Securities are redeemed;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.22.&#160;any other terms of the Series (which may supplement, modify or delete any provision of this Indenture
          insofar as it applies to such Series), including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of Securities of that Series; and</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.2.23.&#160;whether any of the Company&#8217;s direct or indirect Subsidiaries will guarantee the Securities of that Series,
          including the terms of subordination, if any, of such guarantees.</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">All Securities of any one Series need not be issued at the same time and may be issued from time to time, consistent
          with the terms of this Indenture, if so provided by or pursuant to the Board Resolution, supplemental indenture hereto or Officer&#8217;s Certificate referred to above.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;2.3.&#160;<u>Execution and Authentication</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">An Officer shall sign the Securities for the Company by manual, facsimile or electronic signature.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">6</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">If an Officer whose signature is on a Security no longer holds that office at the time the Security is
          authenticated, the Security shall nevertheless be valid.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">A Security shall not be valid until authenticated by the manual signature of the Trustee or an authenticating agent.
          The signature shall be conclusive evidence that the Security has been authenticated under this Indenture.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The Trustee shall at any time, and from time to time, authenticate Securities for original issue in the principal
          amount provided in the Board Resolution, supplemental indenture hereto or Officer&#8217;s Certificate, upon receipt by the Trustee of a Company Order. Each Security shall be dated the date of its authentication.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The aggregate principal amount of Securities of any Series outstanding at any time may not exceed any limit upon the
          maximum principal amount for such Series set forth in the Board Resolution, supplemental indenture hereto or Officer&#8217;s Certificate delivered pursuant to Section&#160;2.2, except as provided in Section&#160;2.8.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">Prior to the issuance of Securities of any Series, the Trustee shall have received and (subject to Section&#160;7.2)
          shall be fully protected in relying on: (a) the Board Resolution, supplemental indenture hereto or Officer&#8217;s Certificate establishing the form of the Securities of that Series or of Securities within that Series and the terms of the Securities of
          that Series or of Securities within that Series, (b) an Officer&#8217;s Certificate complying with Section&#160;10.4, and (c) an Opinion of Counsel complying with Section&#160;10.4.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The Trustee shall have the right to decline to authenticate and deliver any Securities of such Series: (a) if the
          Trustee, being advised by counsel, determines that such action may not be taken lawfully; or (b) if the Trustee in good faith by its board of directors or trustees, executive committee or a trust committee of directors and/or vice-presidents or a
          committee of Responsible Officers shall determine that such action would expose the Trustee to personal liability to Holders of any then outstanding Series of Securities.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The Trustee may appoint an authenticating agent acceptable to the Company to authenticate Securities. An
          authenticating agent may authenticate Securities whenever the Trustee may do so. Each reference in this Indenture to authentication by the Trustee includes authentication by such agent. An authenticating agent has the same rights as an Agent to
          deal with the Company or an Affiliate of the Company.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;2.4.&#160;<u>Registrar and Paying Agent</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The Company shall maintain, with respect to each Series of Securities, at the place or places specified with respect
          to such Series pursuant to Section&#160;2.2, an office or agency where Securities of such Series may be presented or surrendered for payment (&#8220;<font style="font-style: italic;">Paying
            Agent</font>&#8221;), where Securities of such Series may be surrendered for registration of transfer or exchange (&#8220;<font style="font-style: italic;">Registrar</font>&#8221;) and where notices
          and demands to or upon the Company in respect of the Securities of such Series and this Indenture may be delivered (&#8220;<font style="font-style: italic;">Notice Agent</font>&#8221;). The
          Registrar shall keep a register with respect to each Series of Securities and to their transfer and exchange. The Company will give prompt written notice to the Trustee of the name and address, and any change in the name or address, of each
          Registrar, Paying Agent or Notice Agent. If at any time the Company shall fail to maintain any such required Registrar, Paying Agent or Notice Agent or shall fail to furnish the Trustee with the name and address thereof, such presentations,
          surrenders, notices and demands may be made or served at the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent to receive all such presentations, surrenders, notices and demands;&#160;<u>provided</u>,&#160;<u>however</u>, that any appointment of the Trustee as the Notice
          Agent shall exclude the appointment of the Trustee or any office of the Trustee as an agent to receive the service of legal process on the Company.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">7</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The Company may also from time to time designate one or more co-registrars, additional paying agents or additional
          notice agents and may from time to time rescind such designations;&#160;<u>provided</u>,&#160;<u>however</u>,
          that no such designation or rescission shall in any manner relieve the Company of its obligations to maintain a Registrar, Paying Agent and Notice Agent in each place so specified pursuant to Section&#160;2.2 for Securities of any Series for such
          purposes. The Company will give prompt written notice to the Trustee of any such designation or rescission and of any change in the name or address of any such co-registrar, additional paying agent or additional notice agent. The term &#8220;<font style="font-style: italic;">Registrar</font>&#8221; includes any co-registrar; the term &#8220;<font style="font-style: italic;">Paying
            Agent</font>&#8221; includes any additional paying agent; and the term &#8220;<font style="font-style: italic;">Notice Agent</font>&#8221; includes any additional notice agent. The Company or any of
          its Affiliates may serve as Registrar or Paying Agent.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The Company hereby appoints the Trustee the initial Registrar, Paying Agent and Notice Agent for each Series unless
          another Registrar, Paying Agent or Notice Agent, as the case may be, is appointed prior to the time Securities of that Series are first issued.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;2.5.&#160;<u>Paying Agent to Hold Money in Trust</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The Company shall require each Paying Agent other than the Trustee to agree in writing that the Paying Agent will
          hold in trust, for the benefit of Securityholders of any Series of Securities, or the Trustee, all money held by the Paying Agent for the payment of principal of or interest on the Series of Securities, and will notify the Trustee in writing of
          any default by the Company in making any such payment. While any such default continues, the Trustee may require a Paying Agent to pay all money held by it to the Trustee. The Company at any time may require a Paying Agent to pay all money held
          by it to the Trustee. Upon payment over to the Trustee, the Paying Agent (if other than the Company or a Subsidiary of the Company) shall have no further liability for the money. If the Company or a Subsidiary of the Company acts as Paying Agent,
          it shall segregate and hold in a separate trust fund for the benefit of Securityholders of any Series of Securities all money held by it as Paying Agent. Upon any bankruptcy, reorganization or similar proceeding with respect to the Company, the
          Trustee shall serve as Paying Agent for the Securities.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;2.6.&#160;<u>Securityholder Lists</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The Trustee shall preserve in as current a form as is reasonably practicable the most recent list available to it of
          the names and addresses of Securityholders of each Series of Securities and shall otherwise comply with TIA &#167; 312(a). If the Trustee is not the Registrar, the Company shall furnish to the Trustee at least ten days before each interest payment
          date and at such other times as the Trustee may request in writing a list, in such form and as of such date as the Trustee may reasonably require, of the names and addresses of Securityholders of each Series of Securities.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;2.7.&#160;<u>Transfer and Exchange</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">Where Securities of a Series are presented to the Registrar or a co-registrar with a request to register a transfer
          or to exchange them for an equal principal amount of Securities of the same Series, the Registrar shall register the transfer or make the exchange if its requirements for such transactions are met. To permit registrations of transfers and
          exchanges, the Trustee shall authenticate Securities at the Registrar&#8217;s request. No service charge shall be made for any registration of transfer or exchange (except as otherwise expressly permitted herein), but the Company may require payment of
          a sum sufficient to cover any transfer tax or similar governmental charge payable in connection therewith (other than any such transfer tax or similar governmental charge payable upon exchanges pursuant to Sections&#160;2.11, 3.6 or 9.6).</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">Neither the Company nor the Registrar shall be required (a) to issue, register the transfer of, or exchange
          Securities of any Series for the period beginning at the opening of business 15 days immediately preceding the sending of a notice of redemption of Securities of that Series selected for redemption and ending at the close of business on the day
          such notice is sent, or (b) to register the transfer of or exchange Securities of any Series selected, called or being called for redemption as a whole or the portion being redeemed of any such Securities selected, called or being called for
          redemption in part.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">8</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: center; line-height: 1.25;"><br>
        </div>
        <div style="line-height: 1.25;">Section&#160;2.8.&#160;<u>Mutilated, Destroyed, Lost and Stolen
              Securities</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">If any mutilated Security is surrendered to the Trustee, the Company shall execute and the Trustee shall
          authenticate and deliver in exchange therefor a new Security of the same Series and of like tenor and principal amount and bearing a number not contemporaneously outstanding.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">If there shall be delivered to the Company and the Trustee (i) evidence to their satisfaction of the destruction,
          loss or theft of any Security and (ii) such security or indemnity bond as may be required by each of them to hold itself and any of its agents harmless, then, in the absence of notice to the Company or the Trustee that such Security has been
          acquired by a bona fide purchaser, the Company shall execute and upon receipt of a Company Order the Trustee shall authenticate and make available for delivery, in lieu of any such destroyed, lost or stolen Security, a new Security of the same
          Series and of like tenor and principal amount and bearing a number not contemporaneously outstanding.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">In case any such mutilated, destroyed, lost or stolen Security has become or is about to become due and payable, the
          Company in its discretion may, instead of issuing a new Security, pay such Security.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">Upon the issuance of any new Security under this Section, the Company may require the payment of a sum sufficient to
          cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">Every new Security of any Series issued pursuant to this Section&#160;in lieu of any destroyed, lost or stolen Security
          shall constitute an original additional contractual obligation of the Company, whether or not the destroyed, lost or stolen Security shall be at any time enforceable by anyone, and shall be entitled to all the benefits of this Indenture equally
          and proportionately with any and all other Securities of that Series duly issued hereunder.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The provisions of this Section&#160;are exclusive and shall preclude (to the extent lawful) all other rights and remedies
          with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;2.9.&#160;<u>Outstanding Securities</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The Securities outstanding at any time are all the Securities authenticated by the Trustee except for those canceled
          by it, those delivered to it for cancellation, those reductions in the interest on a Global Security effected by the Trustee in accordance with the provisions hereof and those described in this Section&#160;as not outstanding.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">If a Security is replaced pursuant to Section&#160;2.8, it ceases to be outstanding until the Trustee receives proof
          satisfactory to it that the replaced Security is held by a bona fide purchaser.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">If the Paying Agent (other than the Company, a Subsidiary of the Company or an Affiliate of the Company) holds on
          the Maturity of Securities of a Series money sufficient to pay such Securities payable on that date, then on and after that date such Securities of the Series cease to be outstanding and interest on them ceases to accrue.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The Company may purchase or otherwise acquire the Securities, whether by open market purchases, negotiated
          transactions or otherwise. A Security does not cease to be outstanding because the Company or an Affiliate of the Company holds the Security (but see Section&#160;2.10 below).</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">9</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">In determining whether the Holders of the requisite principal amount of outstanding Securities have given any
          request, demand, authorization, direction, notice, consent or waiver hereunder, the principal amount of a Discount Security that shall be deemed to be outstanding for such purposes shall be the amount of the principal thereof that would be due
          and payable as of the date of such determination upon a declaration of acceleration of the Maturity thereof pursuant to Section&#160;6.2.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;2.10.&#160;<u>Treasury Securities</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">In determining whether the Holders of the required principal amount of Securities of a Series have concurred in any
          request, demand, authorization, direction, notice, consent or waiver, Securities of a Series owned by the Company or any Affiliate of the Company shall be disregarded, except that for the purposes of determining whether the Trustee shall be
          protected in relying on any such request, demand, authorization, direction, notice, consent or waiver only Securities of a Series that a Responsible Officer of the Trustee knows are so owned shall be so disregarded.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;2.11.&#160;<u>Temporary Securities</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">Until definitive Securities are ready for delivery, the Company may prepare and the Trustee shall authenticate
          temporary Securities upon a Company Order. Temporary Securities shall be substantially in the form of definitive Securities but may have variations that the Company considers appropriate for temporary Securities. Without unreasonable delay, the
          Company shall prepare and the Trustee upon receipt of a Company Order shall authenticate definitive Securities of the same Series and date of maturity in exchange for temporary Securities. Until so exchanged, temporary securities shall have the
          same rights under this Indenture as the definitive Securities.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;2.12.&#160;<u>Cancellation</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The Company at any time may deliver Securities to the Trustee for cancellation. The Registrar and the Paying Agent
          shall forward to the Trustee any Securities surrendered to them for registration of transfer, exchange or payment. The Trustee shall cancel all Securities surrendered for transfer, exchange, payment, replacement or cancellation and shall destroy
          such canceled Securities (subject to the record retention requirement of the Exchange Act and the Trustee) and deliver a certificate of such cancellation to the Company upon written request of the Company. The Company may not issue new Securities
          to replace Securities that it has paid or delivered to the Trustee for cancellation.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;2.13.&#160;<u>Defaulted Interest</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">If the Company defaults in a payment of interest on a Series of Securities, it shall pay the defaulted interest,
          plus, to the extent permitted by law, any interest payable on the defaulted interest, to the persons who are Securityholders of the Series on a subsequent special record date. The Company shall fix the record date and payment date. At least ten
          days before the special record date, the Company shall send to the Trustee and to each Securityholder of the Series a notice that states the special record date, the payment date and the amount of interest to be paid. The Company may pay
          defaulted interest in any other lawful manner.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;2.14.&#160;<u>Global Securities</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.14.1.&#160;<u>Terms of Securities</u>.
          A Board Resolution, a supplemental indenture hereto or an Officer&#8217;s Certificate shall establish whether the Securities of a Series shall be issued in whole or in part in the form of one or more Global Securities and the Depositary for such Global
          Security or Securities.</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">10</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <br>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.14.2.&#160;<u>Transfer and Exchange</u>.
          Notwithstanding any provisions to the contrary contained in Section&#160;2.7 of the Indenture and in addition thereto, any Global Security shall be exchangeable pursuant to Section&#160;2.7 of the Indenture for Securities registered in the names of Holders
          other than the Depositary for such Security or its nominee only if (i) such Depositary notifies the Company that it is unwilling or unable to continue as Depositary for such Global Security or if at any time such Depositary ceases to be a
          clearing agency registered under the Exchange Act, and, in either case, the Company fails to appoint a successor Depositary registered as a clearing agency under the Exchange Act within 90 days of such event or (ii) the Company executes and
          delivers to the Trustee an Officer&#8217;s Certificate to the effect that such Global Security shall be so exchangeable. Any Global Security that is exchangeable pursuant to the preceding sentence shall be exchangeable for Securities registered in such
          names as the Depositary shall direct in writing in an aggregate principal amount equal to the principal amount of the Global Security with like tenor and terms.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">Except as provided in this Section&#160;2.14.2, a Global Security may not be transferred except as a whole by the
          Depositary with respect to such Global Security to a nominee of such Depositary, by a nominee of such Depositary to such Depositary or another nominee of such Depositary or by the Depositary or any such nominee to a successor Depositary or a
          nominee of such a successor Depositary.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.14.3.&#160;<u>Legends</u>. Any
          Global Security issued hereunder shall bear a legend in substantially the following form:</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#8220;THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN
          THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY. THIS SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND
          MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY, BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR
          A NOMINEE OF SUCH A SUCCESSOR DEPOSITARY.&#8221;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">In addition, so long as the Depository Trust Company (&#8220;DTC&#8221;) is the Depositary, each Global Note registered in the
          name of DTC or its nominee shall bear a legend in substantially the following form:</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#8220;UNLESS THIS GLOBAL NOTE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK
          CORPORATION (&#8220;DTC&#8221;), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY GLOBAL NOTE ISSUED IS REGISTERED IN THE NAME OF CEDE &amp; CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF
          DTC (AND ANY PAYMENT IS MADE TO CEDE &amp; CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE
          REGISTERED OWNER HEREOF, CEDE &amp; CO., HAS AN INTEREST HEREIN.&#8221;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.14.4.&#160;<u>Acts of Holders</u>.
          The Depositary, as a Holder, may appoint agents and otherwise authorize participants to give or take any request, demand, authorization, direction, notice, consent, waiver or other action which a Holder is entitled to give or take under the
          Indenture.</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.14.5.&#160;<u>Payments</u>.
          Notwithstanding the other provisions of this Indenture, unless otherwise specified as contemplated by Section&#160;2.2, payment of the principal of and interest, if any, on any Global Security shall be made to the Holder thereof.</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.3pt; line-height: 1.25;">2.14.6.&#160;<u>Consents, Declaration and
              Directions</u>. The Company, the Trustee and any Agent shall treat a person as the Holder of such principal amount of outstanding Securities of such Series represented by a Global Security as shall be specified in a written statement
          of the Depositary or by the applicable procedures of the Depositary with respect to such Global Security, for purposes of obtaining any consents, declarations, waivers or directions required to be given by the Holders pursuant to this Indenture.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">11</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25;">Section&#160;2.15.&#160;<u>CUSIP Numbers</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The Company in issuing the Securities may use &#8220;CUSIP&#8221; numbers (if then generally in use), and, if so, the Trustee
          shall use &#8220;CUSIP&#8221; numbers in notices of redemption as a convenience to Holders;&#160;<u>provided</u>&#160;that any such notice may state that no representation is made as
          to the correctness of such numbers either as printed on the Securities or as contained in any notice of a redemption and that reliance may be placed only on the other elements of identification printed on the Securities, and any such redemption
          shall not be affected by any defect in or omission of such numbers.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">ARTICLE&#160;III.<br>
          REDEMPTION</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;3.1.&#160;<u>Notice to Trustee</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The Company may, with respect to any Series of Securities, reserve the right to redeem and pay the Series of
          Securities or may covenant to redeem and pay the Series of Securities or any part thereof prior to the Stated Maturity thereof at such time and on such terms as provided for in such Securities. If a Series of Securities is redeemable and the
          Company wants or is obligated to redeem prior to the Stated Maturity thereof all or part of the Series of Securities pursuant to the terms of such Securities, it shall notify the Trustee in writing of the redemption date and the principal amount
          of the Series of Securities to be redeemed. The Company shall give the notice at least 15 days before the redemption date, unless a shorter period is satisfactory to the Trustee.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;3.2.&#160;<u>Selection of Securities to be Redeemed</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">Unless otherwise indicated for a particular Series by a Board Resolution, a supplemental indenture hereto or an
          Officer&#8217;s Certificate, if less than all the Securities of a Series are to be redeemed, the Securities of the Series to be redeemed will be selected as follows: (a) if the Securities are in the form of Global Securities, in accordance with the
          procedures of the Depositary, (b) if the Securities are listed on any national securities exchange, in compliance with the requirements of the principal national securities exchange, if any, on which the Securities are listed, or (c) if not
          otherwise provided for under clause (a) or (b) in the manner that the Trustee deems fair and appropriate, including by lot or other method, unless otherwise required by law or applicable stock exchange requirements, subject, in the case of Global
          Securities, to the applicable rules and procedures of the Depositary. The Securities to be redeemed shall be selected from Securities of the Series outstanding not previously called for redemption. Portions of the principal of Securities of the
          Series that have denominations larger than $1,000 may be selected for redemption. Securities of the Series and portions of them it selected for redemption shall be in amounts of $1,000 or whole multiples of $1,000 or, with respect to Securities
          of any Series issuable in other denominations pursuant to Section&#160;2.2.10, the minimum principal denomination for each Series and the authorized integral multiples thereof. Provisions of this Indenture that apply to Securities of a Series called
          for redemption also apply to portions of Securities of that Series called for redemption.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">Section&#160;3.3.&#160;<u>Notice of Redemption</u>.</div>
        <div style="line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">Unless otherwise indicated for a particular Series by Board Resolution, a supplemental indenture hereto or an
          Officer&#8217;s Certificate, at least 15 days but not more than 60 days before a redemption date, the Company shall send or cause to be sent by first-class mail or electronically, in accordance with the procedures of the Depositary, a notice of
          redemption to each Holder whose Securities are to be redeemed.</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 36pt; line-height: 1.25;">The notice shall identify the Securities of the Series to be redeemed and shall state:</div>
        <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
        <div style="text-indent: 35.45pt; line-height: 1.25;">(a)&#160;the redemption date;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">12</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div>&#160;<br>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;the redemption price;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(c)&#160;the name and address of the Paying Agent;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(d)&#160;if any Securities are being redeemed in part, the portion of the principal amount of such Securities to be
            redeemed and that, after the redemption date and upon surrender of such Security, a new Security or Securities in principal amount equal to the unredeemed portion of the original Security shall be issued in the name of the Holder thereof upon
            cancellation of the original Security;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(e)&#160;that Securities of the Series called for redemption must be surrendered to the Paying Agent to collect the
            redemption price;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(f)&#160;&#160;&#160;that interest on Securities of the Series called for redemption ceases to accrue on and after the
            redemption date unless the Company defaults in the deposit of the redemption price;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(g)&#160;the CUSIP number, if any; and</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(h)&#160;any other information as may be required by the terms of the particular Series or the Securities of a
            Series being redeemed.</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">At the Company&#8217;s request, the Trustee shall give the notice of redemption in the Company&#8217;s name and at its
            expense,&#160;<u>provided</u>,&#160;<u>however</u>&#160;, that the Company has delivered to
            the Trustee, at least 10 days (unless a shorter time shall be acceptable to the Trustee) prior to the notice date, an Officer&#8217;s Certificate requesting that the Trustee give such notice and setting forth the information to be stated in such
            notice.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">Section&#160;3.4.&#160;<u>Effect of Notice of Redemption</u>.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Once notice of redemption is sent as provided in Section&#160;3.3, Securities of a Series called for redemption become
            due and payable on the redemption date and at the redemption price. Except as otherwise provided in the supplemental indenture, Board Resolution or Officer&#8217;s Certificate for a Series, a notice of redemption may not be conditional. Upon
            surrender to the Paying Agent, such Securities shall be paid at the redemption price plus accrued interest to the redemption date.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">Section&#160;3.5.&#160;<u>Deposit of Redemption Price</u>.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">On or before 11:00 a.m., New York City time, on the redemption date, the Company shall deposit with the Paying
            Agent money sufficient to pay the redemption price of and accrued interest, if any, on all Securities to be redeemed on that date.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">Section&#160;3.6.&#160;<u>Securities Redeemed in Part</u>.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Upon surrender of a Security that is redeemed in part, the Trustee shall authenticate for the Holder a new
            Security of the same Series and the same maturity equal in principal amount to the unredeemed portion of the Security surrendered.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">ARTICLE&#160;IV.<br>
            COVENANTS</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
          <div style="line-height: 1.25;">Section&#160;4.1.&#160;<u>Payment of Principal and Interest</u>.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The Company covenants and agrees for the benefit of the Holders of each Series of Securities that it will duly and
            punctually pay the principal of and interest, if any, on the Securities of that Series in accordance with the terms of such Securities and this Indenture. On or before 11:00 a.m., New York City time, on the applicable payment date, the Company
            shall deposit with the Paying Agent money sufficient to pay the principal of and interest, if any, on the Securities of each Series in accordance with the terms of such Securities and this Indenture.</div>
          <div style="line-height: 1.25;">&#160;</div>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">13</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div><br>
          <div style="line-height: 1.25;">Section&#160;4.2.&#160;<u>SEC Reports</u>.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">To the extent any Securities of a Series are outstanding, the Company shall deliver to the Trustee within 15 days
            after it files them with the SEC copies of the annual reports and of the information, documents, and other reports (or copies of such portions of any of the foregoing as the SEC may by rules and regulations prescribe) which the Company is
            required to file with the SEC pursuant to Section&#160;13 or 15(d) of the Exchange Act. The Company also shall comply with the other provisions of TIA &#167; 314(a). Reports, information and documents filed with the SEC via the EDGAR system will be
            deemed to be delivered to the Trustee as of the time of such filing via EDGAR for purposes of this Section&#160;4.2.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Delivery of reports, information and documents to the Trustee under this Section&#160;4.2 is for informational purposes
            only and the Trustee&#8217;s receipt of the foregoing shall not constitute constructive or actual notice of any information contained therein or determinable from information contained therein, including the Company&#8217;s compliance with any of the
            covenants hereunder (as to which the Trustee is entitled to rely exclusively on Officer&#8217;s Certificates). All such reports, information or documents referred to in this Section&#160;4.2 that the Company files with the SEC via the SEC&#8217;s EDGAR system
            shall be deemed to be filed with the Trustee and transmitted to Holders at the time such reports, information or documents are filed via the EDGAR system (or any successor system).</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">Section&#160;4.3.&#160;<u>Compliance Certificate</u>.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">To the extent any Securities of a Series are outstanding, the Company shall deliver to the Trustee, within 120
            days after the end of each fiscal year of the Company, an Officer&#8217;s Certificate stating that a review of the activities of the Company and its Subsidiaries during the preceding fiscal year has been made under the supervision of the signing
            Officers with a view to determining whether the Company has kept, observed, performed and fulfilled its obligations under this Indenture, and further stating, as to each such Officer signing such certificate, that to the best of his/her
            knowledge the Company has kept, observed, performed and fulfilled each and every covenant contained in this Indenture and is not in default in the performance or observance of any of the terms, provisions and conditions hereof (or, if a Default
            or Event of Default shall have occurred, describing all such Defaults or Events of Default of which the Officer may have knowledge).</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">Section&#160;4.4.&#160;<u>Stay, Extension and Usury Laws</u>.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The Company covenants (to the extent that it may lawfully do so) that it will not at any time insist upon, plead,
            or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law wherever enacted, now or at any time hereafter in force, which may affect the covenants or the performance of this Indenture or the
            Securities; and the Company (to the extent it may lawfully do so) hereby expressly waives all benefit or advantage of any such law and covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power
            herein granted to the Trustee, but will suffer and permit the execution of every such power as though no such law has been enacted.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">ARTICLE&#160;V.<br>
            SUCCESSORS</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
          <div style="line-height: 1.25;">Section&#160;5.1.&#160;<u>When Company May Merge, Etc</u>.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The Company shall not consolidate with or merge with or into, or convey, transfer or lease all or substantially
            all of its properties and assets to, any person (a &#8220;<font style="font-style: italic;">successor person</font>&#8221;) unless:</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(a)&#160;the Company is the surviving entity or the successor person (if other than the Company) is a corporation,
            partnership, trust or other entity organized and validly existing under the laws of any U.S. domestic jurisdiction or the state of Israel and expressly assumes the Company&#8217;s obligations on the Securities and under this Indenture; and</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">14</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: center; line-height: 1.25;"><br>
          </div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;immediately after giving effect to the transaction, no Default or Event of Default, shall have occurred and
            be continuing.</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The Company shall deliver to the Trustee prior to the consummation of the proposed transaction an Officer&#8217;s
            Certificate to the foregoing effect and an Opinion of Counsel stating that the proposed transaction and any supplemental indenture comply with this Indenture.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Notwithstanding the above, any Subsidiary of the Company may consolidate with, merge into or transfer all or part
            of its properties to the Company. Neither an Officer&#8217;s Certificate nor an Opinion of Counsel shall be required to be delivered in connection therewith.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">Section&#160;5.2.&#160;<u>Successor Corporation Substituted</u>.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Upon any consolidation or merger, or any sale, lease, conveyance or other disposition of all or substantially all
            of the assets of the Company in accordance with Section&#160;5.1, the successor corporation formed by such consolidation or into or with which the Company is merged or to which such sale, lease, conveyance or other disposition is made shall succeed
            to, and be substituted for, and may exercise every right and power of, the Company under this Indenture with the same effect as if such successor person has been named as the Company herein;&#160;<u>provided</u>,&#160;<u>however</u>, that the predecessor Company in the case of a sale, conveyance or other disposition (other than
            a lease) shall be released from all obligations and covenants under this Indenture and the Securities.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">ARTICLE&#160;VI.<br>
            DEFAULTS AND REMEDIES</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
          <div style="line-height: 1.25;">Section&#160;6.1.&#160;<u>Events of Default</u>.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-style: italic;">Event of
              Default,</font>&#8221; wherever used herein with respect to Securities of any Series, means any one of the following events, unless in the establishing Board Resolution, supplemental indenture or Officer&#8217;s Certificate, it is provided that such
            Series shall not have the benefit of said Event of Default:</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(a)&#160;default in the payment of any interest on any Security of that Series when it becomes due and payable, and
            continuance of such default for a period of 30 days (unless the entire amount of such payment is deposited by the Company with the Trustee or with a Paying Agent prior to 11:00 a.m., New York City time, on the 30th day of such period); or</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;default in the payment of principal of any Security of that Series at its Maturity; or</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(c)&#160;default in the performance or breach of any covenant or warranty of the Company in this Indenture (other
            than defaults pursuant to paragraph (a) or (b) above or pursuant to a covenant or warranty that has been included in this Indenture solely for the benefit of a Series of Securities other than that Series), which default continues uncured for a
            period of 60 days after there has been given, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 25% in principal amount of the outstanding Securities of that Series a
            written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a &#8220;Notice of Default&#8221; hereunder; or</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(d)&#160;the Company pursuant to or within the meaning of any Bankruptcy Law:</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">(i)&#160;commences a voluntary case,</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">15</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">(ii)&#160;consents to the entry of an order for relief against it in an involuntary case,</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">(iii)&#160;consents to the appointment of a Custodian of it or for all or substantially all of
            its property,</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">(iv)&#160;makes a general assignment for the benefit of its creditors,</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">(v)&#160;applies for the granting of a freeze order (<font style="font-style: italic;">hakpaat halichim</font>) under the Israeli Companies Law, 5759-1999, or under the Israeli Insolvency and Economic Rehabilitation Law, 5778-2018; or</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">(vi)&#160;generally is unable to pay its debts as the same become due; or</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(e)&#160;a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that:</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">(i)&#160;is for relief against the Company in an involuntary case,</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">(ii)&#160;appoints a Custodian of the Company or for all or substantially all of its property,</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">(iii)&#160;orders the liquidation of the Company, or</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">(iv)&#160;grants a freeze order (<font style="font-style: italic;">hakpaat halichim</font>) under the Israeli Companies Law, 5759-1999 or under the Israeli Insolvency and Economic Rehabilitation Law, 5778-2018; and the order or decree remains unstayed and in effect for 60
            days; or</div>
          <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(f)&#160;any other Event of Default provided with respect to Securities of that Series, which is specified in a
            Board Resolution, a supplemental indenture hereto or an Officer&#8217;s Certificate, in accordance with Section&#160;2.2.18.</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The term &#8220;<font style="font-style: italic;">Bankruptcy
              Law</font>&#8221; means title 11, U.S. Code or any similar Federal or State law or foreign law for the relief of debtors, including, without limitation, the Israeli Companies Law, 5759-1999 and the Israeli Insolvency and Economic Rehabilitation
            Law, 5778-2018. The term &#8220;<font style="font-style: italic;">Custodian</font>&#8221; means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The Company will provide the Trustee written notice of any Default or Event of Default within 30 days of becoming
            aware of the occurrence of such Default or Event of Default, which notice will describe in reasonable detail the status of such Default or Event of Default and what action the Company is taking or proposes to take in respect thereof.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">Section&#160;6.2.&#160;<u>Acceleration of Maturity; Rescission and
                Annulment</u>.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">If an Event of Default with respect to Securities of any Series at the time outstanding occurs and is continuing
            (other than an Event of Default referred to in Section&#160;6.1(d) or (e)) then in every such case the Trustee or the Holders of not less than 25% in principal amount of the outstanding Securities of that Series may declare the principal amount (or,
            if any Securities of that Series are Discount Securities, such portion of the principal amount as may be specified in the terms of such Securities) of and accrued and unpaid interest, if any, on all of the Securities of that Series to be due
            and payable immediately, by a notice in writing to the Company (and to the Trustee if given by Holders), and upon any such declaration such principal amount (or specified amount) and accrued and unpaid interest, if any, shall become immediately
            due and payable. If an Event of Default specified in Section&#160;6.1(d) or (e) shall occur, the principal amount (or specified amount) of and accrued and unpaid interest, if any, on all outstanding Securities shall&#160;<font style="font-style: italic;">ipso facto</font>&#160;become and be immediately due and payable without any declaration or other act on the part of the Trustee or any Holder.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">16</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">At any time after such a declaration of acceleration with respect to any Series has been made and before a
            judgment or decree for payment of the money due has been obtained by the Trustee as hereinafter in this Article provided,&#160;&#160;the Holders of a majority in principal amount of the outstanding Securities of that Series, by written notice to the
            Company and the Trustee, may rescind and annul such declaration and its consequences if all Events of Default with respect to Securities of that Series, other than the non-payment of the principal and interest, if any, of Securities of that
            Series which have become due solely by such declaration of acceleration, have been cured or waived as provided in Section&#160;6.13.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">No such rescission shall affect any subsequent Default or impair any right consequent thereon.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">Section&#160;6.3.&#160;<u>Collection of Indebtedness and Suits for
                Enforcement by Trustee</u>.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The Company covenants that if:</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(a)&#160;default is made in the payment of any interest on any Security when such interest becomes due and payable
            and such default continues for a period of 30 days, or</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;default is made in the payment of principal of any Security at the Maturity thereof, or</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(c)&#160;default is made in the deposit of any sinking fund payment, if any, when and as due by the terms of a
            Security,&#160;</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"><font style="font-style: italic;">then,</font>&#160;the Company will, upon
            demand of the Trustee, pay to it, for the benefit of the Holders of such Securities, the whole amount then due and payable on such Securities for principal and interest and, to the extent that payment of such interest shall be legally
            enforceable, interest on any overdue principal and any overdue interest at the rate or rates prescribed therefor in such Securities, and, in addition thereto, such further amount as shall be sufficient to cover the costs and expenses of
            collection, including the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel.</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">If the Company fails to pay such amounts forthwith upon such demand, the Trustee, in its own name and as trustee
            of an express trust, may institute a judicial proceeding for the collection of the sums so due and unpaid, may prosecute such proceeding to judgment or final decree and may enforce the same against the Company or any other obligor upon such
            Securities and collect the moneys adjudged or deemed to be payable in the manner provided by law out of the property of the Company or any other obligor upon such Securities, wherever situated.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">If an Event of Default with respect to any Securities of any Series occurs and is continuing, the Trustee may in
            its discretion proceed to protect and enforce its rights and the rights of the Holders of Securities of such Series by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any such rights,
            whether for the specific enforcement of any covenant or agreement in this Indenture or in aid of the exercise of any power granted herein, or to enforce any other proper remedy.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">Section&#160;6.4.&#160;<u>Trustee May File Proofs of Claim</u>.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">In case of the pendency of any receivership, insolvency, liquidation, bankruptcy, reorganization, arrangement,
            adjustment, composition or other judicial proceeding relative to the Company or any other obligor upon the Securities or the property of the Company or of such other obligor or their creditors, the Trustee (irrespective of whether the principal
            of the Securities shall then be due and payable as therein expressed or by declaration or otherwise and irrespective of whether the Trustee shall have made any demand on the Company for the payment of overdue principal or interest) shall be
            entitled and empowered, by intervention in such proceeding or otherwise,</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35.45pt; line-height: 1.25;">(a) to file and prove a claim for the whole amount of principal and interest owing and unpaid in respect of the
            Securities and to file such other papers or documents as may be necessary or advisable in order to have the claims of the Trustee (including any claim for the compensation, reasonable expenses, disbursements and advances of the Trustee, its
            agents and counsel) and of the Holders allowed in such judicial proceeding, and</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">17</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div>&#160;<br>
            <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;to collect and receive any moneys or other property payable or deliverable on any such claims and to
              distribute the same, and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Holder to make such payments to the Trustee and, in the event
              that the Trustee shall consent to the making of such payments directly to the Holders, to pay to the Trustee any amount due it for the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel, and
              any other amounts due the Trustee under Section&#160;7.7.</div>
            <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt
              on behalf of any Holder any plan of reorganization, arrangement, adjustment or composition affecting the Securities or the rights of any Holder thereof or to authorize the Trustee to vote in respect of the claim of any Holder in any such
              proceeding.</div>
            <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
            <div style="line-height: 1.25;">Section&#160;6.5.&#160;<u>Trustee May Enforce Claims Without
                  Possession of Securities</u>.</div>
            <div style="line-height: 1.25;">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">All rights of action and claims under this Indenture or the Securities may be prosecuted and enforced by the
              Trustee without the possession of any of the Securities or the production thereof in any proceeding relating thereto, and any such proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any
              recovery of judgment shall, after provision for the payment of the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel, be for the ratable benefit of the Holders of the Securities in respect of
              which such judgment has been recovered.</div>
            <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
            <div style="line-height: 1.25;">Section&#160;6.6.&#160;<u>Application of Money Collected</u>.</div>
            <div style="line-height: 1.25;">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">Any money or property collected by the Trustee pursuant to this Article shall be applied in the following order,
              at the date or dates fixed by the Trustee and, in case of the distribution of such money or property on account of principal or interest, upon presentation of the Securities and the notation thereon of the payment if only partially paid and
              upon surrender thereof if fully paid:</div>
            <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">First: To the payment of all amounts due the Trustee under Section&#160;7.7; and</div>
            <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">Second: To the payment of the amounts then due and unpaid for principal of and interest on the Securities in
              respect of which or for the benefit of which such money has been collected, ratably, without preference or priority of any kind, according to the amounts due and payable on such Securities for principal and interest, respectively; and</div>
            <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">Third: To the Company.</div>
            <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
            <div style="line-height: 1.25;">Section&#160;6.7.&#160;<u>Limitation on Suits</u>.</div>
            <div style="line-height: 1.25;">&#160;</div>
            <div style="text-indent: 36pt; line-height: 1.25;">No Holder of any Security of any Series shall have any right to institute any proceeding, judicial or otherwise,
              with respect to this Indenture, or for the appointment of a receiver or trustee, or for any other remedy hereunder, unless</div>
            <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
            <div style="text-indent: 35.45pt; line-height: 1.25;">(a)&#160;such Holder has previously given written notice to the Trustee of a continuing Event of Default with
              respect to the Securities of that Series;</div>
            <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
            <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;the Holders of not less than 25% in principal amount of the outstanding Securities of that Series shall
              have made written request to the Trustee to institute proceedings in respect of such Event of Default in its own name as Trustee hereunder;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">18</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div>&#160;<br>
              <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">(c)&#160;such Holder or Holders have offered to the Trustee indemnity or security satisfactory to the Trustee
                against the costs, expenses and liabilities which might be incurred by the Trustee in compliance with such request;</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">(d)&#160;the Trustee for 60 days after its receipt of such notice, request and offer of indemnity has failed to
                institute any such proceeding; and</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">(e)&#160;no direction inconsistent with such written request has been given to the Trustee during such 60-day
                period by the Holders of a majority in principal amount of the outstanding Securities of that Series; it being understood, intended and expressly covenanted by the Holder of every Security with every other Holder and the Trustee that no one
                or more of such Holders shall have any right in any manner whatever by virtue of, or by availing of, any provision of this Indenture to affect, disturb or prejudice the rights of any other of such Holders, or to obtain or to seek to obtain
                priority or preference over any other of such Holders or to enforce any right under this Indenture, except in the manner herein provided and for the equal and ratable benefit of all such Holders of the applicable Series.</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
              <div style="line-height: 1.25;">Section&#160;6.8.&#160;<u>Unconditional Right of Holders to
                    Receive Principal and Interest</u>.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;">Notwithstanding any other provision in this Indenture, the Holder of any Security shall have the right, which
                is absolute and unconditional, to receive payment of the principal of and interest, if any, on such Security on the Maturity of such Security, including the Stated Maturity expressed in such Security (or, in the case of redemption, on the
                redemption date) and to institute suit for the enforcement of any such payment, and such rights shall not be impaired without the consent of such Holder.</div>
              <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
              <div style="line-height: 1.25;">Section&#160;6.9.&#160;<u>Restoration of Rights and Remedies</u>.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;">If the Trustee or any Holder has instituted any proceeding to enforce any right or remedy under this Indenture
                and such proceeding has been discontinued or abandoned for any reason, or has been determined adversely to the Trustee or to such Holder, then and in every such case, subject to any determination in such proceeding, the Company, the Trustee
                and the Holders shall be restored severally and respectively to their former positions hereunder and thereafter all rights and remedies of the Trustee and the Holders shall continue as though no such proceeding had been instituted.</div>
              <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
              <div style="line-height: 1.25;">Section&#160;6.10.&#160;<u>Rights and Remedies Cumulative</u>.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;">Except as otherwise provided with respect to the replacement or payment of mutilated, destroyed, lost or
                stolen Securities in Section&#160;2.8, no right or remedy herein conferred upon or reserved to the Trustee or to the Holders is intended to be exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted by
                law, be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not, to the
                extent permitted by law, prevent the concurrent assertion or employment of any other appropriate right or remedy.</div>
              <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
              <div style="line-height: 1.25;">Section&#160;6.11.&#160;<u>Delay or Omission Not Waiver</u>.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;">No delay or omission of the Trustee or of any Holder of any Securities to exercise any right or remedy
                accruing upon any Event of Default shall impair any such right or remedy or constitute a waiver of any such Event of Default or an acquiescence therein. Every right and remedy given by this Article or by law to the Trustee or to the Holders
                may be exercised from time to time, and as often as may be deemed expedient, by the Trustee or by the Holders, as the case may be.</div>
              <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">19</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div><br>
              <br>
              <div style="line-height: 1.25;">Section&#160;6.12.&#160;<u>Control by Holders</u>.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;">The Holders of a majority in principal amount of the outstanding Securities of any Series shall have the right
                to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee, with respect to the Securities of such Series, provided that</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">(a)&#160;such direction shall not be in conflict with any rule of law or with this Indenture,</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;the Trustee may take any other action deemed proper by the Trustee which is not inconsistent with such
                direction,</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">(c)&#160;subject to the provisions of Section&#160;7.1, the Trustee shall have the right to decline to follow any
                such direction if the Trustee in good faith shall, by a Responsible Officer of the Trustee, determine that the proceeding so directed would involve the Trustee in personal liability, and</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">(d)&#160;prior to taking any action as directed under this Section&#160;6.12, the Trustee shall be entitled to
                indemnity satisfactory to it against the costs, expenses and liabilities which might be incurred by it in compliance with such request or direction.</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
              <div style="line-height: 1.25;">Section&#160;6.13.&#160;<u>Waiver of Past Defaults</u>.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;">The Holders of not less than a majority in principal amount of the outstanding Securities of any Series may on
                behalf of the Holders of all the Securities of such Series, by written notice to the Trustee and the Company, waive any past Default hereunder with respect to such Series and its consequences, except a Default in the payment of the
                principal of or interest on any Security of such Series (<u>provided</u>,&#160;<u>however</u>,
                that the Holders of a majority in principal amount of the outstanding Securities of any Series may rescind an acceleration and its consequences, including any related payment default that resulted from such acceleration). Upon any such
                waiver, such Default shall cease to exist, and any Event of Default arising therefrom shall be deemed to have been cured, for every purpose of this Indenture; but no such waiver shall extend to any subsequent or other Default or impair any
                right consequent thereon.</div>
              <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
              <div style="line-height: 1.25;">Section&#160;6.14.&#160;<u>Undertaking for Costs</u>.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="text-indent: 36pt; line-height: 1.25;">All parties to this Indenture agree, and each Holder of any Security by his acceptance thereof shall be deemed
                to have agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken, suffered or omitted by it as Trustee, the
                filing by any party litigant in such suit of an undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including reasonable attorneys&#8217; fees, against any party litigant in such suit,
                having due regard to the merits and good faith of the claims or defenses made by such party litigant; but the provisions of this Section&#160;shall not apply to any suit instituted by the Company, to any suit instituted by the Trustee, to any
                suit instituted by any Holder, or group of Holders, holding in the aggregate more than 10% in principal amount of the outstanding Securities of any Series, or to any suit instituted by any Holder for the enforcement of the payment of the
                principal of or interest on any Security on or after the Maturity of such Security, including the Stated Maturity expressed in such Security (or, in the case of redemption, on the redemption date).</div>
              <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">ARTICLE&#160;VII.<br>
                TRUSTEE</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
              <div style="line-height: 1.25;">Section&#160;7.1.&#160;<u>Duties of Trustee</u>.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">(a)&#160;If an Event of Default has occurred and is continuing, the Trustee shall exercise the rights and powers
                vested in it by this Indenture and use the same degree of care and skill in their exercise as a prudent person would exercise or use under the circumstances in the conduct of such person&#8217;s own affairs.</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;Except during the continuance of an Event of Default:</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">(i)&#160;The Trustee need perform only those duties that are specifically set forth in this
                Indenture and no others.</div>
              <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
              <div style="text-align: center; line-height: 1.25;"><br>
              </div>
              <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">20</font></div>
                <div style="page-break-after: always;" class="BRPFPageBreak">
                  <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
              </div>
              <div style="line-height: 1.25">&#160;</div>
              <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">(ii)&#160;In the absence of bad faith on its part, the Trustee may conclusively rely, as to
                the truth of the statements and the correctness of the opinions expressed therein, upon Officer&#8217;s Certificates or Opinions of Counsel furnished to the Trustee and conforming to the requirements of this Indenture;&#160;<u>however</u>, in the case of any such Officer&#8217;s Certificates or Opinions of Counsel which by any provisions hereof are specifically required to be furnished to the Trustee, the
                Trustee shall examine such Officer&#8217;s Certificates and Opinions of Counsel to determine whether or not they conform to the form requirements of this Indenture.</div>
              <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">(c)&#160;The Trustee may not be relieved from liability for its own negligent action, its own negligent failure
                to act or its own willful&#160;&#160;misconduct, except that:</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">(i)&#160;This paragraph does not limit the effect of paragraph (b) of this Section.</div>
              <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">(ii)&#160;The Trustee shall not be liable for any error of judgment made in good faith by a
                Responsible Officer, unless it is proved that the Trustee was negligent in ascertaining the pertinent facts.</div>
              <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">(iii)&#160;The Trustee shall not be liable with respect to any action taken, suffered or
                omitted to be taken by it with respect to Securities of any Series in good faith in accordance with the direction of the Holders of a majority in principal amount of the outstanding Securities of such Series relating to the time, method and
                place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee, under this Indenture with respect to the Securities of such Series in accordance with Section&#160;6.12.</div>
              <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">(d)&#160;Every provision of this Indenture that in any way relates to the Trustee is subject to paragraph (a),
                (b) and (c) of this Section.</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">(e)&#160;The Trustee may refuse to perform any duty or exercise any right or power unless it receives indemnity
                satisfactory to it against the costs, expenses and liabilities which might be incurred by it in performing such duty or exercising such right or power.</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">(f)&#160;&#160;&#160;The Trustee shall not be liable for interest on any money received by it except as the Trustee may
                agree in writing with the Company. Money held in trust by the Trustee need not be segregated from other funds except to the extent required by law.</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">(g)&#160;No provision of this Indenture shall require the Trustee to risk its own funds or otherwise incur any
                financial liability in the performance of any of its duties, or in the exercise of any of its rights or powers, if adequate indemnity against such risk is not assured to the Trustee in its satisfaction.</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">(h)&#160;The Paying Agent, the Registrar and any authenticating agent shall be entitled to the protections and
                immunities as are set forth in paragraphs (e), (f) and (g) of this Section&#160;and in Section&#160;7.2, each with respect to the Trustee.</div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
              <div style="line-height: 1.25;">Section&#160;7.2.&#160;<u>Rights of Trustee</u>.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">21</font></div>
                <div style="page-break-after: always;" class="BRPFPageBreak">
                  <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
              </div>
              <div style="text-indent: 35.45pt; line-height: 1.25;">(a)&#160;The Trustee may rely on and shall be protected in acting or refraining from acting upon any document
                (whether in its original or facsimile form) believed by it to be genuine and to have been signed or presented by the proper person. The Trustee need not investigate any fact or matter stated in the document.</div>
              <div>&#160;<br>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;Before the Trustee acts or refrains from acting, it may require an Officer&#8217;s Certificate or an
                  Opinion of Counsel or both. The Trustee shall not be liable for any action it takes or omits to take in good faith in reliance on such Officer&#8217;s Certificate or Opinion of Counsel.</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(c)&#160;The Trustee may act through agents and shall not be responsible for the misconduct or negligence of
                  any agent appointed with due care. No Depositary shall be deemed an agent of the Trustee and the Trustee shall not be responsible for any act or omission by any Depositary.</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(d)&#160;The Trustee shall not be liable for any action it takes or omits to take in good faith which it
                  believes to be authorized or within its rights or powers, provided that the Trustee&#8217;s conduct does not constitute willful misconduct or negligence.</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(e)&#160;The Trustee may consult with counsel and the advice of such counsel or any Opinion of Counsel shall
                  be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder without willful misconduct or negligence, and in reliance thereon.</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(f)&#160;The Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this
                  Indenture at the request or direction of any of the Holders of Securities unless such Holders shall have offered to the Trustee security or indemnity satisfactory to it against the costs, expenses and liabilities which might be incurred
                  by it in compliance with such request or direction.</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(g)&#160;The Trustee shall not be bound to make any investigation into the facts or matters stated in any
                  resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document, but the Trustee, in its discretion, may make
                  such further inquiry or investigation into such facts or matters as it may see fit.</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(h)&#160;The Trustee shall not be deemed to have notice of any Default or Event of Default unless a
                  Responsible Officer of the Trustee has actual knowledge thereof or unless written notice of any event which is in fact such a default is received by the Trustee at the Corporate Trust Office of the Trustee, and such notice references the
                  Securities generally or the Securities of a particular Series and this Indenture.</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(i)&#160;&#160;&#160;In no event shall the Trustee be liable to any person for special, punitive, indirect,
                  consequential or incidental loss or damage of any kind whatsoever (including but not limited to lost profits), even if the Trustee has been advised of the likelihood of such loss or damage.</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(j)&#160;&#160;&#160;The permissive right of the Trustee to take the actions permitted by this Indenture shall not be
                  construed as an obligation or duty to do so.</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="line-height: 1.25;">Section&#160;7.3.&#160;<u>Individual Rights of Trustee</u>.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">The Trustee in its individual or any other capacity may become the owner or pledgee of Securities and may
                  otherwise deal with the Company or an Affiliate of the Company with the same rights it would have if it were not Trustee. Any Agent may do the same with like rights. The Trustee is also subject to Sections&#160;7.10 and 7.11.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="line-height: 1.25;">Section&#160;7.4.&#160;<u>Trustee&#8217;s Disclaimer</u>.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">The Trustee makes no representation as to the validity or adequacy of this Indenture or the Securities, it
                  shall not be accountable for the Company&#8217;s use of the proceeds from the Securities, and it shall not be responsible for any statement in the Securities other than its authentication.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">22</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="line-height: 1.25;">Section&#160;7.5.&#160;<u>Notice of Defaults</u>.</div>
                <div style="margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">If a Default or Event of Default occurs and is continuing with respect to the Securities of any Series and
                  if it is known to a Responsible Officer of the Trustee, the Trustee shall send to each Securityholder of the Securities of that Series notice of a Default or Event of Default within 90 days after it occurs or, if later, after a
                  Responsible Officer of the Trustee has knowledge of such Default or Event of Default. Except in the case of a Default or Event of Default in payment of principal of or interest on any Security of any Series, the Trustee may withhold the
                  notice if and so long as its corporate trust committee or a committee of its Responsible Officers in good faith determines that withholding the notice is in the interests of Securityholders of that Series.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="line-height: 1.25;">Section&#160;7.6.&#160;<u>Reports by Trustee to Holders</u>.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">Within 60 days after each [[&#160;&#9679;&#160;] commencing [&#160;&#9679;&#160;], [&#160;&#9679;&#160;]], the Trustee shall transmit by mail to all
                  Securityholders, as their names and addresses appear on the register kept by the Registrar, a brief report dated as of such anniversary date, in accordance with, and to the extent required under, TIA &#167; 313.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">A copy of each report at the time of its mailing to Securityholders of any Series shall be filed with the
                  SEC and each national securities exchange on which the Securities of that Series are listed. The Company shall promptly notify the Trustee in writing when Securities of any Series are listed on any national securities exchange.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="line-height: 1.25;">Section&#160;7.7.&#160;<u>Compensation and Indemnity</u>.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">The Company shall pay to the Trustee from time to time compensation for its services as the Company and the
                  Trustee shall from time to time agree upon in writing. The Trustee&#8217;s compensation shall not be limited by any law on compensation of a trustee of an express trust. The Company shall reimburse the Trustee upon request for all reasonable
                  out of pocket expenses incurred by it. Such expenses shall include the reasonable compensation and expenses of the Trustee&#8217;s agents and counsel.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">The Company shall indemnify each of the Trustee and any predecessor Trustee (including for the cost of
                  defending itself) against any cost, expense or liability, including taxes (other than taxes based upon, measured by or determined by the income of the Trustee) incurred by it except as set forth in the next paragraph in the performance of
                  its duties under this Indenture as Trustee or Agent. The Trustee shall notify the Company promptly of any claim for which it may seek indemnity. Failure by the Trustee to so notify the Company shall not relieve the Company of its
                  obligations hereunder, unless and to the extent that the Company is materially prejudiced thereby. The Company shall defend the claim and the Trustee shall cooperate in the defense. The Trustee may have one separate counsel and the
                  Company shall pay the reasonable fees and expenses of such counsel. The Company need not pay for any settlement made without its consent, which consent will not be unreasonably withheld. This indemnification shall apply to officers,
                  directors, employees, shareholders and agents of the Trustee.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">The Company need not reimburse any expense or indemnify against any loss or liability incurred by the
                  Trustee or by any officer, director, employee, shareholder or agent of the Trustee through willful misconduct or negligence.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">To secure the Company&#8217;s payment obligations in this Section, the Trustee shall have a lien prior to the
                  Securities of any Series on all money or property held or collected by the Trustee, except that held in trust to pay principal of and interest on particular Securities of that Series.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">When the Trustee incurs expenses or renders services after an Event of Default specified in Section&#160;6.1(d)
                  or (e) occurs, the expenses and the compensation for the services are intended to constitute expenses of administration under any Bankruptcy Law.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
              </div>
              <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">23</font></div>
                <div style="page-break-after: always;" class="BRPFPageBreak">
                  <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
              </div>
              <div><br>
                <div style="text-indent: 36pt; line-height: 1.25;">The provisions of this Section&#160;shall survive the termination of this Indenture.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="line-height: 1.25;">Section&#160;7.8.&#160;<u>Replacement of Trustee</u>.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">A resignation or removal of the Trustee and appointment of a successor Trustee shall become effective only
                  upon the successor Trustee&#8217;s acceptance of appointment as provided in this Section.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">The Trustee may resign with respect to the Securities of one or more Series by so notifying the Company at
                  least 30 days prior to the date of the proposed resignation. The Holders of a majority in principal amount of the Securities of any Series may remove the Trustee with respect to that Series by so notifying the Trustee and the Company. The
                  Company may remove the Trustee with respect to Securities of one or more Series if:</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(a)&#160;the Trustee fails to comply with Section&#160;7.10&#160;;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;the Trustee is adjudged a bankrupt or an insolvent or an order for relief is entered with respect to
                  the Trustee under any Bankruptcy Law;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">(c) &#160;a Custodian or public officer takes charge of the Trustee or its property; or</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(c)&#160;the Trustee becomes incapable of acting.</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">If the Trustee resigns or is removed or if a vacancy exists in the office of Trustee for any reason, the
                  Company shall promptly appoint a successor Trustee. Within one year after the successor Trustee takes office, the Holders of a majority in principal amount of the then outstanding Securities may appoint a successor Trustee to replace the
                  successor Trustee appointed by the Company.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">If a successor Trustee with respect to the Securities of any one or more Series does not take office within
                  60 days after the retiring Trustee resigns or is removed, the retiring Trustee, the Company or the Holders of at least a majority in principal amount of the Securities of the applicable Series may petition any court of competent
                  jurisdiction for the appointment of a successor Trustee.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">A successor Trustee shall deliver a written acceptance of its appointment to the retiring Trustee and to the
                  Company. Immediately after that, the retiring Trustee shall transfer all property held by it as Trustee to the successor Trustee subject to the lien provided for in Section&#160;7.7, the resignation or removal of the retiring Trustee shall
                  become effective, and the successor Trustee shall have all the rights, powers and duties of the Trustee with respect to each Series of Securities for which it is acting as Trustee under this Indenture. A successor Trustee shall mail a
                  notice of its succession to each Securityholder of each such Series. Notwithstanding replacement of the Trustee pursuant to this Section&#160;7.8, the Company&#8217;s obligations under Section&#160;7.7 hereof shall continue for the benefit of the
                  retiring Trustee with respect to expenses and liabilities incurred by it for actions taken or omitted to be taken in accordance with its rights, powers and duties under this Indenture prior to such replacement.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="line-height: 1.25;">Section&#160;7.9.&#160;<u>Successor Trustee by Merger, Etc</u>.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">If the Trustee consolidates with, merges or converts into, or transfers all or substantially all of its
                  corporate trust business to, another corporation, the successor corporation without any further act shall be the successor Trustee, subject to Section&#160;7.10.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="line-height: 1.25;">Section&#160;7.10.&#160;<u>Eligibility; Disqualification</u>.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">This Indenture shall always have a Trustee who satisfies the requirements of TIA &#167; 310(a)(1), (2) and (5).
                  The Trustee shall always have a combined capital and surplus of at least $25,000,000 as set forth in its most recent published annual report of condition. The Trustee shall comply with TIA &#167; 310(b).</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;&#160;</div>
                <div style="line-height: 1.25;">Section&#160;7.11.&#160;<u>Preferential Collection of Claims
                      Against Company</u>.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">The Trustee is subject to TIA &#167; 311(a), excluding any creditor relationship listed in TIA &#167; 311(b). A
                  Trustee who has resigned or been removed shall be subject to TIA &#167; 311(a) to the extent indicated.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">24</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">ARTICLE&#160;VIII.<br>
                  SATISFACTION AND DISCHARGE; DEFEASANCE</div>
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
                <div style="line-height: 1.25;">Section&#160;8.1.&#160;<u>Satisfaction and Discharge of
                      Indenture</u>.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">This Indenture shall upon Company Order be discharged with respect to the Securities of any Series and cease
                  to be of further effect as to all Securities of such Series (except as hereinafter provided in this Section&#160;8.1), and the Trustee, at the expense of the Company, shall execute instruments acknowledging satisfaction and discharge of this
                  Indenture, when</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(a)&#160;either</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">(i)&#160;all Securities of such Series theretofore authenticated and delivered (other than
                  Securities that have been destroyed, lost or stolen and that have been replaced or paid) have been delivered to the Trustee for cancellation; or</div>
                <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">(ii)&#160;all such Securities of such Series not theretofore delivered to the Trustee for
                  cancellation:</div>
                <div style="text-indent: 35.6pt; margin-left: 35.3pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36.75pt; margin-left: 70.55pt; line-height: 1.25;">(1)&#160;have become due and payable by reason of sending a notice of redemption or
                  otherwise, or</div>
                <div style="text-indent: 36.75pt; margin-left: 70.55pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36.75pt; margin-left: 70.55pt; line-height: 1.25;">(2)&#160;will become due and payable at their Stated Maturity within one year, or</div>
                <div style="text-indent: 36.75pt; margin-left: 70.55pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36.75pt; margin-left: 70.55pt; line-height: 1.25;">(3) have been called for redemption or are to be called for redemption within one
                  year under arrangements satisfactory to the Trustee for the giving of notice of redemption by the Trustee in the name, and at the expense, of the Company, or</div>
                <div style="text-indent: 36.75pt; margin-left: 70.55pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36.75pt; margin-left: 70.55pt; line-height: 1.25;">(4)&#160;are deemed paid and discharged pursuant to Section&#160;8.3, as applicable;</div>
                <div style="text-indent: 36.75pt; margin-left: 70.55pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36.75pt; margin-left: 70.55pt; line-height: 1.25;">(5)&#160;and the Company, in the case of (1), (2) or (3) above, has irrevocably
                  deposited or caused to be deposited with the Trustee as trust funds in trust an amount of money or U.S. Government Obligations, which amount shall be sufficient for the purpose of paying and discharging each installment&#160;&#160;of principal
                  (including mandatory sinking fund or analogous payments) of and interest on all the Securities of such Series on the dates such installments of principal or interest are due;</div>
                <div style="text-indent: 36.75pt; margin-left: 70.55pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;the Company has paid or caused to be paid all other sums payable hereunder by the Company; and</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(c)&#160;the Company has delivered to the Trustee an Officer&#8217;s Certificate and an Opinion of Counsel, each
                  stating that all conditions precedent provided for relating to the satisfaction and discharge contemplated by this Section&#160;have been complied with.</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">Notwithstanding the satisfaction and discharge of this Indenture, the obligations of the Company to the
                  Trustee under Section&#160;7.7, and, if money shall have been deposited with the Trustee pursuant to clause (a) of this Section, the provisions of Sections&#160;2.4, 2.7, 2.8, 8.2 and 8.5 shall survive.</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
              </div>
              <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">25</font></div>
                <div style="page-break-after: always;" class="BRPFPageBreak">
                  <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
              </div>
              <div><br>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="line-height: 1.25;">Section&#160;8.2.&#160;<u>Application of Trust Funds;
                      Indemnification</u>.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(a) Subject to the provisions of Section&#160;8.5, all money and U.S. Government Obligations or Foreign
                  Government Obligations deposited with the Trustee pursuant to Section&#160;8.1, 8.3 or 8.4 and all money received by the Trustee in respect of U.S. Government Obligations or Foreign Government Obligations deposited with the Trustee pursuant to
                  Section&#160;8.1, 8.3 or 8.4, shall be held in trust and applied by it, in accordance with the provisions of the Securities and this Indenture, to the payment, either directly or through any Paying Agent (including the Company acting as its
                  own Paying Agent) as the Trustee may determine, to the persons entitled thereto, of the principal and interest for whose payment such money has been deposited with or received by the Trustee or to make mandatory sinking fund payments or
                  analogous payments as contemplated by Sections&#160;8.1, 8.3 or 8.4.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;The Company shall pay and shall indemnify the Trustee against any tax, fee or other charge imposed on
                  or assessed against U.S. Government Obligations or Foreign Government Obligations deposited pursuant to Sections&#160;8.1, 8.3 or 8.4 or the interest and principal received in respect of such obligations other than any payable by or on behalf
                  of Holders.</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(c)&#160;The Trustee shall deliver or pay to the Company from time to time upon Company Order any U.S.
                  Government Obligations or Foreign Government Obligations or money held by it as provided in Sections&#160;8.3 or 8.4 which, in the opinion of a nationally recognized firm of independent certified public accountants or investment bank expressed
                  in a written certification thereof delivered to the Trustee, are then in excess of the amount thereof which then would have been required to be deposited for the purpose for which such U.S. Government Obligations or Foreign Government
                  Obligations or money were deposited or received. This provision shall not authorize the sale by the Trustee of any U.S. Government Obligations or Foreign Government Obligations held under this Indenture.</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="line-height: 1.25;">Section&#160;8.3.&#160;<u>Legal Defeasance of Securities of
                      any Series</u>.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">Unless this Section&#160;8.3 is otherwise specified, pursuant to Section&#160;2.2, to be inapplicable to Securities of
                  any Series, the Company shall be deemed to have paid and discharged the entire indebtedness on all the outstanding Securities of any Series on the 91st day after the date of the deposit referred to in subparagraph (d) hereof, and the
                  provisions of this Indenture, as it relates to such outstanding Securities of such Series, shall no longer be in effect (and the Trustee, at the expense of the Company, shall, upon receipt of a Company Order, execute instruments
                  acknowledging the same), except as to:</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(a)&#160;the rights of Holders of Securities of such Series to receive, from the trust funds described in
                  subparagraph (d) hereof, (i) payment of the principal of and each installment of principal of and interest on the outstanding Securities of such Series on the Maturity of such principal or installment of principal or interest and (ii) the
                  benefit of any mandatory sinking fund payments applicable to the Securities of such Series on the day on which such payments are due and payable in accordance with the terms of this Indenture and the Securities of such Series;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;the provisions of Sections&#160;2.4, 2.5, 2.7, 2.8, 7.7, 8.2, 8.3, 8.5 and 8.6; and</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(c)&#160;the rights, powers, trusts and immunities of the Trustee hereunder and the Company&#8217;s obligations in
                  connection therewith;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="line-height: 1.25;">provided that, the following conditions shall have been satisfied:</div>
                <div style="line-height: 1.25;">&#160;</div>
              </div>
              <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">26</font></div>
                <div style="page-break-after: always;" class="BRPFPageBreak">
                  <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
              </div>
              <div><br>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(d) the Company shall have irrevocably deposited or caused to be deposited (except as provided in
                  Section&#160;8.2(c)) with the Trustee as trust funds specifically pledged as security for and dedicated solely to the benefit of the Holders of such Securities (i) in the case of Securities of such Series denominated in Dollars, cash in
                  Dollars and/or U.S. Government Obligations, or (ii) in the case of Securities of such Series denominated in a Foreign Currency (other than a composite currency), money and/or Foreign Government Obligations, which through the payment of
                  interest and principal in respect thereof in accordance with their terms, will provide (and without reinvestment and assuming no tax liability will be imposed on such Trustee), not later than one day before the due date of any payment of
                  money, an amount in cash, sufficient, in the opinion of a nationally recognized firm of independent public accountants or investment bank expressed in a written certification thereof delivered to the Trustee, to pay and discharge each
                  installment of principal of and interest, on and any mandatory sinking fund payments in respect of all the Securities of such Series on the dates such installments of principal or interest and such sinking fund payments are due;</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(e)&#160;such deposit will not result in a breach or violation of, or constitute a default under, this
                  Indenture or any other agreement or instrument to which the Company is a party or by which it is bound;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(f)&#160;&#160;&#160;no Default or Event of Default with respect to the Securities of such Series shall have occurred
                  and be continuing on the date of such deposit or during the period ending on the 91st day after such date;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(g)&#160;the Company shall have delivered to the Trustee an Officer&#8217;s Certificate and an Opinion of Counsel to
                  the effect that (i) the Company has received from, or there has been published by, the United States Internal Revenue Service a ruling, or (ii) since the date of execution of this Indenture, there has been a change in the applicable U.S.
                  federal income tax law, in either case to the effect that, and based thereon such Opinion of Counsel shall confirm that, the Holders of the Securities of such Series will not recognize income, gain or loss for U.S. federal income tax
                  purposes as a result of such deposit, defeasance and discharge and will be subject to U.S. federal income tax on the same amount and in the same manner and at the same times as would have been the case if such deposit, defeasance and
                  discharge had not occurred;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(h)&#160;the Company shall have delivered to the Trustee an Officer&#8217;s Certificate stating that the deposit was
                  not made by the Company with the intent of defeating, hindering, delaying or defrauding any other creditors of the Company; and</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(i)&#160;&#160;&#160;the Company shall have delivered to the Trustee an Officer&#8217;s Certificate and an Opinion of Counsel,
                  each stating that all conditions precedent provided for relating to the defeasance contemplated by this Section&#160;have been complied with.</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                <div style="line-height: 1.25;">Section&#160;8.4.&#160;<u>Covenant Defeasance</u>.</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-indent: 36pt; line-height: 1.25;">Unless this Section&#160;8.4 is otherwise specified pursuant to Section&#160;2.2 to be inapplicable to Securities of
                  any Series, the Company may omit to comply with respect to the Securities of any Series with any term, provision or condition set forth under Sections&#160;4.2, 4.3, 4.4 and 5.1 and, unless otherwise specified therein, any additional covenants
                  specified in a supplemental indenture for such Series of Securities or a Board Resolution or an Officer&#8217;s Certificate delivered pursuant to Section&#160;2.2 (and the failure to comply with any such covenants shall not constitute a Default or
                  Event of Default with respect to such Series under Section&#160;6.1) and the occurrence of any event specified in a supplemental indenture for such Series of Securities or a Board Resolution or an Officer&#8217;s Certificate delivered pursuant to
                  Section&#160;2.2 and designated as an Event of Default shall not constitute a Default or Event of Default hereunder, with respect to the Securities of such Series, but, except as specified above, the remainder of this Indenture and such
                  Securities will be unaffected thereby; provided that the following conditions shall have been satisfied:</div>
                <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                <div style="text-indent: 35.45pt; line-height: 1.25;">(a) with reference to this Section&#160;8.4, the Company has irrevocably deposited or caused to be irrevocably
                  deposited (except as provided in Section&#160;8.2(c)) with the Trustee as trust funds in trust for the purpose of making the following payments specifically pledged as security for, and dedicated solely to, the benefit of the Holders of such
                  Securities (i) in the case of Securities of such Series denominated in Dollars, cash in Dollars and/or U.S. Government Obligations, or (ii) in the case of Securities of such Series denominated in a Foreign Currency (other than a composite
                  currency), money and/or Foreign Government Obligations, which through the payment of interest and principal in respect thereof in accordance with their terms, will provide (and without reinvestment and assuming no tax liability will be
                  imposed on such Trustee), not later than one day before the due date of any payment of money, an amount in cash, sufficient, in the opinion of a nationally recognized firm of independent certified public accountants or investment bank
                  expressed in a written certification thereof delivered to the Trustee, to pay and discharge each installment of principal (including mandatory sinking fund or analogous payments) of and interest on all the Securities of such Series on the
                  dates such installments of principal or interest are due;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">27</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <div>&#160;<br>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;such deposit will not result in a breach or violation of, or constitute a default under, this
                    Indenture or any other agreement or instrument to which the Company is a party or by which it is bound;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(c)&#160;no Default or Event of Default with respect to the Securities of such Series shall have occurred
                    and be continuing on the date of such deposit;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(d)&#160;the Company shall have delivered to the Trustee an Officers&#8217; Certificate and an Opinion of Counsel
                    to the effect that the Holders of the Securities of such Series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of such deposit and covenant defeasance and will be subject to U.S. federal income
                    tax on the same amount and in the same manner and at the same times as would have been the case if such deposit and covenant defeasance had not occurred;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(e)&#160;The Company shall have delivered to the Trustee an Officer&#8217;s Certificate stating the deposit was
                    not made by the Company with the intent of defeating, hindering, delaying or defrauding any other creditors of the Company; and</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(f)&#160;The Company shall have delivered to the Trustee an Officer&#8217;s Certificate and an Opinion of Counsel,
                    each stating that all conditions precedent herein provided for relating to the covenant defeasance contemplated by this Section&#160;have been complied with.</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;8.5.&#160;<u>Repayment to Company</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">Subject to applicable abandoned property law, the Trustee and the Paying Agent shall pay to the Company
                    upon request any money held by them for the payment of principal and interest that remains unclaimed for two years. After that, Securityholders entitled to the money must look to the Company for payment as general creditors unless an
                    applicable abandoned property law designates another person.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;8.6.&#160;<u>Reinstatement</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">If the Trustee or the Paying Agent is unable to apply any money deposited with respect to Securities of
                    any Series in accordance with Section&#160;8.1 by reason of any legal proceeding or by reason of any order or judgment of any court or governmental authority enjoining, restraining or otherwise prohibiting such application, the obligations
                    of the Company under this Indenture with respect to the Securities of such Series and under the Securities of such Series shall be revived and reinstated as though no deposit had occurred pursuant to Section&#160;8.1 until such time as the
                    Trustee or the Paying Agent is permitted to apply all such money in accordance with Section&#160;8.1;&#160;<u>provided</u>,&#160;<u>however</u>, that if the Company has made any payment of principal of or interest on or any Additional Amounts with respect to any Securities because of the reinstatement of its
                    obligations, the Company shall be subrogated to the rights of the Holders of such Securities to receive such payment from the money or U.S. Government Obligations held by the Trustee or Paying Agent after payment in full to the Holders.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                </div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">28</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <div><br>
                  <br>
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">ARTICLE&#160;IX.<br>
                    AMENDMENTS AND WAIVERS</div>
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;9.1.&#160;<u>Without Consent of Holders</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">The Company and the Trustee may amend or supplement this Indenture or the Securities of one or more Series
                    without the consent of any Securityholder:</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(a)&#160;to cure any ambiguity, defect or inconsistency;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;to comply with Article&#160;V;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(c)&#160;to provide for uncertificated Securities in addition to or in place of certificated Securities;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(d)&#160;to add guarantees with respect to Securities of any Series or secure Securities of any Series;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(e)&#160;to surrender any of the Company&#8217;s rights or powers under this Indenture;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(f)&#160;&#160;&#160;to add covenants or events of default for the benefit of the holders of Securities of any Series;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(g)&#160;to comply with the applicable procedures of the applicable depositary;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(h)&#160;to make any change that does not adversely affect the rights of any Securityholder;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(i)&#160;to provide for the issuance of and establish the form and terms and conditions of Securities of any
                    Series as permitted by this Indenture;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(j)&#160;to evidence and provide for the acceptance of appointment hereunder by a successor Trustee with
                    respect to the Securities of one or more Series and to add to or change any of the provisions of this Indenture as shall be necessary to provide for or facilitate the administration of the trusts hereunder by more than one Trustee; or</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(k)&#160;to comply with requirements of the SEC in order to effect or maintain the qualification of this
                    Indenture under the TIA.</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;9.2.&#160;<u>With Consent of Holders</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">The Company and the Trustee may enter into a supplemental indenture with the written consent of the
                    Holders of at least a majority in principal amount of the outstanding Securities of each Series affected by such supplemental indenture (including consents obtained in connection with a tender offer or exchange offer for the Securities
                    of such Series), for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Indenture or of any supplemental indenture or of modifying in any manner the rights of the
                    Securityholders of each such Series. Except as provided in Section&#160;6.13, the Holders of at least a majority in principal amount of the outstanding Securities of any Series by notice to the Trustee (including consents obtained in
                    connection with a tender offer or exchange offer for the Securities of such Series) may waive compliance by the Company with any provision of this Indenture or the Securities with respect to such Series.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">It shall not be necessary for the consent of the Holders of Securities under this Section&#160;9.2 to approve
                    the particular form of any proposed supplemental indenture or waiver, but it shall be sufficient if such consent approves the substance thereof. After a supplemental indenture or waiver under this section becomes effective, the Company
                    shall send to the Holders of Securities affected thereby, a notice briefly describing the supplemental indenture or waiver. Any failure by the Company to send such notice, or any defect therein, shall not, however, in any way impair or
                    affect the validity of any such supplemental indenture or waiver.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">29</font></div>
                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                  </div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;9.3.&#160;<u>Limitations</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">Without the consent of each Securityholder affected, an amendment or waiver may not:</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(a)&#160;reduce the principal amount of Securities whose Holders must consent to an amendment, supplement or
                    waiver;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;reduce the rate of or extend the time for payment of interest (including default interest) on any
                    Security;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(c)&#160;reduce the principal or change the Stated Maturity of any Security or reduce the amount of, or
                    postpone the date fixed for, the payment of any sinking fund or analogous obligation;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(d)&#160;reduce the principal amount of Discount Securities payable upon acceleration of the maturity
                    thereof;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(e)&#160;waive a Default or Event of Default in the payment of the principal of or interest, if any, on any
                    Security (except a rescission of acceleration of the Securities of any Series by the Holders of at least a majority in principal amount of the outstanding Securities of such Series and a waiver of the payment default that resulted from
                    such acceleration);</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(f)&#160;&#160;&#160;make the principal of or interest, if any, on any Security payable in any currency other than
                    that stated in the Security;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(g)&#160;make any change in Sections&#160;6.8, 6.13 or 9.3 (this sentence); or</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(h)&#160;waive a redemption payment with respect to any Security, provided that such redemption is made at
                    the Company&#8217;s option.</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;9.4.&#160;<u>Compliance with Trust Indenture
                        Act</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 72pt; line-height: 1.25;">Every amendment to this Indenture or the Securities of one or more Series shall be set forth in a
                    supplemental indenture hereto that complies with the TIA as then in effect.</div>
                  <div style="text-indent: 72pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;9.5.&#160;<u>Revocation and Effect of
                        Consents</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">Until an amendment is set forth in a supplemental indenture or a waiver becomes effective, a consent to it
                    by a Holder of a Security is a continuing consent by the Holder and every subsequent Holder of a Security or portion of a Security that evidences the same debt as the consenting Holder&#8217;s Security, even if notation of the consent is not
                    made on any Security. However, any such Holder or subsequent Holder may revoke the consent as to his Security or portion of a Security if the Trustee receives the notice of revocation before the date of the supplemental indenture or the
                    date the waiver becomes effective.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">Any amendment or waiver once effective shall bind every Securityholder of each Series affected by such
                    amendment or waiver unless it is of the type described in any of clauses (a) through (h) of Section&#160;9.3. In that case, the amendment or waiver shall bind each Holder of a Security who has consented to it and every subsequent Holder of a
                    Security or portion of a Security that evidences the same debt as the consenting Holder&#8217;s Security.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">The Company may, but shall not be obligated to, fix a record date for the purpose of determining the
                    Holders entitled to give their consent or take any other action described above or required or permitted to be taken pursuant to this Indenture. If a record date is fixed, then notwithstanding the second immediately preceding paragraph,
                    those Persons who were Holders at such record date (or their duly designated proxies), and only those persons, shall be entitled to give such consent or to revoke any consent previously given or take any such action, whether or not such
                    Persons continue to be Holders after such record date. No such consent shall be valid or effective for more than 120 days after such record date.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">30</font></div>
                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                  </div>
                  <div style="line-height: 1.25">
                    <div>Section&#160;9.6.&#160; <u>Notation on or Exchange of Securities.</u></div>
                  </div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">The Company or the Trustee may place an appropriate notation about an amendment or waiver on any Security
                    of any Series thereafter authenticated. The Company in exchange for Securities of that Series may issue and the Trustee shall authenticate upon receipt of a Company Order in accordance with Section&#160;2.3 new Securities of that Series that
                    reflect the amendment or waiver.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;9.7.&#160;<u>Trustee Protected</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">In executing, or accepting the additional trusts created by, any supplemental indenture permitted by this
                    Article or the modifications thereby of the trusts created by this Indenture, the Trustee shall be entitled to receive, and (subject to Section&#160;7.1) shall be fully protected in relying upon, an Officer&#8217;s Certificate or an Opinion of
                    Counsel or both complying with Section&#160;10.4. The Trustee shall sign all supplemental indentures upon delivery of such an Officer&#8217;s Certificate or Opinion of Counsel or both, except that the Trustee need not sign any supplemental
                    indenture that adversely affects its rights, duties, liabilities or immunities under this Indenture.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">ARTICLE&#160;X.<br>
                    MISCELLANEOUS</div>
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.1.&#160;<u>Trust Indenture Act Controls</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">If any provision of this Indenture limits, qualifies, or conflicts with another provision which is
                    required or deemed to be included in this Indenture by the TIA, such required or deemed provision shall control.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.2.&#160;<u>Notices</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">Any notice or communication by the Company or the Trustee to the other, or by a Holder to the Company or
                    the Trustee, is duly given if in writing and delivered in person or mailed by first-class mail (registered or certified, return receipt requested), facsimile transmission, email or overnight air courier guaranteeing next day delivery,
                    to the others&#8217; address:</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="margin-left: 70.9pt; line-height: 1.25;">if to the Company:</div>
                  <div style="margin-left: 70.9pt; line-height: 1.25;">&#160;</div>
                  <div style="margin-left: 106.3pt; line-height: 1.25;">Chemomab Therapeutics.<br>
                    Kiryat Atidim, Building 7,</div>
                  <div style="margin-left: 106.3pt; line-height: 1.25;">Tel Aviv 6158002</div>
                  <div style="margin-left: 106.3pt; line-height: 1.25;">Israel<br>
                    Attention:<br>
                    Email:</div>
                  <div style="margin-left: 106.3pt; line-height: 1.25;">&#160;</div>
                  <div style="margin-left: 70.9pt; line-height: 1.25;">with a copy to:</div>
                  <div style="margin-left: 70.9pt; line-height: 1.25;">&#160;</div>
                  <div style="margin-left: 106.3pt; line-height: 1.25;">[_____]<br>
                    Attention: [____]<br>
                    Telephone: [____]</div>
                  <div style="margin-left: 106.3pt; line-height: 1.25;">&#160;</div>
                  <div style="margin-left: 70.9pt; line-height: 1.25;">if to the Trustee:</div>
                  <div style="margin-left: 70.9pt; line-height: 1.25;">&#160;</div>
                  <div style="margin-left: 106.3pt; line-height: 1.25;">[_____]<br>
                    Attention: [____]<br>
                    Telephone: [____]</div>
                  <div style="margin-left: 106.3pt; line-height: 1.25;">&#160;</div>
                  <div style="margin-left: 70.9pt; line-height: 1.25;">with a copy to:</div>
                  <div style="margin-left: 70.9pt; line-height: 1.25;">&#160;</div>
                  <div style="margin-left: 106.3pt; line-height: 1.25;">[_____]<br>
                    Attention: [____]<br>
                    Telephone: [____]</div>
                  <div style="margin-left: 106.3pt; line-height: 1.25;">&#160;</div>
                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">31</font></div>
                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                  </div>
                  <div style="text-indent: 36pt; line-height: 1.25;">The Company or the Trustee by notice to the other may designate additional or different addresses for
                    subsequent notices or communications.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">Any notice or communication to a Securityholder shall be sent electronically or by first-class mail to
                    his, her or its address shown on the register kept by the Registrar, in accordance with the procedures of the Depositary. Failure to send a notice or communication to a Securityholder of any Series or any defect in it shall not affect
                    its sufficiency with respect to other Securityholders of that or any other Series.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">If a notice or communication is sent or published in the manner provided above, within the time
                    prescribed, it is duly given, whether or not the Securityholder receives it.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">If the Company sends a notice or communication to Securityholders, it shall send a copy to the Trustee and
                    each Agent at the same time.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">Notwithstanding any other provision of this Indenture or any Security, where this Indenture or any
                    Security provides for notice of any event (including any notice of redemption) to a Holder of a Global Security (whether by mail or otherwise), such notice shall be sufficiently given to the Depositary for such Security (or its
                    designee) pursuant to the customary procedures of such Depositary.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.3.&#160;<u>Communication by Holders with
                        Other Holders</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">Securityholders of any Series may communicate pursuant to TIA &#167; 312(b) with other Securityholders of that
                    Series or any other Series with respect to their rights under this Indenture or the Securities of that Series or all Series. The Company, the Trustee, the Registrar and anyone else shall have the protection of TIA &#167; 312(c).</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.4.&#160;<u>Certificate and Opinion as to
                        Conditions Precedent</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">Upon any request or application by the Company to the Trustee to take any action under this Indenture, the
                    Company shall furnish to the Trustee:</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(a)&#160;an Officer&#8217;s Certificate stating that, in the opinion of the signers, all conditions precedent, if
                    any, provided for in this Indenture relating to the proposed action have been complied with; and</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;an Opinion of Counsel stating that, in the opinion of such counsel, all such conditions precedent
                    have been complied with.</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.5.&#160;<u>Statements Required in
                        Certificate or Opinion</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">Each certificate or opinion with respect to compliance with a condition or covenant provided for in this
                    Indenture (other than a certificate provided pursuant to TIA &#167; 314(a)(4)) shall comply with the provisions of TIA &#167; 314(e) and shall include:</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(a)&#160;a statement that the person making such certificate or opinion has read such covenant or condition;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(b)&#160;a brief statement as to the nature and scope of the examination or investigation upon which the
                    statements or opinions contained in such certificate or opinion are based;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">32</font></div>
                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                  </div>
                  <div style="line-height: 1.25">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(c)&#160;a statement that, in the opinion of such person, such person has made such examination or
                    investigation as is necessary to enable such person to express an informed opinion as to whether or not such covenant or condition has been complied with; and</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">(d)&#160;a statement as to whether or not, in the opinion of such person, such condition or covenant has
                    been complied with.</div>
                  <div style="text-indent: 35.45pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.6.&#160;<u>Rules by Trustee and Agents</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">The Trustee may make reasonable rules for action by or a meeting of Securityholders of one or more Series.
                    Any Agent may make reasonable rules and set reasonable requirements for its functions.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.7.&#160;<u>Legal Holidays</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">A &#8220;<font style="font-style: italic;">Legal
                      Holiday</font>&#8221; is any day that is not a Business Day. If a payment date is a Legal Holiday at a place of payment, payment may be made at that place on the next succeeding day that is not a Legal Holiday, and no interest shall accrue
                    for the intervening period.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.8.&#160;<u>No Recourse Against Others</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">A director, officer, employee or shareholder (past or present), as such, of the Company shall not have any
                    liability for any obligations of the Company under the Securities or the Indenture or for any claim based on, in respect of or by reason of such obligations or their creation. Each Securityholder by accepting a Security waives and
                    releases all such liability. The waiver and release are part of the consideration for the issue of the Securities.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.9.&#160;<u>Counterparts</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">This Indenture may be executed in any number of counterparts and by the parties hereto in separate
                    counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. The exchange of copies of this Indenture and of signature pages by facsimile or
                    electronic format (e.g., &#8220;.pdf&#8221; or &#8220;.tif&#8221;) transmission shall constitute effective execution and delivery of this Indenture as to the parties hereto and may be used in lieu of the original Indenture for all purposes. Signatures of the
                    parties hereto transmitted by facsimile or electronic format (e.g., &#8220;.pdf&#8221; or &#8220;.tif&#8221;) shall be deemed to be their original signatures for all purposes.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">Unless otherwise provided herein or in any other Securities, the words &#8220;execute&#8221;, &#8220;execution&#8221;, &#8220;signed&#8221;,
                    and &#8220;signature&#8221; and words of similar import used in or related to any document to be signed in connection with this Indenture, any Securities or any of the transactions contemplated hereby (including amendments, waivers, consents and
                    other modifications) shall be deemed to include electronic signatures and the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature in ink or
                    the use of a paper-based recordkeeping system, as applicable, to the fullest extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State
                    Electronic Signatures and Records Act, and any other similar state laws based on the Uniform Electronic Transactions Act, provided that, notwithstanding anything herein to the contrary, the Trustee is not under any obligation to agree
                    to accept electronic signatures in any form or in any format unless expressly agreed to by such Trustee pursuant to procedures approved by such Trustee.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.10.&#160;<u>Governing Law; Waiver of Jury
                        Trial; Consent to Jurisdiction</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">THIS INDENTURE AND THE SECURITIES, INCLUDING ANY CLAIM OR CONTROVERSY ARISING OUT OF OR
                    RELATING TO THE INDENTURE OR THE SECURITIES, SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                </div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">33</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <div><br>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">THE COMPANY, THE TRUSTEE AND THE HOLDERS (BY THEIR ACCEPTANCE OF THE SECURITIES) EACH
                    HEREBY IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES OR THE TRANSACTIONS CONTEMPLATED HEREBY OR
                    THEREBY.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">Any legal suit, action or proceeding arising out of or based upon this Indenture or the transactions
                    contemplated hereby may be instituted in the federal courts of the United States of America located in the City of New York or the courts of the State of New York in each case located in the City of New York (collectively, the &#8220;<font style="font-style: italic;">Specified Courts</font>&#8221;), and each party irrevocably submits to the non-exclusive jurisdiction of such courts in any such suit, action or
                    proceeding. Service of any process, summons, notice or document by mail (to the extent allowed under any applicable statute or rule of court) to such party&#8217;s address set forth above shall be effective service of process for any suit,
                    action or other proceeding brought in any such court. The Company, the Trustee and the Holders (by their acceptance of the Securities) each hereby irrevocably and unconditionally waive any objection to the laying of venue of any suit,
                    action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.11.&#160;<u>No Adverse Interpretation of
                        Other Agreements</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">This Indenture may not be used to interpret another indenture, loan or debt agreement of the Company or a
                    Subsidiary of the Company. Any such indenture, loan or debt agreement may not be used to interpret this Indenture.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.12.&#160;<u>Successors</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">All agreements of the Company in this Indenture and the Securities shall bind its successor. All
                    agreements of the Trustee in this Indenture shall bind its successor.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.13.&#160;<u>Severability</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">In case any provision in this Indenture or in the Securities shall be invalid, illegal or unenforceable,
                    the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.14.&#160;<u>Table of Contents, Headings,
                        Etc</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">The Table of Contents, Cross Reference Table, and headings of the Articles and Sections&#160;of this Indenture
                    have been inserted for convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.15.&#160;<u>Securities in a Foreign
                        Currency</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">Unless otherwise specified in a Board Resolution, a supplemental indenture hereto or an Officer&#8217;s
                    Certificate delivered pursuant to Section&#160;2.2 of this Indenture with respect to a particular Series of Securities, whenever for purposes of this Indenture any action may be taken by the Holders of a specified percentage in aggregate
                    principal amount of Securities of all Series or all Series affected by a particular action at the time outstanding and, at such time, there are outstanding Securities of any Series which are denominated in more than one currency, then
                    the principal amount of Securities of such Series which shall be deemed to be outstanding for the purpose of taking such action shall be determined by converting any such other currency into a currency that is designated upon issuance
                    of any particular Series of Securities. Unless otherwise specified in a Board Resolution, a supplemental indenture hereto or an Officer&#8217;s Certificate delivered pursuant to Section&#160;2.2 of this Indenture with respect to a particular
                    Series of Securities, such conversion shall be at the spot rate for the purchase of the designated currency as published in The Financial Times in the &#8220;Currency Rates&#8221; section (or, if The Financial Times is no longer published, or if
                    such information is no longer available in The Financial Times, such source as may be selected in good faith by the Company) on any date of determination. The provisions of this paragraph shall apply in determining the equivalent
                    principal amount in respect of Securities of a Series denominated in currency other than Dollars in connection with any action taken by Holders of Securities pursuant to the terms of this Indenture.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                </div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">34</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <div><br>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">All decisions and determinations provided for in the preceding paragraph shall, in the absence of manifest
                    error, to the extent permitted by law, be conclusive for all purposes and irrevocably binding upon the Trustee and all Holders.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.16.&#160;<u>Judgment Currency</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">The Company agrees, to the fullest extent that it may effectively do so under applicable law, that (a) if
                    for the purpose of obtaining judgment in any court it is necessary to convert the sum due in respect of the principal of or interest or other amount on the Securities of any Series (the &#8220;<font style="font-style: italic;">Required Currency</font>&#8221;) into a currency in which a judgment will be rendered (the &#8220;<font style="font-style: italic;">Judgment
                      Currency</font>&#8221;), the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Trustee could purchase in The City of New York the Required Currency with the Judgment Currency on the day on
                    which final unappealable judgment is entered, unless such day is not a New York Banking Day, then the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Trustee could purchase in The City
                    of New York the Required Currency with the Judgment Currency on the New York Banking Day preceding the day on which final unappealable judgment is entered and (b) its obligations under this Indenture to make payments in the Required
                    Currency (i) shall not be discharged or satisfied by any tender, any recovery pursuant to any judgment (whether or not entered in accordance with subsection (a)), in any currency other than the Required Currency, except to the extent
                    that such tender or recovery shall result in the actual receipt, by the payee, of the full amount of the Required Currency expressed to be payable in respect of such payments, (ii) shall be enforceable as an alternative or additional
                    cause of action for the purpose of recovering in the Required Currency the amount, if any, by which such actual receipt shall fall short of the full amount of the Required Currency so expressed to be payable, and (iii) shall not be
                    affected by judgment being obtained for any other sum due under this Indenture. For purposes of the foregoing, &#8220;<font style="font-style: italic;">New York Banking Day</font>&#8221;
                    means any day except a Saturday, Sunday or a legal holiday in The City of New York on which banking institutions are authorized or required by law, regulation or executive order to close.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.17.&#160;<u>Force Majeure</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">In no event shall the Trustee be responsible or liable for any failure or delay in the performance of its
                    obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear
                    or natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services, it being understood that the Trustee shall use reasonable best efforts which are
                    consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;10.18.&#160;<u>U.S.A. Patriot Act</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">The parties hereto acknowledge that in accordance with Section&#160;326 of the U.S.A. Patriot Act, the Trustee
                    is required to obtain, verify, and record information that identifies each person or legal entity that establishes a relationship or opens an account with the Trustee. The parties to this Indenture agree that they will provide the
                    Trustee with such information as it may request in order for the Trustee to satisfy the requirements of the U.S.A. Patriot Act.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">35</font></div>
                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                  </div>
                  <div style="line-height: 1.25">&#160;</div>
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">ARTICLE&#160;XI.</div>
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">SINKING FUNDS</div>
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;11.1.&#160;<u>Applicability of Article</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">The provisions of this Article shall be applicable to any sinking fund for the retirement of the
                    Securities of a Series if so provided by the terms of such Securities pursuant to Section&#160;2.2, except as otherwise permitted or required by any form of Security of such Series issued pursuant to this Indenture.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">The minimum amount of any sinking fund payment provided for by the terms of the Securities of any Series
                    is herein referred to as a &#8220;<font style="font-style: italic;">mandatory sinking fund payment</font>&#8221; and any other amount provided for by the terms of Securities of such
                    Series is herein referred to as an &#8220;<font style="font-style: italic;">optional sinking fund payment</font>.&#8221; If provided for by the terms of Securities of any Series, the
                    cash amount of any sinking fund payment may be subject to reduction as provided in Section&#160;11.2. Each sinking fund payment shall be applied to the redemption of Securities of any Series as provided for by the terms of the Securities of
                    such Series.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;11.2.&#160;<u>Satisfaction of Sinking Fund
                        Payments with Securities</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">The Company may, in satisfaction of all or any part of any sinking fund payment with respect to the
                    Securities of any Series to be made pursuant to the terms of such Securities (1) deliver outstanding Securities of such Series to which such sinking fund payment is applicable (other than any of such Securities previously called for
                    mandatory sinking fund redemption) and (2) apply as credit Securities of such Series to which such sinking fund payment is applicable and which have been repurchased by the Company or redeemed either at the election of the Company
                    pursuant to the terms of such Series of Securities (except pursuant to any mandatory sinking fund) or through the application of permitted optional sinking fund payments or other optional redemptions pursuant to the terms of such
                    Securities, provided that such Securities have not been previously so credited. Such Securities shall be received by the Trustee, together with an Officer&#8217;s Certificate with respect thereto, not later than 15 days prior to the date on
                    which the Trustee begins the process of selecting Securities for redemption, and shall be credited for such purpose by the Trustee at the price specified in such Securities for redemption through operation of the sinking fund and the
                    amount of such sinking fund payment shall be reduced accordingly. If as a result of the delivery or credit of Securities in lieu of cash payments pursuant to this Section&#160;11.2, the principal amount of Securities of such Series to be
                    redeemed in order to exhaust the aforesaid cash payment shall be less than $100,000, the Trustee need not call Securities of such Series for redemption, except upon receipt of a Company Order that such action be taken, and such cash
                    payment shall be held by the Trustee or a Paying Agent and applied to the next succeeding sinking fund payment,&#160;<u>provided</u>,&#160;<u>however</u>, that the Trustee or such Paying Agent shall from time to time upon receipt of a Company Order pay over and deliver to the Company any cash payment so being
                    held by the Trustee or such Paying Agent upon delivery by the Company to the Trustee of Securities of that Series purchased by the Company having an unpaid principal amount equal to the cash payment required to be released to the
                    Company.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="line-height: 1.25;">Section&#160;11.3.&#160;<u>Redemption of Securities for
                        Sinking Fund</u>.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">Not less than 45 days (unless otherwise indicated in the Board Resolution, supplemental indenture hereto
                    or Officer&#8217;s Certificate in respect of a particular Series of Securities) prior to each sinking fund payment date for any Series of Securities, the Company will deliver to the Trustee an Officer&#8217;s Certificate specifying the amount of
                    the next ensuing mandatory sinking fund payment for that Series pursuant to the terms of that Series, the portion thereof, if any, which is to be satisfied by payment of cash and the portion thereof, if any, which is to be satisfied by
                    delivering and crediting of Securities of that Series pursuant to Section&#160;11.2, and the optional amount, if any, to be added in cash to the next ensuing mandatory sinking fund payment, and the Company shall thereupon be obligated to pay
                    the amount therein specified. Not less than 30 days (unless otherwise indicated in the Board Resolution, Officer&#8217;s Certificate or supplemental indenture in respect of a particular Series of Securities) before each such sinking fund
                    payment date the Securities to be redeemed upon such sinking fund payment date will be selected in the manner specified in Section&#160;3.2 and the Company shall send or cause to be sent a notice of the redemption thereof to be given in the
                    name of and at the expense of the Company in the manner provided in and in accordance with Section&#160;3.3. Such notice having been duly given, the redemption of such Securities shall be made upon the terms and in the manner stated in
                    Sections&#160;3.4, 3.5 and 3.6.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                </div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">36</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <div><br>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed as of the day and
                    year first above written.</div>
                  <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
                  <table cellspacing="0" cellpadding="0" id="z3552dc4f74eb47b9a9c3449d1f67e8c5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                      <tr>
                        <td style="width: 59.88%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                        <td style="width: 40.12%; vertical-align: bottom;" colspan="2">
                          <div style="line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 59.88%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                        <td style="width: 4.06%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                        <td style="width: 36.06%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 59.88%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                        <td style="width: 4.06%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">By:</div>
                        </td>
                        <td style="width: 36.06%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 59.88%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                        <td style="width: 4.06%; vertical-align: bottom;">&#160;</td>
                        <td style="width: 36.06%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">Name:</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 59.88%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                        <td style="width: 4.06%; vertical-align: bottom;">&#160;</td>
                        <td style="width: 36.06%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">Its:</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 59.88%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                        <td style="width: 4.06%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;&#160;</div>
                        </td>
                        <td style="width: 36.06%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 59.88%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                        <td style="width: 40.12%; vertical-align: bottom;" colspan="2">
                          <div style="line-height: 1.25;">[_____], as Trustee</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 59.88%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                        <td style="width: 4.06%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                        <td style="width: 36.06%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 59.88%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                        <td style="width: 4.06%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                        <td style="width: 36.06%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 59.88%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                        <td style="width: 4.06%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">By:</div>
                        </td>
                        <td style="width: 36.06%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 59.88%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                        <td style="width: 4.06%; vertical-align: bottom;">&#160;</td>
                        <td style="width: 36.06%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">Name:</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 59.88%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">&#160;</div>
                        </td>
                        <td style="width: 4.06%; vertical-align: bottom;">&#160;</td>
                        <td style="width: 36.06%; vertical-align: bottom;">
                          <div style="line-height: 1.25;">Its:</div>
                        </td>
                      </tr>

                  </table>
                  <div style="margin-left: 252pt; line-height: 1.25;">&#160;</div>
                  <div style="margin-left: 252pt; line-height: 1.25;">&#160;</div>
                  <div style="text-align: center; line-height: 1.25;">37
                    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>exhibit_5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 5.1</u></div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;"><img width="535" height="86" src="image00001.jpg"></div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">October 16, 2023</div>
      <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z5e0325a645bf47dbb5a0b8ee0786bd56" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Chemomab Therapeutics Ltd.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Kiryat Atidim, Building 7</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Tel Aviv, Israel</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Re:&#160;<font style="font-weight: bold;"><u>Registration Statement on Form F-3</u></font></div>
      <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Ladies and Gentlemen:</div>
      <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">We have acted as Israeli counsel to Chemomab Therapeutics Ltd., a company organized under the laws of the State of Israel
      (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;), in connection with its filing of a registration statement on Form F-3 (the &#8220;<font style="font-weight: bold;">Registration Statement</font>&#8221;) under the Securities Act of 1933, as amended (the &#8220;<font style="font-weight: bold;">Securities Act</font>&#8221;), with the U.S. Securities and Exchange Commission (the &#8220;<font style="font-weight: bold;">Commission</font>&#8221;), which registers the offer, issuance and sale by the Company, from time to time, of up
      to $200,000,000, in the aggregate, of any one or more of the following types of securities, individually or in units:</div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z0fb3b8c9eac74d08939884b8210d7343" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 1.66%; vertical-align: top;">&#160;</td>
          <td style="width: 2.67%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">(a)</div>
          </td>
          <td style="width: 95.67%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif;">American Depositary Shares (&#8220;<font style="font-weight: bold;">ADSs</font>&#8221;), each representing twenty (20) ordinary shares, no par value, of the Company
              (&#8220;<font style="font-weight: bold;">Ordinary Shares</font>&#8221; or &#8220;<font style="font-weight: bold;">Shares</font>&#8221;);</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z988c24b4b9424f57b75538be49ed056f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 1.59%; vertical-align: top;">&#160;</td>
          <td style="width: 2.82%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">(b)</div>
          </td>
          <td style="width: 95.59%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif;">Ordinary Shares;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z0a4b4c611f5a430688e389082c6612a4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 1.66%; vertical-align: top;">&#160;</td>
          <td style="width: 2.67%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">(c)</div>
          </td>
          <td style="width: 95.67%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif;">warrants to purchase Ordinary Shares and/or ADSs (&#8220;<font style="font-weight: bold;">Warrants</font>&#8221;);</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z57861f931db44051916c46dd8d670c9c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 1.59%; vertical-align: top;">&#160;</td>
          <td style="width: 2.82%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">(d)</div>
          </td>
          <td style="width: 95.59%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif;">senior or subordinated debt securities of the Company (the &#8220;<font style="font-weight: bold;">Debt Securities</font>&#8221;) to be issued by the Company
              pursuant to an indenture (a &#8220;<font style="font-weight: bold;">Company Indenture</font>&#8221;) to be executed by the Company and the relevant trustee under the Company Indenture; and/or</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z7aedb559499c452b861b78ef82761a6d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 1.66%; vertical-align: top;">&#160;</td>
          <td style="width: 2.67%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">(e)</div>
          </td>
          <td style="width: 95.67%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif;">units comprised of one or more of the other securities that may be offered under the Registration Statement (the &#8220;<font style="font-weight: bold;">Units</font>&#8221;)

              (collectively, the ADSs, Ordinary Shares, Warrants, Debt Securities and Units are referred to as the &#8220;<font style="font-weight: bold;">Securities</font>&#8221;).</div>
          </td>
        </tr>

    </table>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">We have also acted as Israeli counsel to the Company in connection with the Sales Agreement, dated as of October 16, 2023
      (the &#8220;<font style="font-weight: bold;">Sales Agreement</font>&#8221;), entered into by and between the Company and Roth Capital Partners, LLC (the &#8220;<font style="font-weight: bold;">Agent</font>&#8221;) pursuant to which the Company may offer and sell ADSs having
      an aggregate offering price of up to $2,863,664<font style="font-weight: bold;">&#160;</font>(the &#8220;<font style="font-weight: bold;">ATM Shares</font>&#8221;). The ATM Shares will be issued pursuant to the Registration Statement and the related prospectus
      contained therein covering the ATM Shares.</div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">This opinion letter is furnished to you at your request to enable you to fulfill the requirements of Item 601(b)(5) of
      Regulation S-K under the Securities Act, in connection with the filing of the Registration Statement.</div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">In connection herewith, we have examined the originals, or photocopies or copies, certified or otherwise identified to our
      satisfaction, of: (i) the form of the Registration Statement, to which this opinion letter is attached as an exhibit; (ii) a copy of the amended and restated articles of association of the Company, as currently in effect (the &#8220;<font style="font-weight: bold;">Articles</font>&#8221;); (iii) minutes of the meeting of the board of directors of the Company (the &#8220;<font style="font-weight: bold;">Board</font>&#8221;) at which the filing of the Registration Statement and the actions to be taken
      in connection therewith were approved; (iv) minutes of the meeting of the Board at which the execution of the Sales Agreement and the actions to be taken in connection therewith were approved; and (v) such other corporate records, agreements,
      documents and other instruments, and such certificates or comparable documents of public officials and of officers and representatives of the Company as we have deemed relevant and necessary as a basis for the opinions hereafter set forth. We have
      also made inquiries of such officers and representatives as we have deemed relevant and necessary as a basis for the opinions hereafter set forth.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman', serif; color: #000000;">&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman', serif; color: #000000;">In such examination, we have assumed the
        genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, confirmed as photostatic
        copies and the authenticity of the originals of such latter documents. As to all questions of fact material to these opinions that have not been independently established, we have relied upon certificates or comparable documents of officers and
        representatives of the Company.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">We have also assumed the truth of all facts communicated to us by the Company and that all minutes of meetings of the Board
      that have been provided to us are true and accurate and have been properly prepared in accordance with the Articles and all applicable laws. We have assumed, in addition, that at the time of the execution and delivery of any definitive purchase,
      underwriting or similar agreement between the Company and any third party pursuant to which any of the Securities may be issued (a &#8220;<font style="font-weight: bold;">Securities Agreement</font>&#8221;), the Securities Agreement will be the valid and legally
      binding obligation of such third party, enforceable against such third party in accordance with its terms. We have further assumed that at the time of the issuance and sale of any of the Securities, the terms of the Securities, and their issuance and
      sale, will have been established so as not to violate any applicable law or result in a default under or breach of any agreement or instrument binding upon the Company and so as to comply with any requirement or restriction imposed by any court or
      governmental body having jurisdiction over the Company.</div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Based upon and subject to the foregoing, we are of the opinion that:</div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z9a934597655d4dfa963119784e3115a4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">1.</div>
          </td>
          <td style="width: 96%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif;">With respect to the Ordinary Shares and the Ordinary Shares underlying the ADSs, assuming (a) the taking of all necessary corporate action to authorize
              and approve the issuance of any ADSs and Ordinary Shares, the terms of the offering thereof and related matters (for purposes of this paragraph 1, the &#8220;<font style="font-weight: bold;">Authorizing Resolutions</font>&#8221;), (b) the effectiveness
              of the Registration Statement, and any amendments thereto (including any post-effective amendments), and that such effectiveness shall not have been terminated or rescinded, (c) the delivery and filing of an appropriate prospectus supplement
              with respect to the offering of the Shares in compliance with the Securities Act and the applicable rules and regulations thereunder, (d) approval by the Board of, and entry by the Company into, and performance by the Company under, any
              applicable Securities Agreement, in the form filed as an exhibit to the Registration Statement, any post-effective amendment thereto or to a Report on Form 6-K, pursuant to which the ADSs or Ordinary Shares may be issued and sold, and (e)
              receipt by the Company of the consideration for the ADSs or Ordinary Shares as provided for in the Authorizing Resolutions and in accordance with the provisions of any such Securities Agreement and the applicable convertible Securities, if
              any, pursuant to which the Shares may be issued, such Shares, including any Ordinary Shares issued upon exercise or conversion of any Securities, will be validly issued, fully paid and non-assessable.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z0260ddf419a84ec8bd3ab7fd16ed94aa" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">2.</div>
          </td>
          <td style="width: 96%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif;">With respect to the Ordinary Shares represented by the ATM Shares, assuming that prior to the issuance of any of ATM Shares under the Sales Agreement,
              the price, number of Ordinary Shares represented by the ATM Shares and certain other terms of issuance with respect to any specific placement notice delivered under the Sales Agreement will be authorized and approved by the Board or a pricing
              committee of the Board in accordance with Israeli law, all corporate proceedings necessary for the authorization, issuance and delivery of the Ordinary Shares represented by the ATM Shares shall have been taken and, upon issuance pursuant to
              the terms of the Sales Agreement and in accordance with resolutions of the Board related to the offering of the Ordinary Shares represented by the ATM Shares, the Ordinary Shares represented by the ATM Shares will be validly issued, fully
              paid and non-assessable.</div>
          </td>
        </tr>

    </table>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">You have informed us that you intend to issue the Securities from time to time on a delayed or continuous basis, and this
      opinion is limited to the laws, including the rules and regulations, as in effect on the date hereof. We understand that prior to issuing any Securities you will afford us an opportunity to review the corporate approval documents and operative
      documents pursuant to which such Securities are to be issued (including the Authorizing Resolutions, a Securities Agreement (if applicable) and an appropriate prospectus supplement), and we will file such supplement or amendment to this opinion (if
      any) as we may reasonably consider necessary or appropriate by reason of the terms of such Securities.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">With respect to our opinion as to the Ordinary Shares and the Ordinary Shares underlying the ADSs, including any Ordinary
      Shares issued upon exercise or conversion of any Securities, including the ATM Shares, we have assumed that, at the time of issuance and sale and to the extent any such issuance would exceed the maximum share capital of the Company currently
      authorized, the number of Ordinary Shares that the Company is authorized to issue shall have been increased in accordance with the Articles and as described in the Registration Statement such that a sufficient number of Ordinary Shares are authorized
      and available for issuance under the Articles.</div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Members of our firm are admitted to the Bar in the State of Israel, and we do not express any opinion as to the laws of any
      other jurisdiction. This opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated.</div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">We consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our firm
      appearing under the caption &#8220;Legal Matters&#8221; and &#8220;Enforceability of Civil Liabilities&#8221; in the prospectus forming part of the Registration Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose
      consent is required under Section 7 of the Securities Act, the rules and regulations of the Commission promulgated thereunder or Item 509 of the Commission&#8217;s Regulation S-K under the Securities Act.</div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">This opinion letter is rendered as of the date hereof and we disclaim any obligation to advise you of facts, circumstances,
      events or developments that may be brought to our attention after the effective date of the Registration Statement that may alter, affect or modify the opinions expressed herein.</div>
    <div style="text-indent: 18pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z5ba7078569c54571af9350b8c1d077d4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 60%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 40%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 60%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 40%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 60%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-style: italic;">/s/ Meitar | Law Offices</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
  </div>
  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>5
<FILENAME>exhibit_5-2.htm
<DESCRIPTION>EXHIBIT 5.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
  <div>
    <div class="BRPFPageHeader">
      <div style="text-align: right;"><font style="font-family: 'Times New Roman',Times,serif;"><u><font style="font-weight: bold;"> </font></u></font>
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><font style="font-family: 'Times New Roman',Times,serif;"><u><font style="font-weight: bold;">Exhibit 5.2</font></u><br>
        </font></div>
      <div> <font style="font-family: 'Times New Roman',Times,serif;"><br>
        </font></div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z31b437c3edf34f7db213c203ec64015d">

          <tr>
            <td style="width: 50.32%; vertical-align: bottom;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><img width="134" height="43" src="image00002.jpg"></div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="line-height: 1.25;">&#160;</font></div>
            </td>
            <td style="width: 49.68%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50.32%; vertical-align: bottom;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Joshua A. Kaufman</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">T: +1 212 479 6495</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Josh.kaufman@cooley.com</div>
            </td>
            <td rowspan="1" style="width: 49.68%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">October 16, 2023</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Chemomab Therapeutics Ltd.</div>
    <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">Kirvat Atdim, Building 7</div>
    <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">Tel Aviv, Israel 6158002</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Ladies and Gentlemen:</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">We have acted as special U.S. counsel to Chemomab Therapeutics Ltd., a company organized under the laws of the State of Israel (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221;), in connection with the filing by the Company of a Registration Statement on Form F-3 (the &#8220;<font style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Registration
        Statement</font>&#8221;) with the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold; font-style: italic;">Commission</font>&#8221;) under the Securities Act of 1933, as amended (the &#8220;<font style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Securities Act</font>&#8221;). The Registration Statement includes a prospectus (the &#8220;<font style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Base Prospectus</font>&#8221;), that provides it will be supplemented in the
      future by one or more prospectus supplements (each, a &#8220;<font style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Prospectus Supplement</font>&#8221;). The Registration Statement including the Base Prospectus (as supplemented from time to
      time by one or more Prospectus Supplements), will provide for the registration by the Company of:</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze3b27c8a92ef484ebd87abf1e8441778">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>ordinary shares, no par value, of the Company (the &#8220;<font style="font-weight: bold; font-style: italic;">Ordinary Shares</font>&#8221;);</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z196b715169c84471b38b297750b5af39">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>debt securities, in one or more series (the <font style="color: rgb(0, 0, 0);">&#8220;</font><font style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Debt Securities</font><font style="color: rgb(0, 0, 0);">&#8221;</font>), which may
              be issued pursuant to an indenture to be dated on or about the date of the first issuance of Debt Securities thereunder, by and between a trustee to be selected by the Company (the <font style="color: rgb(0, 0, 0);">&#8220;</font><font style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Trustee</font><font style="color: rgb(0, 0, 0);">&#8221;</font>) and the Company, in the form filed as Exhibit 4.1 to the Registration Statement and one or more indentures
              supplemental thereto with respect to any particular series of Debt Securities (including any supplemental indenture, the <font style="color: rgb(0, 0, 0);">&#8220;</font><font style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Indenture</font><font style="color: rgb(0, 0, 0);">&#8221;</font>);</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2e0a7d94ebcb4038be9c6d2a934ee46b">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>warrants (the <font style="color: rgb(0, 0, 0);">&#8220;</font><font style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Warrants</font><font style="color: rgb(0, 0, 0);">&#8221;</font>) to purchase Ordinary Shares or Debt Securities
              , which may be issued under one or more warrant agreements, to be dated on or about the date of the first issuance of the Warrants thereunder, by and between a warrant agent to be selected by the Company (the <font style="color: rgb(0, 0, 0);">&#8220;</font><font style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Warrant Agent</font><font style="color: rgb(0, 0, 0);">&#8221;</font>) and the Company in the form to be incorporated by reference as an exhibit to the
              Registration Statement (each, a <font style="color: rgb(0, 0, 0);">&#8220;</font><font style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Warrant Agreement</font><font style="color: rgb(0, 0, 0);">&#8221;</font>); and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zadb313194fc24744b9b1ae51fa59638f">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>units comprised of one or more of the Ordinary Shares, Debt Securities or Warrants of the Company (the &#8220;<font style="font-weight: bold; font-style: italic;">Units</font>&#8221;), which may be issued under one or more unit agreements (each, a &#8220;<font style="font-weight: bold; font-style: italic;">Unit Agreement</font>&#8221;), to be dated on or about the date of the first issuance of the Units thereunder, by and between a unit agent to be selected by the Company (the &#8220;<font style="font-weight: bold; font-style: italic;">Unit Agent</font>&#8221;) and the Company .</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The Ordinary Shares, the Debt Securities, the Warrants and the Units plus any additional Ordinary Shares, Debt Securities, Warrants and Units that may be
      registered pursuant to any registration statement that the Company may hereafter file with the Commission pursuant to Rule 462(b) under the Securities Act in connection with an offering by the Company pursuant to the Registration Statement, are
      collectively referred to herein as the &#8220;<font style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Securities</font>.&#8221; The Securities are being registered for offer and sale from time to time pursuant to Rule 415 under the Securities
      Act.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;
      <div style="text-align: left; line-height: 1.25;">Chemomab Therapeutics Ltd.</div>
      <div style="text-align: left; line-height: 1.25;">October 16, 2023</div>
      <div style="text-align: left; line-height: 1.25; font-family: Arial, sans-serif;"><font style="font-family: 'Times New Roman',Times,serif;">Page Two</font></div>
      <div style="text-align: left; line-height: 1.25;"><font class="BRPFPageNumber"> <br>
        </font></div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">In connection with this opinion, we have examined and relied upon such records, documents, certificates, opinions, memoranda and other instruments as in
      our judgment are necessary or appropriate to enable us to render the opinion expressed below. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">In rendering this opinion, we have assumed the genuineness of all signatures; the authenticity of all documents submitted to us as originals; the
      conformity to originals of all documents submitted to us as copies; the accuracy, completeness and authenticity of certificates of public officials; and the due authorization, execution and delivery of all documents where authorization, execution and
      delivery are prerequisites to the effectiveness of such documents.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">We are not hereby rendering any opinion with respect to any Ordinary Shares issuable upon the conversion or exercise, as applicable, of any Debt
      Securities, any Warrants or any Securities that are components of Units. We have also assumed that with respect to any Debt Securities issuable as a component of any Units, the applicable Units will be valid and legally binding obligations of the
      Company, except as may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors&#8217; rights, and subject to general equity principles and to limitations on availability of
      equitable relief including, without limitation, specific performance. We have assumed that (i) the Company is validly existing under the laws of the State of Israel, has the corporate power to enter into and perform its obligations under the Debt
      Securities, the Indenture, the Warrants and the Units in accordance with their respective terms, (ii) upon issuance, the Company will have duly authorized, executed and delivered the Debt Securities, the Indenture, the Warrants and the Units in
      accordance with its organizational documents and the laws of the State of Israel, (iii) any Ordinary Shares issued upon conversion of the Debt Securities or upon exercise of Warrants, or in connection with any Units will be duly authorized, validly
      issued, fully paid and non-assessable and (iv) the execution, delivery and performance by the Company of its obligations under the Debt Securities, the Indenture, the Warrants and the Units will not violate the laws of the State of Israel or any
      other applicable laws (excepting from such assumption the laws of the State of New York).</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Our opinion herein is expressed solely with respect to the laws of the State of New York. Our opinion is based on these laws as in effect on the date
      hereof. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">On the basis of the foregoing and in reliance thereon, and subject to the qualifications herein stated, we are of the opinion that:</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold; color: rgb(0, 0, 0);">1.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);">&#160;</font>With respect to any series of Debt Securities issued under the Indenture and offered under the Registration Statement, provided that: (i) the Registration Statement and any required post-effective amendment
        thereto have become effective under the Securities Act and the Base Prospectus and any and all Prospectus Supplement(s) required by applicable laws have been delivered and filed as required by such laws; (ii) the Indenture has been duly authorized
        by the Company and the Trustee by all necessary corporate action; (iii) the Indenture, in substantially the form filed as an exhibit to the Registration Statement, has been duly executed and delivered by the Company and the Trustee; (iv) the terms
        of the Debt Securities and their issuance and sale, including as to any Ordinary Shares to be issued on the conversion thereof, have been duly authorized by the Company by all necessary corporate action and the Indenture has been qualified under
        the Trust Indenture Act of 1939, as amended; (v) the terms of the Debt Securities and of their issuance and sale have been duly established in conformity with the Indenture so as not to violate any applicable law or result in a default under or
        breach of any agreement or instrument binding upon the Company, so as to be in conformity with the Company&#8217;s then operative articles of association (the &#8220;<font style="font-weight: bold; font-style: italic;">Articles of Association</font>&#8221;), and so
        as to comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company; and (vi) the notes representing the Debt Securities have been duly executed and delivered by the Company and
        authenticated by the Trustee pursuant to the Indenture and delivered against payment therefor, then the Debt Securities, when issued and sold as contemplated by the Registration Statement, the Base Prospectus and the related Prospectus
        Supplement(s) and in accordance with the Indenture and a duly authorized, executed and delivered purchase, underwriting or similar agreement, or upon exercise of any Units in accordance with their terms, will be valid and legally binding
        obligations of the Company, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting creditors&#8217; rights generally, and by general equitable principles (regardless of whether
        considered in a proceeding at law or in equity).</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Chemomab Therapeutics Ltd.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">October 16, 2023</div>
      <div style="line-height: 1.25; font-family: Arial, sans-serif;"><font style="font-family: 'Times New Roman',Times,serif;">Page Three</font></div>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold; color: rgb(0, 0, 0);">2.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);">&#160;</font>With respect to the Warrants issued under the Warrant Agreement and offered under the Registration Statement, provided that (i) the Registration Statement and any required post-effective amendment thereto have
        become effective under the Securities Act and the Base Prospectus and any and all Prospectus Supplement(s) required by applicable laws have been delivered and filed as required by such laws; (ii) the applicable Warrant Agreement has been duly
        authorized by the Company and the Warrant Agent by all necessary corporate action; (iii) the applicable Warrant Agreement has been duly executed and delivered by the Company and the Warrant Agent; (iv) the issuance and terms of the Warrants,
        including as to any Ordinary Shares to be issued on the exercise thereof, have been duly authorized by the Company by all necessary corporate action; (v) the terms of the Warrants and of their issuance and sale have been duly established in
        conformity with the applicable Warrant Agreement and as described in the Registration Statement, the Base Prospectus and the related Prospectus Supplement(s), so as not to violate any applicable law or result in a default under or breach of any
        agreement or instrument binding upon the Company, so as to be in conformity with the Articles of Association, and so as to comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company;
        and (vi) the Warrants have been duly executed and delivered by the Company and authenticated by the Warrant Agent pursuant to the applicable Warrant Agreement and delivered against payment therefor, then the Warrants, when issued and sold as
        contemplated in the Registration Statement, the Base Prospectus and the Prospectus Supplement(s) and in accordance with the applicable Warrant Agreement and a duly authorized, executed and delivered purchase, underwriting or similar agreement,&#160;
        will be valid and legally binding obligations of the Company, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting creditors<font style="color: rgb(0, 0, 0);">&#8217;</font> rights
        generally and by general equitable principles (regardless of whether considered in a proceeding at law or in equity).</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold; color: rgb(0, 0, 0);">3.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);">&#160;</font>With respect to the Units issued under the Unit Agreement and offered under the Registration Statement, provided that (i) the Registration Statement and any required post-effective amendment thereto have
        become effective under the Securities Act and the Base Prospectus and any and all Prospectus Supplement(s) required by applicable laws have been delivered and filed as required by such laws; (ii) the applicable Unit Agreement has been duly
        authorized by the Company and the Unit Agent by all necessary corporate action; (iii) the applicable Unit Agreement has been duly executed and delivered by the Company and the Unit Agent; (iv) the issuance and terms of the Units, including as to
        any Ordinary Shares, Debt Securities or Warrants that are components of such Units, have been duly authorized by the Company by all necessary corporate action; (v) the terms of the Units, including as to any Ordinary Shares, Debt Securities or
        Warrants that are components of such Units, and of their issuance and sale have been duly established in conformity with the applicable Unit Agreement and as described in the Registration Statement, the Base Prospectus and the related Prospectus
        Supplement(s), so as not to violate any applicable law or result in a default under or breach of any agreement or instrument binding upon the Company, so as to be in conformity with the Articles of Association, and so as to comply with any
        requirement or restriction imposed by any court or governmental body having jurisdiction over the Company; and (vi) the Units, including as to any Ordinary Shares, Debt Securities or Warrants that are components of such Units, have been duly
        executed and delivered by the Company and authenticated by the Unit Agent pursuant to the applicable Unit Agreement and delivered against payment therefor, then the Units, when issued and sold as contemplated in the Registration Statement, the Base
        Prospectus and the Prospectus Supplement(s) and in accordance with the applicable Unit Agreement and a duly authorized, executed and delivered purchase, underwriting or similar agreement, will be valid and legally binding obligations of the
        Company, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting creditors' rights generally, and by general equitable principles (regardless of whether considered in a
        proceeding at law or in equity).</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our firm under the caption &#8220;Legal
      Matters&#8221; in the Base Prospectus. We further consent to the incorporation by reference of this opinion into any registration statement filed pursuant to Rule 462(b) under the Securities Act with respect to additional Securities.&#160; In giving such
      consents, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Our opinion set forth above is limited to the matters expressly set forth in this letter, and no opinion is implied or may be inferred beyond the matters
      expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we undertake no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter
      come to our attention or any changes in law that may hereafter occur.</div>
    <br>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Sincerely,</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-variant: small-caps;">Cooley LLP</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">By:&#160; <u>/</u><u><font style="font-style: italic;">s/ Joshua A. Kaufman</font></u></div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Joshua A. Kaufman</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div class="BRPFPageFooter">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 100%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div style="text-align: center; line-height: 1.25;">Cooley LLP&#160;&#160; 55 Hudson Yards&#160;&#160; New York, NY&#160;&#160; 10001-2157<br>
                  t: (212) 479-6000&#160; f: (212) 479-6275&#160; cooley.com</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      </div>
    </div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>exhibit_23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25; text-align: right;"><u><font style="font-weight: bold;">Exhibit 23.1</font></u><br>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">The Board of Directors<br>
      Chemomab Therapeutics Ltd.:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">We consent to the use of our reports dated February 20, 2023 and March 30, 2022, with respect to the consolidated financial statements of
        Chemomab Therapeutics Ltd., incorporated herein by reference and to the reference to our firm under the heading &#8220;Experts&#8221; in the prospectus.</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z2b1732eb06ac4eb78816cf72cd44b071">

        <tr>
          <td style="width: 100%; vertical-align: middle;">
            <div style="line-height: 1.25; font-style: italic;">/s/ Somekh Chaikin</div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 100%; vertical-align: middle;">
            <div style="line-height: 1.25;">Member Firm of KPMG International</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">Tel Aviv, Israel<br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">October 16, 2023</div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>7
<FILENAME>exhibit_107.htm
<DESCRIPTION>FILING FEES TABLE
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div> <br>
    </div>
    <div>
      <div style="line-height: 1.25;">
        <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 107</u></div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">CALCULATION OF FEE TABLE</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">FORM F-3</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Form Type)</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Exact Name of Registrant as Specified in its Charter)</div>
        <div style="text-align: center; line-height: 1.25;"><u>Table 1: Newly Registered&#160; and Carry Forward Securities</u></div>
        <div style="text-align: center; line-height: 1.25;"><u> <br>
          </u></div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z34f3d69d989e48d29c591b21aee7d4e4">

          <tr>
            <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 7%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Security<br>
                Type</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Security<br>
                Class<br>
                Title</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Fee<br>
                Calculation or<br>
                Carry<br>
                Forward<br>
                Rule</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 7%;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Amount<br>
                Registered</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 6%;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Proposed<br>
                Maximum<br>
                Offering<br>
                Price Per<br>
                Unit</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Maximum<br>
                Aggregate<br>
                Offering<br>
                Price</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 6%;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Fee Rate</div>
            </td>
            <td style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Amount of<br>
                Registration<br>
                Fee</div>
            </td>
            <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 6%; text-align: center;">&#160;
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Carry<br>
                Forward<br>
                Form<br>
                Type</div>
            </td>
            <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 6%;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Carry<br>
                Forward<br>
                File<br>
                Number</div>
            </td>
            <td style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 6%;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Carry<br>
                Forward<br>
                Initial<br>
                effective<br>
                date</div>
            </td>
            <td style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Filing Fee<br>
                Previously<br>
                Paid In<br>
                Connection<br>
                with Unsold<br>
                Securities<br>
                to be<br>
                Carried<br>
                Forward</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td colspan="25" rowspan="1" style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center; font-weight: bold;">Newly Registered Securities</td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">Fees to be paid</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 7%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">Equity</div>
            </td>
            <td style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">Ordinary shares, no par value per share</div>
            </td>
            <td style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">Rule 457(o)</div>
            </td>
            <td style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">(1)</div>
            </td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">(2)</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">(3)</div>
            </td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td colspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; line-height: 1.25;">Equity</div>
            </td>
            <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; line-height: 1.25;">Ordinary shares, as represented by American Depositary Shares(4)</div>
            </td>
            <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; line-height: 1.25;">Rule 457(o)</div>
            </td>
            <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(1)</div>
            </td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(2)</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(3)</div>
            </td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td colspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 7%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">Other</div>
            </td>
            <td style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">Warrants</div>
            </td>
            <td style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">Rule 457(o)</div>
            </td>
            <td style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">(1)</div>
            </td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">(2)</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">(3)</div>
            </td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td colspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; line-height: 1.25;">Debt</div>
            </td>
            <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; line-height: 1.25;">Debt Securities</div>
            </td>
            <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; line-height: 1.25;">Rule 457(o)</div>
            </td>
            <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(1)</div>
            </td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(2)</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(3)</div>
            </td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td colspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 7%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">Other</div>
            </td>
            <td style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">Units</div>
            </td>
            <td style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">Rule 457(o)</div>
            </td>
            <td style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">(1)</div>
            </td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">(2)</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="line-height: 1.25;">(3)</div>
            </td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td colspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; line-height: 1.25;">Unallocated<br>
                (Universal) Shelf</div>
            </td>
            <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; line-height: 1.25;">Rule 457(o)</div>
            </td>
            <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; line-height: 1.25;">17,605,622</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(1)</div>
            </td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(2)</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; line-height: 1.25;">17,605,622</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">(3)</div>
            </td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; line-height: 1.25;">0.00014760</div>
            </td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; text-align: center;"><br>
              </div>
            </td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td colspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td colspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              <td colspan="1" style="width: 1%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              <td style="width: 7%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Security<br>
                  Type</div>
              </td>
              <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 7%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Security<br>
                  Class<br>
                  Title</div>
              </td>
              <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 7%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Fee<br>
                  Calculation or<br>
                  Carry<br>
                  Forward<br>
                  Rule</div>
              </td>
              <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 7%;">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Amount<br>
                  Registered</div>
              </td>
              <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
              <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 6%;">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Proposed<br>
                  Maximum<br>
                  Offering<br>
                  Price Per<br>
                  Unit</div>
              </td>
              <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
              <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Maximum<br>
                  Aggregate<br>
                  Offering<br>
                  Price</div>
              </td>
              <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
              <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 6%;">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Fee Rate</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Amount of<br>
                  Registration<br>
                  Fee</div>
              </td>
              <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
              <td colspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 6%; text-align: center;">&#160;
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Carry<br>
                  Forward<br>
                  Form<br>
                  Type</div>
              </td>
              <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
              <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 6%;">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Carry<br>
                  Forward<br>
                  File<br>
                  Number</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 6%;">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Carry<br>
                  Forward<br>
                  Initial<br>
                  effective<br>
                  date</div>
              </td>
              <td style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 6%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Filing Fee<br>
                  Previously<br>
                  Paid In<br>
                  Connection<br>
                  with Unsold<br>
                  Securities<br>
                  to be<br>
                  Carried<br>
                  Forward</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

            <tr>
              <td rowspan="1" style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
              <td colspan="25" rowspan="1" style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Carry Forward Securities</div>
              </td>
            </tr>
            <tr>
              <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">Carry Forward</div>
                <div style="text-align: center; line-height: 1.25;"> Securities</div>
              </td>
              <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
              <td style="width: 7%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">Equity</div>
              </td>
              <td style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
              <td style="width: 7%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">Ordinary shares, no par value per share</div>
              </td>
              <td style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
              <td style="width: 7%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;"><br>
                </div>
              </td>
              <td style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
              <td style="width: 7%; vertical-align: bottom;">&#160;</td>
              <td style="width: 1%; vertical-align: bottom;">
                <div style="line-height: 1.25;"><br>
                </div>
              </td>
              <td style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td style="width: 1%; vertical-align: bottom;">
                <div style="line-height: 1.25;"><br>
                </div>
              </td>
              <td style="width: 1%; vertical-align: bottom;">&#160;</td>
              <td style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td style="width: 1%; vertical-align: bottom;">
                <div style="line-height: 1.25;"><br>
                </div>
              </td>
              <td style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 1%; vertical-align: bottom;">&#160;</td>
              <td style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td colspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
              <td colspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 6%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: top; text-align: center; background-color: rgb(204, 238, 255);">&#160;Equity</td>
              <td rowspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;">Ordinary shares, as represented by American Depositary Shares</div>
              </td>
              <td rowspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
              <td rowspan="1" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">Other</div>
              </td>
              <td rowspan="1" style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">Warrants</div>
              </td>
              <td rowspan="1" style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;">Debt</div>
              </td>
              <td rowspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;">Debt Securities</div>
              </td>
              <td rowspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
              <td rowspan="1" colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: top;">
                <div style="text-align: center; line-height: 1.25;">Other</div>
              </td>
              <td rowspan="1" style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: top; text-align: center;">&#160;Units</td>
              <td rowspan="1" style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 1%; vertical-align: bottom;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;">Carry Forward </div>
                <div style="text-align: center; line-height: 1.25;">Securities</div>
              </td>
              <td rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;">Unallocated (Universal) Shelf</div>
              </td>
              <td rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="vertical-align: bottom; width: 7%; text-align: center; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">Unallocated (Universal) Shelf</div>
              </td>
              <td rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;">Rule 415(a)(6)</div>
              </td>
              <td rowspan="1" style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255);" colspan="1"><br>
              </td>
              <td rowspan="1" style="width: 7%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: right; line-height: 1.25;">182,394,378</div>
              </td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">&#160;$</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: right; line-height: 1.25;">182,394,378</div>
              </td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;">S-3</div>
              </td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; line-height: 1.25;">333-255658</div>
              </td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;
                <div style="text-align: center; line-height: 1.25;">5/17/2021</div>
              </td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;
                <div style="text-align: center; line-height: 1.25;">$19,899</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td colspan="3" rowspan="1" style="vertical-align: bottom; width: 7%; text-align: center; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;&#160; Total Offering Amounts</td>
              <td rowspan="1" style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">$ <br>
              </td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: right; line-height: 1.25;">200,000,000</div>
              </td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="line-height: 1.25;">29,520</div>
              </td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td colspan="3" rowspan="1" style="vertical-align: bottom; width: 7%; text-align: center; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
                <div style="line-height: 1.25;">Total Fees Previously Paid(5)</div>
              </td>
              <td rowspan="1" style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="line-height: 1.25;">19,899</div>
              </td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td colspan="3" rowspan="1" style="vertical-align: bottom; width: 7%; text-align: center; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
                <div style="line-height: 1.25;">Total Fee Offsets</div>
              </td>
              <td rowspan="1" style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: right; line-height: 1.25;">19,899</div>
              </td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">&#160;</td>
              <td rowspan="1" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">&#160;</td>
              <td rowspan="1" style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">&#160;</td>
              <td rowspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" colspan="1">&#160;</td>
              <td colspan="3" rowspan="1" style="vertical-align: bottom; width: 7%; text-align: center; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <div style="line-height: 1.25;">Net Fee Due</div>
              </td>
              <td rowspan="1" style="vertical-align: bottom; width: 1%; text-align: right; background-color: rgb(204, 238, 255); padding-bottom: 4px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 7%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 4px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); padding-bottom: 4px;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 4px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 4px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 4px;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 4px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);">
                <div style="line-height: 1.25;">$</div>
              </td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);">
                <div style="text-align: right; line-height: 1.25;">9,621</div>
              </td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 4px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 4px;">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 4px;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 4px;">&#160;</td>
              <td colspan="1" rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 4px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 4px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 4px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 4px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 4px;">&#160;</td>
              <td rowspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 4px;" colspan="1">&#160;</td>
              <td rowspan="1" style="width: 6%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 4px;">&#160;</td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0P!WD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***3- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 A&:6BDH 7M35SWI<T'IQ0 G.[V
MI0N#0N<<TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %(>E+2$XH !P*CEFCA4O(P4#O7)>*_
M'5EH4,B).HN%4G;D5XEK/QAU?4XYK8-M4D@%1BM(4W(F4K'T5_;^F9_X^T_.
MK5MJ-K='$,RO]#7Q8U_J3'=]NN<D_P#/0UT7ASQ_J_AQBRSR29&/G.[^=:_5
MY$*:/KRD!R:\E\&_%A=6PNI2JC''H*]6MKB.ZMUGB(*.,@UA*+CHS1.Y+111
M4C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!YAQ7T;\,OB NOZ8MO>RC[3& JCH2!Q7)5I.#-(S3/3:*:#D TZL2[A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<M2D=3V'2E4@C/\ %6^AE80'!]:27[N<T[A1D]ZC<KM &22:QJ221<5J>L_
MFUG7Q'+,8R(RO#?@:^BZ\V^$.DPP>&8[P#]XS8/'M7I(KQZS4I7.R*LK"T44
M5D4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/$WANR\2:;+;W,(:3&$;N*\'\2_!Z;0-.DO(9992H)"UVT:_+HS*=.YYL2
M/6F-A>@JP=)U7_GT?\J4Z7J9BV?8GR>^#74ZZ1FJ;*I<'C&37H?PW^'TGB2[
M6^N 1:+P5QR3G_ZU7?"GPFEU58+JX>1 #DKZU] :)HMIHMA';6D0C55 ;'<U
MQUJ[EHC2$$B32M+MM%T]+2U4B,<X-7ESCFC;SDT$\XKD9L.HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "D8D#BEHH 0=*6FG.1BG4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12+GO2T
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M(.!2U PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@%%%%4 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%1M(-VT=:DIA4;LXYH <.G-+3'D6)-SL%4=23P*\]\5?%;2O#MX+8R"1F!Y0
M;OY4TF]A7.]N;J*U@>61U"H,G)KS/Q'\7-)BLYX;*Z3[2C%1M;G(KQ76_&^K
M:AJ-S)#<O]GD/RKD]*YH[65V<?O&.2:ZJ6%E+5F<JB.XN/BSXE:5O+NI=GLU
M<YJWB/4-?E\V\E=F/J:RT/RXQ2J0>E=4:,8&,IMD0A!D(R?SI3#LZL>>G-2.
MZJOO0%^4EG'MS6JY1<S(C!E1R<_6@1F,AU8Y'O3E<=,TXD'OD#K2Y8L7/(Z3
M2_B!KFE6ZQ6MQ($48&&K=TSXM:\EVGVRZD\O/.6KS\2*#P./I33\Y/&16;H*
M3+C-H^JO#OQ*T;6[BWL8KF-KAT&1NYS7:_+G*D'Z&OB:RGFTZX%Q;-LE'0@U
MWG@SXG76BZ@9M5F=XL'@Y-<E3#RB[HVC43/J#/%+7)^#_&^G^++1IX)55@<;
M&X/Y5U8KF9:8M%%%(9SOC?\ Y$[4?^N?]:^.H1DG/3-?8WCC_D3M1_ZY_P!:
M^.(C@GZUV8179E5T1)* (S7T9\#<?\([/_O+_6OG.3F,U]&? W_D79_]Y?ZU
MIBEH94CUBBBBO/.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\O\ Q"FJQ*#;QC:3^/\ ]:OIM!A5'H*\VI;FT.B%[#J***S+.>\<?\B=J/\
MUS_K7QQ$?F/'>OL?QQ_R)^H_]<_ZU\=1=3CKFN_!=3&KL/D_U9KZ+^!O_(NS
M_P"\O]:^=),^6U?1?P-_Y%Z?_>7^M7B]C.B>L4445YIU!1111< HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****5P"BBBF 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%(:!TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBFDG/% #J*** "BBB@ HH)Q10
M 4444 %%%% !1110 449HH **** "BBB@ HHHH **** "BBB@ HHHH **0YS
M0,YH 6BBB@ HHHH **** "BD+ =:6@ HHHH **!10 4444 %%%% !574O^09
M=?\ 7)OY5:JKJ7_(,NO^N3?RIK<#X]\4Y_MZX./^6C?SK)S\N0*U_%)/]NW
M[^8W\ZR.<5[%/X3AEN:W@S_D;K7_ 'Q7V5'_ *M?H*^-_!PQXNM?]X5]C1YV
M+]!7G8CXSKI_"244T9R<TZN<L**** "BBB@ HHHH **** "BBB@ HHHH 8@;
M;R>:<.G- X%5;Z]CL[=Y9&"@ D9[TTKL+DL]Q' A9V QZFN+UWQO# 3# OSC
MOFN7\3>*;K4Y_+MI#$J-SM[US>&ED+RMN8^M>MA, Y:S,)U+:&U+XOU>9WVR
M*$/3BLJ6[N+R0^<^6/7%0 ?/@<"GLFUN&KW(8*G%:(PE4;&>4J.,DG\:N0ZE
M<V#A[9L,/6JPX!+<XIH.[YL=.U4\'!JPE-HWE\7ZNCQLTJE=PSQ7;:5XYMKN
MXBLV3$A7);->5L">^?:G(3$XDB;9(/XA7FXG+HV]U&D:K/H"*17Y4@_2I<UY
MMX4\7.-MI<D,<_?->AQS+*BLIX(S7A5:,J;LSHC*Y)SN]J=0**Q+"BBB@ HH
MHH **** "BBB@ IN13JR=7UB+3H2<C=Z4X0<Y60F[&?XK\1)HUH47F60?*<]
M*\BN;B:^F,]PV9"<\5H>(-6DU6^)<Y53Q6;C:-W7VKZ3 X)05Y'+.IJ(06'S
M=>U+AQ&1GYNU)C!SGK2[78CR\LWI7J5:D:<2$@Q(Q1%^9F('%==HO@:Z>[CF
MN7S RY*XK4\(^#EC=+R[S(#R%;M7?!!&H"#"C@"OF\5CI2?+!G1&GW,6V\(Z
M7;N)$C;</>ME8@H"J!M''2I0<B@#%>;*<I?$S6R$*CT'Y4TIR, ?E4G:FJV:
MFXS*U#P[8:D^ZX0D^U<KX@\#[Q&NFG8!][(S7H-(>!FM:>(J0=TR)03/!-3T
MR;2;E8)@2[=&QQ5=LD#:>1UKV77_  ];:Q:-^["S=G'45Y#=:;=V]W+!Y;;8
MSC=CK7MX3'\ZM-ZF$J5BL7;[II8E\N]MV )S(O3ZTU%?S-JKN<=JZ7PEHLFH
M:FOVF(A5.1FML96@H7%3@TSUBPR;"W/_ $S7^53C.[VHB011)&.BC IU?+RW
M.M"T444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $H.<
M4M9FM:C'INGR22.%RIP332U$SDOB3XVM?#VD26W#3S+A2&Z'_(KY@GN)K^X:
M>X;+,<UM>+]5NM8\0WAN)S)$C_NP>U8"J<=<5Z6&I65V<]2?1$C!RN&(QVI@
M$OW5&XGL*5A)E43+,W05ZS\+/AR=1N5U/458Q1D?NVZ&JJU^160H1<C3^&GP
MMC:!=1U0%O,.Y !C KVZTM(K2!8HU 51@<4Z&VCMH4AA4)&HP%':IJ\R<W+5
MG39!29YH YI<5(PHHHH *:,Y.:=12 0G I !U'>DS\V"*?3 SM6T:SUNQ>SN
MTS$W7%>5^./A)9_V1(^BAHY$7)R,U[)TJ.10RLK#<K#!%-,5CR[X'6$MAX=N
MH9UPZRD9(]S7J@(SBJMMIUK8Q,MI$(@YRV.YJS&NU>>30,?1112 Y[QQ_P B
M?J/_ %S_ *U\=1?Q8ZYK[%\<?\B=J/\ US_K7QS%_$/?K7?@^IC6V'2$E#[5
M]&_ S/\ PCL_^\O]:^<9!\C5]'? P?\ %.S_ %7^M5B]B*1ZQVIF&QUIQ.*6
MO.L=(@Z<TM(::>N<T) /HJ,SQ@X+#-.!#=#185Q3GM2CI11F@84@SFEHH **
M** "BBB@ HHHH **** "BBB@ HHIK.J]3B@!U&:B%Q%G[XJ3.1FG85Q:*;0&
MS2L%QU%%% PHHHH **** "BBB@ HHHH **** "BD()/6EH **:7"]331-&QP
M&!HL*Y)12 YH- Q!G=[4ZBB@ HHHH ****3 ;N^;%.I-M,:1$^\V*=A$F:04
MQ9%?[K9IXZT6"XM%(:6EK<84444P"BBB@ HHHH **** "BBB@!&;% .1FCJ.
M:.V!0 M%-&12/*B<,V,T6%<?142S1L=H89J3M188M%(HQ1F@ .<TM%% !111
M0 4444 %%%% !1110 4ASVI:* $7..:6BD)P* %HIH;(IGG1@XW#-%A7):*0
M,&Z'-(P)[T# D9Q0 0:4"EH"X4AS2T4 -.<BG44W'.<T .I,TC'FD9E098XH
M$.Q1VJ,7$1( 8'-29XHM8+BTF:;R#FG=:&ABT444 %%%% !1110 4444 %-#
M9.*=33@=* '457GNX;5-\T@0>]<1XO\ B3:^'+436YCG).,4U&XKG>/*D8R[
MA?K47VZU_P">Z?G7SIX@^,5[K4'E6P%NQ[K7$?\ "4^(MQ']K3?I6T:$I(ES
M2/L(W]J!GST_.FKJ%JP_UZ?G7Q[_ ,)9XB)*_P!J2_I2?\)5XC09_M2;]*OZ
MK*Q/M$?8OVZU_P">Z?G2K=V[MA9D)] :^.E\5^(VY_M6;]*T-(\<:[IVHI<3
MZA)+&O56QBI^KR&ZD3ZYP&YIPKP[3OCKNFAMI+:/DX+'->NZ=KUCJ$,+1SH9
M)$#;0:QE%K<M,U:*3WIIR3P:FP7'%@.I IN]?[PKB?B9XHD\+:+%=Q@$EL<_
M45Y:OQLN6 _=+6D*?,)NQ]$;US]X4_K7SLGQHN7N8UV+\S8KW7P]?G4]"M;Q
MNLJYI3@X[A%W-2BBBH*"JNI?\@RZ_P"N3?RJU574O^09=?\ 7)OY4UN!\?>*
M/^0_<9Z^8W\ZR,DG K6\4C_B?7 S_P M&Y_&LG;[U[-/X3AEN;'@_P#Y&ZU_
MWA7V1'_JU^@KXX\'_P#(W6O^\*^QX_\ 5K]!7FXCXCKI_".HHI*YRQ:**2@!
M:*B:>-3@L*<KJPX.:+"N/HIO6G4@3$I:**$,****8!1110!#),D49=CA1WKR
M7QCX@FU2^>PCD*VZ'(93C//_ -:NT\5:M!9VLEN7 8CIFO(RQSO/0FO6RW"\
M\N9F,Y65A5XX)Z=Z7H<BG#81SUIN #@5]/"FHJQQR=V+@=>YI ,MR>*#C(_6
MC(S[5JD O4X]*,A6W"D.*  1[T6!H!\K;ASFAD!.,\&C Z#K0>G'2I<>80<P
M%61B"#D$&O3?!OB))K1(;J3]YT )KS$#?P>@YI4E>*X66(D.O3%>3C\)SQT-
MZ<['T*.E+7)>$_$R:A;+;SR@W('S GGI75[@>A!KYB<)0=F=:::'$XHI" 11
MD+Q4#%HHHH ***0G H 6BH);A((B\C  >]<;XE\916\7EVDP$OL:TA2E-V0F
M['1ZYK,.E6;NS@28^4&O'M3UNZU:Z:261@#VS@5'JVJ7>L.K7#LP4Y&35,8/
M7I7O9?@'%WD<]2I?8<".<\FFY(.[OZ4O _I0"#UZU[CBHQ.9ZL4IYF%3EVZ"
MN\\$^%5W?;+M,LN,*W2N:\+Z7)J.K1RQ+N$3?-@5[1;Q^7"@(P0*^;S+$N_(
MCJI1)%14&%4 >@%.I"0*"1C->*= M)7*>*?&VG>'K.;SIT278=OS=Z\ N/BU
MXD:[F,-U+Y6\[<,>F:N-.4MB6SZ<GU>S@G\F20!\XQFKD<BR)N0Y!KX]NO&^
MKWET+F6>0R9SG=6FGQ2\26T05+J4 =/FK9X:25R5/4^LJ3.:\K\"_%&SOM)B
MAU&Y4WO&[<W/2O3K6>.Y@6:(@JXR"#7.TUN7<GJI<:;:SQLK01Y;J=HS5NBE
M>PSE++P196>H_:]H8YS@G(KI8K6"$YCA1#ZJN*FHJI3E+=B22"BBBI&%%%%
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M,4M% "%<C% &!BEHH **** .>\<?\B=J/_7/^M?'$8Y(]Z^Q_''_ ")VH_\
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MJ.8]*NW'58F(_*@#YP^--]%>>)LQ'., _E7G"@B4MZUI>([Z74=8NWD.2LK
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M>8=0[G%-WXSN[4[G%<_XQUE= \/S7[#.P'^1IK5B/*?C+XJL-0L&L+29Q.K
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MT,J*ZGL17/%V=RGL?$H5XV,4J[6'8TO3C.:]=^)GP]-M(VH:?!R1\P4< 5Y
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MO;!7'_#2QFT[PC#!.A5PV<$>PKL:\F<KLZDAN#NSFG44A&1BH*%HI%7 Q2T
M%%%% "4M%%*P$;(2^0:\N^,?A>#4-$%S!!BX!)9QUZBO5:S]<B271;P.BM^Y
M;&1GM5QE9W$U='Q=Y;12-&2<K2;-P.6JWJVZ'6;H;< L>U5" (PV>37L0?-$
MY6K,]A^ =S#:7-_')( SD[0>_2OH =*^.?!EQ-;>+=/6*5U5Y/F /7BOL5/]
M6OT%>77CRR.B#NAU,D_U;?0TX#!ILG^K;Z&LBF?'?C%2WBRZ&['S&L88C%:_
MC+CQ9=<_QFL;&\9->MA](G+4W-OPAHDFO^(8$5VQ&ZM@?G_2OKS3XO(TZVB/
M\$:K^0KYQ^!<:MXQF5@" G?Z&OI<( ,5PXF2<S>"=AU(1S0!@4M<QH%%%% !
M36&:=10!P'Q@'_%O[O'^>#7RW"I\H98GVKZF^,!V^ +L_P">AKY9 "PJR')-
M=N$W,:NP,2&Y.:]/^!.3XOF./X.OX&O+V7)%>P? Z';KLCA>J]?P-=.+^ SI
M;GT'FEII7)IU>2=04444 %%%)CG- "U\V?'1?^*QA8]-G]!7TG7S_P#'&U5M
M62;'(']!6M#XT1/8\<V@N2#QBHY 2AR:<N-O7O3;G[OX5[,M8'-]H^J?@_\
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MX4'_ (N%9X_SR*^LJ\S%?&=-/X0JCK/_ "!;W_KB_P#*KU4=9_Y M[_UQ?\
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MQU$#\Q]Z^Q?''_(G:C_US_K7QW$>& ZYKNP?4QK;!,?W9P*^C?@;_P B]/\
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M )_(OUK"^#NNQZ3J)MG/,PVBOI <@'UKSZ]2:GN=,$FCPS_A0'.?MD7ZTI^
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M%Y_<_2MG-&.J/LNBBBO"/0"BBB@!#TXI ..0#^%*!S2T )L7^Z/RHQ@\4M%
M6$I:**5@"BBBF 4444 %%%% !1110 4444 %%%% !1110 51U+3K;4;5H;A<
MJPQQ5W.>* O&#S33MJ(\/\0^'[C0[PE<F%S\HQTK)C;+<\5[MJFE6VIVYCFC
M#-C@^E>=>(_!#V-F]W S$KT45[N"S!)*,S&=/L<>-V\@4,ICZ'@TYXIHX@98
MRGO35.>K9KV?;1D<W*[AL$B\TU8P'PQ/YTI!4[@>#2["><U3A"2&[B21_/\
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MZ3()[UY1\9] MYM!FU5DS+&, _A_]:KI2M),4E='SNS8'R=ZL6MU+I\Z7$+
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M(J;'B*<C';-)< ;#2KM_6FSXV'/6O8DK1.7J?5'P>_Y$"T_#^0KOJX'X/?\
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M=8Y(K9\9'_BK;KC/SG^=8K<C&*]:BTH')47O'IGP)_Y'*?\ W/Z&OI45\U?
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MP10A,^)[Z9!=OPWWCVJN)Q@Y5O;BOK]_ >A.V3:)D_[(I/\ A M!_P"?1/\
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M^^*T^MI"5)GEV\.3CMTI#)M7YE.?I7MNB?!>]L[E'NE5E!Y^8&O1[/X?Z/'
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M#0 M%%%%@$Z4@;)Z4I&10!@46 6BBB@ IC$DXI](1F@ ' I:09HYS0 M%%%
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0C(I:* $
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4TJ",'I3J:<YXH X;Q7X/%TDEW:\S')"XKS0
MQO;2/#.")!P:^A2!C!%<QJOA"PO8IY(T(G;H?>O0PN-E2T9E*FF>/# ZFG9
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M1FEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!#11BEH$-9 XPPR*S'\/:4TC.UFA9NIK5H/2FI-;!8R1X=TL'BT0"AO
M#VE#_ES2M/)VDXIPY'-/GEW"R*MK8VUB-EO"$4^E6Z9DYI<DFI;8["T9I!DT
MZIU ****H HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@!",T 8I:* "BBB@ HHHH **** "
MBBD- "%MO6C>O=A^=<EXV\;6'A;3?-FF1G;@*#DC\*^?O$/Q#U/4KUI;&X=(
MR>!DBM(P<MB')+<^K?,7'WU_.C>O]X?G7QU_PF>OGY?M;Y_WJL6OC37;>ZCE
MENW* \C=5NA)"YT?7XZ4M>6^ _B?8:R?L,LP25 ,E^,UZ>CK(H=&#*>A!XK%
MJSL6GH/HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **"0!D]*@^VVN<?:(\C_:% $]%0?;+;_GO'_WT*/MEM_SWC_[
MZ% $]%0?;+;_ )^(_P#OH5(AW#<&!4]"* 'T44AX% "T4PR(B[G8*!W)H2:.
M3[CJWT.: 'T444 %%1NP3EF"CW-*DL<@RCJP]CF@!]%%% !114;W$,9P\J*?
M<T 24C9QQ4!O+;_GXC_[Z%*+RVQ_Q\1_]]"@"56SQ3JBCGAD;$<J,?8YJ6@
MHHI#R.* %HJ$W,,9VO,@8=BU)]LMC_RWC_[Z% $]("":KBZ@9\+/&?8,*L#'
M4=Z %HI&!(XH'2@!:*** "BBF22QQ#,CJ@]6.* 'T@J)98YC^ZD5O]TYJ:@
MHHHH **** "BH3=VRM@SQ@^A84GVRVQG[1'_ -]"@">BH/M,$G"31L?9JE5L
MBG8!U-7/>EI:0!24M1O-%%_K)%7/3<<4 245!]LMO^?B/_OH4?;+;_GXC_[Z
M% $]%,CECE&8W5AZJ<T^@ HHHH **C>:*+_62*OU.*<CJZ[D8,/4&@!U%%%
M!141N(0VTRH&],U+0 4444 %%,>1(AND=5'J3BHS>6Q'%Q'_ -]"@">BJZWE
ML!S<1_\ ?0I?MEM_SWC_ .^A0!/1427$,AVI*C'T#5+0 4444 %%127$,3;9
M)44^A;%/5@PRK CV- #J*** "BBB@!JYR<TZF2.B+EG"_4U$MY;8YN(_^^A0
M!8HJ#[9;'I/'_P!]"GJP<Y1@1[&@"0]*1<]Z6B@ HHII!W=: '45"UU CE6F
MC##L6%,-Y;9_X^(O^^A0!9HJ,.LJ!HW##U!IXZ4 +1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7*^-?%UKX8TMY6?,W0(.O2NJKYR^.MY(/$T5L&.PKG&?85=./-*Q,G97.#\
M4>(;CQ-J;7<C,L1X"-6,!C  XH _=[?3FE1_D((XKU:%%)').;;$* MN!I<>
M<N"<8H4 C(I!\F2:Z94U;0A-W'6\LMC,LUO(5<')Q7T-\+?B-;ZM9KIU[(8I
MHAM7?_%7SR@7&_/)[5J>$)9(?&5AM8JK2<X/M7G8BEU.BG+H?9:D,H8'(/2E
MJM8L&LH3G/RBK->>= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% ',^-+62[TQ4C!)SV_"H_!=I):V&UU*G)ZUTTT*S* PR*6.)(EPHQ0 ^B
MBB@ HHHH Q/%4#7&B21H"2>P^E4?"5I+;08=2.>]=.Z*Z[6&12)&B<*,4[Z
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MB@ HHHH 3;\V:6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ Q1BBB@
M HHHH **** "BBB@ HHHH **** "DV_-FEHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HZT44 (!@8I:** "FMGM3J*
M"BBB@!",C%)LXQ3J* &G(X%.HHH **** &;<-D=Z?110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %)MYS2T4 (%P<T$9I:* &E<X]J=110 F*6BB@
MHHHH **** #%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0L!WP# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 1QU)31P*3S!ZT /HIGF
M+ZT>8OK0 ^BF>8OK1YB^M #Z*9YB^M'F+ZT /HIGF+ZT>8OK0 ^BF>8OK1YB
M^M #Z*9YB^M'F+ZT /HIGF+ZT>8OK0 ^BF>8OK1YB^M #Z*9YB^M'F+ZT /H
MIGF+ZT>8OK0 ^BF>8OK1YB^M #Z*9YB^M'F+ZT /HIGF+ZT>8OK0 ^BF>8OK
M1YB^M #Z*9YB^M'F+ZT /HIGF+ZT>8OK0 ^BF>8OK1YB^M #Z*9YB^M'F+ZT
M /HIGF+ZT>8OK0 ^BF>8OK1YB^M #Z*9YB^M'F+ZT /HIGF+ZT>8OK0 ^BF>
M8OK1YB^M #Z*9YB^M'F+ZT /HIGF+ZT>8OK0 ^BF>8OK1YB^M #Z*9YB^M'F
M+ZT /HIGF+ZT>8OK0 ^BF>8OK1YB^M #Z*9YB^M'F+ZT /HIGF+ZT>8OK0 ^
MBF>8OK1YB^M #Z*9YB^M'F+ZT /HIGF+ZT>8OK0 ^BF>8OK1YB^M #Z*9YB^
MM'F+ZT /HIGF+ZT>8OK0 ^BF>8OK1YB^M #Z*9YB^M'F+ZT /HIGF+ZT>8OK
M0 ^BF>8OK1YB^M #Z*9YB^M'F+ZT /HIGF+ZT>8OK0 ^BF>8OK1YB^M #Z*9
MYB^M'F+ZT /HIGF+ZT>8OK0 ^BF>8OK1YB^M #Z*9YB^M'F+ZT /HIGF+ZT>
M8OK0 ^BF>8OK1YB^M #Z*9YB^M'F+ZT /HIGF+ZT>8OK0 ^BF>8OK1YB^M #
MZ*9YB^M'F+ZT /HIGF+ZT>8OK0 ^F/\ =H\Q?6D,BD=: 'K]VEIJL#TIU !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX^:@ZL-P&ZN";6/N_-0VL?./FH [W^U1NQNH&K#<1NK@O[8_>?>H&L?.?FH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 4-8_Y!<_^[7S;XH&=4;ZU])ZQ_R"Y_\ =KYO
M\2#.K$>] (PHXSYE2[.:L0Q?O:'3#F@;(V7I2%?G%/ZT=>: &[?GH"_.:=[T
M>] 6&*O6A5^4T_I1CM0 S;^[H*_(*?[48[4!88R\"AEY%/Z_A1UYH"PW;\]
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MO I^.U'7\* L-9?F%&WYZ=UYH]Z L-"_/0J\FG>]% 6&*O!H"_(:?T_&CVH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH H:S_P @N?\ W:^;_$3?\3@_6OH_6O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 7B>:,\U1^U#UI?M0SG- %W/- /-4?M0SG-'VH>M %X&C/%4?M0]:/M0QC-
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MPI?+&<5$9LFD\_YJ )1$-^*7RQDU%YWS9I!-R: )5B'-'EC;FHQ-C-()N,4
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M.:.HBSYOO2F7WJIN-+O.* Z%H2\]:#+SUJIO.*-YQ0'0MB7WI/-]ZJ[S06-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC- =!=U.4Y!IF,4]!\IH#H(&IC-ELTN.<4TCG% ,],^%!SJ;_2O::\5^$_\
MR%)/I7M5 @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#/UG_D'2?2HM _Y!ZU+K/\ R#I/I46@
M?\@Y: -6BBB@"EJW_(-F_P!VOF_Q1_R&C]:^C]7_ .09-_NU\W^)O^0P3[T#
M10[5/8??:JQ/R9JQ9?>)H ;<_>-5XQQ4UU]ZH$.#B@&AT@^6D_A%*_7%(ISQ
M0 I[4$<BD'.:4'@FA!</XJ,?-2?PYI2?ES0%P'4T <4AXQ2GJ*.@7 #Y:"/E
MH_BQ1_%BCH%P(X%!ZB@=32#G- 7%Q\U'\5 /RYI/X<T,+B@<F@=Z"> :0\8H
M"XN.#1_#0>N*/XL4=0N!'%!'2CJV*!SFCJ%P/448^:D'(S1GY<T(+BC[U ')
MI#]W-*3@"@+@!P:,?+2'@BE/WL4= N&/EH/04#[V*!R31T"X$=*#]Z@'@TG8
MF@+BX^:@?>-)GY<T'@ T!<4#K0.E!XQ0>& HZA<,?+1CY:/XL4#[V*.H7 ]J
M".12#DGVI1T)H"X?Q48^:D_AS1GY<T!<4=30!P:0\ 4IX(]Z N 'RT$?+1_%
MBC^+%'0+@1P*#VH'4BD'.: N*1S1_%2 _+FC^'- 7% Y- [T'A<TAXQ0%Q1T
M-&/EH/4"C^+%'4+@1\M!' H_BQ0.IHZA<#U%&/FI!R#1GY<T +_%0!R:3^'-
M!/ H07%'>C'RTAX(I3][%'0+ACY:#TH_BQ1U)%'0+@1TH/WA0#G-(.1F@+BX
M^:@?>I,_+FCMFAA<4#K0.AH)Z>]!X(%'4+ACY:,?+1_%B@?>Q1U"X'H*".E(
M.2:4'@T!</XJ,?-2 _+FES\N: N ZF@#@TAX&:4\8HZ!< /EHQ\M'1@*/XL4
M= N&.!0>U ZD4@YS1T"XI'(H_BI >":/X<T,+BX^:@=Z"?ES2'C% 7% X- '
MRT'J*/XL4=0N!'RT$<"C^+% Y)HZA<#U%&/FI!SFE!^7-" /XJ .32?PYI2>
M :$%P'>C'RFD/&*4]<4= N'\-!' H_BQ1U;%'0+@1TH/WA0.<T@Z$T!<7'S4
M#[U)GY<T?PYH87% Y- Z&@G %(>"* N+CY:,?+0?O8H'WL4=0N!Z"GCI3!R3
M0IX- "_QTUO]93DY.:CD/ST!?0]*^%'_ "%9/I7M->+?"?\ Y"DGTKVF@044
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!0U;_CR?Z5'HG_ !Y+4FK?
M\>3U'HO_ !YK0!IT444 4M6_Y!LW^[7S=XH'_$Y(]Z^D-7_Y!DW^[7S?XG_Y
M#)/O0-&<P^2K&G\LU5W/R58T_AFH#H%SU-55Z9JW=<$U34\8H0V./3-';-(W
M3% Y&*8NHIXH]J.M&>]) '?%'?%'O1GO0@ <T=LT=*.G%'0 [9H/3-'M1[4=
M #MF@\4=>*.M'0 [XH[XHSWH]Z& >U YHSWHZ4, [9H[9H]J/:CJ 'IFCI1U
MXHZT+< /!Q1CG%'7FC/>A '?%'6CWHZ4( '-';-'2CVHZ ';-!XH]J.M'0 Z
M4=\4=?PH]Z #'.*.IQ1GO1TYH8!0.F:.E'3BCJ =LT=LT>U'M1U #Q11UHSF
MA '?%&.U'O1GO0@ <T4=*/ZT=  =,T=LT>U'M1T .V:#Q1[4=?PHZ &.U'?%
M&>]'O0P#VH'-&>]'3\:& 4=LT>U'M1U #TS11UXH_I1U #P:/:CK1GO0@#OB
MCK1[T9Q0@ <T=LT=*/:CH =LT'IFCVHZ\4= #I1T.*.M'7F@ [XH[XHSWH]Z
M& =:!TS1T_&CIQ1U .V:.V:/:CVHZ@!XHZ4=:.M"W ,<XH[XH]Z,]Z$ #DXH
MHZ<T=/QHZ  Z9H[9H]J/:CH =LT'BCVHZ_A1T /:COBC/>CWH8!WQ0.:,]Z.
ME# .V:.V:.G%'M1U #TS11[4=?PHZ@!XH[XHZT9[T( [XH]J/>C/>A  YH[9
MHZ4>U'0 [9H/3-'M1[4= #I1T.*.M'7F@ QSBCOBC/>CWH8!UH'-'2CI1U .
MV:.V:/:CVHZ@!XIP'%-ZTX'B@!!PV*:X_>4Y>6S3'/[RF'0])^%'_(5D^E>T
MUXM\*/\ D*2?2O::0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %[YHSWI/X*#]T4!<4<4>U(W:@_>% 7%[8H/3%)_'0/OF@+B_P!*.IS2+U-
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M;',0-9FN7BP1ID]Z -9&W)FHF?RZ9I\HEMU(/453U:Z6WZG% &DLF8MU017
M><KFLB+68OLA.^JVF:FDVI,H:@#K">*A\RED<"'=[5B_VI&)=F[G- &TOS-F
MI'.!4%HXDCW5).<)0!'--L .:6&7?WK"U34TB 4MSFG:;J:.0-U '0MRM"<+
M21N'7(IXH *Y#Q8Y6]MOK77UQ7C)L7EM]: .FTM]]LOTJ_65H9S:#Z5JT %,
M=MHI]5KM]B9H DB?>#3\_-5+3I?,5O8U;_Y:4 *[;137?:F:2X^Z*HZA<B"!
M2QQD4 7;>7S,U(S8K+T6X$ZN0<\UHS'% $9ER^*L X3-8JW0^W&/-:DLH2W+
M'TH 6&3>6'I2R2;6Q6;I%TL\DH!S@T^^N!'<!<T ::'*YIU06K[X0:GH 0G!
MI'.$S37ZBH;R41V[$^E $?G_ #=:LQON%<U_:"]=U:^G72S< T :"CYC5>XG
M\N0#/6K6*P-:N?(NDR: +TEX%?&:L6\WF=ZY&YU(&X&&K=T>?S<<T ;$C;5S
M55+@$-STI=0E$41)]*YZWU)2)/FZ4 = )]PZU..8ZP;*\$K8![UO)_J: $B?
M+E?2I2<&LFTNU>^DCSTK48\B@!2/G!JK/<>6^,U+-.L0RQKG-1U%?.)#<4 =
M$C^8H-//3Z5GZ5.)HASVJ\QVHQ/:@""XNO+[TD4_G1=:YW4]24%@&Z5:T*]6
M90N>: .EB&$%-E?:*>OW:S=0NU08S0!/]H&\#-6,[EKFEOU-RBYZFN@B;*@T
M 6$X6G4B]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@"AJW_'D_TJ/1/^/):DU;_CR?Z5'HO_'FM &G1110
M!1U?_D&3?[M?-_B@?\3DCWKZ1U;_ )!LW^[7S?XG_P"0T3[T#1FL/DJQ8<LP
MJNY^6K&G\.U = N>IJJOK5JZX)JJIXQ0AL4^M ]:1ONXH'W13%U%Z48[4'FC
MO20![48[4=\T=\T( Z_A1UYH%':CH >]'O0.F*#TQ1T .G-'2CM0:.@![48[
M4=\T=\T, QVHZ_A1WH'%# />CWH[4=L4=0#WHZ4'IBBCJ =.*,=J#US2]\T(
M!,=J.M'?-%" .M'O0.*.V*.@![T=.:.V*#1T .E'M11WS0P#':CKQ1WS0.N:
M& =:/>B@=,4=0#WH]Z.V*.V*.H!THQCB@\T4+< QVH]J.^:7OFA )UHZT#K1
MVHZ 'O1[T#IBCMBCH >]'3\:.V*#S1T ,=J/:COFCOFA@&.U'7\*.^:!Q0P#
MWH]Z.U';%'4 ]Z.E!Z8H[4=0#I1CM0>31WS0@#':CK1WS10@#K1[T#BCMBCH
M >]'3FCMB@],4= #I1TXHH/7-# ,=J/:COFCOFA@'6CKS10.F*.H![T>]';%
M';%'4 Z4=*#S1UH6X!CM1CM1WS1WS0@#KQ1UH'7-%'0 ]Z/>@=,4=L4= #IS
M1T_&CM0>:.@!CM1[4=Z.^:& 8[4=?PH[YH%# .O-'O1VH'3%'4 ]Z.GXT'IB
MCM1U .E'M0:.^:$ 8[48[4=\T=Z$ =?PH]Z!Q1VHZ 'O1[T=L4'IBCH =*.G
M%%!ZYH ,=J,=J7OFD[YH8!UHZT4#BCJ >]'O1VQ1VQ1U .G-*!Q2&G \4 (O
M#8ICC]Y3QR]-<_O*8=#TCX4?\A23Z5[37BWPH_Y"LGTKVFD(**** "BBB@ I
M&&12T4 5[EO+MV/H*\6\0^(RFM"+?TDQ7LNI'%F_T-?+'BJ[9?%+#<?]=_6@
M#Z8\/W'VG3T.?X17 ^.M=.GZL(@V*ZCP1<>9HZ'/1!7D/Q:NF_X25<'M0![-
MX,OOMFDQ29SFN@OWV6DC>BFN&^%\A?P]!D]J[75?^0?-_N&@#P[6_$K07DR[
M^C&I?"?B%KO4XXRV<M7!:^7EUJ:,$\R$5TW@C2Y(-8MV8'[V: /H>T_X]@?:
MN \>:H;41C=CYZ[^VXMP/:O'/BO*8_*(/_+04 >E^%KG[1I\;9S\HK!\>Z@;
M.-B#C"U>\!.7TF$G^X*Q?B7;-- ^W/W: //D\7,ML1O[^M;?@_7&N=3^]G->
M1W2R0W!BR>M>C?#RPD-TDA!Y% 'N5U-MTHO_ +&:\?N/$Q374AW]7QUKUC4\
MQZ"_M&?Y5\Q7=VS>+4^8X$O]: /J30)O.L5;VK1G'[IOI7/^#I?,T=3[5T,O
M,#_0T >+>*]?,.H/&&Z-BFZ+XA)GC4MU-<GXKWW'B2X0$\24S#Z==VV21DB@
M#Z-T>?S[4-FM&N8\%W/VG2@V<UT] !7"^-VQ>VOUKNJX+QU_Q_VGUH Z?0?^
M/,?2M:LC0#FR7Z5KT %9FKR>7 3[5IUA^(GVVI^E #/#<_G1R<]#6[CYLUR?
M@N3=#-S_ !5UU #)!N%<7XZU#[#;Q<XR:[4GK7D'Q9O]JPJ&Z-0!V'@:[^U6
M[G.:ZN8?(37F?PPO=UJP)ZUZ=+S$?I0!PBW^/$SPYZ5T>KW/DZ87S_#7GTTY
MC\<2C/>NI\4W&S0E.>JT 5O >H?:[BZ&<X:K7B*\\G5$3/6N2^%UR1=W8)ZO
M6GXPG(\10IGJ* .]T>3S+%6K0K)\/?\ (,2M:@!K#)K#\1W/D6,ASVK=/2N)
M\97.('C!ZB@#DFUAA"3N[UU?@_4?M,VTGM7!+8O)IQ?!ZUL>#+HVVH[&/:@#
MUZN%\:W7V>93GH*[>%]\2MZBO-OB,Y\]5'<4 <]%JC32 YKT+PO*9(U/M7FV
MCZ8\L6[!ZUZ9X:MS"B@^E %GQ-<>1:$Y[5YG:ZRQ>8;N]>@>-2?L/'I7EFD6
M#SR3$ _>H [7PY?&:[12>IKT)_EMS]*\]\,Z<\%[&Q!X->@73;;9O]V@#@]'
MU0R>)KF+/1J] 7YD4UX[X=D+>-[T9_BKV*+_ %"GVH YKQ3J'V.-L''%<#+K
M#2Q;]W>MSQ[<%I#&#U%<O8Z9)+IX.#UH ]$\)71GC7)[5T6H-Y5A,_HIKFO"
M%JT 4$=JZ+6_^01<?[AH \@N-9:::4;NC$5M^$]2+Z@D>>M<EI=@]W+<'!/S
MFNI\,Z8\&L1L0>* /4E;]V3[5P^NZGLG9<]#7;8VP-]*\AUVZ,FJR1@_Q8H
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MG06.>B"O)?B>_G>(-W7%>C?#Z?'AZZ.?NK7FOC7_ $B]>7K@T >L_"QQ_8,
M]J[W4N=.G_W#7F?PLF_XED*9[5Z1J3?\2^;_ '#0!\SSP>;XK93WF_K7K^CZ
M.D%U;N%'05Y8Z8\5Y_Z:_P!:]QTE XA;T H Z*(83'M7B_Q@R$A/_345[8%P
MOX5XU\78]T4/_704 =M\/?\ D#0_[@JWXJLQ=0MQGBJG@#C1XO\ <%=%?0^=
M$W':@#Y?U^R\KQ)Y6.]>R?#_ $H+;1OM[5YYXKM-OC0+BO9_!MMY6EQ'':@"
M]XB81:-,/^F9_E7RNZ,_B-I,<"4_SKZ9\;7/DZ<RY^\I%>#V^F[Y)[C'1B:
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M>:!:CU% '-_#MC#>R9XW-6IXP<GQ=:KZ@55\-0?9+V/MN:KGB9/,\:68]0*
M/1M"7;IR#VK3JGIJ>7:(OM5R@!LAPA->9>+[C=?K%GK7I4YQ"Q]J\C\0S>;X
MIMXO4T ;^GZ6&T DCFN/MI39Z\R]/FKU>SM-FD^7CM7DNN+]FU]CT^>@#VK3
M7WV$3>JUYU\0SG5(5]:[_0VW:1;GU05P'Q!_Y#-O0!L>%M,1].#$"NHM+<0R
M8%9'A1@--45T2#YLT <SXR&;0#VKG_!NGK,)B0.M=%XQ_P"/45E^!6&V;ZT
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M:I;]Z!0!(HPN*=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*P]* + Y%+34^[3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** *&K?\>3_2H]$_X\5J35O^/)_I4>B_\ 'DM
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M[-X$T@V-F.,9.:\FA ?Q:0>GG?UKZ TL1QVT84 ?** -0GJ/:O$OBHN98_\
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MG^]7K=QQI[#_ &:\J\),/^$SO1_M5ZM<C-DP_P!F@#QV<_\ %>VO^]7M4?\
MJE^E>(W[>3X]M<_WJ]IMI ]NK>U $@'S51UO_D%SCU0U>5LFJ&M?\@Z;_=-
M'CVD:&;J2X;;_&:](\,Z<;*W48QBLWP1;QSQ7!(Z.:[58%B3"C% $JG)K"\1
M6?VN';C-;2<&F&,2D@C- 'B=[9G3-<@.,?-FO7]$N/M-@K9SQ7GOC^W$.K6Y
M48KLO!K%M+&: .E48%+110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"AJW_'D]1Z+_QY+4FK?\>3_2H]$_X\EH TZ*** *6K?\@V;_=K
MYQ\3_P#(8/UKZ-U?_D&3?[M?-_B<_P#$V)]Z *':I[#_ %C55S\F:LV7!)H
M)^K557[IJS<=354=<4V,=_#0?NBD_BQ0.3BD%QWI2'K2#G- Z$T!<=WI/XJ3
M^'-!^[FA@.'>D'2D)P!0>"* %_AH_AI/XL4H^]BCJ%P/2@]J0<DT+SFA;@6%
M($)JFO-Q4K28C(J.$9;=3!DDO2FJ#Y9ITO.*F:/$/X4A%:WZ&E)_>TD7#$4Q
MSB:@"[<?ZA<5%(?E6G,VZ("H0V[\* 'R<Q$"H[7Y'YJ6 >;Q272&W!/2GU&)
M,<OQ3U'R571MZ U87I28^I#CYZL''E4PKS39&XQ0+J)_#2]J:G/%.')-""X'
MM2]Z:.<T _+FA +_ !4O<TW^'-!^Z#0@N*.]2A@+5_6H3QBHIY"OR>M" ;$I
M89I&C;=6AI]L9$'%3-9GS2,4 C**'BGJA!%:0LR3TI6M"%SB@&9K@[L5&L;;
M\U=$#%^E66LRL.[% D4@1MQ2#O40;]ZR^]2'@B@8O\-'\-!^]BC^+%'4+@>@
MI3VIHY)% YS0%Q3]Z@\&D'W<TUSB/-" E^^"*K6L3"1R:L6'[V0BM'['Y:,V
M*!%'</+-1#[E1M)ARM.3TH ?VH- ^]BD')-'0=QQ[4G\5(#P:/X<T .[T@ZF
MDS\N:#P!0!/'_P >\GTK-BC8L3[U>#8&WUJY;V),1;% &6Z';45NI$AS6Q]D
M)?&*A%H5E/%,:,V53YJ_6K$J':/I5IK4F1>*LM:$@<4",3RV!S5]?]0HJS-9
M%8-V*I,V!MI  [T=J0\8H/4"CH%Q1]V@]*3^+%+_ !8HZ!<.PH/44@Y)H'(-
M 7'K]\4R49?(H+80FGJ-T6Z@0V$<FAOF;%/08!/M4=MF2X ]Z8T. VS*#22_
MZZI;]?)O$'M41YFI /E_U:TU^BTV1NU//*B@!IZBE[TT<C-'\.:$%Q1]ZFGK
M2_PYH;M0%Q[?=I8.M,8\@4J':] BN,M?L!3&C8RMBI[1-^I-6E'9%I'XIV&C
M'B0\TTH?/%:XLR-W%1M:'.<4AHHL^&Q5N%@8R/:LZ?<MP14MK-ERM,$*O$QS
MZU8?[M1S+M8'UIYY2D+H-'W*7M34.>*</O$4 ![4O<4T<YH'0FA!<7^*E[TW
M^'-!/RYH 4=31V-(>,4'@BCH HZ4'[M'\6*3^+%'0+BGH*<.E-')-"G@T /'
M6HV_UE.0Y%1R'#T!T/2OA3_R%9/I7M->+?"?_D*2?2O::!!1110 4444 %-?
M[M.I#R* .=\4Q&322HKA/AW9M#K5Z6'7->GZC;BXMBF*Y_P]I@M-0G;;C<:
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M=+C\NW KE=&TL1.#M[UVD";(P* ):*** "BBB@ HHHH **** "BBB@ HHHH
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MBJZ.QQ_!0(\'DC_TAAZ&I N#4L@'VJ0?[1IK\4#L,_BS2C@F@]*.PHZA80<
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M/04I3>@!J11A<4 0W";E-):)LCQ4[#-(J[10!#=IOCQ45G%Y;$U<89%(JXH
MJW\?F1,/:H-(@\F%ACO6BZ[ABFQ1A!@4 24444 %5KJ/>AJS2,N10!E1VPV]
M*OP1A%I_E@"G#@4 (H^8U3N8=]RC8Z5>%-9 6!H <HP*6BB@"I?1^8F*ATV'
MR@W%7W7<*:B!.E #V^[30/DQ3Z3'% &196VS49'QU-;%1)$%<MZU+0 UE!K/
MFM@9\XK2IA0$YH C@C"BG7"[H&'J*D Q0PR,4 <W#8X9N.]26MGLU!7Q6T(
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M5RZYJDOWLT *W7%*O/%(W7-*O!H !S^% /&:!QF@?=(H$';-&?ES1_!B@_=
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M9<ONOG/O713WQDM"NZN;D7,Q- #CQBDZ'%!YQ0>H- "_Q8H'7%)_%FC^+-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH H:M_QY/]*CT3_CQ6I-6_X\G^E1Z)
M_P >2T :=%%% %'6/^09-_NU\W>)_P#D+$>]?26K?\@V;_=KYO\ %'_(:(]Z
M ,L_ZL5:LN2:KN/EJQI_+M]*!V"XZU4'WJMW/4U57I0-A_'F@?>)H/W<TO\
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MCH* %HHHH **** "BBB@ HHHH *1ONFEI.HH :G2GT@X%+0 4QQ\PI](1S0
MC?=H3[M*?2@<"@!:*** "BBB@ HHHH ***3/- "T444 %%%% "9YI:C!^>I*
M "HR/G%24F.: %HHHH **** "BBB@ HHHH **** "BBB@!#TH'(I'^[0GW:
M$>D8=*>1FC% "CI1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %#5O\
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M.4?N&-0S'?=R$?WJG'_'LPH#H11MN6G]>*CA&*>/O&@!<Y_"DZ\T+WH'W30
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9/N$5' -CR>YJ51A":0#<8%';-(&W"E]J  \4=Z.M&>]" .^*.^*,]Z/>A
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MJ0C(H 1/NTZD'2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>6S3'/[RGQ]*BD^]0,]+^%'_ "%)/I7M->+?"?\ Y"<GTKVF@04444 %%%%
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M@ HHI&.* %II'S9IU% !1110 4444 %%(3@4#I0 M%(#2T %,*\TN?FQ2]Z
M&;:DHHH **** "BBB@ HHHH **** "BBB@!H'S9IU%% !1110 4444 %%%%
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M<3X[MC%K$TF.K5R\C;T7VKT;XG67E;IL=6KS>U/F!O:@!Z_<-'\%+C'%'M0
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M0A": (/'EU]DCB?.,N*Z7P[-Y^G0M_LBN,^*2LUC;E?^>@KJ_!ZD:1!G^X*
M-R^;9:.?05P1'VK4]O7FNXU8XTZ4^U<5H8\S5E)]: .QTRW\F)1CM4.K7?D
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M>K:9_P >:UY5HMH8[P-CO7JVF?\ 'FM %RJNH_\ 'C+_ +M6JJZC_P >,O\
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ME'6F_P .:#T%""X'[AIBC_1VI[]* /W1%(:(H>U>G_#FX$5TWTKS*,8:NO\
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M!2#J-E38*CC^]4DS[L41KGF@0I^]B@=<4$8>D'#$T  YS[4#H3Z4#C- Z$4
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M'/%7/)Q+G%6A@&AEYH QEM?^)D\F.U8DDA.ILOHU=:(\2,?:N3:$_P!JN?\
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M>6>[G%065B!*'Q6W*@*&F01A5H IZA:":#;CI5?2K;RI&&*V64$5!!'MD8T
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MT)'&6%:5J=X JMKJ[7MO]X4 =C;G_1XO]T5-*,QD>U5[;_CVA_W15E_N'Z4
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M]9'A9_\ B6I_NTRZO-MXHSWH ZDR *#FH(Y0T^,UGSWFVUW9[5!IEWYTP.:
M.A([U0N)@LJC/>KKMB(GVKF;F\S=JN?XJ .BDD MR<]JS(;D&X S3KRXV6?7
MM7/P7N)\Y[T =A-(!"#4*7"[3SVJI<W'_$M1\]:PCJFW(S0!U%K.&<C/>M"N
M0TR_WW"C/4UUR\J* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6I6P]2*]'C_U:_2@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?>CI2'[@H;H* %Z?C1[4C=10?OT!<7VHZ\4G\="_>- 7%Z_A1GO2+T- ^X:
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MKRZ_2J6J+_Q3[5<U1L,I]JHZA*KZ(RB@"!Q_Q3T JE=PY2#BM!A_Q(8!4=T
M(H/PH IS1[-3M?PKO8CF-?I7$W@']I6N/:NT@_U2_2@"6BBB@ HHHH ****
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MO1TH]J.H![T>]';%';%/J =*.E!YHZTD 8YQ1[49YS1[T( Z\4=:.AS1THZ
M'O1[T#IBCMBCH >]'2CVH/-'0 QVH[XHSWH[YH8![4=:/>CI^-# .O-'O1TX
MH[8HZ@'O11VQ11U .E'M1UH]Z$ =\48[4=\T9[T( ZT>] XH[8HZ 'O1[T=L
M4'THZ '2CIQ1UHZG- !CM1WQ1GO1GG-# .M'6CI0.*.H![T>]';%';%/J =*
M<!Q33S3@>*0"+PV*8X_>4\<MFF.?WE,.AZ3\*/\ D*2?2O::\6^%'_(4D^E>
MTTA!1110 4444 %%%% #)?\ 5-]*XG1(\:Q?'U)KMI?]4WTKD=$7_B;7?U-
M%68;+O/O7112;M,8^U8FIQ>7<#W-:UD-^F,* .;TW/\ PDC/78Q39E(S7-V-
ML5UEFQ6Q:/NO'7T- &X.5K!U.R$]XIQ6\.%JNR!I0: &V4/DVP3%3OQ&?I2C
M@XI)O]6?I0!Q.LONN0OJ:O+#]GT"? ZBJ6H1[[]?]ZMZYASH[H!U6@#!\*$M
M("?6MOQ-)Y=F#[U2\.V9@QD=ZN>)$\VU"CUH Q-$F*S9SU-=FHW*IKBK6(P/
M'[FNUB.+=3[4 8VM71A) /:N5\/,9?$[N>];^MJ97;%9WA^R,.J&4CK0!U&K
M';;'Z5QME,8O/'J:[/5%\R #VKDVLRDA&/O&@#:TB4_V<[5R-I*3XX8UV6GV
MYCTYEQUKE[>R*>*6EQ0!VFH_-9@^U<7]J*W>W/4UVDW[RVV^U<?)9'[>#C^*
M@#I8I#'IKO[5C6,IN-1&:VIHBNDN/:L?1(2+T,?6@#;UD;--Q[5P.BREM6<?
M[=>A:VFZQQ[5P^CV134V;'5J .GUJ/B.3T6LBUN3/=!<UTNJP[[/I_#7-Z7:
MD7RDCO0!?U ?9[8.*PUD-U<Q@\X:NHUJWWV6 *PM*LC]IY'0T =U:#%M&/\
M9%22?<--AXB4>@IQY0T <!!_R.<E=!XA/^B1UD0P_P#%6R-BMK7TW6R"@#A-
M0YD2MNU<C0Y%K-O8/WT8Q6O%"18-'CK0!DZ&Q340:[Z63_1XS7):;8%+L'%=
M//Q!&OI0!JQ<Q+]*H:I!YENW':KT'^I7Z4EPNZ)A0!F:5;[+3;CO6H!MB/TJ
M&U79#5@\H?I0!QVKSGS6'O5S0$W6TE4M7A/VCZFMK18?)M6R.M %2.+;K"UH
M:R=MH34:QYU%6J76EW6F* .-TN0C47/O7<1MD)]*XZQM2MT6QWKL(%RJ^U $
M&IS^4IY[5QT),^M$UU6M E3]*P],LS]N\S% '7VZXM /:N6U6<P2$ ]:ZZ,8
M@ ]JY/7K8M,N!WH -%)>96]ZK:Y<&/5",UIZ+;%,'%9NN6QDU0G% '2V)\W2
MU/\ LUR%]<F*^V ]6Q79:<FS3%7_ &:XV]M3+J60.C4 =)9+Y6GL_MFN7U2X
M-Q,8\YYKKXE_XEK+_LUR3VQ.H].] '00G[/H,8]JQM#;?J,I_P!JMZYB_P")
M0JCTK(T6 QWCG'4T :7B>4QZ5(/]BL3P+,6@P?[U;?B:(R:>X']VLGP7:F&+
MD?Q4 ;/BB0I9?C47AMRP_"I?$\9>SQ[TSP[$40?2@#I.U4=37_07'M5U3FJ]
M^NZU8>U 'FDG-^RUM>%^+^8>@JDML6UAABM;0(/+U.;CM0!1UMO]+ ]35."/
M9J\!]ZOZY%B_C]VH:WVZI;\>E &KXD/_ !)R:YZT7_0U-=-XBCSHQ%8ME;[K
M)!B@#0T3]V)#[5?GDWZ=/]*@LX?*B8X[4^ >993"@#DKIB-,=/>M1QCPQ;_6
MJUY:G[.PQWK1GBV^'H5]Z 'WR;M,M?85+8-N=!Z5/+!OTJ'CHM9VG38NU7/>
M@#9UCBU/TK'U)\>'$/O6SK'S6Y'M65J,);P\J^] %:UG)L$Y[5S.KL9;^+_>
MKI+&$FTV^@K$FMC)J*<=&H Z2#Y='9?45I:<WEZ.#57R=MEMQVJY$FS2,4 6
MD?S+9OI7$VLICU=QZO776#[E=/:N5GMS%JP;'5Z .AUA\6P;_9K!-T9=/*9[
MUO:JF^QQ_LURUJI:<0^] '0L/^))"*J:BQ6.WK8>WQIL:8Z5G:M;GRX>.E %
M64[[^V/TKMK?_5#Z5R$4.ZYB;'2NOM_]6* ):*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** *.K?\>+_2HM$_X\EJ75O^/%_I46B?\
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MO"@+B]L4=L4G\= ^\: N*>:*1>] ^Z: N+WS1WS2?P4'[E 7%%':D/04-U%
M7%'3%';%)_&*/XZ N+VIP/%,7J:%Z-0(D4U$Q_>4^,\5%)]^@#TOX4?\A63Z
M5[37BWPG_P"0G)]*]IH **** "BBB@ HHHH *0* <TM% "%0: ,4M% "8H
M.:6B@ HHHH **** $VBEHHH *3%+10 A4&EHHH 3 HQ2T4 %)BEHH *3%+10
M F*,4M% !2  4M% "8S1M%+10 4F*6B@ I ,4M% !1110 FT9S01FEHH ;L%
M+M%+10 8I,4M% !1110 4444 (0#2T44 %%%% "8I:** $(S1BEHH *3%+10
M 4F.:6B@ I,"EHH 3%&T4M% !28%+10 F* ,4M% "$9H Q2T4 %%%% ";1G-
M&.:6B@!"H-&T9I:* $(R* H%+10 F* ,4M% "8%&T8Q2T4 )CC%)L&<XIU%
M"8HP,8I:* $"@4FT9IU% "8HQ2T4 (% H*@TM% "8I-@SFG44 %(1FEHH 3
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M#>O%*>?PH'6CM1T .O-'?- Z4=L4= #IS2=/QI>U!YHZ &,#%)[4[O2=\T,
MQQBCK^%+WS2#O0P#KS1[T=J!TQ1U />CISZT'IBCM1U .E&.,4'M1WS0@$QV
MI<9&/2COFE[T(!.OX4>] XH[4= #OFCIS1VQ0>E'0 QC\:3IQ2T'KF@ QQBD
M]J=WS2=\T, ZT=:*!1U />CWH[8H[8HZ@'3GUI5'!I#TIP/% "+PV*8X_>4\
M??IKG][3#H>D?"CC5)/I7M->+?"C_D*R?2O::0@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% %#5O^/%_I4>B?\>2U+JW_'B_TJ+1/^/%: -.
MBBB@"CJ__(,F_P!VOF_Q.?\ B;$^]?2&K_\ (,F_W:^;_$X_XFQ'O0!FD_N\
MU9L>&)JL1\F*M60Y- "78JG&><5<NSFJ2??H D/+8I!U(IV/GS2=&- "#G-
M^Z30.,T#@$4 '\.:"?ES1_#B@_=Q0 'C'O2GJ*0\X]J#R0: #^+%+_%BD_BS
M1_%F@!1U-(.0:!P2:!Q^-  #\N:/X<T?PXH_AQ0 '[H-!XQ0>0!0><>U "G[
MP%'\6*0]<T?Q9H 4<L12#G-'0YH'&?>@ '()HS\N:!P,4?PXH #]W-!. *.V
M*#S^%  >"*4_>Q2'DCVH[YH 7^+%(.2:/XLT#@DT  .0:!]W- X!]Z.V* #/
MRYH/"@T?PXH/(Q0 'C%!X8"@\X]J#R<T +_%B@?>Q2?Q9H'7-  .2:!R#0.,
M^] X&* #^'-!/RYH_AQ1VQ0 '@#WH/!%!Y ]J#SCVH 7^+%'\6*3OFC^+- "
MCJ12#G- X.:!QGWH  ?ES1_#FCMBC^'%  ?N@T'C%!Y&*#SCVH 4]0*/XL4A
MY(-'\6:  ?>Q0.2:.^:!QGWH !R#1GY<T#@$4?PXH /X<T$\"C^'%!Y H #P
M1[TI^]BD/)'M0>N: %_BQ2#EB*/XLT="30  YS0.5)H'&:!P,4 &?ES0?NYH
M_AQ1VQ0 'C%!X(%!YQ[4'D@T +_%B@?>Q2?Q9H'WLT  Y)H'0T#@_6@< ^]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW!2#TH/I0 K=!0?O"@<_A32>: '?QT#[]';--SSF@!R]30O0T'@9]:0=<>M
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M!0O/%(>N/2@!6ZB@_?% Y'TIN><T ._CH'WC1VS30<&@!P[T#[IH/'XT@]*
M%_@H/W!2'TI1SQ0 -VH/WA2'K]*4<C/I0 ?QT#[YIN><TX],T "]30.AI <'
MZTIX_&@ 'W*#]RD'I0?2@!3]T4'JM Y'TIN?G% #WXD%,E]:>_W@:9+_ *O-
M#*/2_A/_ ,A)_P#=KVBO&/A/_P ?['_9KV>@3"BBB@04444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3B@ /4TJGY2*5U.!2!3N% =!#TQ3LY3%(RG=2JISB@!N:<QSBF[3DTY5)4T
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M"@!U%-W"C<* '44W<*-PH =13=PHW"@!U%-W"C<* '44W<*-PH =13=U&X4
M.HINX4;A0 ZBF[N*-PH =13=PHW"@!U%-W"C<* '44W<*-PH =13=PHW"@!U
M%-W4;A0!2U7_ (\G^E1Z+_QY+4FJG-D_TJ/1?^/): -!1\]/I,<TM %'5_\
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M*4G)% %GS?GQ0)?GQ5;/SYHS\^: +(EY- EX-5@<$T@. : +(E^0T>;\F:K
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M\&&:3<,U1^T<]:7S_>CH!>#"DW#%41<>]!G]Z&)%_<-M)N&*I"X]Z3S_ 'H
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MW8JUY7SYH$7S9H JJ"<T '!JTL76D$7!H K8.S-!'R9JSY7R8H,7R8H K$$
M4$'(JR8N!2F+D4 52IW@4;?GQ5HQ?,#1Y7SYH JA?F- 7K5H1?,:01=: *P!
MVDT8^3-61%\IH\KY,4 5B#M!H*]*LF+Y108NE %8K\PHV_/BK1B^84>5\^:
M*H4[L4 ')JT(OFS0(N30!5 )!I,?)FK0BX-'E?)B@"M@[,T$' JSY7R8H,7
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MVBC:*6B@!-M&VEHH 3:*-HI:* $V\4 8%+10 4444 4=7_Y!DW^[7SCXG/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<_LLY^[3AI1VYVT 87.*3FMS^RS_ ':<=*.W.V@#"YHYK;&EG/W:5M+(_AH
MP^:.:W%TLD_=I#I9S]V@##YI>:W%THG^&D_LL_W: ,/FEYQ6[_91VYVTW^S#
M_=H P^:7FMTZ40/NTT:6<_=H Q.:.:W&TL@_=H72R3]V@##YI.:W#I9S]VG+
MI1(^[0!A<TG-;G]EG^[3O[*.W.V@#"YI.:W/[+/]VG-I1 ^[0!A<T<UMC2SG
M[M*VED'[M &'S1S6XNEDG[M(=+.?NT 8?-+SBMT:42/NTW^S#_=H P^:7FMW
M^RCMSMIO]EG^[0!A\TO-;C:41_#0-+)/W: ,/FCFMPZ60?NT+I1/\- &'S2<
MUN'2SG[M.&E';G;0!A<XI.:W/[+/]VG'2CMSMH PN:.:VQI9S]VE;2B/X: ,
M/FCFMP:62?NT'2R#]V@#"YI>:W%THG^&D_LL_P!V@##YI><5NC2CMSMIO]F'
M^[0!A\TO-;ITH@9VTT:6<_=H Q.:.:W&TL@_=H72R3]V@##YI.:W#I9!^[3E
MTHD?=H PN:3FMS^RS_=IW]E';G;0!A<TG-;G]EG^[3CI1 ^[0!A<T<UMC2SG
M[M*VED'[M &'S1S6XNEDG[M(=+.?NT 8?-+SBMT:42/NTW^RS_=H P^:7FMW
M^RCMSMIO]EG^[0!A\TO-;K:40/NTT:6<_=H Q.:.:W&TL@_=H72R?X: ,/FD
MYK<.EG/W:<-*)&=M &%SBDYK<_LL_P!VG'2CMSMH PN:3FMS^RSG[M*VE$?P
MT 8?-'-;@TLD_=H.ED'[M &'S2<YK=72B?X:4:4>?EH Y^1FS2(2YQ6X^DD@
MG;1;Z4=_W: .S^$I/]K2+Z+7MB'DUY)\,[(V^K2-C'%>MJ,$T /HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** *=RNZTD'J*\QU72?,U+=MKU5TS&P]:PKC2P\^[;
M0!P=SH_^CCY:B_L?]RORUZ!)I8:/&VF_V2-@&V@#S[^Q\?P_I1_8_P#L_I7?
M_P!DC^[1_9 _NT <!_8_^S^E+_8_^S^E=]_9 _NT?V0/[M '"QZ/P?EJ/^Q^
M?NUZ NE #[M-_L@?W: .%_L?]U]VH_['_P!FO0/[*&W&VF_V0/[M '"R:/\
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M_F'RTLFC_-]VN]&D@'[M*VD@G[M '!1Z/S]VF-H_S'Y:] 720#]VD.DC/W:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME)L'I3Z* &[!Z4FP>E/HH ;L'I2;!Z4^B@!FP>E+L'I3J* &;!Z4NP>E.HH
M9L'I2[!Z4ZB@!FP>E+L'I3J* &;!Z4;!Z4^B@!NP>E)L'I3Z* &[!Z4FP>E/
MHH ;L'I2;!Z4^B@!FP>E&P>E/HH 9L'I2[!Z4ZB@!FP>E+L'I3J* &;!Z4NP
M>E.HH 9L'I1L'I3Z* &;!Z4;!Z4^B@!NP>E)L'I3Z* &[!Z4FP>E/HH ;L'I
M2;!Z4^B@!FP>E&P>E/HH 9L'I2[!Z4ZB@!FP>E+L'I3J* &;!Z4NP>E.HH 9
ML'I1L'I3Z* &[!Z4;!3J* &;!Z4;!Z4^B@! H%+110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% #&/S4^HV'S"I* &9^?%/J,#YZDH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** $(YI:** $QS2T44 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %3! T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .7^(O_ "(FI?\ ;+_T:E>#5[S\1?\ D1-2_P"V7_HU*\&KBQ/Q
MGV_#7^Z2_P 3_)!1117.?0A7T;X:_P"15T?_ *\H?_0!7SE7T;X:_P"15T?_
M *\H?_0!73AMV?,<3?PJ?J_R-2BBBNP^."BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***@O;VVTZREO+R98;>)=SNW
M0#^I[ =Z!I.3LMROK&L66A:;)?7TNR). !RSMV51W)_^N< $UXGXP\87/BB]
MVKNAT^)LPP$\D_WV]6_ET'<FEXE\2WOB;4C=71V1)D00*<K$O]2>Y[^P  QJ
MX:M9RT6Q]UE63PPJ56KK/\O^#YA1116![H4444 %%%=#I?@CQ#J\44]OI[);
MR, )9F$8P<'=@\E<'.0#[9II-[&=6M3I1YJDDEYG/45ZGI?PBC"A]6U)BQ4Y
MBM%P <\'>PY&.VT=?;GIO^%=>%?^@5_Y,2__ !5:K#S9X]7B'!TY65Y>B_SL
M>#45]&_\(UH/_0$TW_P$3_"C_A&M!_Z FF_^ B?X5?U9]SE_UFI?\^W]Z/G*
MBOHW_A&M!_Z FF_^ B?X55O/!7AN^V>=H]LNS./(!AZ^NPC/3O1]6EW''B:A
M?WH.WR/GRBO9[WX5:%<-*]M+=VK,OR(KAT0XZX8;B,\D;ORKF=0^$NJ0;FL+
MZVNE5-V) 8G9N?E Y'IR2.O;K6;H370[J.>8*KIS6]5_2//J*TM4T#5M%8C4
M;">!0P7S"N4)(R ''RDX]#V/I6;6336YZL)QG'F@[KR"BBB@H]E^$O\ R*MU
M_P!?K_\ H"5WE<'\)?\ D5;K_K]?_P! 2N\KT:7P(_.,V_WVIZA1116AYP44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8^QRS/(8EJE55I_@_P#)_P!>1V'PE_Y%6Z_Z_7_] 2N\K@_A+_R*MU_U^O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R/$VMQ
M^'] N=08J9%7;"C?QR'[HQD9'<XYP#6O7COQ4UN2[UQ-(0LL%FH9QT#R, <]
M<$!2,< C+5G5GR1N>CE>#^MXF--[+5^B_JQPMS<RWEW-=3OOFF=I)&P!EB<D
MX''6HJ**\X_1DDE9!1110,*]!^'?@N+5L:QJ2;[2-RL,#*<2L/XCG@J#Q@=2
M"#P"#@^"_#3>)-<6)QBSM\2W!(.&7/W,CH6Y[C@$]L5[W%%'#$D42+'&BA41
M!@*!T '85T4*7-[S/G,]S1T8_5Z3]Y[OLO\ -CZ***[3XH**** "BBB@ HHH
MH **** "BBB@ HHHH *9+%'-$\4J+)&ZE71QD,#U!'<4^B@+V,CP_P"'[;PY
M;W5M9LQMYK@SHC<F,%5&W/<?+P??OU.O112225D74J3J2<YN[84444R HHHH
M **** "BBF2RQPQ/+*ZQQHI9W<X"@=23V% ;CZ*XC6/BAHNG/)#9))J$R< Q
MD+%G."-YYZ<Y (/'/IQ6H_%#Q#=RYM&@L8PS86.,.2#T#%LY(]0!U-92KPB>
MMA\DQE=7Y>5>>GX;_@>V52N]7TRPE$5[J-I;2%=P2:=4)'K@GIP?RKYSN[Z[
MOY1+>W4]S(%VAYI"Y ],GMR?SJO6+Q/9'KPX87VZGW+_ (/Z'T;_ ,)+H/\
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MOEZKNG:MJ.DR^9I][/;,65F$;D!B.FX=&'7@YZFFL3W1C5X8TO3J?>OU_P"
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M8G?8^/E&4).,E9H****"0HHHH **** "BBF2RQPQ/+*ZQQHI9W<X"@=23V%
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MW4_>*C+-R2-S'DXR<9/%7ZZXX9?:/E<3Q+5D[4(V7GJ_\E^)Y=_PI[_J._\
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M%<W,5G:374[[(84:21L$X4#).!STKYRUK59=;UFZU*8;6G?<%X.U>BKD 9P
M!G'.*])^*^N206MMHL$B@7"^;<*4YVAALP>F"P;IS\H[=?)ZXL1.[Y>Q]KP[
M@O9TGB);RV]/^"_T"BBBN<^C"G11232I%$C22.P5$09+$] !W--KUOX9^$_L
MD":_=_ZZ="+>)D^XA/W^1G) XQ_">^[BZ<'.5D<6/QL,'1=26_1=V2^"_AW_
M &3.NI:P(Y;M<-! IW+$<9RW8L#P,9 QD$G&/0:**]"$%%61^>XK%U<54]I5
M=W^044451S!1110 4444 8?B3PMIWB6R>.YC6.YVXBNE0;XR,XY[KR<K[]C@
MCPG6-'O="U*2QOHMDJ<@CE77LRGN#_\ 6.""*^DJP_%/ANV\2Z1);2(OVE%+
M6TI."CXXYP?E/&1_4 C"K24U=;GMY3FTL++V=36#_#^NJ/GJBI;FWEL[N:UG
M39-"[1R+D'# X(R..M15PGWB::N@HHHH&?0'@WQ%'XBT"&9I5:]B4)=(#R&_
MO$8'#8SQQU'8UT->%_#G6&TOQ7!"TNVVO?W$@.2"Q^X<#ONP,GH&/UKW2O0H
MSYXZGYWF^"6$Q+C'X7JO\OE^04445J>6%07M[;:=92WEY,L-O$NYW;H!_4]@
M.]3UYI\6M8:."ST>*7'FYGG49!*@X09Z$$[CCGE0>.\5)<L;G7@<*\5B(T>^
M_IU/.-:U676]9NM2F&UIWW!>#M7HJY &<  9QSBJ%%%>:W=W9^EPA&$5&*LD
M%%%%!0Z**2:5(HD:21V"HB#)8GH .YKVCP7X"@T6!;W5(HY]2?#!6 9;?!R
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M;XEH<U"-7^5V^_\ X8[6BBBNT^+"O ?'>H?VCXSU%PTACA?R%60_=V#:P'/
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MTX!W)W[>PKRFBKIRY97./'85XJ@Z*ERWZVO_ )'U#17R]16_UKR/G_\ 5?\
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M%+.[G 4#J2>PKYAKDQ70^LX77\5^GZA1117*?6!1110 4444 %%%% !1110
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M444 %%%% !1110 4444 %%%% !1110 5R_Q%_P"1$U+_ +9?^C4KJ*R_$O\
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M5\5^,;WQ3.@=/L]G%S';*^X;L<LQP,GKCC@?B3E4JJ"\SU<MRJKC))[0ZO\
MR_K0]@\*>(_^$GL;N]6'R84NFAA4_>*!5.6[9))Z=.G/4[U<'\)?^15NO^OU
M_P#T!*[RJIMN*;.;,*4*.*G3@K),****LXSYPU_2VT77[W3B&"P2D)O8$E#R
MI)'&2I!_&LVO1OBUI7DZE9ZK&F%G0PRE8\#>O(+-W)!P,]D_+SFO-J1Y9-'Z
M9E^(^L8:%7JUKZ]0HHHJ#L.R^&VN_P!D^)%M)6Q;:AB%N.DG\!Z$]25[#YLG
MI7M]?+U>[>!_%D?B/2UBN)E_M2!?WZ;=N\9X<#N.F<=#V (KKP]3[+/DN(L
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MDB!QC'4N,Y]P,=>37GU<,H.+LS[O"XNCBH>TI.Z_+U"BBBI.D**** "BBB@
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M2LC\_J5)5)N<W=L****9 4444 <O\1?^1$U+_ME_Z-2O!J]Y^(O_ "(FI?\
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M?IGC K2HKKITHPV/C\?FM?&Z2TCV7Z]PHHHK4\P**** "BBB@ HHHH ****
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MN?"\08SVV(]E':'Y]?\ (****W/!"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,:Y\)>'KJ!H9-&LE5L9,4(C;KGAEP1^!K&O/AAX;N=GD
MQ7-IMSGR)B=WUW[NGMCK7945+A%[HZJ>.Q-/X*C7S9P?_"I=!_Y^]2_[^)_\
M11_PJ70?^?O4O^_B?_$5WE%3[*'8W_M;&_\ /QG!_P#"I=!_Y^]2_P"_B?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT8X:/75_H%%%%=9\@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5R_P#PKKPK_P! K_R8E_\ BJ**3BGNC:EB
M*M&_LI.-^S:#_A77A7_H%?\ DQ+_ /%4?\*Z\*_] K_R8E_^*HHJ?9P[&OU_
M%_\ /V7_ ($_\P_X5UX5_P"@5_Y,2_\ Q57])\*:)H5VUUIMEY$SH8V;S7;*
MD@XPQ(Z@444U"*U2)GC,3.+C*I)I^;-FBBBJ.8**** "BBB@ HHHH **** "
*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
